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Abstract
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide
(PACAP) have been implicated in a wide range of functions in the central and peripheral
nervous systems, including smooth muscle relaxation, the promotion of neuronal
survival, modulation of the immune system and the control of embryonic growth. The
VIP type 2 (VIP2) receptor is a seven-transmembrane G-protein coupled receptor
belonging to the secretin/glucagon receptor subfamily, and is one of two such receptors
cloned to date that bind both VIP and PACAP with high affinity. Studies of the
distribution of the VIP2 receptor have provided some clues as to the possible functions
of this receptor, and in particular have led to the proposal that this receptor may be
largely responsible for mediating the neuroendocrine effects of VIP. However the
absence of well characterised specific antagonists for the VIP2 receptor has proved to be
a major obstacle to the delineation of the physiological role of this receptor. The work
presented in this thesis has focused on the isolation and characterisation of mouse and
human genomic clones encoding the VIP2 receptor, which should allow molecular
genetic approaches to be used in future studies of the functions of this receptor.
As a result of hybridisation screening of a mouse genomic A2001 library and a human
genomic PI library, 6 bacteriophage clones that together span the entire coding region
of the mouse VIP2 receptor gene (Vipr2), and a single PI clone that was shown to
contain at least part of human VIP2 receptor gene (VIPR2), were isolated.
Characterisation of the intron/exon structure of the mouse Vipr2 gene, achieved mainly
by direct sequencing of A, DNA and PCR amplification of introns, revealed that the gene
contained at least 12 introns, with sizes that range from 66 bp to at least 12 kb, and
spans a minimum of 50 kb in total. Following the isolation of a 6 kb subclone which
included the first exon and 5' sequence from the Vipr2 gene, 3 kb of the putative
promoter region of the gene was sequenced. The proximal 5' region of the Vipr2 gene
was found to be GC rich and CpG rich. No TATA box sequences were apparent
within the region immediately upstream of the proposed transcription start site, but a
computer-based search for possible transcription factor binding sites identified potential
Spl and AP2 sites. Other potential regulatory sites that were found within the 3 kb
sequence included possible binding sites for islet-1-like factors, the pituitary factor Pit-
1, cAMP responsive factors, serum response factor, interferon stimulated gene factor-
2, STAT factors, and factors that bind to the conserved lymphokine element 0.
The chromosomal localisation of the VIP2 receptor gene in human and mouse was
determined through collaborative work, in which the VIPR2 PI clone and a 4 kb
subclone from the mouse gene were used as probes in fluorescence in situ hybridisation
experiments. The mouse gene was mapped to the telomeric region of mouse
chromosome 12 (12F2), and the human gene was mapped to 7q36.3. These results
were interesting from two points of view: i) the genes localise to regions within the
mouse and human genomes, that had not previously been recognised as being syntenic,
and may therefore define a new region synteny, ii) the localisation of the human gene to
7q36.3 placed it within the previously defined minimal critical region for the brain
developmental disorder holoprosencephaly type 3 (HPE3). However, subsequent,
more detailed mapping of the position of the gene relative to the chromosomal
deletions/rearrangements found in patients with HPE3, demonstrated that although one
copy of the VIPR2 gene is deleted in some patients who have HPE3 and may contribute
to the phenotype observed in these cases, it is not the gene responsible for HPE3.
To Mum and Dad
with love.
Research is the process of going up alleys to see if they are blind.
—Marston Bates, 1967.
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Nomenclature
The nomenclature used for the receptors of the secretin/glucagon family and the genes
encoding these receptors, has been subject to several changes during the course of the
studies reported in this thesis, and further changes are likely in the future. The situation
with regard to receptors that have high affinity binding sites for vasoactive intestinal
peptide and/or pituitary adenylate cyclase activating polypeptide is particularly
confusing, and in the case of the VIP2 receptor at least three different names for this
receptor are currently in use in the published literature. However, as at present there is
little or no consensus as to what the "correct" system for naming these receptors should
be, the nomenclature that has been used in this thesis is as follows:
Receptors
i) The first high affinity VIP receptor to be isolated (Ishihara et al., 1992) is
referred to as the VIP type 1 receptor in this thesis, and is abbreviated to VIPi
receptor. However, despite its name it should be noted that this receptor binds
both VIP and PACAP with high and approximately equal affinities. This
receptor is also sometimes referred to as the PACAP/VIP type 2 receptor, PVR2
(Rawlings and Hezareh, 1996).
ii) The second high affinity VIP receptor to be isolated (Lutz et al., 1993) is
referred to as the VIP type 2 receptor in this thesis, and is abbreviated to VIP2
receptor. Like the VIP] receptor, this receptor binds both VIP and PACAP
with high and approximately equal affinity. This receptor has also been called
the PACAP/VIP type 3 receptor, PVR3 (Rawlings and Hezareh, 1996), and
the "helodermin-preferring" VIP receptor (Robberecht et al., 1988; Svoboda et
al., 1994). The mouse homologue of the receptor is sometimes referred to as
PACAPR3 (Inagaki et al., 1994)
iii) The only high affinity "PACAP-specific" receptor that has been isolated to date
(reviewed by Arimura and Shioda, 1995) is referred to as the PACAP type I
receptor in this thesis. This receptor, which is also called the PACAP/VIP type
1 receptor, PVR1 (Rawlings and Hezareh, 1996), does bind VIP, but with an
affinity that is greatly reduced relative to that for PACAP.
Receptor Genes
i) The genes encoding the human VIPi receptor, VIP2 receptor and PACAP type I
receptor, are referred to as the VIPR1 gene, VIPR2 gene, and PACAPR1 gene
respectively. Lower case letters are used to designate the symbols for the
correspending mouse genes, which are: the Viprl gene, the Vipr2 gene and the
Pacaprl gene.
ii) It is recognised that gene the word "gene" is not strictly necessary when the
convention of italicising gene symbols has been followed, and that similarly if
the distinction between human genes and those of other species had been made
through the differential use of upper and lower case gene symbols, the word
"human" is often superfluous when used immediately prior to the gene
symbol. However, these additional words have frequently been used in this
thesis, in an attempt to make its findings comprehensible to pharmacologists as
well as geneticists and molecular biologists.
iii) Genes other than those for VIP, PACAP or their receptors are generally
described using the full names of the protein products that they encode, and are
not italicised. Exceptions to this include: cases where the gene name gives little
clue to the nature of the gene product (e.g. the goosecoid gene); and situations
where the same gene is mentioned several times.
cDNAs
Due to the current problems surrounding the receptor nomenclature, the gene
symbols described above have also been used when describing the cDNAs,
although in order to emphasise that the cDNA is not a direct product of the gene,
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Chapter 1
General introduction
1.1 Vasoactive Intestinal Peptide (VIP)
1.1.1 VIP: evolution, structure and distribution
VIP is a 28 amino acid carboxy-amidated peptide that was originally isolated from
porcine gut (Said & Mutt, 1970), and has subsequently been shown to belong to a
family of structurally related peptides (see Figure 1.1) that includes: secretin, peptide
histidine isoleucine (PHI), peptide histidine methionine (PHM), helodermin, pituitary
adenylate cyclase activating polypeptide (PACAP), gastric inhibitory peptide (GIP),
glucagon, glucagon-like peptides (GLP) and growth hormone releasing hormone
(GHRH). This family of peptides, which is often referred to as the secretin/glucagon
family (Mutt, 1988), can be divided into two main subgroups, one including secretin,
VIP, PHI, PACAP, and GHRH, and the other including glucagon, the glucagon like
peptides, and probably also GIP (Campbell & Scanes, 1992). In evolutionary terms, it
has been suggested that the secretin/glucagon peptide family has expanded through a
cascade of gene duplication events (frequently coupled with exon duplications or
losses) and mutations, which began with the duplication of a single ancestral gene
(Campbell & Scanes, 1992). To date, VIP has been isolated from mammals (Carlquist
etal., 1982; Carlquist etai., 1979; Dimaline et al., 1984; Eng etai, 1986), birds
(Nilsson, 1975), reptiles (Wang & Conlon, 1993), amphibians (Chartrel et al., 1995)
and fish (Wang & Conlon, 1995). However, the detection of PACAP-like
immunoreactivity in the Drosophila central nervous system (Zhong & Pena, 1995), and
the finding that VIP-like and PHI-like proteins exist in nematodes (Foster & Lee,
1996), have strongly suggested that peptides of the secretin/glucagon family are also
present in invertebrate species, and very recently two cDNAs (each encoding PACAP
and another member of the peptide family) were isolated from a protochordate (McRory
& Sherwood, 1997).
All peptides of the secretin/glucagon family are synthesised in the form of precursor
proteins, which are subsequently cleaved to release the mature peptides. However, in
vertebrates, the presence of more than one bioactive peptide within a precursor protein
is a feature that is common to only three members of this family: the glucagon
precursor, which when cleaved releases glucagon and several other peptides including
the glucagon-like peptides (GLP-1 and GLP-2) (Bataille et al., 1996; Lund et al.,
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1982); the PACAP precursor, in which PACAP and PACAP-related polypeptide (PRP)
are present (Ohkubo et al., 1992); and the VIP precursor, which contains both VIP and
PHI/PHM (Itoh et al., 1983). In the case of the peptides released from the glucagon
precursor protein, distinct tissue-specific roles for some of these peptides are starting to
emerge (Bataille et al., 1996), but at present the biological importance of PRP and
PHI/PHM is not clear. No specific receptors for PHI/PHM have been identified to
date, and the actions of these peptides (which appear to be mediated by VIP receptors)
generally seem to mirror those of VIP, although they are often less potent (Huang &
Rorstad, 1990; Jensen etal., 1981; Robberecht etal., 1982; Suzuki et al., 1984).
The amino acid sequence of VIP has been strongly conserved throughout evolution,
and is particularly well conserved in mammals where, with the exception of guinea pig
(Eng et al., 1986) and opossum (Eng et al., 1992), its sequence is identical in all
mammalian species from which it has been isolated. However, despite the rapid
accumulation of information regarding the primary stmcture of VIP and other members
of the secretin glucagon family, the characteristics of the 3-dimensional structures of
these peptides (a critical factor in the understanding of ligand/receptor specificity), have
emerged much more slowly and are still not entirely clear. In general though, it has
been shown that members of the secretin/glucagon family adopt a largely a-helical
conformation, particularly towards their carboxyl-terminal (C-terminal) regions
(Gronenborn et al., 1987; Sasaki et al., 1975). NMR and computer-based analyses of
VIP indicate that it adopts a bent N-terminal conformation (Filizola et al., 1997),
followed by a C-terminal region consisting of two a-helical stretches (spanning amino
acids 7-15 and 19-27) that are linked by a more flexible region of undefined structure
(Theriault et al., 1991). The amino acids in the N-terminal region of VIP appear to be
critical for the peptide's biological activity (Fournier et al., 1984), whereas the C-
terminal region in general and the second of the two helices (amino acids 19-27) in
particular, have been strongly implicated in mediating peptide/receptor binding
interactions and specificities (Gourlet et al., 1996b; Wulff et al., 1997), a process
which may involve interactions between potential 'coiled coil' motifs found in the C-
terminal regions of the secretin/glucagon peptide family and in the N-terminal domains
of their receptors (Momany & Bowers, 1996).
Following its isolation from gut, VIP has been found to be widely distributed
throughout mammalian central and peripheral nervous systems. Within the central
nervous system (CNS) the highest concentrations of VIP are found in the cerebral
cortex, the hypothalamus (especially in the suprachiasmatic nucleus), and the central
amygdaloid nucleus (Loren et al., 1979), but VIP is also present at significant levels in
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many other regions of the CNS, particularly in the brainstem (Eiden et al., 1982),
hippocampus (Roberts et al., 1984; Samson et al., 1979), and the dorsal horn and
lumbosacral regions of the spinal cord (Anand et al., 1983; Gibson et al., 1984).
Peripheral regions that are innervated by VIP-containing fibres include the smooth
muscle and glands of the gastrointestinal tract (Polak etal., 1974), the respiratory tract
(Laitinen et al., 1985; Lundberg et al., 1984), and the genitourinary tract (Helm et al.,
1981; Larsen et al., 1981). In the cardiovascular system VIP-immunoreactivity is
found mainly in the nerves supplying arteries, especially the mesenteric and uterine
arteries (Delia et al., 1983; Weihe et al., 1984). Specific peripheral organs and tissues
in which VIP has been detected include the intestine (Said & Mutt, 1970), lungs (Said,
1988), heart (Forsgren, 1989), kidney (Barajas et al., 1983), eye (Loren et al., 1980),
skin (Hartschuh et al., 1984), and bone (Hohmann et al., 1986). In the endocrine
system VIP is found in the pancreas, (where heavy VIP innervation is seen around the
islets; Bishop et al., 1980), the adrenal cortex and medulla (Ehrhart-Bornstein et al.,
1991; Holzwarth, 1984), the ovaries (Gozes & Tsafriri, 1986), the vas deferens and
prostate (Larsen et al., 1981), the thymus (in which VIP mRNA has been detected;
Gomariz et al., 1993), the thyroid gland (Ahren et al., 1980b), the pineal gland
(Uddman et al., 1980), the anterior pituitary (Lam, 1991), the median eminence
(Ceccatelli et al., 1988), and hypophysial portal blood (Shimatsu et al., 1981). The
presence of VIP-containing nerves within lymphoid tissues of the immune system is
also well documented (Fink & Weihe, 1988; Weihe et al., 1991). However, although it
has been recognised for some time that certain non-neuronal cells seem to be able to
synthesise VIP, e.g. Merkel cells in the skin (Hartschuh et al., 1984), amacrine cells of
the retina (Okamoto et al., 1992), and eosinophils (Aliakbari et al., 1987), it was only
quite recently that it was discovered that VIP is also produced by B and T lymphocytes
(Gomariz etal., 1994; Leceta et al., 1996).
At the transcriptional level, expression of the VIP gene can be induced by cyclic-AMP
(cAMP) and by phorbol esters, which activate factors that bind to a cAMP/phorbol ester
responsive element in the VIP gene's proximal promoter region (Yamagami et al.,
1988), and a more distal phorbol ester-specific responsive element (Hahm & Eiden,
1996). Leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) can
stimulate VIP expression through a cytokine response element (CyRE) in the gene's
promoter (Symes et al., 1994), and a glucocorticoid receptor binding site which is
involved in the pituitary modulation of VIP gene transcription has also been
identified(Chew et al., 1997). Other stimuli that have been shown to affect VIP levels
in certain cells and tissues, include: steroids (e.g. oestrogen; Hammond et al., 1997;
Kasper et al., 1992), prolactin (which exerts a negative regulatory effect in pituitary
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Hammond et al., 1997), retinoic acid (which increases VIP mRNA levels in
neuroblastoma cells; Georg et al., 1994), ascorbic acid (Brick et al., 1985), and
depolarising agents (Sun et al., 1992). However, the modes by which these latter
factors exert their effects on VIP levels are not entirely clear.
1.1.2 Actions of VIP
Although the role initially ascribed to VIP was that of a gastrointestinal hormone, it
soon became apparent that this peptide also acts as a neurotransmitter and
neuromodulator in both the central and peripheral nervous systems (Bryant et al., 1976;
Fahrenkrug, 1979; Larsson et al., 1976). Early studies of the function of VIP led to the
identification of a wide range of roles for this neuropeptide, including: neuronal
excitation in regions such as the cerebral cortex, hippocampus, and spinal cord (Dodd et
al., 1979; Jeftinija et al., 1982; Pawelzik et al., 1992; Phillis et al., 1978); smooth
muscle relaxation, including vasodilatation and bronchodilatation within the
cardiovascular and respiratory systems respectively (Altiere & Diamond, 1984; Bitar &
Makhlouf, 1982; Morice et al., 1983; Pompa et al., 1990); the promotion of water and
ion secretion (Krejs et al., 1980; Nathanson et al., 1983); and the regulation of
metabolism (particularly glycogenolysis) in the CNS (Magistretti, 1990; Sorg &
Magistretti, 1991) and liver (Feliu et al., 1983).
VIP also has important actions on the endocrine system, where it is involved in the
stimulation of steroidogenesis (Davoren & Hsueh, 1985; Kasson et al., 1986; Tornell et
al., 1988), and the promotion of the release of several endocrine hormones. Within the
pituitary VIP has been shown to increase oxytocin and vasopressin release from the
neurohypophysis (Ottesen et al., 1984), whereas its effects on the anterior pituitary
include enhancement of interleukin-6 production (Spangelo et al., 1990), the
stimulation of prolactin secretion during lactation (Abe et al., 1985; Escalada et al.,
1996; Kato et al., 1978), and the potentiation of luteinising hormone release (Hammond
et al., 1993), responses which together with the high concentrations of VIP present in
the hypophysial-portal blood, have led to the suggestion that VIP may act as a
hypophysiotrophic hormone. Nevertheless, although VIP undoubtedly plays a critical
role in the regulation of pituitary functions, the actions of VIP within the hypothalamic-
pituitary axis by no means represent the limit of the effects of VIP on the endocrine
system, as this peptide has also been found to be involved in many other endocrine
pathways, for example, the promotion of catecholamine secretion from the adrenal
medulla (Cheung & Holzwarth, 1986) and aldosterone and corticosterone secretion
from the adrenal cortex (Cunningham & Holzwarth, 1988; Hinson et al., 1996),
stimulation of thyroid hormone secretion (Ahren etal., 1980a), the enhancement of
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serotonin N-acetyltransferase activity and melatonin release from the pineal gland
(Simonneaux et al., 1990; Yuwiler, 1983), and the stimulation of glucose-induced
insulin secretion from pancreatic islets (Kato et al., 1994; Schebalin et al., 1977).
VIP is an important modulator of the immune system, and is involved in a diverse array
of functions ranging from the regulation of cytokine levels (Ganea, 1996) to the
modulation of adherence, chemotaxis, and phagocytosis (de la Fuente et al., 1994;
Litwin et al., 1992). With regard to the regulation of cytokine expression, VIP has
been shown to act at both the transcriptional and post-transcriptional levels to inhibit the
expression of interleukin (IL)-2 in activated T-cells, and inhibits IL-4 production at the
post-transcriptional level, at least partly as a result of IL-2 inhibition (Wang et al.,
1996). Inhibition of IL-10 by VIP in activated T-cells, has been shown to occur at the
transcriptional level (Martinez etal., 1996), and it also appears that VIP can act
indirectly (through effects on macrophage-like cells) to suppress the proliferation of IL-
7 responsive B-cells. In addition to these effects, VIP plays a role in the regulation of
B-cell antibody production and isotype switching (Kimata & Fujimoto, 1995), and the
ability of VIP to rescue thymocytes from glucorticoid-induced apoptosis suggests a
possible function for this peptide in the regulation of thymocyte development (Ernstrom
et al., 1995).
The role of VIP in the regulation of cell growth and survival has been extensively
studied, and represents an area in which the number of actions ascribed to VIP appears
to be constantly expanding. Neverthless, it is in many ways one of the most poorly
understood aspects of VIP's functions, as these effects of VIP appear to be highly
dependent upon the system being examined, and it is clear that VIP acts as a modulator
(Muller et al., 1995), as opposed to a predefined promoter or inhibitor of growth,
differentiation, and survival. The effects of VIP on growth and survival, can generally
be divided into 3 main categories:
i) the neurotrophic and neuroprotective effects that are mediated by the actions of VIP
on astroglial cells, a process in which VIP stimulation (at concentrations as low as 0.9
nM) leads to the release of several survival promoting factors including IL-1
(Brenneman et al., 1996) and activity dependent neurotrophic factor (ADNF, a peptide
that has neuroprotective effects even when present at femtomolar concentrations;
Brenneman & Gozes, 1996)
ii) the actions of VIP on neuroblasts, neuroblastoma cells and other transformed cell
lines, where it appears that VIP can either promote or inhibit cell proliferation
depending on the particular cell line or type being studied (reviewed by Muller et al.,
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1995), a characteristic that might conceivably reflect differences or alterations in the VIP
effector systems in these cells (similar to the switch in the expression of PACAP and
VIP receptors that has been reported to occur during phenotypic interconversion in
human SH-IN neuroblastoma cells; Lelievre et al., 1996).
iii) the dramatic effects of VIP on embryonic growth and development, which were first
reported by Gressens et al., who showed that administration of VIP (10"7-10"9M) to
whole cultured mouse embryos at embryonic day (E) 9.5, resulted in a dramatic
increase in embryonic growth and (at 10~' M) a 5-6-fold increase in cell mitosis
(Gressens et al., 1993).
Other growth-regulatory actions of VIP that do not fit into the above categories include:
VIP-mediated suppression of apoptosis in the ovary (an effect that is partly antagonised
by insulin-like growth factor-binding protein 3; Flaws et al., 1995), and the recently
reported involvement of VIP in stimulating the expression and secretion of human
intestinal trefoil factor (hITF; Ogata & Podolsky, 1997), which has been found in the
gut and in PC12 (pheochromocytoma) cells (Probst et al., 1997), and is a member of a
large family of growth factor-like peptides (De et al., 1994).
Finally, although it would not be appropriate to try to list all the proposed functions of
VIP in this space, the role of VIP in the regulation of circadian rhythms should be
mentioned, as it is currently attracting a lot of attention in the scientific literature. VIP is
present in both the pineal gland and in the suprachiasmatic nucleus (SCN), where in
rodents, levels of the peptide display a diurnal variation (Kaku et al., 1986; Okamoto et
al., 1991). Immunohistochemical and retrograde tracing studies support the idea that
SCN derived VIP is involved in transmitting information to the pineal (Teclemariam-
Mesbah et al., 1997). The recent demonstration that antisense antagonism of VIP leads
to the temporary abolition of circadian patterns of corticosterone secretion (but not
stress related secretion) in rats (Scarbrough et al., 1996), is particularly interesting, but
it is not clear whether such findings can be extrapolated to humans as it has been
reported that in the human SCN VIP levels do not display significant diumal variation
(Hofman et al., 1996).
1.1.3 VIP receptors: evidence for VIP receptor heterogeneity
Many, but not all, of the effects of VIP result from the ability of this peptide to stimulate
increases in intracellular cAMP levels through interactions with receptors on the cell
surface, a process in which the involvement of G-proteins is indicated by sensitivity to
GTP and GTP analogues (Christophe et al., 1986; Quick et al., 1978). Early studies of
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VIP binding sites, carried out using a combination of ligand binding and
biochemical/immunological approaches, clearly indicated that considerable
heterogeneity existed amongst VIP receptors, both between tissues, and between
different species. However, the nature/cause of this apparent heterogeneity was less
clear, particularly in studies based solely on the determination of molecular weights of
the binding sites by SDS-polyacrylamide gel electrophoresis following ligand-receptor
crosslinking, since, as pointed out by Robberecht et al., 1990, it is difficult to
distinguish between variations due to differences in the receptor's intrinsic amino acid
structure, and those that might be due to altered levels of glycosylation or proteolysis.
In comparison, ligand-binding approaches produced results that were somewhat easier
to interpret, and it soon became apparent that several tissues, including rat kidney
(Magistretti et al., 1988), human normal and cancerous gastric mucosa (Gespach et al.,
1988), and mammalian lung (Dickinson et al., 1986; Schaffer et al., 1987), contain two
classes of receptor for VIP, comprising a high and a lower affinity binding site. Other
lines of evidence which suggested that multiple types of VIP receptors exist, included
the observation that in rat brain two distinct populations of VIP binding site can be
distinguished on the basis of their sensitivity to GTP (which promotes the dissociation
of ligands from G-protein-coupled receptors). The finding that in some regions of the
brain, VIP binding is much more sensitive to GTP than in other regions, seems to
indicate that two different types of VIP binding site exist, only one of which couples to
a GTP-sensitive G-protein, are present in brain. Indeed, in some areas such as the
olfactory bulb, the medial geniculate thalamic nucleus, the ventrolaterial thalamic
nucleus, and the pituitary, the vast majority of VIP binding was GTP-insensitive.
However at present, the basis of this differential sensitivity to GTP remains unclear.
Finally, it should also be noted that several reports on VIP-receptor interations have
described a VIP receptor, which binds the lizard-venom derived peptide helodermin
with a higher affinity than it binds VIP. This receptor, which is found on the human
SUP-T1 lymphoma cell line and some other neoplastic cell lines, is coupled to adenylate
cyclase, but displays a distinctly different binding profile for VIP and related peptides,
which results in the following order of potency: helodermin > PACAP-38 > PACAP-
27 > VIP (Christophe et al., 1993; Robberecht et al., 1996). In contrast to the situation
with the GTP-insensitive binding sites, the identity of the helodermin-preferring VIP
receptors is now clear and is discussed further in section 1.4.2.
1.2 Pituitary adenylate cyclase activating polypeptide (PACAP)
Despite the fact that PACAP was not identified until 19 years after the isolation of VIP,
characterisation of this peptide and its actions has progressed extremely rapidly, and has
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been greatly assisted by the fact that (in contrast to the situation with VIP, where there
were gaps of about 10 years between isolation of the peptide, the cloning of the VIP
gene and the cloning of VIP receptor cDNAs) the cloning of the PACAP gene (Ohkubo
et al., 1992), and the cloning of cDNAs encoding receptors for PACAP (Ishihara et al.,
1992; Lutz et al., 1993; Pisegna & Wank, 1993), have followed the isolation of this
peptide in fairly rapid succession .
1.2.1 PACAP, structure and distribution
PACAP exists in two post-translationally processed forms: a 38 amino acid amidated
peptide (PACAP-38) from sheep hypothalamus, that was initially isolated during a
search for novel peptides that could stimulate pituitary adenylate cyclase (Miyata et al.,
1989), and a C-terminally shortened form of this peptide, PACAP-27, which was
subsequently isolated from side fractions obtained during PACAP-38 purification
(Miyata et al., 1990). PACAP-27 and the corresponding N-terminal region of PACAP-
38 display 68% homology to the amino acid sequence of VIP, and were immediately
recognised as members of the secretin/glucagon peptide family. Structural studies of
PACAP indicate that it has conformation that is generally very similar to that of VIP and
other members of the secretin/glucagon subfamily (Wray etal., 1993; see 1.1.1).
However it has been suggested that the distinct biological activities of VIP and PACAP-
27 may be largely the consequence of a switch from Ala to Gly at amino acid 4 (Coy et
al., 1996; see also Figure 1.1), whereas in the case of PACAP-38, experiments
involving the generation of chimeric peptides have indicated that the C-terminal
extension 28-38 contains sequences that are important for binding affinity with regard
to PACAP-specific binding sites (but not those shared with VIP), and may help to
stabilise the peptide's structure (Gourlet et al., 1996a).
In mammals, PACAP has a relatively wide distribution within the CNS, where the
highest levels of this peptide are found in the hypothalamus (particularly the supraoptic
nucleus and paraventricular nucleus), and the median eminence (Christophe, 1993),
whereas lower levels can be detected in regions such as the hippocampus, frontal cortex
and cerebellum (Vertongen et al., 1992). Endocrine organs in which PACAP or
PACAP transcripts have been detected include the posterior lobe of the pituitary gland
and to a lesser extent the intermediated lobe (Kimura et al., 1994); the pancreas
(Arimura & Shioda, 1995); and the rat seminiferous tubules, in which PACAP mRNA
is expressed in a stage specific manner (Kononen et al., 1994). In the rat immune
system PACAP is found to be present in most lymphoid tissues, in which PACAP
immunoreactivity appears to be located mainly in lymphocyte-like cells (Gaytan et al.,
1994).
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1.2.2 Actions of PACAP
The presence of PACAP in the hypothalamus and median eminence, together with its
demonstrated actions in increasing intracellular cAMP in cultured pituitary cells,
strongly suggest that this peptide might have hypophysiotrophic actions. PACAP has
been shown to stimulate gonadotrophin release from perifused rat pituitary cells (Tsujii
et al., 1994), and has also been implicated in the promotion of pro-opiomelanocortin
peptide secretion from the AtT-20 corticotroph cell line (Braas et al., 1994), and
stimulation of IL-6 secretion from cultured rat astrocytes (Gottschall et al., 1994).
Other reported functions of PACAP include the stimulation of catecholamine secretion
from cells of the adrenal medulla (Watanabe et al., 1995), the promotion of glucose-
induced insulin secretion from the pancreatic islets (Bertrand et al., 1996), and a
possible involvement in the regulation of the early stages of spermatogenesis (Kononen
et al., 1994). Early studies of PACAP binding sites indicated that like VIP, the effects
of PACAP were mediated by G-protein coupled receptors, and also suggested that in
some tissues, particularly lung and liver, VIP and PACAP might share binding sites, a
factor that was to explain at least to some extent, the partially overlapping actions of
these peptides on some cells and tissues (Shivers et al., 1991).
1.3 The secretin/glucagon receptor subfamily
The rat secretin receptor was first cloned by Ishihara et al., in 1991, from an expression
library containing cDNA transcripts derived from the NG108-15 (neuroblastoma/glioma
hybrid) cell line, and from initial analysis of its cDNA and the deduced amino acid
sequence, was predicted to have a seven-transmembrane structure that was very similar
to that of the rhodopsin-like 7-TM G-protein coupled receptors. When expressed in
COS cells the cloned receptor bound iodinated secretin, and interacted with the alpha
subunit of Gs to activate adenylate cyclase. However, at the amino acid level, the
secretin receptor was found to show little or no homology to the sequences of
previously characterised members of the 7-TM G-protein coupled receptor superfamily
(which had generally been shown to display at least -20-30% homology to one
another), and it was therefore suggested that the secretin receptor represented a new
type of 7-TM G-protein coupled receptor (Ishihara et al., 1991).
As is often the case when clones encoding novel types of proteins are isolated, the
cloning of the rat secretin receptor sparked a search for related clones, which in this
instance were thought likely to encode other peptide receptors. Two main approaches
have been used in attempts to identify receptors that are related to the secretin receptor:
i) expression-based cloning methods, which at least initially were based on the theory
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(now substantiated) that peptides that are structurally related to secretin, i.e. the
secretin/glucagon family, would be strong candidates as ligands for these receptors
(Jelinek et al., 1993; Thorens, 1992); and ii) homology-based cloning involving either
low stringency hybridisation (often across species) of receptor cDNA clones to cDNA
and genomic libraries (Gremlich et al., 1995; Sreedharan et al., 1993), or a PCR-based
strategy using degenerate primers designed to bind to regions of the cDNA sequence
that (following the isolation of other receptors related to the secretin receptor) have been
found to be highly conserved in this G-protein coupled receptor subfamily (Lutz et al.,
1993; Mayo, 1992; Svoboda et al., 1994). As predicted, a considerable number of
clones encoding receptors with sequences related to that of the secretin receptor have
now been isolated, including clones encoding receptors for the glucagon/secretin
peptide family members: GHRH (Gaylinn et al., 1993; Mayo, 1992), glucagon (Jelinek
et al., 1993; Lok et al., 1994; MacNeil et al., 1994), GLP-1 (Dillon et al., 1993;
Graziano et al., 1993; Thorens, 1992), VIP (Ishihara et al., 1992; Lutz et al., 1993;
Sreedharan et al., 1993; Svoboda et al., 1994), PACAP (Hashimoto et al., 1993;
Hosoya etal., 1993; Morrow et al., 1993; Ogi etal., 1993; Pisegna & Wank, 1993;
Spengler et al., 1993; see also VIP receptor references above), and GIP (Gremlich et
al., 1995; Usdin et al., 1993; Volz etal., 1995; Yamadaeta/., 1995b). However,
somewhat surprisingly, very soon after the cloning of the rat secretin receptor, it
emerged that the calcitonin receptor (Lin et al., 1991) and the receptor for
parathyroid/parathyroid hormone related peptide (PTH/PTHrP; Jiippner et al., 1991)
have sequences that are similar to that of the rat secretin receptor (although the amino
acid sequences of these peptides do not display any significant homology to those of the
secretin/glucagon peptide family), and it has subsequently been shown that in addition
to the calcitonin and PTH/PTHrP receptors, the calcitonin gene related peptide (CGRP)
receptor, and corticotrophin releasing factor (CRF) receptor, also belong to the
secretin/glucagon 7-transmembrane G-protein coupled receptor subfamily (Aiyar et al.,
1996; Chen et al., 1993; Kapas & Clark, 1995; Lovenberg et al., 1995).
Other secretin-receptor-related clones that have been isolated include a rather unusual
group of molecules that have a seven transmembrane region very similar to those found
in members of the secretin/glucagon receptor subfamily, but also possess a greatly
extended N-terminal domain region that contains numerous epidermal growth factor¬
like modules. So far, two clones encoding this type of molecule have been isolated
from mammals: one of which encodes an EGF module-containing mucin-like hormone
receptor 1 (EMR1; Baud et al., 1995), whereas the other was found to encode an
activation-induced antigen (CD97) from leukocytes (Hamann et al., 1995). However,
as other unusual properties of these molecules have gradually emerged, for example,
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the requirement for intracellular processing of CD97 from its pro-protein form into a
noncovalently associated two-subunit structure (Gray et al., 1996), the perceived
relationship between these molecules and the glucagon /secretin receptor subfamily has
become more distant, and these molecules are now generally considered to form a new
receptor subgroup that is closely related but distinct from the secretin/glucagon receptor
subfamily.
All members of the secretin/glucagon receptor subfamily that have been cloned so far
have been found to be capable of stimulating adenylate cyclase through coupling to G$,
and many of them appear to be able to activate additional pathways that result in
increased intracellular calcium and inositol phosphate (reviewed by Segre & Goldring,
1993), although in most cases the details of the non-cAMP-mediated signalling
pathways and the G-proteins involved in them, are not yet clear. Structural features that
are shared by members of the secretin/glucagon receptor subfamily include the presence
of a hydrophobic putative N-terminal signal sequence, a relatively large N-terminal
extracellular domain containing at least 4 conserved cysteine residues (which are
thought to be critical for the correct structure of the ligand binding domain), and several
consensus sites for N-linked glycosylation (Laburthe et al., 1996). Particularly high
conservation of the amino acid sequences of the 3rd and 7th transmembrane domains
has also been noted (Lutz et al, 1993), and it has recently been reported that in
comparison with the rhodopsin family, the predicted structure of secretin/glucagon
subfamily receptors differs with respect to the relative positions of transmembrane
helices 2, 3, and 7 (Donnelly, 1997).
1.4 Cloned receptors for VIP and/or PACAP
To date, three types of receptors that bind VIP and/or PACAP have been cloned, two of
which bind both VIP and PACAP with approximately equal affinities, whereas the third
type of receptor displays a distinct preference for PACAP and has a much lower affinity
for VIP. Reports of the cloning of these three types of receptors were first published
within an -18 month period from April 1992- November 1993 (Ishihara et al., 1992;
Lutz et al., 1993; Pisegna & Wank, 1993), since which time no further types of
receptors for these peptides have been isolated, although pharmacological data relating
to the apparent GTP-insensitivity of some VIP receptors (Hill et al., 1992) has been
used to argue that additional receptors for VIP exist (Gressens et al., 1994; see Chapter
5 section 5.4.6 for further discussion of this issue).
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1.4.1 The VIPi receptor
The VIPi receptor (the first of the VIP/PACAP receptors to be cloned) was initially
isolated from a rat lung cDNA library by low stringency hybridisation using the rat
secretin receptor cDNA as a probe (Ishihara eta/., 1992). The isolated clone which
was found to encode a 459 amino acid protein (with a putative 30 amino acid N-
terminal signal sequence), shares the predicted 7-transmembrane topology of the
secretin receptor, and following expression of the clone in mouse COP cells the
receptor was found to bind both VIP and PACAP with high affinity. In COSGsl cells,
this receptor, latter named the VIPi receptor, was found to stimulate increases in cAMP
levels in response to PACAP-38, PACAP-27, and VIP (EC50 of VIP within this
system = 0.57 nM), and also responded to helodermin, PHM , and secretin, although
these peptides displayed significantly lower potencies than VIP or PACAP (Ishihara et
al., 1992). Studies of the VIP] receptor's distribution, carried out in parallel with the
initial characterisation of the rat cDNA clone, indicated that transcripts encoding the
VIPi receptor are found predominantly in the lung, liver, intestine, and are present at
lower levels in the thymus. Relatively high levels of Viprl transcripts were also
detected in certain regions of the brain, especially the hippocampus, the mitral layer of
the olfactory bulb, and the neurons of the cerebral cortex (Ishihara et al., 1992). Later
investigations (including those on the human homologue of this receptor) have largely
confirmed this distribution pattern, whilst indicating that transcripts encoding the VIPi
receptor are also present in other cells and tissues, such as the heart, vas deferens, some
areas of the kidney, the walls of pancreatic blood vessels, the uterus, the adrenal
medulla, Raji B-lymphoblasts and both stimulated and unstimulated T-cells (Delgado et
al., 1996b; Sreedharan et al., 1993; Usdin et al., 1994; Wei & Mojsov, 1996).
A cDNA encoding the human homologue of the rat VIPi receptor, was isolated by
hybridisation screening of a human colonic adenocarcinoma HT29 cDNA library (again
using a secretin receptor cDNA derived probe), and has been found to encode a protein
that displayed 84% homology to the rat VIPi receptor at the amino acid level
(Sreedharan et al., 1993). When stably-transfected into Chinese hamster ovary (CHO)
cells or human embryonic kidney (HEK) cells the VIPi receptor was found to be able
to couple to two distinct signalling pathways, one leading to the increase in intracellular
cAMP that is characteristic of receptors of the secretin/glucagon subfamily, and the
other leading to increases in intracellular calcium (Sreedharan et al., 1994).
Actions of VIP and PACAP in which the VIPj receptor has been implicated include: the
inhibition by VIP and PACAP of glucocorticoid-induced apoptosis of rat CD4+ CD8+
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thymocytes (Delgado et al., 1996a); inhibitory effects of VIP on the chemotaxis of the
VIPl receptor expressing human T-cell line HuT 78, a process which in contrast is
stimulated in cells expressing the VIP2 receptor (Xia et al., 1996a); and possibly, the
modulation of the responsiveness of dorsal horn neurons to sensory stimuli (Dickinson
et al., 1997).
1.4.2 The VIP2 receptor
The cDNA encoding the rat VIP2 receptor was first isolated from rat pituitary and
olfactory bulb by Lutz et al., and contains an open reading frame (ORF) of 437 amino
acids which includes a 22 amino acid hydrophobic signal sequence at the N-terminal
end (Lutz et al., 1993). Comparison of the predicted amino acid sequence of this
receptor with those of other members of the secretin/glucagon receptor subfamily
reveals that it is most closely related to the VIPl receptor and the PACAP type 1
receptor with which it shares -50% homology at the amino acid level (Lutz et al.,
1993). However, the N- and C- terminal ends of these receptors display a high level of
divergence, and although, like the VIPl receptor, the VIP2 receptor binds both VIP and
PACAP with high affinity, the order of potency of VIP, PACAP and related peptides
for cAMP production in COS cells transfected with the rat Vipr2 cDNA is: VIP -
PACAP-27 - PACAP-38 - helodermin > PHI » rat GHRH (Lutz et al., 1993). Thus,
in contrast to the VIPl receptor where helodermin is less potent than VIP in stimulating
the accumulation of cAMP (Ishihara et al., 1992), VIP and helodermin appear to be
approximately equipotent at the VIP2 receptor. Other notable differences between the
potencies of ligands at the VIPl ar)d VIP2 receptors, include: the complete insensitivity
of the VIP2 receptor to secretin (Usdin et al., 1994), a peptide which at the VIPl
receptor results in increases in cAMP albeit with a potency that is approximately 30-
100 fold less than that of VIP (Ishihara et al., 1992; Usdin et al., 1994); and the
observation that higher concentrations of VIP, PHI, and PACAP-38 are necessary for
VIP2 receptor activation than for activation of the VIPl receptor (Usdin et al., 1994).
Studies of the tissue distribution of mRNA transcripts encoding the rat VIP2 receptor
(encoded by the Vipr2 gene) have demonstrated that mRNA for this receptor is present
at relatively high levels in the suprachiasmatic nucleus, thalamus, hippocampus, the
internal granular layer of the olfactory bulb, and several hypothalamic nuclei (Lutz et
al., 1993; Sheward et al., 1995; Usdin et al., 1994). Vipr2 transcripts are also found at
moderate levels in many other areas of the CNS, particularly the midbrain and
brainstem, and are present in several endocrine tissues, including: the pituitary
(especially the anterior lobe, where the density of Vipr2 transcripts rises dramatically
during pregnancy), pancreatic islets, ducts and spermatocytes within the testes,
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granulosa cells of the ovary, the pineal gland, the adrenal cortex, and the medulla and
cortex of the thymus, a distribution that has led to the proposal that the VIP2 receptor
may mediate the neuroendocrine effects of VIP (Usdin et al., 1994). Indeed, in many
tissues, and particularly in the CNS (Usdin et al., 1994), the distribution of the Vipr2
transcripts appears to be complementary to that of the Viprl transcripts , and it is
interesting to note that in addition to its prevalence in neuroendocrine tissues, the VIP2
receptor appears to be the only one of the cloned VIP or PACAP receptors (i.e. the
VIPi, VIP2, and PACAP type I receptors) for which transcripts have been detected at
significant levels in skeletal muscle (Wei & Mojsov, 1996), and is also the only VIP
receptor that is present at significant levels in the stomach and duodenum (Usdin et al.,
1994).
Clones encoding the mouse and human homologues of the rat VIP2 receptor have also
been isolated (Inagaki et al., 1994; Svoboda et al., 1994), and in each instance the
cellular origin of the cDNA library from which the clone was isolated has pointed to
previously characterised functions of VIP in which the VIP2 receptor has later been
implicated.
The cDNA encoding the mouse VIP2 receptor (also known as PACAPR3) was initially
isolated (using PCR-based methods) from a cDNA library that was derived from the
mouse insulin-secreting (3-cell line MIN6, and (in agreement with the pancreatic islet
expression of rat Vipr2 mRNA later described by Usdin et al., 1994, see above) has
been shown to be present in mouse pancreatic islets and several other insulin secreting
cell lines (Inagaki et al., 1994). Like the rat VIP2 receptor, the mouse VIP2 receptor is
positively coupled to cAMP signalling pathways (EC50 of VIP = 3.2 nM in COSGsl
cells). However, following the expression of the Vipr2 clone in Xenopus oocytes,
PACAP-27, PACAP-28, and VIP, at 0.1 nM, have been found to be capable of
stimulating calcium-activated chloride currents, an observation which led to the still
somewhat controversial suggestion that the mouse VIP2 receptor can be coupled to
phospholipase C (PLC) signalling pathways in some systems (Inagaki et al., 1994).
Nevertheless, although there have been no other reports of recombinant VIP2 receptors
coupling to PLC in cell lines, PACAP-38 has been shown to stimulate insulin secretion
in the MIN6 cell line from which the mouse VIP2 receptor was cloned (Inagaki et al.,
1994), and there is now substantial evidence to indicate that the VIP2 receptor mediates
the effects of VIP and PACAP on glucose-induced insulin secretion (as indicated by the
approximately equipotent effects of VIP and PACAP, but the failure of secretin to
stimulate insulin secretion; Bertrand et al., 1996), which in addition to increases in
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cAMP and intracellular calcium, involves a novel signalling pathway that is sensitive to
the phosphatidylinositol 3-kinase inhibitor wortmannin (Straub & Sharp, 1996).
While the isolation of the mouse VIP2 receptor prompted new studies on the actions of
VIP and PACAP in the stimulation of insulin secretion, the isolation and
characterisation of the human homologue of this receptor (Svoboda et al., 1994) has
indicated that other aspects of VIP's actions in which the VIP2 receptor might play an
important role, are the modulation of the immune system and the regulation of cell
growth. Indeed, it seems that as suggested by Svoboda et al., the human VIP2
receptor, which was cloned (using a method based on low stringency PCR) from
cDNA derived from the human CD4+ T-cell lymphoma cell line SUP-T1, is in fact the
receptor that was previously described as the 'helodermin-preferring VIP receptor (see
section 1.2.3; Christophe et al., 1993; Robberecht et al., 1988), and thus by inference
the human VIP2 receptor is likely to be present on several other cancer cell lines
including the human THP-1 monocyte/macrophage cell line, the human lung carcinoma
small cell line NCJ-H345, and the B16 mouse melanoma cell line (reviewed by
Christophe et al., 1993; Robberecht et al., 1990). Moreover, as it has been suggested
that in some cases receptors with helodermin-preferring binding characteristics are
revealed in malignant cell lines, but are virtually undetectable in the corresponding
normal tissues (Robberecht et al., 1990), it is interesting to note that in CD4+ and
CD8+ T-lymphocytes, expression of transcripts encoding the VIP2 receptor is only
induced following stimulation through the T-cell receptor-associated CD3 molecule,
whereas in cell lines representing immature thymocytes and T-helper 2 cells, transcripts
encoding the VIP2 receptor have been shown to be present at significant levels, and are
the only VIP receptor transcripts detected (Delgado et al., 1996b).
Other actions of VIP and PACAP, in which the VIP2 receptor has been implicated to
date include: i) the inhibitory effects of VIP (and to a lesser extent PACAP) on
interleukin-2 (IL-2) production by CD4+ T-lymphocytes (Tang et al., 1996), in which a
role for the VIP2 receptor has been indicated by the ability of the recently characterised
selective VIP2 receptor agonist Ro 25-1553 (a synthetic VIP analogue; Gourlet et al.,
1997) to inhibit IL-2 production (Tang et al., 1995); ii) the effects of PACAP in the
regulation of testicular germ cell protein synthesis (West et al., 1995) and its (proposed)
role in early spermatogenesis (Kononen et al., 1994), which are thought to be mediated
solely by VIP2 receptors (since transcripts encoding the VIPi and PACAP type I
receptors cannot be detected by RT-PCR in the germ cells; Krempels et al., 1995); and
iii) the recently reported antiproliferative effect of VIP and PACAP on the T98G human
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glioblastoma cell line, a cell line which appears to express Vipr2 transcripts but not
those encoding the VIPi or PACAP type I receptors (Vertongen et al., 1996).
As the principal cytokine responsible for T-cell proliferation, IL-2 is an important target
for the action of immunosuppressive drugs (reviewed by Cavalieri, 1996). Therefore
elucidation of the pathways by which VIP causes inhibition of IL-2, and in particular
the possible effects of the VIP/PACAP system on calcineurin (a calcium/calmodulin
regulated protein phosphate implicated in pathways leading to IL-2 gene expression;
Batiuk et al., 1997) will be important, as it may suggest new ways in which IL-2 levels
can be modulated. Similarly, the characterisation of the modes by which the VIP2
receptor acts to regulate insulin secretion and the regulation of cell growth, could also
potentially open new therapeutic possibilities for diabetes and cancer respectively.
Nevertheless, although of great interest, it seems almost certain that the functions of the
VIP2 receptor that have been characterised to date, represent only a small fraction of the
number of processes in which this receptor will eventually be shown to act. The
generally low levels of Vipr2 gene transcripts even in tissues where the transcripts are
most abundant (Usdin et al., 1994) is likely to have hindered, at least to some extent,
attempts to correlate the distribution of this receptor with its possible functions, but as it
is now becoming increasingly apparent that in some cells and tissues Vipr2 expression
is developmentally regulated (e.g. in the testes) and/or can be dramatically induced
under certain conditions (e.g. upon T-cell activation or during lactation), critical clues to
the identity of the stimuli responsible for increasing Vipr2 expression levels might be
gained from examination of the Vipr2 gene's promoter region.
1.4.3 The PACAP type I receptor
The cDNA encoding the rat PACAP type I receptor was first isolated by Pisegna and
Wank (1993), who used a rat Viprl cDNA probe to screen a cDNA library constructed
from the rat pancreatic acinar carcinoma cell line AR4-2J. Characterisation of the
isolated cDNA clone revealed that it contained an open reading frame that is predicted
to encode a protein of 495 amino acids (including a 19 amino acid N-terminal signal
sequence), and displays 50% identity to the rat VIP) receptor at the amino acid level
(Pisegna & Wank, 1993). Following transfection of the Pacaprl cDNA into COS-7
cells, comparative studies of possible ligands for this receptor demonstrated that
PACAP-38 and PACAP-27 acted approximately equipotently in the stimulation of the
accumulation of intracellular cAMP through this receptor (EC50 0.6-1.6 nM), whereas
VIP and secretin had little effect. Thus, in contrast to the characteristics of the VIPl
and VIP2 receptors, where VIP and PACAP have similar potencies to one another, the
AR4-2J derived receptor displayed a very definite preference for PACAP, and in
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recognition of this was named the PACAP type I receptor. Within weeks of the
publication of the rat Pacaprl cDNA sequence, four other laboratories also published
the sequences of the PACAP type I receptor (Hashimoto et al., 1993; Hosoya et al.,
1993; Morrow et al., 1993; Spengler et al., 1993), which in one case (Spengler et al.,
1993) included a report of the isolation of 5 splice variants of the receptor (with
sequence alterations in the region encoding the receptor's third intracellular loop). In
contrast to the VIPj and VIP2 receptors, the PACAP type I receptor has been shown to
be capable of stimulating both intracellular cAMP and inositol triphosphate (IP3)
accumulation when the receptor is stably transfected into CHO cells (Delporte et al.,
1995). However as splice variation in this receptor has been shown to be tissue-
specifically and developmentally regulated (D'Agata et al., 1996), the discovery that the
expression of different variants of the PACAP type I receptor leads to changes in both
ligand recognition and G-protein coupling (Spengler et al., 1993), indicates that splice
variation is likely to represent an additional level at which the end result(s) of this
receptor's action can be modulated.
Studies of the distribution of the the PACAP type I receptor and its transcripts indicate
that in the CNS this receptor is abundant in many regions, including: the gray matter of
the spinal cord, several hypothalamic nuclei (particularly the supraoptic and
paraventricular nuclei), thalamus, olfactory bulb, brainstem, cerebral cortex,
cerebellum, hippocampus, and basal ganglia, whereas in the endocrine system
transcripts encoding this receptor are prevalent in the anterior pituitary, the pineal gland,
the adrenal medulla, pancreas, and testicular spermatids (see Arimura & Shioda, 1995;
Christophe, 1993; Spengler et al., 1993). Thus, it appears that each of the receptors for
PACAP and/or VIP (i.e. the VIPl, VIP2 and PACAP type I receptors) has a different
distribution (and probably also different functions) within the nervous system, although
a considerable degree of overlap in these patterns exists in some cells and tissues.
Functions of VIP and PACAP in which the PACAP type I receptor has been implicated
to date, include: the regulation of sympathetic neuron catecholamine secretion (Braas &
May, 1996), and mediation in the hypothalamic tract of the phase-shifting effects that
dark pulses during the daytime have on the circadian clock (Hannibal et al., 1997).
1.5 Aims
The main aim of the work presented in this thesis was to isolate and characterise mouse
genomic clones encoding the VIP2 receptor, as in the absence of suitable antagonists
that are specific for the VIP2 receptor, the production of transgenic Vipr2-nu\\ mice is
currently the most promising approach to the determination of the functions of this
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receptor. However, as the process of isolating clones suitable for use in transgenic
constructs, was likely to include the isolation of clones containing the 5' flanking
sequences of the Vipr2 gene, it was also hoped that by studying the promoter region, it
would be possible to identify some of the factors that might be responsible for
regulating the tissue-and cell-restricted expression patterns of this gene.
In view of the role of VIP in the regulation of cell growth and survival, the isolation of
a human clone encoding the VIP2 receptor, and the subsequent determination of the
localisation of the gene in mouse and human, was also a major aim of this study, as this
would greatly assist the identification of any previously mapped mouse or human




2.1 Isolation and purification of plasmid DNA
2.1.1 Plasmid minipreps
Standard SDS-alkaline lysis method
A single bacterial colony was used to inoculate 3 ml of L-broth (containing the
appropriate antibiotic), and the culture was grown overnight in a 37°C incubator with
gentle shaking. The bacterial cells were collected in an Eppendorf tube by
centrifugation at 10,000g for 5 minutes in a microcentrifuge. The supernatant was
removed, and the cells were then resuspended in 100 pi of alkaline lysis solution 1 (see
2.5.2). Alkaline lysis solution 2 (200 pi; see 2.5.2) was then added to the cell
suspension, and the tube contents were mixed by rapidly inverting the tube. After the
tubes had been incubated on ice for 5 minutes, to allow cell lysis to occur, 150 pi of ice
cold alkaline lysis solution 3 (see 2.5.2) was added, and the reactions were mixed by
flicking the tubes. A further 5 minute incubation on ice was followed by centrifugation
at 10,000g for 7 minutes, and the supernatant (-400 pi) was then transferred to a fresh
tube where it was mixed with an equal volume of phenolxhloroform, and centrifuged
for 2 minutes at 10,000g in a microcentrifuge. The supernatant was carefully removed
and transferred to another Eppendorf tube. Two volumes of ethanol were added to the
supernatant to precipitate the DNA, and after a 2 minute incubation at room temperature,
the precipitated DNA was collected by centrifugation at 10,000g for 5 minutes. The
DNA pellet was then washed in 70% ethanol, dried at 37°C for 5-10 minutes, and was
finally resuspended in 50 pi of TE (pH 8.0) containing 20 pg/ml RNase A (50
units/mg; Boehringer Mannheim).
SDS-alkaline lysis/PEG precipitation method
This method was used to isolate plasmids for automated fluorescent sequencing, prior
to the availability of Wizard™ 373 DNA purification kits (Promega). The SDS-alkaline
lysis section of the protocol is almost identical to that described above, with the
exception of the addition of an RNase A step (final concentration 20 pg/ml, 20 minute
incubation at 37°C). However, following ethanol precipitation of the plasmid DNA ,
the dried DNA pellet was resuspended in 33.6 pi of ddH20, and then precipitated using
6.4 pi of 5M NaCl and 40 pi of 13% PEG. The precipitation reaction was mixed
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briefly and then left on ice for 20 minutes, after which the DNA was pelleted by
centrifugation at -12,000 rpm (10,000g) in a microcentrifuge for 15 minutes at room
temperature. The supernatant was carefully removed using a glass Pasteur pipette, and
the pellet was washed with 70% ethanol, air dried at room temperature, then dissolved
in 20 |ill of ddH20. To estimate the volume of miniprep DNA that would be needed for
a sequencing reaction, a 2 |xl aliquot of the plasmid DNA was run on an agarose
minigel, alongside plasmid DNA of known concentration
Wizardr™ 373 plus DNA purification system (Promega)
This commercial kit is specifically designed to be used to isolate plasmid miniprep DNA
for use in automated sequencing reactions for the Applied Biosystems (ABI) 373
sequencer. Although the kit was not available at the start of this project, it replaced the
modified SDS-alkaline lysis/PEG precipitation method during the later stages of this
work, and was used in the preparation of template DNA from most of the plasmid
subclones of the mouse Vipr2 gene.
Plasmid DNA was prepared according to the manufacturer's instructions for the
isolation of high copy number plasmids (although a vacuum manifold was not
available), and the plasmid DNA was eluted from the Wizard column by the addition of
100 p.1 of ddH20 (preheated to 65°C). The volume of plasmid DNA solution that was
recovered following purification using a Microcon™-100 microconcentrator (Amicon)
ranged from 4 -50 jxl, but in all cases the final volume was made up to at least 20 p.1
with ddH20, and (after 2 |il had been checked on an agarose minigel) 0.5-5 pi of DNA
was generally used in each sequencing reaction.
2.1.2 Plasmid maxipreps
Alkaline lysisfollowed by equilibrium ultracentrifugation in a caesium chloride-
ethidium bromide gradient
A 2 ml overnight bacterial culture (grown from a single bacterial colony grown in L-
broth + 50 fig/ml ampicillin) was used to inoculate 500 ml of media (L-broth + 50
|Ltg/ml ampicillin), which was in turn grown overnight at 37°C in an orbital shaker.
Plasmid DNA was then isolated according to Treisman's alkali lysis method for the
large scale preparation of plasmid DNA (published in Sambrook et al., 1989), and the
DNA was subsequently purified by equilibrium centrifugation in a CsCl-ethidium
bromide gradient.
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The bacterial cells from the 500 ml culture were collected by centrifugation at 6000 rpm
for 10 minutes in a Sorvall GSA rotor at 4°C, and the cell pellet was then resuspended
in 18 ml of alkaline lysis solution 1. Following the addition of 40 ml of alkaline lysis
solution 2, the contents of the centrifuge bottle were mixed by inversion and left at
room temperature for 5-10 minutes. Ice cold alkaline lysis solution 3 (20 ml) was then
added, and the bottle was shaken vigorously, then left on ice for 10 minutes. After
centrifugation at 6000 rpm for 15 minutes in a Sorvall GSA rotor at 4°C, the rotor was
stopped without braking, and the supernatant was filtered through 4 layers of
cheesecloth, into a clean centrifuge bottle. Isopropanol (0.6 of a volume) was mixed
with supernatant to precipitate the DNA, and following a 10 minute incubation at room
temperature, the DNA was pelleted by centrifugation at 8000 rpm for 15 minutes at
room temperature (Sorvall GSA rotor). The DNA pellet was washed with cold 70%
ethanol, dried, and then resuspended in 3 ml of TE.
To prepare the DNA for equilibrium centrifugation in a CsCl-ethidium bromide
gradient, the DNA solution was transferred to a 10 ml total volume of the DNA sample
was made up to exactly 4 ml with TE. Ethidium bromide (400 |ll of a 10 mg/ml stock
solution) and CsCl (4.4 g) were then dissolved in the DNA solution, and the tube was
left on ice for 5-10 minutes to allow protein to precipitate. After centrifugation at 2000
rpm for 5 minutes in an MSE Chilspin centrifuge (Fisons), a Pasteur pipette was used
to carefully transfer the supernatant to a 6 ml polyallomer quick seal ultracentrifuge tube
(Sorvall® Instruments). The tube was then topped up with balance solution (400 jllI of
ethidium bromide + 4.4 g of CsCl + 4 ml TE), sealed, and centrifuged (together with a
balance tube if necessary) overnight at 45,000 rpm in a TV-1665 rotor (Sorvall
ultracentrifuge) at 20°C. Plasmid DNA (the lower of the two bands) was removed
using a 19-gauge needle and a 2 ml disposable syringe, and the ethidium bromide was
removed from the solution by repeated extraction with an equal volume of
isopropanol/H20/CsCl (1:1 isopropanol:H20, saturated with CsCl). The lower
(aqueous) layer was then transferred to a 15 ml disposable plastic tube, where 0.3 ml of
sodium acetate (pH 5.2) was added, and the total volume of the solution was made up
to 3 ml with ddH20. Ethanol (6 ml) was then added, and the tube was left at -20°C for
1-2 hours to allow the DNA to precipitate. The DNA was collected by centrifugation at
2000 rpm for 10-15 minutes in a Fisons MSE Chilspin centrifuge, dried, and then
dissolved in TE. The DNA was then reprecipitated, washed in 70% ethanol, and was
finally resuspended in 0.5-1 ml of TE.
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Qiagen plasmid maxi kit (Qiagen Ltd)
Qiagen plasmid maxi kits (Qiagen Ltd.) were generally used in situations where DNA
from only 1 or 2 different plasmids was required. Plasmid DNA was prepared from a
250 ml overnight culture of bacteria, according to the manufacturer's instructions for
the isolation of high copy number plasmids, and was found to be comparable in quality
to that obtained following CsCl-ethidium bromide gradient ultracentrifugation of
plasmid DNA.
2.2 Manipulation of purified DNA
2.2.1 Restriction enzyme digestion of DNA
Restriction enzymes used in these studies were purchased from Promega Ltd. and
Boerhinger Mannheim Ltd.
Unless otherwise stated, restriction enzyme digests of plasmid DNA or PCR products,
were generally set up in a total reaction volume of 20-30 pi containing: 0.5-1.5 pg of
DNA, 5-10 units of restriction enzyme, and ddH20. The reaction components were
mixed by vortexing, spun briefly in a microcentrifuge, then incubated at 37°C for 3-12
hours. If removal of the restriction enzyme(s) was necessary for subsequent
manipulations, a Magic™AVizard™ DNA clean-up kit (Promega) was used (according
to the manufacturer's instructions) to purify the restriction fragments. Digested DNA
that was not to be used immediately, was stored at -20°C until required.
2.2.2 Agarose gel electrophoresis of DNA
Agarose gels (0.8-1.5% w/v) were prepared using Ultrapure agarose (Gibco-BRL),
and contained lx Tris-borate EDTA (TBE), which was also used as the running buffer.
However, in cases where a Geneclean II® kit (BIO 101 Inc.; see 2.2.3) was to be used
to isolate DNA from the gel, Tris-acetate EDTA (TAE) was used in the gel and as the
running buffer (final concentration lx), since this avoided the need for the use of the
Geneclean TBE modifier.
The agarose was dissolved in the electrophoresis buffer, by heating (4 minutes at
medium power in a microwave oven), and once the solution had cooled to about 60°C,
ethidium bromide (10 mg/ml stock solution) was added to a final concentration of 1
pg/ml. Agarose minigels (30 ml), were set up and mn using Horizon® 58 minigel kits
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(Gibco/BRL). Standard agarose gels (100 ml) were poured in 11x13.9 cm gel trays
with 14 well combs, and were run in horizontal tanks for submerged gel electrophoresis
(Gibco/BRL).
DNA samples were mixed with loading dye (see 2.5.1) prior to loading, and were run
alongside DNA molecular weight markers. The DNA markers used were either Hind
III digested lambda DNA restriction fragments, or a 1 kb DNA ladder (Gibco-BRL).
Electrophoresis was carried out at room temperature using a voltage gradient of 1-4
volts/cm. Gels were then examined on a UY transilluminator, and photographed as
described in 2.3.5.
2.2.3 Isolation of gel slices
Following the separation of DNA fragments (restriction fragments or PCR products) by
electrophoresis on agarose gels, a sterile razor blade was used to excise gel slice(s)
containing any DNA fragments that were required for further experiments. Excision of
the gel slice(s) was carried out on a UV transilluminator (in the minimum time
possible), and after any excess agarose had been cut away, each agarose embedded
DNA fragment was transferred to a separate 1.5 ml Eppendorf tube. If at all possible,
the DNA was extracted from the gel slices immediately (see 2.2.4), but when this was
not feasible, the Eppendorf tubes containing the slices were wrapped in tinfoil and
stored at -20°C.
2.2.4 Extraction of DNA from agarose gel slices
Extraction of DNA from agarose gel slices was carried out using either a Geneclean II®
kit (BIO 101 Inc.) or a QIAEX gel extraction kit (Qiagen Ltd.). The QIAEX kit was
used in the vast majority of experiments, and was generally preferred to the Geneclean
II® kit, as it allowed the use of TBE buffer in the gel without the necessity for
additional steps during DNA extraction. The kits were used according to the
manufacturers' instmctions, and the DNA was eluted from the silica gel/matrix by the
addition of 20-30 |ll of TE or ddH20.
2.2.5 Preparation of plasmid vector DNA for subcloning
Plasmid vector DNA (5 |lg) was linearised by digestion with the appropriate restriction
enzyme(s) in a total reaction volume of 50 fil (containing: lOx restriction enzyme
reaction buffer, 30-50 units of restriction enzyme, and ddH20) at 37°C for 2-3 hours.
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In cases where digestion of the vector DNA had produced DNA ends that were
compatible with one another (and could potentially recircularise during ligation
reactions), the 5' ends of the linearised vector DNA were dephosphorylated to prevent
intramolecular ligation. Twenty eight microlitres of linearised vector DNA was added
to 16 pi of ddH20, 5 pi of calf intestinal alkaline phosphatase (CIAP) buffer
(Boehringer Mannheim), and 1 pi of CIAP (molecular biology quality, ca. 20xl()3
units/ml; Boehringer Mannheim). The dephosphorylation reaction was incubated for 30
minutes at 37°C, after which the reaction was terminated by the addition of EDTA to a
final concentration of 5 mM.
The linearised DNA was separated from any residual supercoiled plasmid DNA, by
electrophoresis through a 0.8% agarose lx TAE gel. A gel slice containing the linear
vector DNA was cut from the agarose gel, and the DNA was isolated from the gel slice
using a QLAEX gel extraction kit (Qiagen Ltd.). A few microlitres of the QIAEX
isolated DNA was then checked on an agarose minigel (alongside DNA markers) to
estimate the final concentration of the vector DNA.
2.2,6 Ligation reactions/subcloning
Insert DNA for use in subcloning was usually prepared by electrophoretic separation of
the DNA of interest on an agarose gel, followed by QIAEX extraction of DNA from a
gel slice, or when electrophoretic separation of the DNA product(s) was not required,
purification of the DNA using a Magic™AVizard™ DNA clean-up kit (Promega).
Ligation reactions were generally set up in a total reaction volume of 10 pi containing:
100-200 ng of linearised vector DNA, insert DNA (to give a 2:1 molar ratio of
insert:vector DNA), 1 pi of T4 DNA ligase buffer (Promega), 1 pi (1 unit) of T4 DNA
ligase (Promega), and ddPQO to 10 pi.
PCR products were ligated into pGEM®-T vector (Promega; see section 2.6 for vector
map), using pGEM-T vector system I (Promega), according to the manufacturer's
instructions.
Depending on the facilities available, ligation reactions were either incubated in a water
bath at 12°C in the cold room overnight, or were started in a beaker of water (10°C ) in
an ice bucket and then left to revert to room temperature overnight. The reactions were
then spun briefly in a microcentrifuge, and if necessary, stored at 4°C until required.
Half of the ligation reaction (5 pi) was used to transform 200 pi of competent cells (see
2.4.3).
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2.3 Analysis of purified DNA
2.3.1 Southern blotting
Two methods of Southern blotting were used:
DNA transfer under high salt conditions (neutral pH)
This method was used for Southern blotting of the AEMBL3 G4 clone, the subclones
of this lambda clone, and the bacteriophage PI VIPR2 clone (Chapters 3 and 4; see
section 2.6 for vector maps). Restriction enzyme digests of DNA from the clones were
run on an agarose gel (0.8-1.0% agarose, lx TBE pH 8.3, 1 flg/ml ethidium bromide),
which was photographed prior to blotting. The agarose gel was then placed in a small
plastic box containing depurination solution, and was incubated in this solution for 15
minutes at room temperature with gentle shaking. After removal of the depurination
solution, the gel was rinsed briefly with ddH20, and was then soaked in denaturing
solution for 30 minutes at room temperature (again with gentle shaking). Another brief
rinse with ddH20 was then followed by the addition of neutralisation solution, and the
gel was then left on the shaker at room temperature for at least 30 minutes (during
which time the original batch of neutralisation solution was replaced with fresh solution
after about 15 minutes). Details of the depurination, denaturation, and neutralising
solutions are given in section 2.5.
A piece of Genescreen Plus nylon membrane (DuPont/NEN) was cut to the size of the
agarose gel, and left to soak in lOx SSC for 15 minutes. DNA from the neutralised gel
was then transferred to the nylon membrane by capillary blotting, using lOx SSC as the
transfer solution. Standard transfer apparatus and procedures (Sambrook et al., 1989)
were employed, and the assembled blot was left for at least 12 hours to allow transfer to
take place. Once the transfer apparatus had been disassembled, the nylon membrane
was washed in 0.4 N NaOH for 30-60 seconds, after which it was transferred to a
solution consisting of 0.2 M Tris and 2x SSC, and left there for 2-3 minutes. The
membrane was then left to air dry at room temperature, before being placed between 2
pieces of 3MM paper (Whatman) and baked at 80°C for 1.5 hours to immobilise the
transferred DNA.
DNA transfer under alkaline conditions
For all Southern blots of the X2001 Vipr2 clones and subclones (Chapters 3 and 6; see
section 2.6 for vector map), alkaline transfer conditions were used with Appligene
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Positive™ nylon membrane (Appligene Oncor). Restriction enzyme digests of the
clones were run on agarose gels, and photographed prior to blotting, as described in the
previous method for DNA transfer under high salt conditions. The gel was then
denatured in a solution of 0.4 N NaOH, for 30 minutes with gentle shaking at room
temperature.
Standard capillary transfer Southern blot apparatus (Sambrook et al., 1989) was used to
transfer the DNA onto the membrane, and 0.4 N NaOH was used as the transfer
solution. Once the blot had been set up, it was left for 8-12 hours to allow transfer to
occur, after which the blot was disassembled, and the membrane was rinsed in 2x
SSC. The membrane was then either transferred immediately into prehybridisation
solution, or was placed in a small zip-seal plastic bag with a few millilitres of 2x SSC
and stored at 4°C until required.
Prehybridisation and hybridisation ofSouthern blots
Prehybridisation and hybridisation of Southern blots was carried out in sealed plastic
bags which were placed in a box of water on a shaking table in a large incubator. The
incubator, water, prehybridisation solution and wash solutions were preheated to the
appropriate prehybridisation or wash temperature(s), and were then maintained at that
temperature until required.
Blots were prehybridised and hybridised in 20 ml of a solution containing : 50%
formamide (deionised), 5x Denhardt's reagent, 0.5% SDS, and 100 |Llg/ml herring
testis DNA (sheared and denatured). After the blot had been prehybridised for at least 1
hour, the radiolabelled probe (see 2.3.2) was added to the prehybridisation solution,
and hybridisation of the probe to the membrane was then allowed to occur overnight.
Prehybridisation and hybridisation were carried out at 45°C unless otherwise stated,
and after removal of the hybridisation solution, the membranes were usually washed at
55°C, first in a solution of 2x SSC, 0.1% SDS (2 washes, 20-30 minutes each), then
in a solution of 0.2x SSC, 0.1% SDS (2 washes, 20 minutes each). However,
variations were made in the duration and temperature of the wash steps in some cases
where the radioactive signal from the membrane was particularly weak or strong. The
washed membranes were left to air dry at room temperature, then wrapped in clingfilm
and exposed to Fuji RX film (Fuji) in an autoradiography cassette with two intensifying
screens. The exposure times (which ranged from a few seconds to 24 hours) and
temperatures employed (-70°C or room temperature) depended upon the strength of the
radioactive signal (as judged using a Geiger counter).
-26-
2.3.2 Preparation, radiolabelling, and purification of probes
Probes for blots and library screens were prepared from agarose gel slices (1 x TAE gel)
containing the appropriate DNA restriction fragment or PCR product (which in most
cases was derived from the rat Vipr2 cDNA). The DNA was isolated from the gel
slices using either a QIAEX gel extraction kit (Qiagen Ltd.) or in a few cases a
Geneclean II® kit (BIO 101 Inc.), and was eluted in 20-40 fil of ddH20. A small
volume (2-4 pi) of the purified DNA was then run alongside DNA markers (1 kb DNA
ladder, Promega) on an agarose mini gel, so that the concentration of the DNA could be
estimated, and 50-100 ng of DNA was then radiolabelled with oc-32p dCTP (3000
Ci/mmol; from either Amersham or DuPont/NEN).
During the early work that was carried out on the XEMBL3 G4 Vipr2 clone (Chapter
3), probes for blots and plaque screens, were labelled by primer extension (using
hexanucleotide primers of random sequence) according to the method of (Feinberg &
Vogelstein, 1983). However, all probes used during studies of the ?i2001 Vipr2
clones, subclones (Chapters 3 and 6), and the bacteriophage PI clone (Chapter 4), were
labelled using a Ready-To-Go™ DNA labelling kit (Pharmacia) according to the
manufacturers instructions. In both cases the probes were purified (to remove
unincorporated nucleotides) by centrifugation (at 2000 rpm for 4 minutes) through a
Sephadex G50 spun-column (Nu-Clean D50 column, Kodak).
Probes were boiled in a water bath for ~5 minutes (immediately prior to use) and then
cooled on ice before they were added to the hybridisation solution.
2.3.3 Automated fluorescent sequencing of DNA
Sequencing reactions
Sequencing reactions were carried out using either an ABI PRISM™ Ready Reaction
DyeDeoxy™ Terminator Cycle Sequencing Kit or its successor the ABI PRISM™ Dye
Terminator Cycle Sequencing Ready Reaction Kit with AmpliTaq® DNA Polymerase,
FS (Perkin Elmer). Plasmid DNA for use in sequencing reactions was prepared using
either the SDS-alkaline lysis/PEG precipitation method or a Wizard™ 373 plus DNA
purification system (Promega), both of which are described in section 2.1.1. PCR
products that were to be sequenced directly (i.e. without being subcloned) were purified
using Microcon™ -100 concentrators (Amicon), as described in Chapter 3 , where
details of the methods used in the preparation and sequencing of lambda DNA clones
are also given. All sequencing reactions were set up according to the manufacturer's
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instructions unless otherwise stated. Sequencing products were resuspended in 4 pi of
sequencing gel DNA loading buffer (see 2.5.1), and were heated to 90°C for 3-5
minutes then cooled on ice, immediately before being loaded onto the gel.
Preparation ofsequencing gel
Sequencing reactions were run on 24-well, 24 cm well-to-read, denaturing
polyaery lamide gels (4.75% acrylamide). To prepare the gel mix, 40 g of urea (ultra
PURE®, Gibco-BRL) was dissolved in 32.5 ml of ddH20 (with stirring and gentle
heating), and after the solution had been allowed to cool to room temperature, 9.5 ml of
a 40% 19:1 acrylamiderbisacrylamide solution (Bio-Rad) was added. The gel solution
was deionised by mixing the solution with Amberlite MB-1 resin (Sigma) for 5-10
minutes, and both the deionised gel solution and 8 ml of lOx TBE (pH 8.8) were then
filtered through a 0.45 |im cellulose nitrate membrane filter (Whatman), using a vacuum
filtration apparatus, to remove the resin and de-gas the gel mix. Polymerisation
reagents [400 pi of a 10% (w/v) ammonium persulphate solution and 45 pi of
N,N,N',N' -tetramethyl-l,2-diaminoethane (TEMED; Sigma)] were mixed with the gel
solution just before use, and the gel was then poured immediately (using a 50 ml
syringe). Gels were left to polymerise (at room temperature) for at least 2 hours before
use.
Electrophoresis conditions
Sequencing reactions were run using an ABI 373 DNA Sequencer (Applied
Biosystems), operating on the full scan sequencing option. Sequencing gels were pre-
run for at least 10 minutes before the sequencing reactions were loaded onto the gel,
and the samples were then electrophoresed at 30 watts for 12-16 hours. The running
buffer used for both the pre-run and main electrophoresis run, was lx TBE (pH 8.8).
Sequence analysis
Collection and preliminary analysis of the sequence data was carried out by the ABI 373
data collection and analysis programs (Applied Biosystems).
The processed data was then transferred to the DNA sequence analysis program
Genejockey II (Biosoft), which was used to carry out the initial steps in the analysis of
the sequence data e.g. removal of vector sequences, sequence comparisons, and
alignment of sequence contigs. Sequence database homology searches were generally
carried out using the NCBI BLASTN program (National Centre for Biotechnology
Information, Bethesda, USA).
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2.3.4 PCR amplification of DNA
With the exception of some of the early PCR amplifications from VIPR2 PI clone
template DNA (Chapter 4), all PCR reactions were set up in a flow-hood that was not
used for any other nucleic acid work. Standard precautions taken to prevent
contamination of the PCR reactions, included the use of separate pipettes, and aerosol
resistant pipette tips. All reagents were stored in small aliquots, and master mixes were
used wherever possible (to reduce the number of pipetting steps involved).
Thermocycling was carried out using a Perkin Elmer DNA thermal cycler. The specific
cycling conditions used for particular reactions, and details of the reagents and primers
used, can be found in the methods section(s) of the relevant chapter(s).
Primers were obtained from Cruachem Ltd.
2.3.5 Photography and autoradiography
Photographs of UV transilluminated agarose gels were originally taken using a
Polaroid® CU-5 land camera (5" lens) and Polaroid® 667 film.
Autoradiography was carried out using Fuji RX medical X-ray film (Fuji) and
autoradiography cassettes with two intensifying screens (Fuji). Filters were wrapped in
clingfilm before being placed in the cassettes. Films were exposed at -70°C, or at room
temperature if the radioactive signal from the filter was very strong, and were then
developed using Kodak LX24 X-ray developer and Kodak Industrex manual fixer.
2.4 Microbiological methods
2.4.1 General growth and maintenance of bacterial cultures
Standard aseptic technique procedures were used when working with bacterial cultures,
and all glassware used had been baked at 200°C for 2-3 hours (in a Gallenkamp hotbox
oven) to sterilise it. Bacteria were grown at 37°C unless otherwise stated. Agar plates
on which bacteria had been plated were inverted and left in a 37°C incubator overnight.
Liquid cultures of bacteria were placed in an orbital incubator (at 37°C, 200 rev/min)
overnight. Liquid cultures of < 50 ml were set up from single isolated colonies of
plated bacteria, whereas larger volume cultures were generally set up from 2 ml
overnight liquid cultures.
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Ampicillin (50 flg/ml) was added to culture media that was to be used for selection and
growth of bacterial clones containing pBluescript or pGEM plasmid vectors (see section
2.6 for vector maps), whereas kanamycin (25 fig/ml) was added to culture media that
was to be used for the growth of bacterial clones containing the bacteriophage PI vector
yAd\0-sacB\l (see section 2.6 for vector map).
Plates of bacterial colonies were sealed with parafilm and stored in the cold room for up
to 3 weeks. Glycerol stocks were used for the long term storage of bacteria at -70°C
(see 2.4.5)
2.4.2 Preparation of competent bacterial cells
A single isolated colony of XL 1-Blue or JM109 bacterial cells (grown on M9+thiamine-
HC1 plates, see 2.5.5), was used to inoculate 2 ml of L-broth, and the culture was
grown overnight at 37°C. The 2 ml culture, was then in turn used to inoculate a flask
containing 40 ml of L-broth, and growth was allowed to continue until the OD600 of
the bacterial culture was between 0.3 and 0.5. The flask of cells was then placed on
ice, and from this point onwards all steps were carried out on ice, and centrifugations
were carried out at 4°C. Once the culture had cooled, it was transferred to a sterile pre-
chilled Oakridge tube, and the cells were collected by centrifugation at 6500 rpm for 5
minutes in a Sorvall SS-34 rotor. The supernatant was removed, and the pellet was
resuspended in 10 ml of ice-cold 0.1 M MgCl2- The cell suspension was then
centrifuged again (6500 rpm for 5 minutes in a Sorvall SS-34 rotor) to pellet the cells,
which this time were resuspended in 2 ml of ice-cold 0.1 M CaCl2, and then left on ice
for 45 minutes. Lollowing a final centrifugation (6500 rpm for 5 minutes in a Sorvall
SS-34 rotor), the cells were resuspended in 2 ml of ice cold MOPS/CaCl2/glycerol
solution (see below), and then incubated on ice for a further 20 minutes. The
competent cells were then aliquoted into ice-cold Eppendorf tubes (200 pl/tube), snap
frozen (in a dry ice/ethanol bath), and stored at -70°C until required.
The MOPS/CaCl2/glycerol solution contained:




2.4.3 Transformation of bacterial cells
For each transformation reaction, a 200 jj.1 aliquot of competent cells was taken from
storage at -70°C, and allowed to defrost on ice. Once the cell suspension had thawed, 3
pi of AnalaR® DMSO (BDH Chemicals Ltd.) was added to the tube, and was mixed
with the cell suspension by very gently flicking the tube. Approximately 5 pi of
ligation mix was then added, and after the contents of the tube had been gently mixed
again, the transformation reactions were left on ice for at least an hour. The cells were
then heat shocked in a 42°C water bath for 2-3 minutes, and returned to ice where they
were left for a further 15 minutes. Transformation reactions that involved the
retransformation of a previously isolated plasmid, were plated directly onto selection
plates (see 2.4.4) at this stage. However, in cases where ligation reactions were being
used to transform bacterial cells (and the expected number of transformants was low),
the cells were transferred to a 5 ml sterile disposable plastic tube, and following the
addition of 2 ml of L-broth, the cells were grown at 37°C for 1 hour with gentle
shaking. The cells were then pelleted by centrifugation, resuspended in 100 pi of L-
broth, and spread onto selection plates (see 2.4.4).
2.4.4 Selection of transformed cells
Blue/white colour screening (based on the a-complementation system) was used to
select transformed JM109 or XL 1-blue cells. After transformation with plasmid DNA
(see 2.4.3) the bacteria were spread onto AIX selection plates (see 2.5.5) that had been
dried and pre-warmed to 37°C. The plates were then inverted, and left in a 37°C
incubator overnight to allow the bacteria to grow. If colonies were visible on the plates
the next morning, the plates were sealed and left in the cold room for 1 -2 hours to allow
the colour to develop fully. Although pure white colonies were usually indicative of
transformants, colonies which had small blue centres were sometimes selected (in
addition to any white colonies) in cases where the plasmid inserts of interest were small
(< 200 bp), as these fragments do not always completely inactivate the amino terminal
encoding region of the lacZ gene.
2.4.5 Preparation of glycerol stocks
Glycerol stocks containing a final concentration of -20% glycerol were prepared by
adding 700 pi of sterile 80% glycerol solution to a test tube containing a 2 ml overnight
bacterial culture. Each glycerol stock was divided between 3 pre-cooled Eppendorf
tubes (-900 pl/tube). The glycerol stocks were then snap frozen (in a dry ice/ethanol
bath), and stored at -70°C.
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2.5 Composition of buffers, solutions, and media
2.5.1 Buffers
TE (pH 8.0)
10 mM Tris.Cl (pH 8.0)
1 mM EDTA (pH 8.0)
TAE
stock solution (50x)
242 g of Tris base
57.1 ml of glacial acetic acid
100 ml of 0.5 M EDTA (pH 8.0)
deionised H2O to 1 litre
TBE
stock solution (lOx)
108 g of Tris base
55 g of boric acid
40 ml of 0.5 M EDTA (pH 8.0)
deionised H2O to 1 litre
Batches of TBE stock solution that were to be used for agarose gel
electrophoresis were adjusted to pH 8.3 with boric acid, whereas those that










500 ml of SM buffer contained:
2.9 g of NaCl
1.0gofMgSO4.7H2O
25 ml of 1 M Tris.Cl (pH 7.5)
2.5 ml of 2% gelatine solution
H2O to 500 ml
The buffer was sterilised by autoclaving at 121 °C, 15 lb in~2 for 20 minutes, and 100
ml aliquots were then transferred to sterile glass bottles.
Sequencing gel DNA loading buffer
The buffer used for loading sequencing reactions onto ABI 373 sequencing gels
consisted of a 5 to 1 ratio of deionised formamide: 25 mM EDTA (pH 8.0) containing
50 mg/ml blue dextran.
Agarose gel DNA loading buffer (6x)
0.25% bromophenol blue
0.25% xylene cyanol FF
30% glycerol in water
2.5.2 Alkaline lysis solutions for plasmid isolation
Alkaline lysis solution 1
50 mM glucose
25 mM Tris.Cl (pH 8.0)
10 mM EDTA (pH 8.0)
This solution was sterilised by autoclaving at 121°C, 15 lb in"2 for 20 minutes,
and was then stored at 4°C.
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Alkaline lysis solution 2
0.2 N NaOH (diluted from 5 N stock)
1% SDS
Alkaline lysis solution 3
100 ml of alkaline lysis solution 3 contained:
60.0 ml of 5 M potassium acetate
11.5 ml of glacial acetic acid
28.5 ml of ddH20
2.5.3 Solutions for Southern blotting
Solutions usedfor blotting ofDNA onto Genescreen Plus nylon membrane
(NEN/DuPont)
Depurination : 0.25 N HC1
Denaturation : 0.4 N NaOH, 0.6 M NaCl
Neutralisation : 1.5 M NaCl, 0.5 M Tris.Cl (pH 7.0)
Transfer: lOx SSC (see 2.5.4)
Solution usedfor alkaline blotting ofDNA onto positive-charged nylon membrane
(Appligene Oncor)
Denaturation and transfer: 0.4 N NaOH
2.5.4 Hybridisation solution components
20xSSC (standard saline citrate)
1 litre of 20x SSC contained: 175.3 g of NaCl and 88.2 g of sodium citrate, which
were initially dissolved in 800 ml of deionised water. The pH of this solution was
adjusted to 7.0 using 10 N NaOH, and deionised water was then added to give a final
volume of 1 litre. The solution was then divided into 3 batches of -330 ml, which were
sterilised by autoclaving at 121°C, 15 lb in~2 for 20 minutes.
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20x SSPE (salt-sodium phosphate-EDTA)
1 litre of 20x SSPE contained: 175.3 g of NaCl, 27.6 g of NaH2PC>4.H20, and 7.4 g
of EDTA, which were initially dissolved in 800 ml of deionised water. The pH of this
solution was then adjusted to pH 7.4 using 10 N NaOH, and the final volume of the
solution was subsequently made up to 1 litre by the addition of deionised water. The
solution was then divided into 3 batches of -330 ml, which were sterilised by
autoclaving at 121°C, 15 lb in~2 for 20 minutes.
Denhardt's reagent
Denhardt's reagent was prepared as a 50x stock solution containing:
5 g of Ficoll type 400
5 g of polyvinylpyrrolidone
5 g of bovine semm albumin (BSA) fraction V
and deionised H2O to 500 ml
The solution was filtered, aliquoted into 50 ml batches, and then stored at
-20°C.
Deionisedformamide
Deionised formamide was prepared using Amberlite MB-1A resin (Sigma). The resin
was added to the formamide (-5 g per 100 ml of formamide) and stirred (with a
magnetic stirrer) at room temperature for at least one hour. After being filtered through
Whatman No. 1 paper (to remove the resin), the deionised formamide was aliquoted
into 50 ml batches and stored at -20°C
Non-homologous DNA
A 10 mg/ml solution of herring testis DNA in deionised water was prepared, and
passed through a 17-gauge syringe needle several times in order to shear the DNA. The
sheared DNA was boiled for 10-15 minutes in a water bath (to denature the DNA), and
then cooled on ice. In cases where the DNA was not used immediately, it was
aliquoted, and stored at 4°C. These aliquots were boiled again (for 5-10 minutes) and
cooled on ice before use.
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2.5.5 Bacterial media and antibiotics
B-agarose
To prepare 1 litre of B-agarose, 10 g of Bacto®-tryptone (Difco) and 8 g of NaCl were
dissolved in deionised water to give a final volume of 1 litre. This solution was
transferred into glass bottles, where 1.5 g of agarose was added per 100 ml, and the
bottles of media were then autoclaved at 121°C, 15 lb in~2 for 20 minutes.
B soft top-agarose
Prepared as described for B-agarose, but 0.7 g of agarose was added per 100 ml of
solution.
L-broth
To prepare 1 litre of L-broth, 10 g of Bacto®-tryptone (Difco), 5 g of Bacto®-yeast
extract (Difco), and 5 g of NaCl were dissolved in -900 ml of deionised water. The pH
of the solution was adjusted to pH 7.0-7.5 using 5 N NaOH, and deionised water was
added to give a final volume of 1 litre. The L-broth was then transferred into glass
bottles and autoclaved at 121°C, 15 lb in~2 for 20 minutes
L-agar
Prepared as described for L-broth, but after the solution had been transferred into glass
bottles 1 g of Bacto®-agar was added per 100 ml of solution.
Minimal agar +7 mM thiamine-HCl (M9 mediafor maintenance ofJM109 cells)
1 litre of M9 agar + thiamine-HCl was prepared from:
6 g of disodium hydrogen phosphate (Na2HPC>4)
3g of potassium dihydrogen phosphate (KH2PO4)
lg of ammonium chloride (NH4CI)
0.5g of NaCl
15g of Bacto®-agar
to which ddH20 was added to 1 litre. The pH was then adjusted to 7.4 by addition of
10 N NaOH, and the solution was autoclaved at 121°C, 15 lb in~2 for 20 minutes. The
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solution was then allowed to cool below 50°C before the following (autoclaved or filter
sterilised) components were added:
10.0 ml of 20% glucose
2.0 ml of lMMgS04
0.1 ml of lMCaCl2
1.0 ml of 1M thiamine-HCl
2x YT-broth
To prepare 1 litre of 2x YT-broth, 16 g of Bacto®-tryptone, 10 g of Bacto®-yeast
extract, and 5 g of NaCl, were dissolved in 900 ml of deionised water. The pH of the
solution was adjusted to 7.0 with 5 N NaOH (if necessary), and after the final volume
of the solution had been adjusted to 1 litre (with deionised water), the 2x YT-broth was
transferred into glass bottles, and autoclaved at 121°C, 15 lb in~2 for 20 minutes.
Antibiotics
Ampicillin and kanamycin solutions were prepared in ddH20, and were filter sterilised
through a 0.2 |im filter.
Ampicillin
stock solution: 50 mg/ml
working concentration: 50 (tg/ml (in both liquid cultures and agar plates)
Kanamycin
stock solution: kanamycin monosulfate 25 mg/ml
working concentration: 25 fig/ml (in both liquid cultures and agar plates)




0.1 M stock solution contained: 1 M stock solution contained:
0.24 g of IPTG
ddH20 to 10 ml
2.38g of IPTG
ddH20 to 10 ml
IPTG solutions were filter sterilised using a 0.2 pm filter, and then stored at
-20°C
5-bromo-4-chloro-3-indolyl-[5-D-galactoside (X-gal)
Stock solutions of X-gal (50 mg/ml) in N, N'-dimethylformamide were purchased from
Promega, and were stored in light-tight containers at -20°C
AIX plates
AIX plates (for blue/white colour screening of potential transformants) contained 50
|lg/ml ampicillin, 0.1 mM IPTG, and 50 pg/ml X-gal, and were prepared by adding the
appropriate stock solutions (see above) to molten L-agar that had been allowed to cool
to 50°C. The supplemented L-agar was poured into small petri dishes (90 mm
diameter), and allowed to set. The AIX plates were then dried at 37°C for ~1 hour, and
either used immediately or stored at 4°C until required (3 weeks maximum).
2.6 Cloning vectors
Plasmid vectors used during these studies included: pBluescript II SK (Stratagene; see
Figure 2.1 for vector map); pGEM®-7Zf (Promega; see Figure 2.2 for vector map);
and pGEM®-T vector (Promega; see Figure 2.3 for vector map).
Mouse genomic libraries that were screened had been constructed in the bacteriophage
lambda based vectors AEMBL3 (Frischauf et al., 1983; see Figure 2.4 for vector map)
or ?i2001 (Karn et al., 1984; see Figure 2.5 for vector map), and the human genomic
library had been constructed in bacteriophage PI based vector pAdlO-sacBII
(Sternberg, 1990; Pierce and Sternberg, 1992a; Pierce and Sternberg, 1992b; see
Figure 2.6 for vector map).
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Figure2.1:MapofpBluescri tIISK(Stratagene)
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loxP = 34 bp viral recombination sites on which the PI cyclisation recombinase protein (Cre) can act.
kan = kanamycin resistance gene
sacB = gene encoding the enzyme levansucrase
AdlO stuffer = 10 kb adenovirus derived stuffer fragment
pac = 162 bp site that is recognised and cleaved by phage-encoded pacase proteins
(orients the DNA for packaging)
Reference: Pierce and Sternberg, 1992b.
Chapter 3
Isolation and characterisation of the mouse
vasoactive intestinal peptide type 2 receptor gene
(Vipr2)
3.1 Introduction
The work that led up to the studies described in this chapter, began with the PCR
screening of rat pituitary cDNA, using degenerate PCR primers that had been designed
to bind to the highly conserved sequences that are found within the regions encoding
the predicted 3rd and 7th transmembrane domains of members of the secretin/glucagon
receptor subfamily (Lutz et al., 1993). Of the three different classes of PCR product
that were identified, two appeared to represent novel receptor encoding sequences,
whereas the third class of PCR product corresponded to part of the published calcitonin
receptor cDNA sequence (Gorn et al., 1992; Lin et al., 1991). Subsequent isolation
(from a rat olfactory bulb cDNA library) and characterisation of full length cDNA
clones corresponding to the two novel sequences, revealed that one of the clones
encoded a splice-variant of the PACAP type 1 receptor (Morrow et al., 1993), and the
other encoded a second receptor for VIP and PACAP, the vasoactive intestinal peptide
type 2 (VIP2) receptor (Lutz et al., 1993), which became the focus of the work
reported in this thesis (see Chapter 1).
While the isolation and characterisation of full length clones of these novel cDNAs was
in progress, the 500 bp PCR product (clone 4 /Ac(500)4) representing the region of
cDNA encoding transmembrane domains 3-7 of the VIP2 receptor, was used as a
probe to screen a XEMBL3 mouse genomic library. One positive clone was isolated,
and this clone, which was named XG4 (to indicate that it was the genomic clone that
had been isolated by the Ac(500)4 Vipr2 partial cDNA probe), provided the starting
point for the characterisation of the mouse Vipr2 gene.
Although cDNAs encoding at least 6 members of the secretin/glucagon receptor
subfamily had been isolated by this time (Ishihara et al., 1991; Ishihara et al., 1992;
Jiippner et al., 1991; Lin et al., 1991; Mayo, 1992; Thorens, 1992), the only published
information relating to the structure of the genes that encoded these receptors was an
abstract (Kronenberg, 1992) which stated that the rat PTH/PTHrP receptor gene
contains "a series of introns that separate individual putative transmembrane domains
and discrete portions of the amino-terminal extracellular domain", and a paper on the
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cloning of a cDNA encoding the rat GHRH receptor, which reported the existence of a
possible site of splice variation within the region encoding the 3rd intracellular loop of
the receptor, and described the rat GHRH receptor gene as "quite large" and
"interrupted by numerous introns within the coding region" (Mayo, 1992). Together,
these reports indicated that the presence of introns was probably a common feature of
the genes that encoded members of this receptor subfamily. However, they provided
few clues to suggest what the total size of the mouse Vipr2 gene might be, or give any
clear indication of how many introns the gene was likely to contain. Therefore,
although there were several possible approaches that could be taken to characterise the
structure of the mouse Vipr2 gene (including PCR amplification of introns, restriction
mapping, or direct sequencing of the clones), the characterisation of the initial mouse
genomic clone (XG4) was begun without any specific plan as to how the structure of
the gene would finally be determined, as the choice of method(s) would depend to a
large extent on the size of the introns (if any) within the Vipr2 gene.
Preliminary characterisation of the ?iG4 clone indicated that, like the rat GHRH receptor
gene (Mayo, 1992) and PTH/PTHrP receptor gene (Kronenberg, 1992), the mouse
Vipr2 gene contained several introns. However, some problems were encountered
with this genomic clone, and by the time that a second genomic library (which had the
additional advantage of being ES-cell derived and therefore preferable for the long term
transgenic aims of this work) had been screened for further Vipr2 gene clones, the gene
structures of several other members of the receptor gene subfamily had been published
(Kong etal., 1994; Lin etcil., 1993; Maget et al., 1994; Zolnierowicz et al., 1994).
These included: the gene structure of the rat, mouse and human PTH/PTHrP receptor
genes (reported to contain at least 15 exons; Kong et al., 1994), the pig calcitonin gene
(at least 14 exons; Zolnierowicz et al., 1994), the majority of the rat glucagon receptor
gene structure (at least 12 exons; Maget et al., 1994), and the positions of the introns
in the mouse GHRH receptor gene (at least 13 exons; Lin et al., 1993). Furthermore,
a common pattern had begun to emerge in the intron/exon structure of these receptor
genes, which allowed the positions of the mouse Vipr2 gene's intron/exon boundaries
to be predicted by comparison of its cDNA sequence with the exon sequences of other
members of the receptor gene subfamily.
Following the isolation of a series of X clones that together spanned the mouse Vipr2
gene (with the exception of part of intron 4), the predicted structure of the Vipr2 gene
was used as a template to design primers that could be used to sequence (outwards
from the exon sequences) across the predicted exon/intron junctions. These primers
were used to establish the sequences and positions of the Vipr2 gene's exon/intron
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junctions, and the sizes of all but one of the identified introns were subsequently
determined using a combination of PCR and restriction mapping.
3.2 Methods
3.2.1 Preparation of phage lysates
Plate lysates
A single bacterial colony of the E. coli host strain (LE392 in the case of the AEMBL3
library, and Q358 in the case of the X2001 library), was used to inoculate 10 ml of L-
broth containing 10 mM MgSC>4 + 0.2% maltose, and the culture was left to grow
overnight at 37°C, with gentle shaking. The bacteria were then pelleted in 30 ml
Oakridge tubes, by centrifugation at 4000 rpm for 10 minutes at 4°C in a Sorvall SS-34
rotor. After removal of the supernatant, the pellet was resuspended in a small volume
(3-5 ml) of 10 mM MgS04, and then diluted further (with 10 mM MgSC>4) until the
bacterial suspension reached an OD600 of -0.5. Phage stocks were diluted in SM
buffer (see Chapter 2) to give a final concentration of -3.6 x 10^ plaque forming units
(pfu) per 100 pi.
Large (140 mm diameter) B-agar plates were prepared (see Chapter 2), dried, and then
warmed in an incubator at 37°C. Twenty plates were prepared for each X clone in cases
where the lysate was to be used for a DNA maxiprep, and 5 plates were prepared when
the lysate was going to be used for DNA midipreps or kept for use as a phage stock.
While the plates were being warmed, an appropriate volume of soft top-agarose (-10
ml per plate) was melted (in a microwave oven), allowed to cool to 46°C, and then
placed in a water bath (pre-heated to 46°C) where it was maintained at that temperature
until required. Adsorption of the phage to the bacteria, was carried out in 10 ml test
tubes that had been pre-warmed to 37°C in a heating block. For each plate that had
been prepared, 0.5 ml of the bacterial cell suspension and 70 |ll of the phage dilution
were added to one of the 10 ml test tubes and gently mixed before being left at 37°C for
-20 minutes to allow adsorption to take place. Magnesium sulphate was added to the
soft top-agarose (1 ml of 0.1 M MgSC>4 stock/100 ml of soft top-agarose) just prior to
use, and 7 ml of soft top-agarose was then added to the first test tube. After addition of
the agarose, the contents of the tube were mixed by inverting the tube, and then poured
immediately onto one of the pre-warmed B-agar plates. This process was repeated with
each of the remaining test tubes. The plates were left at room temperature, until the top-
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agarose had set, and were then incubated (upright) in an oven at 37°C for 6-8 hours or
until the plaque formation (resulting from lysis of the bacteria) was confluent. Once
lysis was complete, 10 ml of SM buffer was added to each plate, and the plates were
left on a slowly rotating shaker in the cold room overnight. The following morning,
the SM buffer was carefully removed from the plates using disposable Pasteur pipettes,
and transferred to a centrifuge bucket, where chloroform was added (1 pi per ml of
lysate). The chloroform and lysate were mixed gently, to kill any remaining bacteria,
and centrifuged for 10 minutes at 7000 rpm in a Sorvall GSA rotor at 4°C, to pellet any
debris. The supernatant (phage lysate) was then removed, and stored at 4°C (over a
few drops of chloroform) until required.
Liquid lysates
A single bacterial colony of the E. coli host strain (LE392 in the case of the AEMBL3
library, and Q358 in the case of the X2001 library), was used to inoculate 10 ml of L-
broth containing 10 mM MgSC>4 + 0.2% maltose, and the culture was left to grow
overnight at 37°C, with gentle shaking. This 10 ml culture was then used to inoculate
250 ml of L-broth containing 10 mM MgS04 and 0.2% maltose, which in turn was left
to grow at 37°C in an orbital shaker until the OD600 °f the culture reached about 0.5.
At this point, 6 x 10' 0 pfu of phage stock was added to the culture, and the culture was
then shaken quite vigorously (-200 cycles/minute) at 37°C, until lysis of the bacterial
cells by the phage caused a very obvious clearing of the previously opaque bacterial
culture and string-like clumps of bacterial debris became visible at the bottom of the
flask. Chloroform (0.5 ml) was then added to the culture and incubation at 37°C in the
orbital shaker was continued for a further 10 minutes, after which the contents of the
flask were transferred into a centrifuge bottle and centrifuged for 10 minutes at -8000
rpm in a Sorvall GSA rotor at 4°C. The supernatant was carefully decanted into a clean
250 ml bottle, and was stored at 4°C (over chloroform) until required.
3.2.2 Titration of phage stocks/libraries
For each titration 7 small (90 mm diameter) B-agar plates (see Chapter 2) were
prepared, dried, and then warmed in an incubator at 37°C just prior to use. E. coli host
cells for the phage infections were grown as described in section 3.2.1 (plate lysate
method), and resuspended at an OD600 of ~0-5 in lOmM MgSOq.
Serial 10-fold dilutions of the phage suspension were made in SM buffer, to generate a
series of dilutions that spanned a concentration range from 10"^ to 10"10 of the
concentration of the original phage suspension, and each of the dilutions within this
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range was then used to infect the E. coli host cells. Seven 10 ml test tubes were pre¬
heated to 37°C in a heating block (one test tube for each phage dilution, and one tube
for a negative control reaction). Each of the tubes was labelled to indicate which one of
the six phage dilutions (or -ve control reaction) would be added to it, and the seven B-
agar plates were also labelled accordingly.
A 100 |itl aliquot of the appropriate phage dilution was added to each of the labelled
tubes, and 100 pi of SM buffer was added to the -ve control tube. This was followed
by the addition of 200 pi of the bacterial cell suspension, to each of the seven tubes,
and after gently mixing, the reactions were left at 37°C for 20 minutes, so that the
phage could adsorb to the bacteria. Soft top-agarose containing 10 mM MgS04 was
prepared as described in section 3.2.1 (plate lysate method), and 3 ml of the soft top-
agarose was added to the first test tube. After addition of the agarose, the contents of
the tube were quickly mixed by inversion, and then immediately poured onto the
appropriately labelled B-agar plate. The process was repeated with the other six test
tubes, and the plates were then left at room temperature to set, before being inverted
and incubated at 37°C overnight to allow plaques to form. Plates on which plaque
growth was confluent, or the plaques had begun to merge with one another were
discarded, as were any plates on which there were no plaques. The number of plaques
on one of the remaining plates (preferably one with 10-300 plaques) was then counted,
and used to calculate the titre of the original phage stock.
The phage dilutions used in this assay should be suitable for the titration of phage
stocks whose titres lie between 3 x 10^ pfu/ml and 1 x 10^ pfu/ml.
3.2.3 Isolation of X DNA
Qiagen column kits
Qiagen lambda midi- and maxi-kits (Qiagen Ltd.) were used as the standard method for
the isolation of X DNA throughout this study. Phage lysates were prepared using either
the plate lysate or liquid lysate methods described in section 3.2.1, the choice of
method depending on the rate of growth of the clone in question. For midipreps of X
DNA -40 ml of phage lysate was used as the starting material, and for maxipreps of X
DNA -150 ml of phage lysate was used. Isolation of X DNA, using the Qiagen lambda
kits, was carried out according to the manufacturer's instmctions.
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Phage purification on DEAE-cellulose columns, and subsequent isolation of Pi DNA by
proteinase K-SDS treatment
During attempts to obtain satisfactory preparations of X DNA from the /VEMBL3 Vipr2
clone (XG4), a second method of X DNA isolation was also tried. This method which
was published by Raikhinstein and Hanukoglu (1992), combined: ultracentrifugation of
the phage lysate, purification of the phage particles on a DEAE-cellulose minicolumn,
and a proteinase K-SDS lysis-based protocol for the recovery of X DNA.
Six phage lysate plates were prepared from phage stocks as described in section 3.2.1
(plate lysate method), and were incubated overnight at 37°C to allow lysis to occur.
The following morning, the plates were transferred to the cold room, where they were
cooled for at least an hour before being overlaid with 10 ml of cold SM buffer and left
at 4°C with gentle shaking for a further 2 hours. The lysate was then carefully removed
using Pasteur pipettes, and centrifuged: i) for 10 minutes at 12,000g in a Sorvall SS-34
rotor at 4°C (to pellet debris); ii) for 30 minutes at 100,000g in a TH-641 swingout
ultracentrifuge rotor (Sorvall) at 4°C (to precipitate the phage particles). After
resuspension in 3 ml of 10 mM Tris (pH 8), the phage suspension was applied to the
top of a DEAE-cellulose column (2 ml of preswollen Whatman DE-52 in a syringe
barrel) that had been equilibrated with 10 mM Tris (pH 8). The column was then
washed sequentially with: i) 3 ml of wash buffer (5 mM magnesium acetate, 30 mM
sodium acetate, 10 mM Tris pH 8), ii) 1 ml of elution buffer (50 mM magnesium
acetate, 10 mM Tris pH 8), and iii) 0.6 ml of elution buffer. The phage enriched
fraction should be eluted following the addition of the second aliquot (iii) of elution
buffer. Therefore, the runthrough resulting from the addition of i and ii was discarded
whereas the liquid eluted following the addition of iii was carefully collected in an
Eppendorf tube. The phage enriched fraction was treated with ribonuclease A (2 pi of a
10 mg/ml stock), and incubated at 37°C for 30 minutes. Proteinase K (15 pi of a 1
mg/ml stock) and 25 pi of 10% SDS were then added to the reaction, and incubation at
37°C was continued for another 15 minutes. Addition of 100 pi of 3 M potassium
acetate, was followed by an incubation at 88°C for 15 minutes, after which the reaction
was cooled on ice, then centrifuged at 12,000g for 15 minutes in a microcentrifuge in
the cold room. The supernatant was carefully transferred to a new tube, where 700 pi
of isopropanol was added to precipitate the DNA, and the reaction was left at -20°C for
1-2 hours. Finally, the precipitated DNA was pelleted by centrifugation at 12,000g for
15 minutes at 4°C, washed with 70% ethanol, dried, and then resuspended in 80 pi of
10 mM Tris pH 8.
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3.2.4 Restriction enzyme digestion and Southern blotting of X clone
DNA
In general, ~1 |_lg of DNA from the A.EMBL3 G4 clone, or -2-3 |ig of DNA from a
?i2001 clone (for vector maps see Chapter 2 Figures 2.4 and 2.5), was digested in a
total reaction volume of 20 |ll containing the appropriate lOx reaction buffer and -20
units of restriction enzyme (10 units/|LLl stock). The reactions were incubated for at least
4 hours at 37°C.
Southern blotting of DNA from the X clones was carried out as described in Chapter 2.
GeneScreen Plus membrane (NEN/Dupont) was used with neutral transfer conditions
in the case of the AEMBL3 G4 clone, whereas Appligene Positive™ nylon membrane
(Appligene Oncor) was used with alkaline transfer conditions for the Southern blotting
of clones that had been isolated from the A2001 mouse genomic library.
3.2.5 Probes
Rat Vipr2 cDNA derived probes that were used to isolate mouse genomic clones
included: a 5' 260 bp probe which spans the region from bp 1 to bp 260 of the rat
cDNA; a 5' 1 kb probe which spans the region from bp 1 to bp 999 of the rat cDNA;
and a full length rat cDNA probe which spans the entire published rat Vipr2 cDNA
sequence (Lutz et al., 1993). The 500 bp PCR product Ac(500)4 spans the region
corresponding to bp 711 to bp 1192 of the rat cDNA sequence, and the PCR amplified
cDNA derived 'gap' probe used to screen for intron 4 containing clones, spans the
region corresponding to bp 222 to bp 553 of the rat cDNA sequence.
Q12, the mouse Vipr2 cDNA 5' RACE product, extends from 54 bp upstream of the
published mouse Vipr2 cDNA sequence (Genebank accession number D28132; Inagaki
et al., 1994) to bp 192 of the published sequence.
A schematic diagram of the relationship between these cDNA derived probes and the
predicted exon structure of the mouse Vipr2 gene is shown in Figure 3.1.
3.2.6 Rapid freezing method for transformation of bacteria
This one step method, which simply consists of a 1 minute incubation of the bacterial
cell/plasmid mixture in liquid nitrogen, was published by Takahashi et al., (1992), who
developed it as a means of transforming non-competent cells with plasmid DNA.
However, the authors also found that the use of this method could produce a tenfold
increase in the number of transformants obtained from competent DH5oc cells, relative
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Figure 3.1
Schematic diagram illustrating the relationship between the predicted
exons of the mouse Vipr2 gene and the probes used in the isolation and

























to the number obtained following heat shock treatment. In this study the method was
tried on competent XL-1 blue cells.
3.2.7 Plaque purification
The aim of this process was to re-isolate a single positive plaque from a phage stock
that had up to this point been presumed to be homogeneous. In order to obtain phage
plates from which single plaques could be easily isolated, the AG4 phage stock (titre
1.5 x 1C)6 pfu/|Ltl) was diluted by a factor of 10^ using SM buffer, and adsorption
reactions were then set up containing 250 pi, 150 pi, 100 pi, 50 pi, or 10 pi of the
phage dilution + 500 pi of bacterial cell suspension (see 3.2.1, plate lysate method).
Plating and growth of the phage was carried out as described in section 3.2.1 (plate
lysate method), and plaque lifts were then taken from two of the phage plates (in this
case those generated from 250 pi of phage dilution and 50 pi of phage dilution) as
described in section 3.2.10. Following hybridisation of the filters (see 3.2.10) with
the Ac(500)4 probe (see 3.2.5), two positive plaques were picked and each was placed
in a separate Eppendorf tube containing 1 ml of SM buffer and a drop of chloroform.
The tubes were left at room temperature for ~2 hours to allow the phage to diffuse out
of the agarose. The phage suspensions were then used in the generation of two phage
lysate stocks (from plate lysates, see 3.2.1), one of which was subsequently used to
prepare a liquid lysate (see 3.2.1) from which AG4 DNA was isolated using a Qiagen
lambda maxi-kit (Qiagen Ltd.) as described in 3.2.3.
3.2.8 Cycle sequencing of X DNA using 32p end-labelled primers
Cycle sequencing of the A.G4 clone, and a control plasmid containing the 500 bp PCR
product Ac(500)4 from the rat Vipr2 cDNA (see 3.2.5), was carried out using a fmol®
DNA cycle sequencing system (Promega). The primer used in the reactions was 992W
5' GGGCAAAGTTGACTAC 3', which had been designed to bind to bases 253-238
of Ac(500)4. Sequencing of the plasmid and X DNA was carried out according to the
manufacturer's recommendations.
3.2.9 Dot blots of X clone DNA
Dot blots of DNA from the AG4 clone were prepared on GeneScreen Plus nylon
membrane (NEN/DuPont). A 6 x 6 grid of 1 cm^ squares was lightly pencilled onto
the membrane, and the membrane was then wet in 6x SSC for a few minutes before
use. Two DNA solutions were prepared, one containing -200 ng/pl of A.G4 DNA in
6x SSC, and the other (a vector-only control) containing -200 ng/pi of AEMBL3
vector arms in 6x SSC. Both DNA solutions were boiled for 10 minutes in a water
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bath, to denature the DNA, immediately cooled on ice, and then centrifuged briefly.
After residual 6x SSC had been allowed to drain from the nylon filter, the filter was
placed on a lid from a small plastic box, so that only the edges of filter touched the lid.
Eleven 2 |il samples of the AG4 DNA were then applied to the filter (two samples on
each row of the grid, except for the last row), followed by four 2 |il samples of the
AEMBL3 vector DNA control (one sample on each of the first four rows of the grid).
The filter was then left for 10 minutes on a pad of 3 MM paper (Whatman) that had
been soaked in denaturing solution (1.5 M NaCl, 0.5 M NaOH), before being moved
to a pad of 3 MM paper (Whatman) that had been soaked in neutralising solution (1 M
NaCl, 0.5 M Tris-HCl pH 7.0), where the filter was left for a further 10 minutes.
After removal from the neutralising solution, the filter was left to dry at room
temperature, and then baked at 80°C for 2 hours. Prehybridisation and hybridisation of
the filter were carried out as described in Chapter 2 (Southern blot method).
3.2.10 Screening of a mouse ES-cell-derived genomic library
The mouse ES-cell-derived genomic library used in this study was constructed in the
bacteriophage A, vector A2001 (Karn et al., 1984; see Figure 2.5 for vector map), and
was provided by Dr. H. Cooke (MRC Human Genetics Unit).
The preparation of the host bacteria (E. coli strain Q358) that were used in the plating of
the phage library, timing and temperature conditions for the phage adsorption steps,
preparation of B-agar plates and soft top-agarose, and subsequent plating of the
infection reactions, were carried out as described in section 3.2.1 (plate lysate method)
unless otherwise stated below.
Plating ofphageforprimary screens
On receipt of the library its titre was determined as described in 3.2.2 and was found to
be ~1C)9 pfu/ml. For primary screens of the library a 1/2500 dilution of the library
stock was made with SM buffer (to give a phage suspension with ~4 x 10^ pfu/100
jLLl), and a series of 20 adsorption reactions were set up. Each adsorption reaction
contained 100 |il of the phage dilution + 600 |il of bacterial host cell suspension, and
was thus expected to lead to the generation of ~4 x 10^ plaques. Following
adsorption, the phage/bacteria infection reactions were plated onto 20 large (140 mm
diameter) B-agar plates, and once the agarose had set, the plates were inverted and
incubated at 37°C until the plaques were almost confluent (with only a thin web of
bacterial growth still visible). The plates were then removed from the incubator, sealed
with parafilm, and stored in the cold room overnight.
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Plaque lifts
Plaque lifts were carried out using BioBlot-NC nitrocellulose blotting membrane 132
mm discs (Costar®). Two duplicate filters were prepared from each of the plates. The
filters were labelled in pencil on the 'wrong side', to indicate which plate they
represented, and whether they were the first or second plaque lift from that plate. The
first filter was then placed on the surface of the appropriate agar plate, and was left in
contact with the plaques for 1 minute, while orientation marks were applied to both the
plate and the filter (in positions corresponding to 12, 6, and 8 o'clock) using an 18
gauge needle. The filter was then transferred sequentially to trays containing: i)
denaturing solution (1.5 M NaCl, 0.5 M NaOH) in which the filter was left to float for
30 seconds before being immersed and left for a further 1 minute; ii) neutralising
solution (1.5 M NaCl, 0.5 M Tris pH 8.0) in which the filter was immersed for 5
minutes; iii) a wash solution consisting of 3x SSC, in which the filter was left for a few
minutes before being transferred to 3MM paper (Whatman) where it was left to dry. A
second filter was then placed on the same phage plate, and was left in contact with the
plaques for 3 minutes. Orientation marks were made on the second filter at identical
positions to those made on the plate and the first filter, and the filter was then passed
through the denaturation, neutralisation, and wash steps, described in i-iii. This
process was repeated for each of the phage plates, and the filters were then placed
between two sheets of 3MM paper (Whatman) and baked in an oven for 1.5 hours at
80°C.
Hybridisation
Prehybridisation and hybridisation of the filters were carried out in a solution
containing: 50% deionised formamide, 6x SSPE, 5x Denhardt's solution, 0.5% SDS,
and 100 |lg/ml of single stranded herring testis DNA (added just prior to
prehybridisation). The filters were divided into two sets, one set comprising the first
lift that was taken from each of the plates, and the other set comprising the second lift
from each plate. Each set of filters was placed in a plastic bag to which -100 ml of
prehybridisation solution was added, and the bags were then sealed. For
prehybridisation, the bags were placed in a large plastic box containing water that had
been preheated to 42°C, and the box was then placed on a gently rotating shaker in an
incubator that had also been preheated to 42°C. Probe labelling was carried out as
described in Chapter 2, and after prehybridisation had been allowed to proceed for at
least an hour, the probe was boiled in a water bath for 5 minutes, cooled immediately
on ice, and then added to the filter bags (which were subsequently resealed).
Following an overnight hybridisation at 42°C, the filters were removed from the bags,
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carefully separated, and then washed at 50°C with gentle shaking, first in a solution
containing 2x SSC, 0.1% SDS, and then in a solution containing 0.5x SSC, 0.1%
SDS. Both solutions had been preheated to 50°C before use, and two separate 20
minute washes were carried out in each solution. After these washes, the filters were
left to dry at room temperature for a few minutes before being taped onto sheets of
3MM paper (Whatman) that had been cut to fit the inside of autoradiography cassettes.
The orientation marks on the filters were highlighted with fluorescent paint, and each
sheet of paper and its attached filters were then covered with clingfilm, placed in an
autoradiography cassette with two intensifying screens and Fuji RX film (Fuji), and
stored at -70°C overnight.
Picking positive plaques
Once the autoradiographs had been developed, autoradiographs from duplicate filters
were aligned over a light box, so that the positions of positive clones could be
identified. If positive clones were seen, the appropriate phage plate was placed on top
of the autoradiographs on the light box, and the orientation marks on the plate were
aligned with those on the autoradiographs of the filters from that plate. Following
primary screens, positive plaques were picked using the wide end of a yellow (200 |ll)
pipette tip, and following secondary or tertiary screens, positive plaques were picked
using the fine end of a glass Pasteur pipette. Each agarose plug that was selected was
placed in a separate 1.5 ml sterile Eppendorf tube that contained 250 |ll of SM buffer
and 10 |ll of chloroform. The tubes were left at 4°C overnight to allow the phage to
elute from the agarose plugs, and were then stored at this temperature until required.
Plating ofphagefor secondary screens
For each positive clone that had been picked in the primary screen of the library, 1 in
10^ and 1 in 3x10)6 dilutions were prepared from the phage that had eluted from the
agarose plug. Two adsorption reactions containing 100 jil of phage dilution + 600 fil
of bacterial host cell suspension were set up for each positive clone (one reaction for
each of the phage dilutions). The reaction mixtures were plated onto B-agar plates, and
once the agarose had set, the plates were inverted and incubated at 37°C until plaques
were clearly visible. One of the two plates that had been produced from each primary
screen positive was then selected for use in the secondary screen. The aim was to try to
maximise the chances of obtaining positive clones on the plate used for the secondary
screen while trying to ensure that if positives were identified they could be isolated as
single plaques (ie. the density of plaques on the plated should be high but not so high
that the plaques are converging), and in most instances the plates from the 1 in 3x10)6
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dilutions of the phage were selected. Plaque lifts, hybridisation, and the selection of
positive plaques from the secondary screens, were carried out as described for the
primary screens of the library. Tertiary screens were not usually necesary.
Preparation of phage lysates, and subsequent isolation of DNA from positive clones,
were carried out as described in sections 3.2.1 and 3.2.3.
3.2.11 Direct automated fluorescent sequencing of A DNA
Direct sequencing of A, clone DNA was carried out using an ABI 373 automated
fluorescent sequencer and an 'ABI PRISM™ Dye Terminator Cycle Sequencing Ready
Reaction Kit with AmpliTaq® DNA polymerase, FS (Perkin Elmer). Lambda DNA for
use in sequencing was isolated using Qiagen lambda maxi- or midi- kits (see 3.2.3),
resuspended in ddH20 (-100 |al in the case of midipreps and 300 jllI in the case of
maxipreps), and 5 fxl (-1-2 (ig) of the DNA was then used as a template in each
sequencing reaction.
Sequencing reactions were carried out according to the manufacturer's instructions,
with the following exceptions: i) The amount of template DNA used was greater than
the recommended amount (0.25-0.5 p.g) for double stranded templates, but the increase
was found to give better sequencing results from X DNA, presumably due to the
increase in the concentration of target binding sites, as this would be substantially lower
in a given weight of a A, DNA clone than in the same weight of smaller molecular
weight plasmids or PCR products; ii) all sequencing reactions were heated to 90°C for
5 minutes (as opposed to the recommended 2 minutes) as this was also found to lead to
better results.
The sequencing primers used in these reactions were designed using the 'Primer'
software package (HGMP Resource Centre, Cambridge, UK). To design primers that
would bind to the mouse Vipr2 gene, the mouse Vipr2 cDNA sequence was used as a
template for the primer design program, and the entire sequence was searched for the
presence of possible 'forward or 'reverse' primer binding sites for primers that were at
least 18 bp long and had a melting temperature that was between 57°C and 63°C.
Using a prediction of the mouse Vipr2 gene's structure (that had been derived from an
alignment of the mouse Vipr2 cDNA sequence with the exon sequences of members of
the receptor gene sub-family whose structures had already been determined by other
groups), a few primers were initially selected that would bind to exons that lay towards
the 5' and 3' ends of the Vipr2 gene. However, as the analysis of the Vipr2 gene
progressed additional primers were selected and new primers were designed until
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eventually there were enough primers to sequence all the known intron/exon boundaries
of the Vipr2 gene, and sequence across some of its introns. The PCR primers used in
direct sequencing of the mouse Vipr2 gene clones (or in the subsequent PCR
amplification of Vipr2 gene introns), are listed in Table 3.1. Primers 8484 and 7363
(also included in Table 3.1) are primers that were designed to bind to sequences in the
left and right arm respectively of the 7.2001 vector (see Figure 2.5 for vector map).
3.2.12 PCR amplification of mouse Vipr2 gene introns
From the possible primers that were identified in the initial 'Primer' search of the
mouse Vipr2 cDNA sequence, and other sequencing primers that had been
subsequently designed to sequence the Vipr2 gene (see 3.2.11), pairs of primers were
selected, in which the individual primers were expected to bind to opposite strands of
adjacent exons of the Vipr2 gene, and lead to the amplification of the intervening intron
when used in PCR reactions containing the Vipr2 gene as template. Twelve pairs of
primers were required initially (one pair for each intron), and although in some cases it
proved necessary to design new primers for use in PCR (either because of potential
primer dimer formation or because of large differences in the melting temperatures of
the primers) in the vast majority of cases the primers used were those that had already
been successfully used in sequencing of the Vipr2 gene X clones. The PCR primers
used in the direct sequencing of the mouse Vipr2 gene clones, or in the PCR
amplification of Vipr2 gene introns, are listed in Table 3.1.
For each PCR reaction 1 pi of midiprep DNA from an appropriate X clone was used as
a template in a reaction mix containing: 2 pi of 10 mM dNTP mix (Boehringer
Mannheim), 10 pi of magnesium-free lOx PCR reaction buffer (Promega), 4 pi of 50
mM MgCl2, 2 pi of each of the two primers (15 pM stock solutions), 78 pi of tissue
culture grade water (Sigma), and 1 pi of Taq DNA polymerase (Promega). The
reaction components were mixed by vortexing, then spun briefly in a microcentrifuge.
The reactions were then carefully overlaid with two drops of light white mineral oil
(Sigma), and the tubes were placed in the PCR machine. After an initial denaturation at
94°C for 5 minutes, the reactions underwent 35 cycles consisting of: denaturation at
94°C for 1 minute, annealing at 57°C for 1 minute, and extension at 72°C for 1.5
minutes + 4 seconds/cycle. Following a final extension period at 72°C for 10 minutes,
the reactions were cooled to 4°C and maintained at this temperature until they could be
collected. Analysis of the PCR products was carried out by electophoresis of 20 pi of
each reaction through a 0.8% agarose TBE gel.
Table 3.1
PCR and sequencing primers used to characterise the mouse Vipr2 genomic clones
were designed using the published mouse cDNA sequence (Inagaki et al., 1994) as a
template where possible (i.e. for exon primers). The number given in the far left hand
column 'Primer' is the number that has been used to refer to that primer in the main
text. The primer sequences are presented in a 5'—» 3' direction. Where applicable the
position of the primer within the published mouse cDNA sequence is given in the far
right hand column, and in these cases the direction in which the primer faces when
bound to its target sequence within the VIPR2 gene can be deduced from order of the
numbers given in this column, i.e. if the site in the mouse cDNA is given as 1-20 then
the primer will bind to the top strand of the mouse cDNA sequence (shown in Figure
3.10) and sequence derived from the primer will extend downstream towards the 3' end
of the mouse cDNA, whereas if the sequence is given as 20-1, the primer will bind to
the bottom strand of the mouse cDNA sequence and will extend upstream towards the
5' end of the mouse cDNA sequence.
Primers marked with an asterisk (*) are designed to bind to the A2001 vector arms, and
the superscript a has been used to denote that primer 4336 was originally designed to
bind to human as opposed to mouse Vipr2 cDNA sequences, and contains a two bp
mismatch in comparison to the mouse target sequences.













3755 22 TGGGACAACATCACATGCTGGC exon 3 215-236
4340 20 CAGATGTTGGTGGCAATGAC exon 10 987-1006
4341 22 CAAGTCCACACTGCTGCTAATC exon 11 1030-1051
4342 23 GTATAGAACTGCTACCACCAGGC exon 12 1174-1152
4343 22 GATTAGCAGCAGTGTGGACTTG exon 11 1051-1030
4344 20 GCCTCGCCATCTTCTTTTCA exon 13 1225-1206
4336 20 AGTGGCGTCTGGGACAACAT exon 3 206-225a
5990 20 GGCCTGGTGGTAGCAGTTCT exon 12 1151-1170
5991 22 GGCCATTTATACCTTGGGCTAC exon 5 430-451
5992 20 GCAGTAGCAGGTCAGCACCA exon 1 85-66
5993 21 TCTCCTTCATGCTGAGAGCCA exon 6 549-569
7122 20 TCTGATTCTCCGTTTGGCTG exon 2 197-178
7363 22 AGAAGTCCAACCCAGATAACGA N/A* N/A*
7853 20 CTAAGCAGCCAAACGGAGAA exon 2 173-192
7854 22 GCCCAAGGTATAAATGGCCTTC exon 5 448-427
7890 20 TCTGGATGGATGCTGCTCAC exon 2 120-101
7891 20 CTGAATACTTTGGGGCAGGG exon 3 288-269
7892 20 AGAGAGGCGAGTTGCTGTCC exon 8 844-825
7893 20 GTGAGCAGCATCCATCCAGA exon 2 101-120
7894 20 TACTGGCTTCTGGTGGAGGG exon 7 701-720
7895 20 CACAAACGACCACAGCATCC exon 9 868-887
7896 20 ACAATGCTGATGAAGAGGGC exon 10 957-938
7897 20 ATGCTGTGGTCGTTTGTGTC exon 9 885-866
7898 21 ATGTCTCTGACCATCCATCGC exon 4 353-333
7899 22 CACTAGCGATGGATGGTCAGAG exon 4 328-349
7900 23 GCAGTAGACCTGAGCTGGAGTAG exon 6 620-598
7901 23 GACAGCAACTCGCCTCTCTTTAG exon 8 826-848













8482 20 CACTCCCTGCCTCTGTCATC N/A* N/A*
8483 18 CAAGGACCGAGGCAGCAC exon 1 23-40
8484 20 GCACCAGCAACCAGCAGTAG exon 1 98-79
9200 19 TGGGAGGAAGGATGGCTAC exon 7 761-743
9628 23 AGGAGAGGAAGAGGTTTAGGTGG exon 6 554-532
9629 22 AGGTGGATGTAGTTCCTTGTGC exon 6 537-516
9630 21 GGACAGCGTGCTCTACTCCAG exon 6 586-606
14367 25 CTGGCCTTTTGTGTCTAAACCTGCT intron 10 N/A
14368 25 GATAATTCTGGTGGGACTGGAAAGG intron 10 N/A
14400 25 CTACTTCCCTCTGAAGTGCAGGACC 5' N/A
14891 25 AAGATTATGCTGAAAGGACCCTGAT 5' N/A
14892 25 CCTCTCCrGTAAAATQGAATOGATG intron 10 N/A
15026 25 ATCACTAAGCACACAGCCTATCTCC intron 10 N/A
15075 23 GTAGCCCCTAATGGGTCGAGTGT 5' N/A
15132 24 GGTATGGGGGGACTTTTGGTATAG 5' N/A
15133 25 GTGAAGAAGGTCTTTGGATGGATAC intron 10 N/A
15585 23 TGCTTTGGTCATGGTGTCTGTTC intron 10 N/A
15586 23 CCAACCCTGATAGAACCCAACAT intron 10 N/A
15587 23 ATTGCTGACCCAAAACTTCACTG 5' N/A
15588 23 ATCTGCCCATTATCTTTCTCCCC 5' N/A
17982 22 TrGCTTGTCTTAGCTCTTTGGC intron 4 N/A
17983 20 GGTAGGACAAGGCCACAGGA intron 2 N/A
17984 21 GAGCCTCCTTCTTCCCTGATG intron 2 N/A
18439 22 GAGACATGGAAGACTCGAAAGC intron 5 N/A
18440 24 ACAGAAAGTAAATCCTCAGTGGTC intron 2 N/A
18441 23 CAGGGTAAGGACATTGAGTCCAG intron 2 N/A
19458 26 TAGTAACCTACATCTGACCAAAGTCC intron 5 N/A
19459 20 GCAGGATGTCTCATGCCAGT intron 2 N/A













19461 20 CAGTAGCCTGGGTATGCTGG intron 6 N/A
19773 23 TACAGGGAATTACTGCTGGATGG intron 2 N/A
19774 23 ATATTACCCAGCTCTGCCCAGTC intron 2 N/A
19775 23 GATTCCTACCTGTCAATGGAAGA intron 4 N/A
20847 23 CCCAGAAGAAAGCAAGAGATTCC intron 5 N/A
20848 22 GGGGGAAACAAACAGAGTTGAG intron 5 N/A
22567 23 GTGTATGCTCATCTACGAAAGGA intron 6 N/A
22568 23 GCTAGACACCAGTCAGCCTTCTG intron 6 N/A
22569 22 AATGTCTGTCCAAGTCAGCACG intron 6 N/A
22570 21 TTATCCAAACAGATCGCTGCC intron 6 N/A
3.2.13 Preparation of PCR products for direct automated fluorescent
sequencing
PCR products that were to be sequenced directly (i.e. those that were not subcloned
into plasmids before being sequenced), were purified using Microcon™-100
microconcentrators (Amicon), according to the manufacturer's instmctions for the
purification of PCR products.
3.2.14 Long PCR
Attempts at PCR amplification of introns 2 and 4 were carried out using the Expand™
long template PCR system (Boehringer Mannheim). The primers used in attempts to
amplify intron 2 using A clone ES9 as template DNA were 13896 5'
CCATCCAGAATGTCGCTTTCATCTAGAAATAC 3' and 13897 5'
GTAGAAATTGCTGAATACTTTGGGGCAGG 3', and those used in attempts to
amplify intron 4 from mouse total genomic DNA (Promega) were 13898 5'
GGAAACATAAGCAAAAACTGCACTAGCGAT 3' and 13899 5'
GTAAGAGACATCAGAGAAACACTGTAGCCCAAG 3'.
PCR reactions were carried out in 0.5 ml thin-walled GeneAmp reaction tubes (Perkin
Elmer). PCR buffer 1 (lOx concentration, with 17.5 mM MgCl2) which was used in
the reactions, is the recommended buffer for the amplification of human genomic DNA
fragments of 0.5-12 kb or A DNA fragments of 0.5-25 kb, and all PCR reactions were
set up according to the manufacturer's instructions for the amplification of fragments
within these size ranges (PCR system 1; Boehringer Mannheim).
An initial denaturation at 94°C for 2 minutes, was followed by ten cycles of:
denaturation at 94°C for 10 seconds, annealing at 65°C for 30 seconds, and elongation
at 68°C for 15 minutes. This in turn was followed by fifteen cycles of: denaturation at
94°C for 10 seconds, annealing at 65°C for 30 seconds, and elongation at 68°C for 15
minutes +20 seconds/cycle. After a final extension phase at 68°C for 7 minutes, the
reactions were cooled to 4°C and were maintained at this temperature until they could be
collected. Analysis of the PCR products was carried out by electrophoresis through a
0.8 % agarose TBE gel.
3.2.15 'Shotgun' subcloning of A clone fragments from 'long introns'
Generally, this method was used in cases where several different restriction fragments
had to be subcloned from a single A clone. However, it was also occasionally used
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when attempts to clone a single restriction fragment using other methods (e.g. those
involving the isolation of DNA from an agarose gel slice) had failed.
In most cases, two restriction digest reactions were set up, in which approximately 5
pig of DNA from the A clone of interest, was digested in a total reaction volume of 40
pi, containing the appropriate restriction enzyme(s) and lOx reaction buffer. After
incubation at 37°C for 6-8 hours, the two digests were pooled, and the restriction
fragments were purified using a Wizard™ DNA clean-up system (Promega) according
to the manufacturer's instructions. The A DNA fragments were eluted from the
Wizard™ column by the addition of 40 pi of ddH20 (preheated to 65°C). Plasmid
vector DNA (usually pGEM®-7Zf(+), Promega; see Figure 2.2) was prepared as
described in Chapter 2. Various ratios of plasmid: A DNA were tested in a series of
ligation reactions, which in addition to A DNA and vector, contained 1 pi of T4 DNA
ligase (Promega), 1 pi of lOx ligase buffer (Promega), and ddH20 to 10 pi. The
ligation reactions were incubated at 4°C overnight, and each ligation was then used to
transform competent bacterial cells (as described in Chapter 2).
Following the use of this 'shotgun' subcloning method, it was often necessary to select
more transformants than normal for plasmid minipreps, particularly if the target
fragments were relatively large in size, as subclones containing the smaller products
from the A DNA digest tended to predominate.
3.2.16 PCR amplification of plasmid insert fragments
PCR amplification of Vipr2 gene intron 5 and intron 6 fragments, from the ESI 1
derived plasmid subclone Xho (2), was achieved using two separate pairs of PCR
primers that each consisted of: one plasmid vector primer, and one internal Vipr2 gene
primer (that bound to sequence from exon 6 of the Vipr2 gene).
An M13/pUC reverse primer (GIBCO) was used in conjunction with the primer 9629
5' AGGTGGATGTAGTTCCTTGTGC (exon 6) to amplify the intron 5 derived
sequence from the Xho (2) subclone, and an M13/pUC forward primer (GIBCO) was
used together with primer 9630 5' GGACAGCGTGCTCTACTCCAG 3' (exon 6) to
amplify the intron 6 derived portion of the plasmid's insert. Xho (2) plasmid DNA was
prepared using a Wizard™ 373 plus DNA purification kit (Promega), and for each PCR
reaction 1 pi (-0.5 pg) of the plasmid miniprep was used as a template in a reaction mix
containing: 2 pi of 10 mM dNTP mix (Boehringer Mannheim), 10 pi of magnesium-
free lOx PCR reaction buffer (Promega), 4 pi of 50 mM MgCl2, 2 pi of the
appropriate M13/pUC primer (10 pM stock), 6.5 pi of the appropriate exon 6 primer
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(3.2 |iM stock), 1 |il of Taq DNA polymerase (Promega) and tissue culture grade water
(Sigma) to 100 pi. The reactions were vortexed, spun briefly in a microcentrifuge,
then overlaid with light white mineral oil (Sigma). Thermocycling and subsequent
analysis of the PCR products were carried out as described in section 3.2.13.
3.3 Results
3.3.1 Restriction enzyme digestion and Southern blot analysis of the
putative Vipr2 mouse genomic clone A.G4
Initial restriction enzyme digests carried out on AG4 DNA that had been prepared using
a plate lysate derived phage suspension and a Qiagen lambda maxi-kit (see 3.2.1 and
3.2.3), gave surprisingly poor results. Despite the relatively high concentration of
restriction enzyme used in the digestion reactions and the fairly long incubation time of
these reactions (see 3.2.4), it seemed that only partial digestion of the DNA was
occurring (as indicated by the disproportionate weakness of some of the restriction
fragment bands relative to their molecular weight when the digest products were
analysed on an agarose gel; see Figure 3.2 for example). Possible explanations for this
included: the presence of impurities in the DNA preparation, too short an incubation
time, the presence of insufficient restriction enzyme in the digestion reactions, or the
presence of too much restriction enzyme in the digestion reactions -which can lead to
star activity with some enzymes. However, although various different sets of reaction
conditions were tried, using both the original Qiagen column isolated XG4 DNA and a
new preparation of AG4 DNA that had been isolated from DEAE-cellulose column
purified phage by proteinase K-SDS treatment (see 3.2.3), satisfactory restriction
enzyme digests of the XG4 DNA were not obtained.
Southern blot analysis of a BamH I digest of the AG4 clone, clearly identified a single
hybridising band of ~4 kb following hybridisation with the rat Ac(500)4 probe (Figures
3.3a and 3.3b). Unfortunately, the strong hybridisation signal on the autoradiograph
originated from a band of DNA that seemed to be significantly underrepresented in
BamH I digests of the A.G4 clone, and in some digests of the clone this 4 kb fragment
and a smaller BamH I restriction fragment of < 2 kb were only just visible on the 1 %
agarose gel (see Figures 3.3a and 3.3b). Nevertheless, since it appeared that the
isolation of this 4 kb BamH I fragment would be likely to lead to confirmation that the
XG4 clone contained Vipr2 gene sequence, and provide a starting point for the analysis
of the mouse Vipr2 gene, attempts to subclone this restriction fragment were pursued.
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Figure 3.2
Gel showing restriction enzyme digests of clone A,G4





























XHindIIImarkers ^G4EcoRI A-G4BamRI XG4EcoRVXhoI XG4EcoRIiCla XG4EcoRl/PstI XG4EcoRl/XbaI XG4EcoRI/Not AG4EcoR1/EcoRV
Figure 3.3a
Bam H I restriction digest of A.G4 DNA separated on an agarose gel in
preparation for Southern blotting
(A ruler has been photographed alongside the gel so that if necessary the positions of
the molecular weight markers can be estimated on the corresponding autoradiograph of













Hybridisation pattern observed when a Southern blot taken from the gel
of restriction digested XG4 DNA shown in Figure 3.3a is incubated with
the radiolabeled Vipr2 rat Ac(500)4 cDNA probe
The faint 4 kb BamR I restriction fragment arrowed in 3.3a hybridises strongly to the
probe
(The autoradiograph is shown at actual size)
XHindIIImarkers XG4uncut XG4BamH.l
3.3.2 Attempts to subclone the 4 kb BamH I restriction fragment from
the ^.G4 clone
As anticipated, the subcloning of the \CA 4 kb BamH I fragment proved to be
difficult. The very limited amount of this DNA fragment that could be isolated in an
agarose gel slice following electrophoresis of AG4 BamH I digests, was the main
problem, and even when gel slices from several lanes were pooled prior to purification
of the DNA from the agarose, very little if any DNA could be visualised when 4 |ll out
of a total of 20 |ll of the GeneClean® purified restriction fragments (see Chapter 2) was
run on a 1% agarose mini gel. In cases where the 4 kb restriction fragment was visible
on the gel, ligation reactions with Bluescript SK plasmid (Stratagene) were set up (see
Chapter 2), and after initial subcloning attempts in which the standard heat shock
protocol was used (see Chapter 2) had failed to generate colonies containing the 4 kb
subclone of interest, a recently published 'freeze shock' transformation method was
tried (Takahashi et al., 1992; see 3.2.6). However, although the latter method seemed
to result in an approximately 2-fold increase in the number of transformants obtained
relative to the numbers seen following use of the 'heat shock' based method,
transformants containing plasmids with the 4 kb BamH I insert fragment were not
obtained.
3.3.3 Further Southern blot analysis of the X.G4 clone
The failure of attempts to subclone the 4 kb BamH I restriction fragment from the A.G4
clone, led to efforts to identify other restriction fragments that hybridised to the
Ac(500)4 probe, and in particular, hybridising fragments that were more abundant
within AG4 DNA digests than the previously identified 4 kb BamH I fragment. A
Southern blot was therefore prepared from a gel on which Cla I, EcoR V, and Pst I
digests of AG4 DNA had been separated (Figure 3.4a), and the blot was then
hybridised with the Ac(500)4 probe. The results of this hybridisation clearly showed
that in the lanes containing Cla I or EcoR V digested XG4 DNA, only undigested or
large molecular weight fragments near the top of the gel, hybridised to the probe,
whereas in the lane containing Pst I digested AG4 DNA, the probe had hybridised only
to a single band of just under 4 kb (Figures 3.4a and 3.4b). The fact that hybridisation
had occurred only to this single band within the Pst I digest, and was quite intense,
ruled out the possibility of partial digestion as the cause of any underrepresentation of
this band within the digest, as if partial digestion had occurred, hybridisation to other
fragments in the digest or to uncut DNA would have been expected. Nevertheless,
when the band from which the hybridisation signal had originated was located on the
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Figure 3.4a
Restriction digests of A.G4 DNA separated on an agarose gel in
preparation for Southern blotting
(A ruler has been photographed alongside the gel so that if necessary the positions of
the molecular weight markers can be estimated on the corresponding autoradiograph of


















Hybridisation pattern observed when a Southern blot taken from the gel
of restriction digested XG4 DNA shown in Figure 3.4a is incubated with
the radiolabeled Vipr2 rat Ac(500)4 cDNA probe
The under-represented band of just under 4 kb (arrowed in Figure 3.4a) hybridises
strongly to the probe.
(The autoradiograph is shown at actual size)
XHindIIImarkers XG4ClaI A-G4EcoRV XG4PstI
photograph of the agarose gel that was taken prior to Southern blotting (Figure 3.4a), it
was clear that this Pst I restriction fragment was underrepresented to an even greater
degree than the previously identified 4 kb BamH I fragment, and consequently there
seemed little point in trying to subclone it.
3.3.4 Plaque purification of the XG4 clone
The identification of two AG4-derived restriction fragments that hybridised to the
Ac(500)4 probe, but were both significantly underrepresented in restriction digests,
was a cause for serious concern. However, as it now appeared that partial digestion of
the ?iG4 DNA was not likely to be the cause of these problems, other potential causes
had to be considered, including the possibility that a contaminating phage might have
become predominant in the phage stocks. After the SM buffer and bacterial stocks had
been checked to ensure that they were not the source of any contaminating phage or
plasmid DNA, the decision to carry out a plaque purification of the 3.G4 phage stock,
was finally made. The results subsequently obtained from the hybridisation screening
of the XG4 phage stock during the plaque purification process (see 3.2.7 for methods),
were strange, and difficult to interpret. Of the two phage plates that were used to take
plaque lifts for use in the hybridisation screening of the phage stock, one phage plate
had been prepared using one fifth of the number of phage that had been used in the
preparation of the second plate. Following hybridisation of the plaque lift filters with
the Ac(500)4 probe, the hybridising plaques from the plate that had the greater density
of plaques (Figure 3.5), were found to represent -77% of the total number of plaques
on that plate, a value which, allowing for inefficiencies in the plaque lift and
hybridisation procedures, might be consistent with that expected from stocks of plaque
purified phage clones. In contrast, the hybridising plaques from the plate with the
lower density of plaques, were found to represent only -14% of the total number of
plaques on the plate. However, the rather odd background pattern seen on the filters
from the lower density plaques (Figure 3.5), suggested that factors affecting the plaque
lift process from this plate may have been responsible for the low levels of
hybridisation in this case, and consequently the plaque purification process was
continued (see 3.2.7) following selection of two positive plaques from the plate that
had the higher plaque density.
3.3.5 Attempt at direct sequencing of X DNA using a 32p end-labelled
primer
Direct sequencing of 7.G4 DNA using thefmol® DNA cycle sequencing system
(Promega; see 3.2.8), was tried as an alternative approach to confirming that the 1G4
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Figure 3.5
Autoradiographs of filters from the plaque purification plates, following
hybridisation with the radiolabeled Ac(500)4 cDNA probe
(A=low plaque density filter, B=higher plaque density filter)
 
clone contained mouse Vipr2 gene sequence, following the failure of subcloning
attempts. The primer (992W) that was selected for use in these sequencing reactions
was chosen because it had been shown to bind to the central region of the rat Vipr2
cDNA probe Ac(500)4 that was originally used to isolate the 7.G4 clone.
Unfortunately, this approach proved to be unsuccessful, as no sequence data was
produced from \GA template DNA in sequencing reactions using this primer, although
the generation of a very small amount of sequence data from the Ac(500)4 insert of the
control plasmid demonstrated that the primer was priming correctly in this sequencing
reaction.
3.3.6 Preparation, restriction digestion, and subcloning of 7.G4 DNA
prepared from the new XG4 phage lysate stocks
The titre of the phage stocks that were produced following plaque purification of the
XGA phage was significantly higher than that of the original ?iG4 stock, 10^ pfu/ml as
opposed to 1.5 1()9 pfu/ml, and therefore, although a liquid lysate method of phage
preparation had been tried unsuccessfully with the previous 7.G4 phage stock, this
method (see 3.2.1) was tried again, and this time was successful. Following isolation
of DNA from the phage lysate, using a Qiagen lambda maxi-kit (Qiagen Ltd; see
3.2.3), a BamH I restriction digest of the newly isolated DNA was set up in order to
see whether underrepresented bands were still generated. The difference between the
products of this DNA digest and previous digests of 7.G4 DNA with the same enzyme,
when the restriction products were analysed on an agarose gel, was amazing. Some
quite strong bands that had been seen previously were now completely absent, and
most importantly, the 4 kb BamH I restriction fragment that had previously proved
impossible to subclone, now appeared as a strong easily visible band. The 4 kb BamH
I restriction fragment from the new batch of ?iG4 DNA, was then subcloned into
pBluescript SK (Stratagene; for vector map see Chapter 2 Figure 2.1) without any
problems, and a Southern blot was prepared from a gel on which BamH I digests of
both the new batch of ?iG4 DNA and the AG4 4 kb BamH I subclone (known as BSc4)
had been run (Figure 3.6a). Hybridisation of the Southern blot with the Ac(500)4
probe, resulted in strong hybridisation of the probe to the 4 kb fragment from the XGA
DNA and also to the 4 kb insert fragment from the BSc4 plasmid (Figures 3.6a and
3.6b), thus confirming that the hybridising fragment had been successfully subcloned.
Preliminary sequencing of the BSc4 subclone (using forward and reverse M13/pUC
vector primers), showed that the sequence from one end of the 4 kb insert
corresponded to mouse intronic repeat sequences, whereas sequence from the other end
of the insert showed a high degree of similarity to sequence from the 3' untranslated
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Figure 3.6a
Restriction digests of new (plaque purified) XG4 DNA and subcloned
4 kb BamH I restriction fragments, separated on an agarose gel in
preparation for Southern blotting.
(A ruler has been photographed alongside the gel so that if necessary the positions of
the molecular weight markers can be estimated on the corresponding autoradiograph of











AHindIIImarkers AG4BamHI BSc4amHI BSc4amHI BSc4amHI pBluescriptBamHI
Figure 3.6b
Hybridisation pattern observed when a Southern blot taken from the gel
of restriction digested DNA shown in Figure 3.6a is incubated with the
radiolabeled Vipr2 rat Ac(500)4 cDNA probe
The 4 kb fragments from the BSe4 subclones and the 4 kb BamH I fragment from the
A.G4 digest, all hybridise strongly to the probe.
(The autoradiograph is shown at actual size)
A,Hind.Illmarkers A,G4BamHI BSc4amHI BSc4amHI BSc4amHI pBluescriptBamHI
region of the rat Vipr2 cDNA. This sequence data, together with the clear hybridisation
of the BSc4 insert to the Ac(500)4 probe, strongly suggested that the BSc4 subclone
contained mouse Vipr2 gene sequence that began upstream of sequence corresponding
to the 3' end of the Ac(500)4 probe (bp 1192 of the rat Vipr2 cDNA) and continued
into the 3' untranslated region of the gene.
3.3.7 Analysis of dot blots of AG4 DNA, using probes from the 5'
region of the rat Vipr2 cDNA
In order to try to establish whether the AG4 clone contained the 5' end of the mouse
Vipr2 gene, two dot blots of AG4 DNA were set up (as described in section 3.2.9) for
use in hybridisation reactions with probes derived from the 5' region of the rat Vipr2
cDNA. The first dot blot was hybridised with the rat Vipr2 5' 1 kb cDNA probe, and
following autoradiography a clear hybridisation signal was detected in regions
containing AG4 DNA (Figure 3.7). However hybridisation of the second blot with the
rat Vipr2 5' 260 bp cDNA probe, did not produce any hybridisation signal following
autoradiography. Since the rat Vipr2 5' 1 kb cDNA fragment overlaps with the 5' half
of Ac(500)4 and ends at bp 999 of the rat cDNA sequence, the positive hybridisation
result with the 5' 1 kb probe suggested that the AG4 clone contains sequence 5' of the
mouse genomic equivalent of rat Vipr2 cDNA bp 999, but the failure of the AG4 DNA
to hybridise to the 5' 260 bp probe, indicated that the 5' end of the Vipr2 gene is not
present in this A clone.
3.3.8 Subcloning of restriction fragments from BSc4
A preliminary restriction map of the BSc4 subclone was constructed on the basis of the
results obtained from BamH I, Hind III, and Pst I, single and double restriction
enzyme digests of the plasmid (Figure 3.8). An -1.25 kb BamR VHind III restriction
fragment (BH1.25) from the 5' end of the BSc4 insert, the directly adjacent -1.8 kb
Hind III/Pst I restriction fragment (HP1.8) which spanned the central region of the
insert, and an -700 bp Pst VBamH I restriction fragment containing the remaining
sequence from the 3' end of the insert, were then subcloned into pBluescript SK
(Stratagene; see Figure 2.1). Initially there was some uncertainty as to whether the 3'
Pst I site at the 3' end of the BSc4 insert, was within the insert sequence or was part of
the plasmid polylinker sequence, and consequently the 3' -700 bp restriction fragment
from the insert was cloned in the form of both a Pst I fragment (P700) and a Pst




Dot blot of A.G4 DNA following hybridisation to the radiolabeled rat
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3.3.9 Southern blot analysis and sequencing of subcloned fragments
from BSc4
As a first step towards identifying the regions of the Vipr2 gene that were present in
BSc4, a Southern blot was prepared from a gel on which the insert DNA from the
BSc4 subclones BH1.25, HP1.8, PB700, and P700, had been separated from the
vector sequence, and this blot was used in hybridisation reactions with probes that had
previously been shown to hybridise to AG4 DNA.
Following an attempted hybridisation of the blot with the rat Vipr2 1 kb 5' cDNA probe
no hybridisation to the insert fragments of any of the subclones was observed.
However, after hybridisation of the blot with the Ac(500)4 probe, bands representing
hybridisation to the insert fragment of the HP1.8 subclone and the insert fragment of
the BSc4 control plasmid, could be clearly seen (Figures 3.9a and 3.9b). This
suggested that the HP1.8 subclone contained mouse Vipr2 exon sequence which
corresponded to at least part of the sequence present within the Ac(500)4 probe i.e. bp
711 to bp 1192 of the rat Vipr2 cDNA sequence. Since BSc4 was thought to end
within the 3' untranslated region (UTR) of the mouse Vipr2 gene, the failure of P700
and PB700 (which were derived from the 3' end of BSc4) to hybridise to the Ac(500)4
probe was not surprising, as the Ac(500)4 probe ends 187 bp upstream of the 3' UTR
in the rat Vipr2 cDNA. However, the absence of any detectable hybridisation between
BH1.25 and either the 5' 1 kb probe or the Ac(500)4 probe, seemed to indicate that
either this subclone was composed largely of intron sequence, or if Vipr2 gene exon
sequences were present in BH1.25 then they were significantly different from those
found in rat.
Fortunately, at around this stage of the study, the mouse Vipr2 cDNA sequence was
published (Genebank accession number D28132; Inagaki et al., 1994), and by aligning
this sequence with the published exon sequences of other members of the receptor gene
sub-family (whose gene structures had already been published), a prediction of the
structure of the mouse Vipr2 gene was made (see Figure 3.10).
Subsequent sequencing of subclones BH1.25, HP1.8, P700 and PB700, generally
confirmed the conclusions that had been suggested by the Southern blot analysis, and
through comparison with the mouse cDNA sequence, produced the first definitive
information relating to the mouse Vipr2 gene's structure.
The data obtained from the use of forward and reverse vector primers demonstrated that
subclones P700 and PB700 were identical with the exception of a few additional base
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Figure 3.9a
Restriction enzyme digests of DNA from BSc4 and BSc4-derived
subclones (BH1.25, HP1.8, P700, and PB700), separated on an agarose
gel in preparation for Southern blotting.
(A ruler has been photographed alongside the gel so that if necessary the positions of
the molecular weight markers can be estimated on the corresponding autoradiograph of






































Hybridisation pattern observed when a Southern blot taken from the gel
shown in Figure 3.9a is incubated with the radiolabeled Vipr2 rat
Ac(500)4 cDNA probe
The probe can be seen to have hybridised to the plasmid inserts of HP1.8 and BSc4
(The autoradiograph is shown at actual size)
1kbladder BH1.25amHV indIII HP1.8indlll/ stI P700stI PB700stU amHI Bsc4amHI
Figure 3.10
Diagram showing the predicted positions of introns within the mouse
Vipr2 gene (as determined from sequence alignment with other members
of the secretin/glucagon receptor gene subfamily).
Within the mouse Vipr2 cDNA sequence, positions that are predicted to correspond to
intron sites within the Vipr2 gene are indicated with a red arrow, and are labelled
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Pvu II Bsp 1286 I
1340 1350 1360 1370 1380 1390 1400





1410 1420 1430 1440 1450 1460 1470




Nde I Ban I
1480 1490 1500 1510 1520 1530 1540
I I I I I I I
CTTAACTCTGATCCTCATGTGTAACTTGATTGAAACACCAATTATTATTGTCAAACTCTAGCCTTTAAGC
GAATTGAGACTAGGAGTACACATTGAACTAACTTTGTGGTTAATAATAACAGTTTGAGATCGGAAATTCG
1550 1560 1570 1580 1590 1600 1610
I I I I I I I
CATCTTCTTCATAATATGGCTCAGCCATATTCTACTTTCAAAGAGAGCAAGGAAGCCAGGTGGCTGTGAA
GTAGAAGAAGTATTATACCGAGTCGGTATAAGATGAAAGTTTCTCTCGTTCCTTCGGTCCACCGACACTT
1620 1630 1640 1650 1660 1670 1680
I I I I I I I
CATCAAAACTGGATTCTAGTACCTATGAAGAGAACAAGGAGGAAGATTCCAGTTCCCCTACTGCCTCCTG
GTAGTTTTGACCTAAGATCATGGATACTTCTCTTGTTCCTCCTTCTAAGGTCAAGGGGATGACGGAGGAC
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I I I I I I I
CTTCCTGGTCCCCCTAGCCTTGAGTTGTGTCCTGTGGAACTACATCTGGACAGCCACACCCTTGCCATTC
GAAGGACCAGGGGGATCGGAACTCAACACAGGACACCTTGATGTAGACCTGTCGGTGTGGGAACGGTAAG
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2040 2050 2060 2070 2080 2090 2100
I I I I I I I
TGTGACTTGTCCATTCAGCCCAGGGTTTGTTCTCTAGCCAATAGAAAACTGTTGCATTGTTAAAGAAAAT
ACACTGAACAGGTAAGTCGGGTCCCAAACAAGAGATCGGTTATCTTTTGACAACGTAACAATTTCTTTTA
2110 2120 2130 2140 2150 2160 2170





2180 2190 2200 2210 2220 2230 2240
I I I I I I I
CCGATACTTGCCAATAACAATCCATATTTTTCCGATGTTTTTGCAACTGTGGGCAAGCAGACCTGAGGAA
GGCTATGAACGGTTATTGTTAGGTATAAAAAGGCTACAAAAACGTTGACACCCGTTCGTCTGGACTCCTT
2250 2260 2270 2280 2290 2300 2310




Pvu II Pst I Bsp 1286 I
2320 2330 2340 2350 2360 2370 2380
I I I I I I I
AAGACTATGTCGTGGTCCAGTGCAAGGACTGTAGGTTCTGTACCTAGTGTTCTGGCACAGCCTATGTAAC
TTCTGATACAGCACCAGGTCACGTTCCTGACATCCAAGACATGGATCACAAGACCGTGTCGGATACATTG
2390 2400 2410 2420 2430 2440





pairs of vector polylinker sequence that was present at the end of P700, and both
subclones spanned genomic sequence corresponding to region from bp 1345 (-20 bp
upstream of the TAG translation 'stop' codon) to bp 2005 (in the 3' UTR) of the mouse
Vipr2 cDNA sequence.
Initial sequencing of subclone HP 1.8, using vector primers, showed that this subclone
contained genomic sequence corresponding to bp 1021-1344 of the mouse Vipr2 cDNA
sequence, and also contained -465 bp of intron sequence 5' to the start of the exon
sequence (cDNA bp 1021). Since this region of the mouse cDNA sequence was
thought to be encoded by predicted exons 11, 12, and 13 of the mouse gene, primers
(4341, 4342, 4343, 4344 and 5990) that were designed to bind to these exons, were
also used to sequence this subclone. The data obtained from these sequencing
reactions, confirmed that the intron/exon junctions in this region were present at the
positions predicted in Figure 3.10. An intron of 66 bp was found at the site of
predicted intron 11, and an intron of unknown size ( > 1 kb) was found at the site of
predicted intron 12. These results are consistent with the Southern blot results which
indicated that only sequences 3' of those corresponding to the rat 5' 1 kb Vipr2 cDNA
probe (i.e. the start of predicted exon 10) were present in the HP1.8 subclone.
In contrast to the other subclones, sequencing of subclone BH1.25 with vector
primers, did not reveal any sequences that displayed homology to the mouse Vipr2
cDNA sequence (although -500 bp of sequence was obtained from each side of the
insert). However, as this subclone was derived from the region that lies directly
upstream of subclone HP1.8 (which appeared to begin in intron 10 of the mouse Vipr2
gene), did not hybridise to rat Vipr2 cDNA probes on Southern blots, and could not be
sequenced using the exon 10 primer 4340, it seemed likely that BH1.25 consisted
entirely of sequence from intron 10.
3.3.10 Initial screen of the X2001 ES-cell-derived mouse genomic
library, for clones containing the Vipr2 gene
Although the BSc 4 subclone had been successfully isolated from the new XG4 phage
stocks, and was shown to contain sequences from the 3' end of the mouse Vipr2 gene,
attempts to isolate further Vipr2 gene derived restriction fragments from the AG4 clone
were discontinued when it was found that later preparations of DNA from the phage
stock were beginning to display the same type of anomalous restriction patterns that had
been observed with the original AG4 DNA preparation prior to plaque purification. The
reason for the apparent instability of the XG4 clone was not clear. However, as it
seemed that repeated plaque purifications would be required if the study of this clone
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was to be pursued any further, it was decided that it would be better in the long run, to
isolate new clones from another library.
Nevertheless, there was a positive side to this unexpected change of plan, as it provided
the opportunity to screen a mouse genomic library that was derived from ES-cells, a
factor which was not important with respect to the characterisation of the mouse Vipr2
gene's structure, but could be critical if the clones were to be used in gene targeting
studies at a later stage.
Plaque lifts were prepared from a mouse ES-cell derived genomic library (constructed
in the vector ?i2001; see Figure 2.5 for vector map) as described in section 3.2.10, and
following hybridisation of these filters with the full length rat Vipr2 cDNA probe, 31
positive clones were detected. Sixteen of the positive clones hybridised very strongly
to the Vipr2 cDNA probe, whereas the other fifteen hybridised more weakly. All 31
positive plaques were 'picked' (see 3.2.10), but initially only the ten plaques (clones
A1-A10) which were thought to show the strongest hybridisation to the probe, were
used in the initial secondary screen.
In the secondary screen, as in the primary screen, two filters were prepared from each
of the phage plates (see 3.2.10). However as one of the aims of the work on the Vipr2
gene was to isolate and characterise clones that contained the promoter region of the
Vipr2 gene, there was a particular interest in isolating clones containing the 5' end of
the Vipr2 gene's coding sequence, and consequently in the secondary screen, one filter
from each of the plates was hybridised with the full length rat Vipr2 cDNA probe,
while the other filter was hybridised with the 5' 260 bp probe. The results of these
hybridisations demonstrated that whereas all but one (A2) of the original 10 positive
clones hybridised to the full length rat Vipr2 cDNA probe in the secondary screen, none
of the 10 positive clones hybridised to the 5' 260 bp probe. Therefore, using the
autoradiographs from the filters that had been hybridised with the full length cDNA
probe, single plaques were isolated from the 9 positive plates, and were stored in SM
buffer until required (see 3.2.10). The filters that had been hybridised with the 5' 260
bp probe were then rehybridised with the rat Vipr2 5' 1 kb cDNA probe in an attempt to
determine whether any of these clones contained Vipr2 gene sequences that lay 5' of
those isolated from the A.G4 subclone BSc4, and with this probe, 5 positive clones
(Al, A3, A8, A9, and A10) were identified.
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3.3.11 Sequencing of selected clones from the initial screen of the
library
DNA for use in sequencing was prepared from 5 of the clones that had been isolated in
the secondary screen of the library. These clones included 4 clones that had hybridised
to both the 5' 1 kb probe and the full length Vipr2 cDNA probe ( A1, A3, A8, and A9),
and one clone (A7) that had hybridised only to the full length cDNA probe.
Preliminary sequence analysis of these clones was carried out by testing the ability of
two sequencing primers 3755 (which binds to sequence within predicted exon 3 of the
mouse gene) and 7992 (which binds to sequence within the 3' UTR of the mouse gene)
to sequence the clones. As suggested by the failure of these clones to hybridise to the
5' 260 bp rat Vipr2 cDNA probe (which ends at a point which corresponds to
predicted exon 3 of the mouse gene), none of the 5 clones was successfully sequenced
by primer 3775, although all 5 clones were sequenced correctly by the primer 7992.
These results suggested that all 5 clones originated from the 3' end of the mouse Vipr2
gene and did not contain exon sequence that extended further 5' than exon 4 of the
gene.
3.3.12 Screening of the X2001 mouse genomic library, for clones
containing the 5' region of the mouse Vipr2 gene
Since the 5 strongly hybridising clones that had been sequenced, all contained the 3'
end of the mouse Vipr2 gene, it began to appear that the clones that had initially shown
weaker hybridisation to the rat full length Vipr2 cDNA probe, might contain the 5' end
of the Vipr2 gene. To investigate this possibility, another secondary screen of the
X2001 library was carried out, this time using 11 plaques (clones Bl-B 11) that had
hybridised fairly weakly in the primary screen of the library. In this secondary screen
one set of filters was hybridised with the rat 5' 1 kb Vipr2 cDNA probe, while the
replica filters were hybridised with the rat 5' 260 bp probe. Out of the 11 clones, 8
clones (B2, B3, B4, B5, B7, B8, B9, and B11) hybridised to the rat 5' 1 kb Vipr2
cDNA probe, and 2 of these clones (B7 and B9) also hybridised to the 5' 260 bp
probe. A single plaque representing each of the hybridising clones was picked, and
stored in SM buffer until required.
3.3.13 Restriction digests, Southern blot analysis, and sequencing of
Vipr2 clones isolated from the A.2001 mouse genomic library
Further analysis of DNA from clone A8 (one of the 4 clones which had hybridised to
both the full length cDNA and the 1 kb 5' probe), and initial analysis of DNA from
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clones B7 and B9 (which had hybridised to the 5' 260 bp probe), was carried out using
a selection of sequencing primers (including 4336, 4340, 4343, 5991, 5992, 5993,
7122, 7898 and 9200) that were designed to bind to different exons of the mouse Vipr2
gene (see Table 3.1). The results of these preliminary sequencing reactions
demonstrated that DNA from B7 and B9 could be sequenced with the predicted exon 3
and exon 4 primers (4336 and 7898 respectively), and B9 DNA could also be
sequenced with the predicted exon 2 primer 7122. DNA from A8 was successfully
sequenced with predicted exon 7, 10, and 11 primers (9200, 4340, and 4343), and as it
had been previously been established that A8 DNA could be sequenced with primer
7992 from the 3' UTR of the mouse Vipr2 gene, it appeared that clone A8 began in the
intron 6/exon 7 region and extended into the 3' UTR of the mouse Vipr2 gene. With
the exception of intron 1 which did not appear to be present in either of the 5' clones,
the only Vipr2 gene exons that were not spanned by A8 or B9, were exons 5 and 6.
However, by testing exon 5 and exon 6 primers (5991 and 5993) on template DNA
from some of the other positive clones from secondary screen B (3.3.12), two clones
were identified: B3 (which contains exon 6), and B11 (which contains exons 5 and 6).
Subsequent studies then focused on the characterisation of clones B3, B7, A8, B9, and
B11, which from this point onwards are referred to as ES3, ES7, ES8, ES9, and ES11
respectively (regardless of whether they were isolated in secondary screen A or B).
Restriction digestion and Southern blotting of these clones was carried out first, with
the aim of identifying restriction fragments that contained Vipr2 gene exon sequences,
and obtaining some indication of the extent of overlap between the 5 clones.
Sequencing results had already demonstrated that clones ES7 and ES9 both contained
exons 3 and 4 of the mouse Vipr2 gene. However, when Southern blots of ES7 and
ES9 DNA were hybridised with the 5' 260 bp Vipr2 cDNA probe (which contained
sequences corresponding to regions within exons 1-3 of the mouse gene), some distinct
differences were found in the hybridisation patterns produced by these two clones
(Figures 3.1 la, 3.1 lb, 3.12a, 3.12b), indicating that the homology between might not
extend very far beyond exons 3 and 4 (a conclusion which was in agreement with the
failure of the exon 2 primer 7122 to sequence ES7 DNA). ES3 and ESI 1, which had
both been shown to sequence with the exon 6 primer, showed some similarities in their
hybridisation patterns, when blots of these clones were hybridised with the 5' 1 kb
Vipr2 cDNA probe (originally used to isolate these clones). Hybridising restriction
fragments that were of similar sizes from these two clones included: an ~4 kb Xho I
fragment, an ~ 4 kb Ava I fragment, and an ~5 kb BamR VSca I fragment (Figures
3.13a, 3.13b, 3.14a, 3.14b). Thus, it appeared that at least within the region spanned
by the 5' 1 kb cDNA probe, there was probably a substantial degree of overlap between
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Figure 3.11a
Restriction enzyme digests of DNA from clone ES7, separated on an
agarose gel in preparation for Southern blotting.
(A ruler has been photographed alongside the gel so that if necessary the positions of
the molecular weight markers can be estimated on the corresponding autoradiograph of














































































Hybridisation pattern observed when a Southern blot taken from the gel
of restriction digested ES7 DNA shown in Figure 3.11a is incubated
with the radiolabeled Vipr2 rat 5' 260 bp cDNA probe
(The autoradiograph is shown at actual size)
1kbladder ES7coRI ES7HindIII ES7NdeI ES7PvuI ES7SacI ES7SeaI ES7StuI ES7XbaI ES7XhoI ES7NotI ES7Sa/I ES7S/k?I 1kbladder
Figure 3.12a
Restriction enzyme digests of DNA from clone ES9, separated on an
agarose gel in preparation for Southern blotting.
(A ruler has been photographed alongside the gel so that if necessary the positions of
the molecular weight markers can be estimated on the corresponding autoradiograph of






























1kbladder ES9coRI ES9HindIII ES9NdeI ES9PvuI ES9SacI ES9SeaI ES9StuI ES9SalI ES9SpeI ES9Xhol/SpeI ES9XhoHEcoRI ES9XhoI/HindII
1kbladder
Figure 3.12b
Hybridisation pattern observed when a Southern blot taken from the gel
of restriction digested ES9 DNA shown in Figure 3.12a is incubated
with the radiolabeled Vipr2 rat 5' 260 bp cDNA probe
(The autoradiograph is shown at actual size)
1kbladder ES9coRI ES9HindIII ES9NdeI ES9PvuI ES9SacI ES9SeaI ES9StuI ES9SalI ES9SpeI ES9XhoVSpeI ES9^oI/E'coRI ES9XhoVHindIII
Figure 3.13a
Restriction enzyme digests of DNA from clone ES3, separated on an
agarose gel in preparation for Southern blotting.
(A ruler has been photographed alongside the gel so that if necessary the positions of
the molecular weight markers can be estimated on the corresponding autoradiograph of




















1kbladder ES3XhoI ES3AvaI ES3XhoHAval ES3PstI ES3PstVXhol ES3SeaI ES3XhoV eal ES3Sea1/BamHI ES3BamRl/XhoI 1kbladder
Figure 3.13b
Hybridisation pattern observed when a Southern blot taken from the gel
of restriction digested ES3 DNA shown in Figure 3.13a is incubated
with the radiolabeled Vipr2 rat 5' 1 kb cDNA probe
An ~4 kb hybridising Xho I fragment from ES3, which also appears to be present in
ESI 1 is arrowed in green, whereas an ~5 kb BamH I/Sea I fragment that hybridised to
the probe and was also detected in Southern blots of ESI 1, is arrowed in blue.
(The autoradiograph is shown at actual size)
1kbladder ES3XhoI ES3AvaI ES3XhoVAvaI ES3PstI ES3P^I/A%oI ES3SeaI ES3XhoIISea ES3SeaVBaniHI ES3BamlAVXhoI 1kbladder
Figure 3.14a
Restriction enzyme digests of DNA from clone ES11, separated on an
agarose gel in preparation for Southern blotting.
(A ruler has been photographed alongside the gel so that if necessary the positions of
the molecular weight markers can be estimated on the corresponding autoradiograph of























Hybridisation pattern observed when a Southern blot taken from the gel
of restriction digested ES11 DNA shown in Figure 3.14a is incubated
with the radiolabeled Vipr2 rat 5' 1 kb cDNA probe
A hybridising BamH I/Sea I fragment of ~5 kb that also appears to be present in ES3
and ES8, is arrowed in dark blue; and an ~4 kb hybridising Xho I fragment that is
found in both ES11 and ES3 is arrowed in green. The -5.5 kb Xho I fragment
arrowed in red is unique to ES 11 (i.e. is not present in ES3) and is thought to contain
the region of ES 11 that lies 5' to the start of ES3.
(The autoradiograph is shown at actual size)
1kbladder ES11XhoI ES11AvaI ES11XhoVAval ES11Pstl ES11PstVXhI ES11SeaI ES11XhoU caI ES11SeaVBamHI ES11BamHl/XhoI 1kbladder
ES3 and ESI 1. Indications that ES3 and ESI 1 may also overlap with the 5' end of
clone ES8, were provided by the identification of an ~5 kb BamU I/Sea I fragment
from ES8, which (as in the case of the similar sized BamH I/Sea I fragments from ES3
and ESI 1) hybridised to the 5' 1 kb cDNA probe (Figures 3.15a and 3.15b), and in
agreement with sequencing data, which had shown that ES8 contained sequences
corresponding to predicted exons 7-13 of the mouse Vipr2 gene, the number of
hybridising bands increased substantially when the ES8 blot was subsequently
hybridised with the full length Vipr2 cDNA probe (Figure 3.16).
Having gained some idea of which regions of the Vipr2 gene were contained within
each of the A clones, the A vector primers 7363 and 8482 were used to obtain sequence
data from the extreme 5' and 3' ends of the clones, and together with further
sequencing studies in which the exact exon content of each clone was determined
(using the exon specific primers listed in Table 3.1) this allowed the construction of a
map of the positions of these clones relative to the exons and introns of the mouse
Vipr2 gene. The results obtained from these studies (and those from subsequent
experiments in which the mouse Vipr2 gene's intron sizes were determined; see
sections 3.3.14 - 3.3.22), are summarised in Figure 3.17.
Primers that were designed to sequence outwards from the predicted exon sequences,
across exon/intron boundaries, were then used (with A DNA from the appropriate clone
as a sequencing template) to determine the sequence of each of the exon/intron
boundaries within the mouse Vipr2 gene (with the exception of the 5' boundary of
intron 1 for which an appropriate A template had not yet been isolated). The sequences
of all of the known exon/intron boundaries within the mouse Vipr2 gene, and the
positions of any of the mouse VIP2 receptor's amino acids that are interrupted by these
boundaries, are given in Table 3.2 The positions of the sequencing primers used are
shown in Figure 3.18 and their sequences are given in Table 3.1
3.3.14 PCR amplification of introns from the mouse Vipr2 gene
Once the intron/exon boundaries present within the insert sequences of the Vipr2 gene
clones had been established, attempts were made to amplify the intron sequences
present within these clones, so that the sizes of the introns within the mouse Vipr2 gene
could be determined. Twelve pairs of primers were designed initially, one pair to span
each intron of the mouse Vipr2 gene, and following PCR reactions in which these
primers were used with the appropriate A clone as template DNA, a single strong band
of PCR product was obtained from 6 of the PCR reactions (those designed to amplify
introns 3, 7, 8, 9, 11, and 12; Figures 3.19 and 3.20).
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Figure 3.15a
Restriction enzyme digests of DNA from clone ES8, separated on an
agarose gel in preparation for Southern blotting.
(A ruler has been photographed alongside the gel so that if necessary the positions of
the molecular weight markers can be estimated on the corresponding autoradiograph of









































Hybridisation pattern observed when a Southern blot taken from the gel
of restriction digested ES8 DNA shown in Figure 3.15a is incubated
with the radiolabeled Vipr2 rat 5' 1 kb cDNA probe
An ~5 kb ES8 BamH I/Sea I fragment, that hybridised to the 5' 1 kb probe, and also
appears to be present in ES3 and ESI 1, is arrowed in dark blue.
(The autoradiograph is shown at actual size)
1kbladder ES8XhoVBamRl ES8BamH.V, eaI ES8Seal/XhoI 1kbladder
Figure 3.16
Hybridisation pattern observed when a Southern blot taken from the gel
of restriction digested ES8 DNA shown in Figure 3.15a is incubated
with the radiolabeled full-length rat Vipr2 cDNA probe
Notably more bands are seen to hybridise to the full-length probe than to the 5' 1 kb
Vipr2 cDNA probe (see Figure 3.15b)
(The autoradiograph is shown at actual size)
1kbladder ES8XhoUBamH.I ES8BamHV caI ES8SeaIIXho 1kbladder
Figure3.17
MapofthemouseVipr2gen(incl dingapartialfEc Rl/XhoIrest ictionsi s)
EcoRIandXhodigestsoflambdaclo eenco ingthuseVipr2 ,havsf lyal wt ec nstr ctionfp rtialp

































Exon/Intron boundaries of the mouse Viprl gene
The exon/intron boundaries surrounding each intron of the mouse Vipr2 gene, are
paired in this table. Exon sequences are shown in black and intron sequences are shown
in green. In cases where the exon/intron junction interrupts an amino acid codon, the
amino acid and its position are given in the right hand column. However, when the
junction lies between codons, the amino acids situated on either side of the junction are
shown in brackets.
Boundary Sequences Amino Acid Interrupted





exon 2/intron 2 junction
GAATCAGAGAGGTAGGTTTGGGGA
Ala-50
intron 2/exon 3 junction
GCCTCTCCTTCTAGCCTGCAGCGGTGT
exon 3/ intron 3 junction
TCTACAGCAGACCAGGTATTTGCATTGATT
Gly-86
intron 3/ exon 4 junction
AAATTTACTTTCCAGGAAACATAAGCAA
exon 4/ intron 4 junction
GGATGAGAGTAAGGTAGGTGCCCGACCCG
None (Lys-118-Ile-119)
intron 41 exon 5 junction
exon 5/intron 5 junction
CTGCCTCTTCAGGTAAGGAACAAAA
Arg-151
intron 5/ exon 6 junction
CTCTCCCACTTCAGGAAGCTGCACTGCA
exon 6/ intron 6 junction
CAGCCAGCCTCCTGGGTAAGACTATCCTG
None (Tip-198-Val-199)
intron 61 exon 7 junction
TTCTCTCACTGTCTCTGGTTCCAGGTTGGCTGCAAGCTCAG
exon 7/intron 7 junction
CTGATCGGATGGGGTAAGGGCTTCATATTC
Gly-249
intron 7/ exon 8 junction
ATGGGTCTCTCCACAGCATCCCCAGTGT
Boundary Sequences Amino Acid Interrupted
exon 8/ intron 8 junction
TAGAAGACACAGGGTAAGTGCTATATGTGC
Gly-269
intron 8/ exon 9 junction
TTTCTTTCTCTCTAACAGTTGCTGGGACACAAACG
exon 9/ intron 9 junction
AATTTCTATTGTAGTAAGTAGCTGCC
None (Val-292-Val-293)
intron 9/ exon 10 junction
TCCTTTCTTGTCTCTGTGCAGGTCAACTTTGCCCTCTT
exon 10/ intron 10 junction
AGTCACAGTACAAGTGAGTATCTGCTTG
Lys-323
intron 10/ exon 11 junction
TCCTTCTCCTTTTACTAGGAGGCTTGCCAAGTC
exon 11/ intron 11 junction
TTGGTTCCTTCCAGGTAAGTATGGGAGGTG
None (Gln-366-Gly-367)
intron 11/exon 12 junction
CTCTGTCTCTTTGCAGGGCCTGGTGGTAGCAG
exon 12/ intron 12 junction
CTTCCTGAACAGTGAGGTAAGTCCTTTGTCAGC
None (Glu-380-Val-381)
intron 12/ exon 13 junction
CACGCTCATCCCCAGGTACAGTGTGAACTGA
Figure3.18
DiagramshowingthestructureofmouseVipr2gen ,andt p r ximatloc ti nfthsequencing primersthatwereusedindetermin tionoft ge 'sxon/intronboundar s.
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Figure 3.19
PCR products obtained from the amplification of intron 3 of the mouse
Vipr2 gene
Reactions in which the exon 3 primer 4336 and the exon 4 primer 7898 were used on
ES9 template DNA, resulted in the production of an intron 3 product of -2.0 kb.
(Also shown on this gel is the -2.5 kb product produced by primer 4336 and the ?i2001

















1kbladder ES94336/7898(int.3) ES94336/7898(int.3) ES94336/7363 ES94336/7363 -vecontrol4336/7898 -vecontrol4336/7363 1kbladder
Figure 3.20
PCR products obtained from the amplification of introns, 7, 8, 9, 11,
and 12 of the mouse Vipr2 gene
ES8 DNA was used as a template in all cases, and a strong single band of DNA was
produced from each of the amplification reactions.
Exon 7 primer 7894 and exon 8 primer 7892 produced an intron 7 product of — 1.1 kb
Exon 8 primer 7901 and exon 9 primer 7897 produced an intron 8 product of ~1.2 kb
Exon 9 primer 7895 and exon 10 primer 7896 produced an intron 9 product of 405 bp
(previously determined by sequencing)
Exon 11 primer 4341 and exon 12 primer 4342 produced an intron 11 product of 66 bp
(also previously determined by sequencing)
Exon 12 primer 5990 and exon 13 primer 4344 produced an intron 12 product of -1.1
kb
1kbladder ES85990/4344(int.12) ES87894/7892(int.7) ES87894/7892(int.7) ES87901/7897(int.8) ES87901/7897(int.8) ES87895/7896(int.9) ES87895/7896(int.9) ES84341/4342(int.ll) ES84341/ 342(int.11) ES85990/4344(int.12) 1kbladder
The PCR primers (4340 and 4343) that had been used in the initial attempt to amplify
intron 10, resulted in the generation of two bands of PCR products, one of ~ 1.2 kb
and one of -3.5 kb (Figure 3.21). However, PCR reactions that were carried out using
the same exon 10 primer (4340) with the exon 12 primer (4342), also produced a single
band of PCR product that was in the region of 3.5 kb (Figure 3.22), and as sequencing
of the A, clones had previously established that exon 11 and intron 11 were 130 bp and
66 bp long respectively, it appeared that intron 10 probably spans about 3.5 kb.
Similar problems were encountered in attempts to amplify intron 5 (using primers 5991
and 7900) and intron 6 (using primers 5993 and 9200), although in these cases the
problem was more extreme, as the primers produced multiple PCR products over a
wide range of sizes. Nevertheless, in both cases the replacement of the original exon 6
primer (7900 for intron 5 and 5993 for intron 6) with an alternative primer (9628 for
intron 5 and 9630 for intron 6), resulted in the generation of a single strong band of
DNA which was the predominant PCR product. In the case of the intron 5
amplification reactions this product was -600 bp long, whereas the predominant
product from the intron 6 amplification reactions was -1.2 kb long (Figure 3.23).
The failure of clone ES9 to sequence with primers that had been designed to bind to
predicted exon 1 of the mouse Vipr2 gene, suggested that this clone did not extend 5'
of intron 1 of the gene, a theory which was supported by the finding that sequencing of
this clone with the vector primer 8482 (which sequenced the 5' end of the ES9 clone)
did not produce recognisable Vipr2 exon sequence. However, as it remained possible
that the failure of the clone to sequence with exon 1 primers was due to the high GC
content of the first exon of the Vipr2 gene, PCR reactions were carried out in which the
exon 2 primer 7122 and the vector primer 8482 were used to amplify those sequences
within clone ES9 that lay upstream of exon 2. A PCR product of -1.2-1.3 kb was
produced in these reactions (Figure 3.24), and was subcloned into pGEM T-vector
(Promega; see Figure 2.3 for vector map) in preparation for sequencing.
Attempts to amplify intron 2 from ES9 template DNA (using primers 7853 and 7891,
or 7893 and 7891) were unsuccessful, and as indicated in section 3.3.13, none of the
clones that had been characterised spanned intron 4 of the Vipr2 gene.
The primer pairs used in the amplification of the mouse Vipr2 gene introns, and the
results obtained, are summarised in Table 3.3
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Figure 3.21
PCR products obtained from the amplification of introns 10, 11, and 12
of the mouse Vipr2 gene
In attempts to amplify intron 10 (using the exon 10 primer 4340 and the intron 11
primer 4343 on ES8 template DNA) PCR products of -3.5 kb and -1.2 kb were
produced. The intron 11 and intron 12 amplification reaction products shown on this
gel have previously been shown in Figure 3.20.
N)4^-
lkbadder ES84340/4343(int.1 ) ES84340/4343(int.10) ES84341/4342(int.1 ) ES84341/4342(int.1 ) ES85990/4344(int.12) ES85990/4344(int.12) -vecontrol4340/4343 -vecontrol4341/4342 -vecontrol5990/4344 1kbladder
Figure 3.22
PCR products obtained from the amplification of a fragment that spans
intron 10 and intron 11 of the mouse Vipr2 gene
The exon 10 primer 4340 and exon 12 primer 4342 were used with ES8 template DNA
to amplify a fragment of Viprl DNA that spans intron 10 and intron 11. The reaction
was set up in triplicate, and in each case a single PCR product of -3.5 kb can be seen.
1kbladder ES84340/4342(int.10+11) ES84340/4342(int.10+11) ES84340/4342(int.10+11) 1kbladder
Figure 3.23
PCR products obtained from attempts to amplify intron 5 (using primers
5991 and 9628) and intron 6 (using primers 9630 and 9200 or 8482 and
9200)
In intron 6 amplification reactions using the exon 6 primer 9630 and the exon 7 primer
9200 on ESI 1 template DNA, a predominant band of 1.2 kb can be seen.
In intron 5 amplification reactions using the exon 5 primer 5991 and the exon 6 primer
9628 on ESI 1 template DNA, a predominant band of 600 bp can be seen.
[Intron 6 amplification reactions using the A2001 vector primer 8482 and exon 7 primer
9200 on ES3 template DNA were unsuccessful (only low molecular weight primer
dimers were produced)]
If
1kbladder ES39200/8482 ES39200/8482 ES119200/9630(int.6) ES119200/9630(int.6) ES119628/5991(int.5) ES119628/5991(int.5) -vecontrol9200/8482 -vecontrol9200/9630 -vecontrol9628/5991 1kbladder
Figure 3.24
PCR products obtained from the amplification of the region of intron 1
of the Vipr2 gene that is present at the 5' end of clone ES9
Two primer pairs were tried in these reactions:
i) the A.2001 vector primer 8482 and the exon 1 primer 8484 (ES9 template DNA)
ii) the ^2001 vector primer 8482 and the exon 2 primer 7122 (ES9 template DNA)
However, as can be seen from the gel opposite, the 8482/8484 reaction appeared
unsuccessful, whereas the 8482/7122 reactions produced an extremely strong band of
PCR product which had a size of approximately 1.2-1.3 kb.
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3.3.15 Direct sequencing of the PCR products obtained from the
amplification of the mouse Vipr2 gene's introns
Sequencing of the intron PCR products with primers that had been used in the original
PCR reactions, demonstrated that the PCR products from introns 3, 7, 9, 10 + 11, and
12, contained sequence corresponding to that found at the appropriate Vipr2 gene
intron/exon junctions in the X clone inserts. The intron 8 PCR product was also found
to contain the expected sequences, although in this case the proximity of the PCR
primers to the ends of the exons, meant that the PCR product had to be cloned into a
plasmid vector and sequenced using vector primers in order to establish the sequence of
the intron/exon boundaries. In contrast, the PCR products from introns 5 and 6, were
each found to contain the expected sequences at one end of the PCR product but not at
the other, and it appeared that in both cases the primer that had been designed to bind to
exon 6 (primer 9628 in the intron 5 PCR reaction, and 9630 in the intron 6 PCR
reaction) had mis-primed.
Subcloning and Sequencing of intron 10 of the mouse Vipr2 gene
As intron 10 of the mouse Vipr2 gene was positioned within the region predicted to
encode the third intracellular loop of the VIP2 receptor, a site at which splice variation
had been detected (Mayo, 1992; Spengler et al., 1993) in transcripts encoding two
other members of the secretin/glucagon receptor subfamily, the complete sequence of
intron 10 was determined in an attempt to establish whether there was the potential for
splice variation to occur within this region of the mouse Vipr2 gene. Following the
subcloning of the intron 10+11 PCR product (see 3.3.14 for details of the PCR
reaction), a total of 9 primers were used to successively sequence inwards from either
end of intron 10 (Figure 3.18). However, although analysis of the sequence data
obtained from intron 10 (see Appendix 1) revealed that a sequence matching the
consensus sequence for splice acceptor sites (Mount, 1982) was present at bp 1315-
1342 of intron 10, subsequent analysis of potential open reading frames (ORFs) and a
search for possible splice donor sites did not lead to the identification of any potential
patterns of splice variation that seemed likely to lead to the generation of receptor
variants.
3.3.16 Further attempts at the PCR amplification of introns 2, 4, 5 and
6 of the mouse Vipr2 gene
Of the introns whose sizes had not yet been determined, there was reason to suspect
that at least two of these introns, introns 2 and 4, might be too large to amplify by
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conventional PCR methods. In the case of intron 4, these suspicions were based
purely on the fact that the Vipr2 cDNA probe had failed to detect any clones that
spanned intron 4 of the Vipr2 gene. However, for intron 2, strong evidence in support
of this idea was provided by the finding that intron 3 spanned only ~2 kb (see 3.3.14),
as it had previously been established that clone ES9 (which contains introns 2 and 3)
began -1.2 kb before the end of intron 1 (see 3.3.14) and ended a short distance (365
bp) into intron 4 (Figure 3.17). Consequently, during further attempts to amplify
intron 2 from ES9 template DNA, and attempts to isolate intron 4 from total mouse
genomic DNA, long PCR reagents and thermocycling conditions were used (which are
reported to be capable of amplifying fragments of up to 27 kb from X DNA and up to
40 kb from total genomic DNA, see 3.2.14). Nevertheless, despite these efforts to
extend the size range of the fragments that could potentially be amplified during these
reactions, no PCR products with sizes that were compatible with the predicted
minimum sizes of introns 2 or 4 were obtained.
As there was no reason other than the failure of initial PCR attempts, to suggest that
introns 5 and 6 of the mouse Vipr2 gene were particularly large, further attempts to
amplify these introns were made using standard PCR conditions. In both cases it
appeared that a lack of specificity on the part of the exon 6 primers was largely to blame
for the failure of the initial PCR reactions, but this was puzzling, as all of these exon 6
primers generated the expected sequence data from ES11 template DNA in sequencing
reactions. Since the main difference between the conditions used for sequencing
reactions and those used in the PCR reactions was the primer/template annealing
temperature, which was 57°C in the PCR reactions as opposed to 50°C in sequencing,
the effects of lowering the annealing temperature in the PCR reactions were
investigated. However, in contrast to the clear results obtained from sequencing
reactions, the use of a 50°C annealing temperature in PCR reactions aimed at
amplifying either intron 5 or intron 6, resulted in the production of multiple PCR
products which ranged in size from <500 bp to >5 kb (Figure 3.25).
3.3.17 Rescreen of the ?i2001 mouse genomic library, for clones that
span intron 4 of the mouse Vipr2 gene
In order to try to isolate a genomic clone that spanned intron 4 of the mouse Vipr2
gene, a rat Vipr2 cDNA probe that spanned the coding region corresponding to exon 3-
exon 6 of the mouse gene, was amplified from the full length rat Vipr2 cDNA sequence
using primers 4336 and 9629 (Table 3.1), radiolabeled, and then used to rescreen the
7,2001 mouse genomic library. Six positive clones (GC4, GD2, GD3, GD6, GD7,
and GD9) were identified in the primary screen, and following secondary and tertiary
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Figure 3.25
PCR products obtained in attempts to isolate intron 5 and intron 6 of the
mouse Vipr2 gene using MgCl2 concentrations and primer annealing
temperatures similar to those used for automated fluorescent cycle
sequencing.
Reactions using primer pair 5991/9629 (designed to amplify intron 5) and those using
primer pair 9630/9200 (designed to amplify intron 6), were carried out with ES11
template DNA. However in both cases a large number of bands were produced
including several that were of fairly high intensity, a result that made it very difficult to
identify the 'correct' product.
uj
1kbladder ES115991/9629(int.5) ES115991/9629(int.5) ES115991/9629(int.5) ES119630/9200(int.6) ES119630/9200(int.6) ES119630/9200(int.6) 1kbladder
screens, 5 positive clones (GC4, GD3, GD6, GD7, and GD9) were isolated.
However, sequencing of DNA prepared from each of these clones, showed that 4 of
the clones (GC4, GD3, GD6, and GD7) could be successfully sequenced with the exon
4 primer 7899, but not the with the exon 5 primer 7854 or the exon 6 primer 7900,
whereas the other clone (GD9) sequenced with the exon 5 and 6 primers but not with
the exon 4 primer. Therefore, although sequencing reactions with the X vector primers
7363 and 8482 indicated that the 5 clones were all different from one another, it
appeared that none of these clones spanned intron 4 of the mouse Vipr2 gene.
3.3.18 Rescreen of the 7.2001 mouse genomic library, for clones that
contain the 5' end of the mouse Vipr2 gene
Although the mouse and rat Vipr2 cDNA sequences showed very little divergence
within the region of coding sequence that lay directly downstream of the translation
start site, no clones containing sequence from predicted exon 1 of the mouse Vipr2
gene had been isolated in the initial screen of the mouse genomic library. However,
although there appeared to be very little sequence divergence between the 5' UTRs of
the mouse and rat Vipr2 cDNA sequences, it was possible that the relatively short
region (-90 bp) of homology between the rat and mouse sequences prior to intron 1
had not been sufficient for the detection of clones containing this region of the gene.
Therefore, when a 5' RACE PCR product (Q12) from the mouse Vipr2 cDNA was
isolated in our laboratory, and was shown to contain an additional 34 bp of sequence
extending 5' of the start of the rat Vipr2 cDNA, a decision was made to rescreen the
library using an - 190 bp Pst UXba I restriction fragment from the 5' end of the 5'
RACE product as a probe.
Hybridisation of the radiolabelled 5' RACE product restriction fragment (Q12 Pst UXba
I) to the plaque lift filters (previously used for the 'intron 4 rescreen' see 3.3.17)
resulted in the identification of 3 positive clones (ESC4, ESC5, and ESDI). However
the signal from clone ESC5 was weaker than that from the other two clones, and in
secondary screens only the ESC4 and ESDI plaque picks produced positive
hybridisation results. Initial sequence analysis of ESC4 and ESDI DNA (prepared
from liquid lysates, using Qiagen columns) was carried out using the mouse Vipr2 gene
predicted exon 1 primers 8483 and 8484 . DNA from clone ESC4 could not be
successfully sequenced with these primers, but the sequence data obtained from ESD1
DNA clearly demonstrated that this clone contained sequence corresponding to that
found at the extreme 5' end of the published mouse Vipr2 cDNA sequence (GeneBank
accession number D28132; Inagaki et al., 1994), and that found at the 5' end of the
mouse Vipr2 5' RACE product Q12.
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In addition to verifying that clone ESDI contained the 5' end of the coding region of the
mouse Vipr2 gene, the initial sequence data obtained from ESDI also provided: i) the
sequence of the exon 1/intron 1 junction (primer 8483) -the only known intron/exon
junction sequence that remained to be determined within the Vipr2 gene, and ii) the first
sequence data (-300 bp) from the putative promoter region of the mouse Vipr2 gene
(primer 8484).
Subsequent sequencing reactions with the \ vector primers 7363 and 8482, showed
that the 3' end of clone ESDI was situated a short distance (-36 bp) into intron 2 of the
mouse Vipr2 gene, whereas the 5' end of the clone was within a region of
unrecognised DNA sequence. Nevertheless, as later characterisation of the ESDI clone
showed that intron 1 of the mouse Vipr2 gene spanned -2.2 kb (see 3.3.19), it
appeared that clone ESDI must contain several kilobases of the putative promoter
region of the mouse Vipr2 gene. This clone therefore provided the starting point for
studies aimed at the identification and subcloning of fragments from the putative
promoter region, the results of which are described in Chapter 6.
3.3.19 PCR amplification of intron 1 of the mouse Vipr2 gene
As mentioned in the previous section, the isolation of clone ESDI, and the subsequent
demonstration (from sequencing data) that this clone contained intron 1 of the mouse
Vipr2 gene, finally provided a \ DNA template from which this intron could be
amplified by PCR. Three combinations of PCR primer pairs and 3 slightly different
DNA templates were used in attempts to isolate this intron: i) the exon 1 primer 8483
and the exon 2 primer 7122 were used with the ESDI Xba I subclone D1X2 as
template DNA; ii) the exon 1 primer 8483 and the vector primer 7363 (from the 3' end
of ESDI) were used with ESDI template DNA; and iii) the exon 1 primer 8483 and the
plasmid vector primer T7 were used with the ESDI Xba I subclone D1X8* as template
DNA. Reactions i and ii resulted in the generation of strong single bands of PCR
product that were ~2.2kb and -2.3 kb respectively (Figure 3.26). In reaction iii, a
predominant PCR product of -1.6 kb was generated, but the presence of at least two
other weaker PCR products in this reaction, hinted at the possibility of mispriming, and
this was subsequently confirmed by sequencing reactions which demonstrated that
primer 8483 had not primed correctly in PCR reaction iii. Nevertheless, sequencing of
the PCR products from reactions i and ii indicated that in each of these cases, the PCR
primers had primed correctly, and as the sequence obtained from the ends of these two
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Figure 3.26
PCR products obtained from the amplification of intron 1 of the mouse
Vipr2 gene
Three different sets of primer pairs were tested for their ability to amplify intron 1 of the
Vipr2 gene, and produced the following results:
i) in the reactions where the exon 1 primer 8483 and the exon 2 primer 7122, were
used with Xba I subclone D1X2 as template DNA, a product of -2.2 kb can be
seen.
ii) in the reactions where the exon 1 primer 8483 and the vector primer 7363 (from
the 3' end of ESDI), were used with ESDI template DNA, a product of -2.3 kb
can be seen
iii) in the reactions where the exon 1 primer 8483 and the plasmid vector primer T7,
were used with the ESDI Xba I subclone D1X8 as template DNA, a
predominant product of 1.6 kb can be seen but some fairly strong secondary
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PCR products included both the 5' and 3' boundaries of intron 1, this demonstrated
that intron 1 of the mouse Vipr2 gene spans -2.2 kb.
*Further details of these subclones (which both contain intron 1 of the mouse Vipr2
gene, are given in Chapter 6.
3.3.20 Subcloning and sequencing of DNA fragments spanning introns
2, 5, and 6 of the mouse Vipr2 gene
The sizes of introns 2, 5, and 6 of the mouse Vipr2 gene were eventually determined
through the subcloning and sequencing of restriction fragments from the X clones that
were known to span these introns (ES9 for intron 2, and ESI 1 for introns 5 and 6).
The restriction enzymes that were selected for use in the 'shotgun' subcloning (see
3.2.15) of restriction fragments from these introns were enzymes that did not cut within
the X vector arms other than at the polylinker site. Xba I was used in the case of intron
2, as it was known to release the insert fragment from clones and was also predicted to
cut at a site within exon 2 of the Vipr2 gene (thus providing a reference point for
determining the positions of the other Xba I restriction fragments), whereas for introns
5 and 6 a combination of single and double digests was carried out using Xho I (which
releases the insert fragment) and Sea I (which was predicted to cut in exon 7 of the
mouse Vipr2 gene).
Following digestion of ES9 DNA using Xba I, 8 different restriction fragments could
be seen when the products were run on an agarose gel (Figure 3.27), and a series of
plasmid subclones containing these restriction fragments was isolated using the method
described in 3.2.15. Sequencing of the ES9 subclones using vector primers (T7 and
SP6), allowed the identification of the 2 subclones that were derived from the 5' and 3'
ends of ES9, and the order and positions of the intervening fragments were then
determined by sequencing the junction regions between the subclones (using ES9 DNA
as a template, and primers that were designed to sequence outwards from the
appropriate end of subclones). The final order of the subclones, their sizes, and the
positions of the primers that were used, are shown in Figure 3.28. All but one of the
subclones contained at least some intron 2 sequence, and once a small gap in the middle
of the subclone contig had been closed by direct sequencing of ES9 DNA (see Figure
3.28), the size of intron 2 of the mouse Vipr2 gene was estimated to be -12.6 +/-1 kb.
The first step towards determining the sizes of introns 5 and 6 was the subcloning of
two Xho I restriction fragments (of -4 kb and -5.5 kb) from clone ES11 (which
begins towards 3' end intron 4). The presence of the 4 kb Xho I fragment, but not the
5.5 kb fragment, in Xho I digests of ES3 (which begins in intron 5) had indicated that
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Figure 3.27
Gel electrophoresis of ES9 DNA following restriction digestion
In lane 3 (ES9 Xba I) the 8 Xba I restriction fragments (that were later subcloned into
pGEM®-7Zf) can be seen to range from -600 bp (just visible, appears as two dots) to
-4 kb
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the 5.5 kb fragment originated from the region of ES11 that lay 5' to the start of ES3,
and this was confirmed by the sequence data obtained from the clones, which showed
that the 5.5 kb Xho I subclone (ES 11 Xh5) could be successfully sequenced with the
exon 5 primer 5991 but not with exon 6 primers 9629 or 9630, whereas the 4 kb
subclone (ES 11 Xh4) could be sequenced with the exon 6 primers but not the exon 5
primers. To determine whether the two Xho I fragments were situated directly adjacent
to one another within ESI 1, the region corresponding to presumed junction between
the two subclones was sequenced (using primer 19458 and ESI 1 template DNA). The
results obtained clearly indicated that the two fragments were directly adjacent, and
therefore together spanned intron 5 of the mouse Vipr2 gene. However, as ES 11 Xh4
contained regions of both intron 5 and intron 6, it was not known what proportion of
the ES 11 Xh4 insert belonged to intron 5. Therefore, PCR reactions were carried out
in which the regions of the insert between the plasmid vector primers (pUC/M 13
forward and reverse primers) and the exon 5 primers 9629 (which extends towards
intron 5) or 9630 (which extends towards intron 6) were amplified. A single band of
PCR product of ~ 3 kb was produced using primer 9629 in conjunction with the
pUC/M 13 reverse primer, and a single product of -1.1 kb was generated using primer
9630 in conjunction with the pUC/M13 forward primer (Figure 3.29). This
demonstrated that -3 kb of ESI 1 Xh4 was composed of intron 4 sequence, and -1 kb
of ES 11 Xh4 was composed of intron 5 sequence. The proportion of intron 5
sequence in the subclone ES 11 Xh5, and the distance from the 3' end of ES 11 Xh4 to
the start of exon 7, were subsequently determined through the mapping of the positions
of 3 subcloned Sea I restriction fragments and 3 subcloned Sea UXho I restriction
fragments, from ESI 1. The results of these mapping studies are summarised in Figure
3.30, from which it can be seen that intron 5 of the mouse Vipr2 gene spans - 7.3 kb
and intron 6 spans -5.8 kb.
3.3.21 Retrospective PCR analysis of introns 5 and 6 of the mouse
Vipr2 gene
The estimated sizes of introns 5 and 6 (-7.3 kb and -5.8 kb respectively; see 3.3.20)
suggested that these introns were close to the upper size limit of fragments that could be
amplified by conventional PCR. Nevertheless, products of approximately these sizes
could be seen amongst the multiple PCR products that had been obtained from the
intron 5 and 6 amplification reactions in which the primer/template annealing
temperature had been lowered to 50°C (see section 3.3.16 and Figure 3.25 ).
Attempts to increase the specificity of these reactions, by reducing the number of PCR
cycles from 35 to 30, had a particularly significant effect on the intron 5 amplification
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Figure 3.29
PCR products obtained from the amplification of the regions of subclone
ES11 Xh4 that are situated between:
i) the vector pUC/Ml 3 reverse primer (RP) site and that for the exon 6 upstream-facing
primer 9629,
ii) the pUC/M13 forward primer (FP) site and that for the exon 6 downstream-facing
primer 9630.
The product seen in the two RP/9629 reactions clearly shows that the 9629 primer site
is ~3 kb from one side of the plasmid vector, whereas the two FP/9630 reactions show
that the 9630 primer site is -1.1 kb from the other side of the plasmid vector.
1kbladder ES11Xho(2)RP/9629 ESllXho(2)RP/9629 ESllXho(2)FP/9630 ES11Xho(2)FP/9630 1kbladder
Figure3.30
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reactions, and when the reaction products were separated on an agarose gel, a single
band of -7 kb and a low molecular weight band of 'primer dimers' were seen (Figure
3.31). Unfortunately, the effect that this modification had on the intron 6 amplification
reactions was less drastic (Figures 3.31 and 3.32), and although a distinct band of
~5.5-6 kb could be seen on an agarose gel, this was not the only PCR product
produced in the intron 6 amplification reactions.
Following Microcon™-100 purification of the 7 kb intron 5 PCR product (see 3.2.13),
and gel extraction of the ~5.5-6 kb intron 6 PCR product (using a QIAEX gel extraction
kit; see Chapter 2), the isolated PCR products were sequenced using primers that were
designed to prime to internal regions of the appropriate intron and generate sequencing
products that extended outwards to the ends of the introns. This worked well with the
intron 5 PCR product, which, when sequenced with primers 20847 and 20848,
generated sequence data that corresponded to known intron 5 sequence and terminated
at the exon target sites of the primers that had been used in the intron 5 PCR
amplification reactions. However, the results of the sequence analysis of the intron 6
PCR product, were less clear, as when this PCR product was sequenced with the
intron 6 primers 22568 and 22569, a dramatic decrease in the strength of the
sequencing signal, as opposed to termination of the signal, was seen at the site of the
original exon 7 primer, and a more gradual decrease in the signal strength was observed
around the site of the original exon 6 primer (Figures 3.33 and 3.34), suggesting that
non-specific secondary products from the intron 6 PCR reaction had been present in the
gel slice.
3.3.22 Second rescreen of the A.2001 mouse genomic library, for clones
that would close the intron 4 'gap'
Since intron 4 was now the only Vipr2 gene intron for which a size had not been
determined, a final effort was made to isolate this intron .
During the sequencing of Xba I restriction fragments from the intron 2 region of clone
ES9 (3.3.20), it had been noticed that the sequence obtained from the 5' end of the ES9
Xba I subclone 2 (see Figure 3.28), aligned (from -bp 316) with sequence data that
had been obtained from reactions in which clone ES7 (also known as B7; see 3.3.12 )
was sequenced using the A, vector primer 7363. This placed the 5' end of clone ES7 ~
1.1 kb from the intron 2/exon 3 junction, and since the total length of exon 3, intron 3
and exon 4 was -2.2 kb, it appeared that all but -3.3 kb of the > 14 kb ES7 insert
must be from intron 4 of the mouse Vipr2 gene. Further sequencing of clone ES7,
confirmed that this clone contained exons 3 and 4 of the mouse Vipr2 gene, but the
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Figure 3.31
PCR products obtained from reactions in which primers designed to
amplify intron 5 (5991 and 9629) and intron 6 (9630 and 9200) of the
mouse Viprl gene were used on ES11 template DNA.
In each of the four intron 5 amplification reactions an isolated DNA band of
approximately 7 kb (which is very similar to the estimated size of intron 5 that was
predicted from restriction mapping studies ; see Figure 3.30) is the only clearly visible
product apart from the 'primer dimers' seen towards the bottom of the gel. In the intron
6 amplification reactions multiple products can be seen, but the largest of these is close
in size (~5-6 kb) to that estimated from restriction mapping studies (5.8 kb; see Figure
3.30) and the reaction was therefore re-run on another gel to obtain a more accurate
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Figure 3.32
PCR products obtained from a PCR reaction in which primers (9630 and
9200) designed to amplify intron 6 of the mouse Vipr2 gene were used
on ES11 template DNA.
Six identical reactions were set up, and although in each case multiple PCR products
were produced, a DNA band of just under 6 kb (a size very close to that expected from
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failure of attempts to sequence this clone using the exon 5 primer 7854, indicated that
ES7 did not contain the whole of intron 4. To establish whether any of the clones that
had been isolated previously, overlapped with the 3' end of ES7, a primer (17982) that
was designed to bind to a site near the 3' end of the ES7 insert, was tested in
sequencing reactions containing template DNA from clones ES9, GC4, GD3, GD6,
GD7, GD9, ESI 1, and ES7 (positive control). However, apart from ES7, none of the
clones were successfully sequenced by this primer 17982, a result which suggested that
ES7 extended further into intron 4 (from the exon 4/intron 4 junction) than clones ES9,
GC4, GD3, GD6, or GD7, but did not extend far enough to overlap with the 5' ends
of clones GD9 or ES11 (clones that contain the intron 4/exon 5 junction).
As the minimum size of intron 4 was at this stage estimated to be -12 kb (at least 11 kb
from ES7 + -1 kb from ESI 1), two genomic Vipr2 probes (as opposed to the rat
cDNA probe used earlier) were used in the final attempt to close the intron 4 'gap'.
Both probes were subcloned genomic restriction fragments from intron 4 of the mouse
Vipr2 gene, one was a 3.5 kb EcoR VXba I restriction fragment that contained the 3'
end of clone ES7, and the other was a 1.3 kb Sea VXho I restriction fragment from the
5' end of ESI 1 (ESI 1 S/X 2; see Figure 3.30). Twenty pairs of plaque lift filters were
screened in total, and in order to try to isolate a clone that spanned the gap between the
two probes, one set of filters was incubated with each of the radiolabeled probes, in
the hope of identifying a clone that hybridised to both probes. However, in the primary
screen no plaques were seen to hybridise to both probes, although several plaques were
found to hybridise to one or other of the probes. Six plaques were selected from the
primary screen (3 plaques that hybridised to the ES7 probe, and 3 that hybridised to the
ESI 1 probe), but following secondary screens only 2 clones (ES9B and ESI OB) were
found to produce duplicate positives with the ES7 derived probe, and 1 clone (ES8A)
produced duplicate positives with the ES 11 derived probe.
Sequencing of X DNA from ES9B, ESI OB, and ES8A, revealed that only ESI OB
could be successfully sequenced with primer 17982 (which was designed to bind to the
3' end of ES7). However, in agreement with the failure of this clone to hybridise to the
ES 11 derived probe from the 3' end of intron 4, ES 10B could not be sequenced with
the exon 5 primer 7854. Therefore, although it seemed likely that ES10B extended at
least as far into intron 4 (from the 5' end of the intron) as ES7 and possibly further, it
was unlikely that ESI OB on its own could close the gap in the intron 4 contig.
Unfortunately, sequencing of clone ES8A (the only clone isolated using the ESI 1
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located only ~ 100 bp upstream of the start of ES11, and no overlap between the 5' end
of ES8A and the 3' end of ES10B was found in the sequence data.
Nevertheless, to determine how far ESI OB extended beyond the end of ES7, an EcoR
VXho I and several EcoR I restriction fragments were subcloned from ESI OB (using
the 'shotgun' cloning method described in 3.2.15). Preliminary sequence analysis of
these subclones (using T7 and SP6 primers) resulted in the identification of two
subclones that contained previously determined intron 4 sequences: i) an -2.5 kb EcoR
VXho I restriction fragment (ES 1 OB E/X) which began at the 5' end of the ES 10B
insert sequence, and ii) an -4 kb EcoR I restriction fragment (ES10B E2) that began at
the same point in intron 4 as the -3.5 kb EcoR VXho I subclone from the 3' end of
ES7, and was shown (by sequencing of the junction region using ESI OB X DNA as a
template) to lie directly adjacent to the 3' end of subclone ES10B E/X (see Figure
3.35). This placed the 3' end of clone ES7 -3.5 kb from the 5' end of the 4 kb
subclone ESI OB E2, and since it had been shown (through the sequencing of ES 10B
E/X ) that the 5' end of ES 10B lay -2.5 kb upstream of ES 10B E2, the overlap
between the 5' end of the -13 kb insert sequence from ES 10B and the 3' end of the
ES7 insert, was estimated to be -6 kb. Therefore, as ES10B extended -7 kb further
into intron 4 than ES7, but did not overlap with ESI 1 sequence from the 3' end of the
intron, it appears that intron 4 of the mouse Vipr2 gene spans >19 kb.
3.4 Discussion
The results presented in this chapter indicate that the introns and exons within the
protein encoding region of the mouse Vipr2 gene are likely to span over 59 kb in total
(see Figures 3.17, 3.18, and Table 3.4). The exons that were identified range in size
from 42 bp to 171 bp (excluding the 5' and 3' UTRs), and the introns range in size
from 66 bp to >19 kb. With the possible exception of the intron 7/exon 8 junction
(where the sequence data obtained is suspected to contain an error), all of the
exon/intron junctions conform to the consensus GT-AG rule for splice junctions
(Breathnach et al., 1978). Twelve introns and thirteen exons were found in the mouse
Vipr2 gene, and the positions of the intron sequences within the gene were very similar
to those of introns in other members of the secretin/glucagon receptor gene family.
Indeed, apart from intron 1, all of the Vipr2 gene introns were found very close to the
locations that had been predicted from the alignment of the mouse Vipr2 cDNA
sequence with the exon sequences of other members of the receptor gene subfamily.
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Table 3.4
All the sizes given are approximate with the exception of those for intron 9 and intron
11 (which were calculated from data produced during sequencing of the mouse Vipr2
clones). The size of intron 4 is unknown but is estimated to be at over 19 kb (see main
text for details). *As the position of the polyadenylation site of the mouse Vipr2
transcripts had not been established at the time this work was carried out, and the total
length of the cDNA was therefore unknown. The transcript size (~ 3.7 kb) used in the
calculation of the minimum size of the mouse Vipr2 gene was taken from the results of
northern blots (probed for the presence of Vipr2 transcripts), published by Inagaki et
al., 1994..
Summary of mouse Vipr2 gene
intron sizes
Intron number Intron size (kb)
1 -2.2
2 -12.5 (+/- l)
3 -2.0









Total length of introns isolated so far = -56.2 kb
Length of mRNA sequence* = -3.7 kb
59.9 kb
As further information about the gene structures of other members of the
secretin/glucagon receptor family has accumulated (Aino et al., 1995; Albrandt et al.,
1995; Burcelin et al., 1995; Liaw et al., 1996; Lok et al., 1994; Sreedharan et al.,
1995; Tsai-Morris et al., 1996; Yamada et al., 1995b), it has become increasingly
apparent that the positions of the exon/intron boundaries, particularly those in the
regions encoding the transmembrane domains, are very highly conserved among
members of this receptor gene subfamily. The positions of the introns that were
identified in the mouse Vipr2 gene indicate that: the predicted transmembrane region
(TM) 1 of the receptor is encoded by exon 5; TM2 is encoded by exon 6; TM3 and first
half of TM4 (TM4a) is encoded by exon 7; TM4b is encoded by exon 8; TM5a is
encoded by exon 9; TM5b is encoded by exon 10; TM6 and TM7a are encoded by exon
11; TM7b is encoded by exon 12; and the predicted cytoplasmic tail and 3' UTR are
encoded by exon 13 (see Figure 3.36). This basic intron/exon structure is shared with
the majority of other receptor genes from this subfamily that have been characterised to
date, including: the PTH/PTHrP receptor gene (Kong et al., 1994), the human GIP
receptor gene (Yamada et al., 1995b), the rat CRF type I receptor gene (Tsai-Morris et
al., 1996), the human VIP type I receptor gene (VIPR1; Sreedharan et al., 1995), the
mouse PACAP type I receptor gene (Pacaprl; Aino et al., 1995), the mouse GHRH
receptor gene (Lin et al., 1993), and the human and mouse glucagon receptor genes
(Burcelin et al., 1995; Lok et al., 1994). However, two notable exceptions exist: i) the
pig and human calcitonin receptor genes, in which a single exon spans the region
encoding TM5b, TM6, and TM7a (Albrandt et al., 1995; Zolnierowicz et al., 1994),
i.e. there is no intron at the position that corresponds to that of intron 10 of the mouse
Vipr2 gene; and ii) the rat glucagon receptor gene, in which a single exon spans the
region encoding TM6 and TM7 (Maget et al., 1994), i.e. there is no intron at the
position that corresponds to that of intron 11 of the mouse Vipr2 gene. Interestingly,
the human gene encoding the secretin/glucagon receptor family related molecule CD97
(see Chapter 1), which is thought to have evolved from an ancestral secretin/glucagon
receptor family gene, is similar to the rat glucagon receptor gene in that TM6 and TM7
are encoded by a single exon (Hamann et al., 1996). However, as it has been
proposed that the rat glucagon receptor may represent an intermediate form in the
evolution of the more commonly observed two exon division of this region
(TM6+TM7a, and TM7b) (Tsai-Morris et al., 1996), it seems likely the CD97 gene
diverged from the secretin/glucagon receptor gene family before the current structures
of genes like those encoding the CRF and VIP receptors had evolved.
The regions of the secretin/glucagon receptor family genes that encode the predicted N-
terminal extracellular domains of the receptors, display greater variability in their
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Figure3.36
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organisation than those encoding the transmembrane-spanning regions and C-terminal
tails. As with the amino acid sequences of the N-terminal regions of these receptors,
the exon/intron structures of the N-terminal encoding regions of the receptor genes are
generally well conserved across species for a given receptor, but often vary
significantly between different members of the receptor gene family. Nevertheless,
despite the increased variability within this region, a common intron/exon pattern in
which the N-terminal region is encoded by 4 exons, is found in several members of the
receptor gene family including the genes encoding the GHRH receptor (Lin et al.,
1993), calcitonin receptor (Albrandt et al., 1995; Zolnierowicz et al., 1994), glucagon
receptor (Burcelin et al., 1995; Lok et al., 1994; Maget et al., 1994), CRFj receptor
(Tsai-Morris et al., 1996), and the VIP] receptor (Sreedharan et al., 1995). The data
obtained in this study shows that the mouse Vipr2 gene also has 4 exons encoding the
predicted N-terminal extracellular domain of the receptor (Figure 3.36), and therefore
differs from: i) the mouse PACAP type I receptor gene (the protein product of which
shares -50% sequence homology with the mouse VIP2 receptor; Inagaki et al., 1994)
and the PTH/PTHrP receptor gene, which both contain additional exons within this
region (2 additional exons in the case of the PACAP type I receptor gene, and 1
additional exon in the case of the PTH/PTHrP receptor gene: Aino et al., 1995; Kong et
al., 1994); ii) the human CRF type 2 receptor gene, in which 3 exons encode the
predicted N-terminal extracellular domain of the receptor (Liaw et al., 1996).
The PTH/PTHrP receptor gene, pig calcitonin receptor gene, and the GIP receptor
gene, have each been shown to contain 5' untranslated exons (3, 2, and 1 respectively;
McCuaig et al., 1995; Yamada et al., 1995b; Zolnierowicz et al., 1994), and there is
evidence to suggest that several other genes from the secretin/glucagon receptor
subfamily also contain 5' untranslated exons. PCR-based studies of rat PACAP type I
receptor cDNAs indicate that the Pacaprl gene is likely to contain at least 3 non-coding
exons within its 5' UTR (Chatterjee et al., 1996a), and it appears that the rat glucagon
receptor also contains at least 2 untranslated exons in its 5' UTR (Maget et al., 1996b).
However, in many cases these 5' untranslated exons had not been detected when the
structures of the genes were initially published, and therefore although no 5'
untranslated exons have been identified within the VIPR1 gene as yet, the possibility
that such exons exist cannot be excluded. Similarly, despite the fact that the Vipr2
gene exons identified during this study span the entire 5' untranslated and coding
regions of the published mouse cDNA sequence, it is entirely possible, and perhaps
even probable, that unidentified 5' untranslated exons exist within the mouse Vipr2
gene, particularly if they are transcribed in a tissue specific fashion (as occurs in the
PTH/PTHrP receptor gene (Amizuka et al., 1997; McCuaig et al., 1995; and probably
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also in the rat glucagon receptor gene; Maget et al., 1996a; Maget et al., 1996b).
Attempts to define the transcriptional start site(s) within the Vipr2 gene have been made
(see Chapter 6), and suggest that at least in the mouse AtT20 cell line, the 5'
untranslated region of the Vipr2 transcripts is encoded by the same exon as the ATG
translational start site. To date, these studies have not been extended to other cell lines
or tissues. Nevertheless, if candidate 5' untranslated exons are eventually identified
from studies of Vipr2 cDNA sequences, there is a reasonable chance that any
corresponding regions of mouse genomic DNA would be present within clone ESDI,
which appears to have a total insert size of > 20 kb (close to the upper size limit of -23
kb for ^2001 inserts; Karn et al., 1984) and is predicted to contain at least 17.5 kb of
Vipr2 gene 5' flanking sequence.
The genes encoding members of the secretin/glucagon receptor family, range
considerably in size. At the lower end of the size range, are the rat and mouse glucagon
receptor genes, which have coding regions that span -4 kb, and were characterised
almost entirely by subcloning and sequencing of X clones that were isolated from
genomic libraries (Burcelin et al., 1995; Maget et al., 1994). In contrast the pig
calcitonin receptor gene, which is the largest member of the secretin/glucagon receptor
gene family to be isolated to date, spans approximately 70 kb in total (including its two
5' untranslated exons), and was characterised using a combination of partial digestion
restriction mapping, subcloning, and PCR amplification of X clones (Zolnierowicz et
al., 1994). With a coding region that is estimated to span at least 59 kb of genomic
DNA, the mouse Vipr2 gene is one of the largest of the members of this receptor gene
family that have been cloned to date, and at present appears to be second in size only to
the pig calcitonin receptor gene [although if the human calcitonin receptor gene
(Albrandt et al., 1995) has a 5' UTR exon structure similar to that found in pig
(Zolnierowicz et al., 1994), it may also be larger than the mouse Vipr2 gene]. Another
large gene from this family is the mouse Pacaprl gene, which is reported to span over
50 kb (Aino et al., 1995), a size which includes only one of the three 5' untranslated
exons that have been shown to be present in the rat gene (Chatterjee et al., 1996a).
However, the human VIPR1 gene, (the product of which, shows -50% homology to
the rodent VIP2 receptor at the amino acid level; Sreedharan et al., 1995) is much
smaller than either the mouse Vipr2 gene or the Pacaprl gene, and with a protein
coding region that spans -22 kb of genomic DNA (Sreedharan et al., 1995), is similar
in size to the coding region of the PTH/PTHrP receptor gene (Kong et al., 1994).
The two largest introns identified within the mouse Vipr2 gene, introns 2 and 4 (which
are -12.5 and >19kb respectively), are located in the region that encodes the predicted
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N-terminal extracellular domain of the receptor (see Figure 3.36). Problems were
encountered in determining the sizes of both of these introns, and although the
approximate size of intron 2 was eventually estimated by the addition of restriction
fragments sizes, this was not an ideal way to determine the size of this intron, and there
could easily be an error of +/- 1 kb in the final value. The reason for the failure of
attempts to amplify intron 2 using long PCR, is not fully understood, but it may be due
at least in part, to the quality of the ES9 template DNA that was used, as although no
problems were encountered with the use of this DNA in other procedures (including
automated fluorescent sequencing, which is generally very sensitive to template
quality), the success of the Expand™ long template PCR system (Boehringer
Mannheim) is reported to be highly dependent on the purity of the template DNA that is
used. Similar problems may have affected attempts to amplify intron 4 using this
method, as although human genomic DNA specifically produced by Boehringer
Mannheim for use with the Expand™ long template system, has been successfully used
in our laboratory to amplify fragments from the human VIPR2 gene, mouse genomic
DNA is not available from this company. However, it is equally possible that the
conditions used in attempts to amplify intron 4 were not optimal (as this becomes
increasingly critical when amplifying longer fragments, particularly from total genomic
DNA templates), or that intron 4 of the mouse Vipr2 gene is larger than the maximum
size (-27 kb) that can be efficiently amplified from genomic DNA by this system.
Although the isolation of mouse genomic clones that span intron 4 of the Vipr2 gene, is
not essential for the determination of this intron's size (as if necessary the intron size
could be estimated by long range restriction mapping and blotting) it would greatly
assist the process. Since it has now been shown that this intron is likely to span over
19 kb, the inability of the original cDNA probe to isolate clones that spanned intron 4,
is no longer surprising. However, although the switch from a cDNA probe to the use
of genomic probes (see 3.3.22) helped in the isolation of clones that extended further
into intron 4 from its 5' end, the failure of any of the library screens to identify a clone
that extended more than -1 kb into intron 4 from the 3' end of this intron, seemed
strange when the library had provided more than adequate coverage of other regions of
the mouse Vipr2 gene, and could be an indication that this region is somewhat resistant
to cloning.
Interestingly, introns 2 and 4 are two of only three introns whose sizes have not yet
been determined in the human VIPR2 gene, (although intron 2 is known to span >5 kb;
E. Lutz, unpublished data), but the problems that have been encountered in attempts to
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amplify these introns by PCR from human genomic DNA, suggest that they may also
be amongst the largest introns in the human gene.
As indicated by the large variation in the sizes of the genes that encode members of the
secretin/glucagon receptor subfamily, the sizes of the introns present in these genes
vary widely from one receptor gene to another, and there is no overall pattern in the
spacing of the exons in genes that encode different members of the receptor subfamily.
On the other hand, the size of a given receptor gene does appear to be conserved to
some extent across species boundaries. For example, the coding region of the
glucagon receptor gene spans ~4 kb in rat and mouse (Burcelin et al., 1995; Maget et
al., 1994), and -5.5 kb in human (Lok et al., 1994), whereas the rat, mouse, and
human PTH/PTHrP receptor genes each span -22 kb (including one of the 5'
untranslated exons; Kong et al., 1994). Attempts were made to examine (from the
published literature) whether the sizes (or relative sizes) of individual introns within a
given receptor gene were generally conserved across species boundaries, but the low
number of secretin/glucagon receptor subfamily genes that have been cloned from more
than one species, and the small scale diagrammatic form in which the gene structures
are often published, made it difficult to obtain any conclusive answers to this question.
Nevertheless, from the sizes of the mouse Vipr2 gene introns that were determined in
this study, it appears that several of the mouse Vipr2 gene's introns (1, 7, 8, 11, and
12) are similar or identical in size to those found in the human gene, despite distinct
species differences in the sizes of introns 3, 5, 6, 9, and 10. The similarities in the
sizes of some of these introns could of course be completely coincidental, but the
pairwise distribution of the conserved (7&8, 11&12) and nonconserved (5&6, 9&10)
intron sizes is curious, and although its significance, if any, is not entirely clear, it may
in some way reflect the rearrangements that occurred during the evolution of the VIP
receptor type 2 gene.
Splice variation has been found to occur in transcripts of several members of the
secretin glucagon receptor gene family (see also Chapter 1). The positions within the
receptor transcripts at which alternative splicing has been detected, vary between
different members of the receptor subfamily, and include inserts in the regions
encoding: the C-terminal section of the 3rd intracellular loop [as in the the PACAP type
I receptor (Spengler et al., 1993) and the GHRH receptor (Mayo, 1992)]; the first
intracellular loop [as in the CRF type I receptor receptor (Chen et al., 1993) and pig
calcitonin receptor (Zolnierowicz et al., 1994)]; and the first extracellular loop [as in the
rodent calcitonin receptor (Sexton et al., 1993)]. More recently there have also been
reports of: variation (a 29 amino acid insertion) within the C-terminal tail of the human
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GIP receptor (Gremlich et al., 1995); two additional rat CRF type I receptor gene
transcript variants in which the sequences corresponding to exon 3 or exons 7,11, and
12 of the gene are deleted (Tsai-Morris et al., 1996); splice variation within rat CRF
type 2 receptor gene transcripts that results in the generation of receptor variants that
have different N-terminal domains (Lovenberg et al., 1995); human calcitonin receptor
gene transcripts that lack both the 48 bp insert in the region encoding the 1st
intracellular loop and the region encoding the first 47 amino acids of the receptor's N-
terminal extracellular domain (Albrandt et al., 1995); a mouse and human PACAP type
I receptor variant, which (in contrast to the previously identified 3rd intracellular loop
variants of this receptor), results in the deletion of a 21 amino acid region (encoded by
exons 5 and 6) from the N-terminal extracellular domain of the receptor (Pantaloni et
al., 1996); the identification of four patterns of splice variation in transcripts of the rat
PTH/PTHrP receptor gene, including one variant which affects the protein coding
region and leads to the deletion of the exon (exon S) encoding the receptor's putative
signal peptide (Joun et al., 1997); and the isolation of two variants of human
PTH/PTHrP receptor gene mRNAs, both of which lack the sequence corresponding to
the first exon (El) of the N-terminal-encoding region, although in one of these
transcripts this is replaced by sequence from the intron directly upstream of exon E2
(Jobert et al., 1996).
So far, the only evidence to suggest that splice variation might exist in transcripts of the
VIPR1 gene, comes from an isolated report, which describes the characterisation of
two human VIPR1 cDNA clones that display complete divergence within the region
encoding the 67 amino acid N-terminal domain (Couvineau et al., 1994). However,
although the human VIPR1 gene has now been cloned (Sreedharan et al., 1995), the
point of amino acid sequence divergence between the predicted sequences encoded by
the two cDNA variants does not correspond to an identified exon/intron junction within
the VIPR1 gene, and the mechanism underlying the generation of these two forms of
VIPR1 transcripts has not been established.
To date, no variants of the Vipr2 cDNA sequence have been published, but the
existence of such variants cannot be discounted, especially in light of the recent cascade
of publications relating to splice variation in the transcripts of other members of the
secretin/glucagon receptor family. Analysis of genomic sequence data is not the usual
way to begin to search for splice variation, as normally these variants can be detected
by reverse-transcriptase (RT)-PCR of RNA from appropriate tissues. However,
although RT-PCR experiments in our laboratory had failed to detect any transcripts
encoding VIP2 receptor variants, it was possible that the generally low levels of Vipr2
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transcripts (Usdin et al., 1994), perhaps combined with even lower levels of some
splice variant transcripts [as has been found for several other splice variants in this
receptor subfamily (Albrandt etal., 1995; Jobert et al., 1996; Joun etal, 1997;
Zolnierowicz et al., 1994)], could make the detection of any splice variants very
difficult.
Intron 10 of the mouse Vipr2 gene was selected for sequence analysis primarily
because: i) it corresponded (in terms of position within the receptor's gene structure) to
the region in the rat Pacaprl gene that contains a "cassette" of two alternatively spliced
84 bp sequences (leading to the generation of 5 splice variants; Spengler et al., 1993),
and at that time was the only identified source of splice variation within the gene
encoding the PACAP type I receptor (the receptor which together with the VIPi
receptor is the most closely related receptor to the VIP2 receptor at the amino acid
level); ii) the rat PACAP type I receptor was the only member of this receptor subfamily
for which splice variation had clearly been shown to result in alterations in receptor
signal transduction , a factor that was of particular interest in light of the controversy
over apparent discrepancies between the signalling properties of the cloned
VIP/PACAP receptors and those of previously characterised endogenous VIP receptors
within the brain (Gressens et al., 1994; Hill et al., 1994; Hill et al., 1992; Olah et al.,
1994).
Analysis of the sequence data obtained from intron 10 of the mouse Vipr2 gene did not
lead to the identification of any potential patterns of splice variation, and it seems
unlikely that splice variation exists within this region of the Vipr2 gene. Nevertheless, it
should be noted that most of the intron 10 derived sequence data was obtained from the
sequencing of only one strand of the receptor gene, and only one clone containing the
PCR amplified intron 10 PCR product was sequenced (whereas ideally both strands
would have been sequenced in each of several independent clones containing the PCR
product). Therefore, the error rate within the intron 10 sequence data may be slightly
higher than normal, and although improbable, it is conceivably that this might have
hindered the recognition of splice site consensus sequences.
Other Vipr2 gene introns that we would have liked to have sequenced include introns 5
and 6, which are situated in regions of the gene that encode the first intracellular loop
and first extracellular loop respectively (see Figure 3.36), sites at which splice variation
has been detected in other members of the receptor subfamily. However, these introns
proved to be extremely difficult to amplify by PCR. In retrospect it is now clear that
this was due at least in part to the length of the introns, which in the case of intron 5
(-7.3 kb), was approaching the size limit for amplification using standard PCR
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conditions, but as this was not established until late in these studies, there was not
enough time to sequence these introns.
Another difficulty that was puzzling at the time, but can now be explained, is the failure
of the early attempts to sequence the AEMBL3 G4 Vipr2 clone using the sequencing
primer 992W and the Promega finol® DNA cycle sequencing system (3.3.5), as
following the determination of the Viprl gene's exon/intron boundaries it became
apparent that this primer [which would bind to bp 941-926 of the published mouse
Vipr2 cDNA sequence; GeneBank accession number D28132; (Inagaki et al., 1994)]
crosses the exon 10 intron 9 junction (resulting in bp mismatches between the genomic
target sequence and the primer's three most 3' nucleotides).
The isolation of clone ESD1, which contains the first protein coding exon of the mouse
Vipr2 gene, was particularly important with respect to the long term aim of generating
Vipr2-null mice (because inclusion of the gene's ATG translation start site and first
coding exon in a gene replacement construct should help to ensure that the truncated
gene products, which could be partially functional, are not produced). In contrast to
the other Vipr2 clones that were isolated from the A2001 library, a probe derived from a
mouse Vipr2 5' RACE product had to be used in order to identify a clone (ESDI)
containing the 5' end of the mouse Vipr2 gene's coding sequence. As this probe was
both mouse specific and contained an extra 34 bp of 5' UTR sequence (relative to the
rat 260 bp Vipr2 cDNA probe), there were several possible explanations for its
success, including the possibility that the rat and mouse sequences diverged towards
the start of their 5' UTRs, a feature that has been noticed in the rat and human glucagon
receptor genes (Lok et al., 1994). However, since it has subsequently been shown that
the rat Vipr2 cDNA contains 5' untranslated sequence that corresponds very closely to
that of the mouse Vipr2 5' RACE product, the most likely explanation for the failure of
the rat 260 bp 5' probe to detect clones containing exon 1, is that the length of
homology between the probe and its target DNA, prior to intron 1 of the Vipr2 gene,
was not enough to allow efficient hybridisation.
During the characterisation of clones encoding the mouse VIP2 receptor, a large amount
of sequence data was obtained from the exons and introns of the Vipr2 gene, and
although most of this data consists of sequence derived from one strand of the receptor
gene, each region of the contigs that were generated from this data was generally
derived from the results of at least 3 separate sequencing reactions. These contigs,
which include the sequence surrounding all the known exon/intron boundaries of the
mouse Vipr2 gene, and a substantial amount of intron sequence (including the complete
sequences of introns 9, 10, and 11), are shown in Appendix 1.
-82-
In summary, the results presented in this chapter have demonstrated that the exon/intron
organisation of the mouse Vipr2 gene is very similar to that of other members of the
secretin/glucagon receptor gene subfamily, and at a size of >59 kb this gene lies
towards the upper end of the size range for those genes from this subfamily that have
been characterised to date. Further work, including the use of pulse field gel
electrophoresis and long range restriction mapping of genomic DNA will probably be
necessary in order to establish the size of intron 4, which at present is estimated to span
at least 19 kb. However, these studies, which also resulted in the isolation of a clone
containing the first coding exon and a substantial amount of the gene's 5' flanking
sequence (including the putative promoter region), represent the first characterisation
(in any species) of the structure of the gene encoding the VIP2 receptor, and have
subsequently enabled transgenic approaches to the characterisation of the VIP2
receptor's functions to be initiated in our laboratory.
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Chapter 4
Isolation of a PI clone encoding the human
VIPR2 gene
4.1 Introduction
Although much of this project focused on the isolation and characterisation of the
mouse Vipr2 gene, we were also interested in obtaining clones that encoded the human
homologue of this gene, as it was hoped that this would allow: i) determination of the
chromosomal localisation of the human gene and the investigation of any possible links
with human genetic diseases; ii) comparison of the sequence and structure of the mouse
and human genes; and iii) examination of the promoter and other regulatory sequences
of the human gene.
Work on the isolation of the human VIPR2 gene was initiated shortly after the isolation
of the 4 kb subclone from the 3' region of the mouse Vipr2 gene (see Chapter 3). At
this stage the human VIPR2 cDNA sequence had not been published, and consequently
rat Vipr2 cDNA sequences had to be used as probes in the isolation of the human gene.
Nevertheless, those receptor cDNAs from this subfamily, that had been cloned from
both rat and human, had generally been shown to display a high level of homology
between the two species (Lok et al., 1994; Mayo, 1992; Ogi et al., 1993; Perrin et al.,
1993; Schipani et al., 1993; Sreedharan et al., 1993), and although there were only a
few cases where the rodent and human gene structures from members of this subfamily
had been published, there were indications that the intron/exon structure of these
receptor genes might also be highly conserved between species (Kong et al., 1994; Lok
etal., 1994; Maget etal., 1994).
Previous studies of the 4 kb subclone from the 3' end of the mouse Vipr2 gene had
shown that this fragment of the gene contained only a small proportion of the Vipr2
gene's total coding sequence (Chapter 3), and thus suggested that the total length of the
mouse gene might be quite large. The reported sizes of other members of the receptor
gene subfamily that had been characterised at this time, ranged from ~4 kb for the
coding regions of the rat and mouse glucagon receptor genes (Burcelin et al., 1995;
Maget et al., 1994) to -70 kb for the porcine calcitonin receptor gene (Zolnierowicz et
al., 1994). This raised the possibility that the full length sequence of the human VIPR2
gene might be too large to be found within any single clone from a Abased genomic
library, a factor which could cause difficulties if it was later necessary to reconstruct the
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gene from overlapping clones in order to express it in cultured cells and/or transgenic
mice . The possibility of screening a genomic library constructed in a high capacity
vector was therefore examined, as the use of this type of library would significantly
increase the chance of isolating the entire human VIPR2 gene within one clone. This
option also offered the added advantage that clones in high capacity vectors such as
YACs and cosmids usually produce much stronger signals than X clones when used as
probes for the chromosomal localisation of genes by in situ hybridisation.
The main obstacle to the use of any of the high capacity vectors that were available, was
that we did not have pulse field gel electrophoresis equipment (which is required for the
resolution of DNA fragments of > -20 kb; Birren & Lai, 1994). This meant that it
would have been unpractical to work with YAC clones (insert size range -100 kb to 1
mb; Burke et al., 1987), and left the option of either cosmid libraries (maximum insert
size -45 kb; Collins & Hohn, 1978), or the more recently developed bacteriophage PI
libraries (maximum insert size -100 kb; Sternberg, 1990). A human genomic library
constructed in the bacteriophage PI vector was chosen in preference to a cosmid library
on the basis of the greater insert size of the PI clones (which at an average of >75 kb
was larger than the porcine calcitonin receptor gene), and the availability of a pre-
gridded human genomic PI library which would reduce 'hands-on' time and allow the
rapid identification of any possible positive clones. Other advantages of PI clones over
YAC and cosmid clones are thought to include lower levels of cloning artifacts, and
greater stability of the clones during propagation (Lengauer et al., 1994; Weitzel &
Patel, 1994), the latter factor being particularly important considering the problems that
had been encountered with the mouse X.EMBL3 Vipr2 clone (Chapter 3).
The copy number of the PI plasmid in bacterial cells is controlled by the lac operon
promoter, which permits the copy number of the otherwise single-copy PI plasmid to
increase by up to 20-fold in the presence of the lac inducer isopropyl-(3-D-
thiogalactopyranoside (IPTG), and should therefore allow the relatively easy isolation
of large quantities of DNA from these clones. However, although a putative human
VIPR2 gene clone was identified from the library, severe problems were encountered in
trying to obtain sufficient quantities of PI DNA to analyse this clone further, and it
became increasingly apparent that extensive subcloning of this PI clone in order to
isolate the human VIPR2 gene was not a realistic aim within the time available.
Nevertheless, despite these difficulties, enough PI DNA was eventually isolated to
allow the human chromosomal localisation of this clone to be determined by
fluorescence in situ hybridisation (see Chapter 5), and confirmation that the PI clone
contained VIPR2 gene sequence was subsequently obtained by PCR.
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4.2 Methods
4.2.1 Hybridisation screening of the PI human genomic library
The human genomic PI library that was used in these studies was obtained while still in
preliminary form, from Dr. F. Francis at the ICRF in London, but has now been
completed, characterised and incorporated into the ICRF Reference Library Database
System. The library (which is derived from a human lymphoblastoid cell line) is
constructed in the bacteriophage PI vector ^Ad\Q-sacB\l (see Chapter 2 Figure 2.6 for
vector map) and is presented in the form of duplicate pairs of filters which carry
gridded arrays of PI clones. At the time that we obtained the library it consisted of two
pairs of duplicate filters each of which carried a gridded array of 144 x 144 clones (the
2 filters together providing an ~lx genome coverage).
The probes used to screen the PI library were derived from the rat Vipr2 cDNA
sequence. The regions of the rat cDNA sequence that are spanned by the Ac(500)4 and
5' 1 kb probes have been described in Chapter 3. The rat Vipr2 cDNA 3' -1.2 kb
probe spans the region from bp 910 to bp 2125 of the published rat Vipr2 cDNA
sequence (Lutz et al., 1993). Probe preparation and labelling reactions were carried out
as described in Chapter 2.
Hybridisations were carried out according to the recommendations that were provided
with the PI library. Thus, in contrast to the ES library screens that were described in
Chapter 3, the PI library filters were prehybridised and hybridised at 65°C in a solution
containing 7% SDS, 0.5 M sodium phosphate buffer (pH 7.2), 1% BSA, and 1 mM
EDTA. The filters were prehybridised for a minimum of 2 hours, after which the probe
was added and hybridisation was left to proceed overnight. The following morning,
the hybridisation solution was removed and the filters were washed in a solution
containing 40 mM sodium phosphate buffer (pH 7.2) and 0.1 % SDS. Two 30 minute
washes were carried out, at 65°C, in 500 ml of wash solution which had been pre¬
heated to that temperature. After these washes, excess wash solution was allowed to
drain from the filters, which were then wrapped in cling film and exposed to Fuji RX
film (Fuji) for 8-12 hours at -70°C in cassettes with two intensifying screens. When a
potential positive clone was identified on the autoradiographs, the filters were then re-
exposed for a longer time period (-24 hours) so that the 'background signal' produced
by the gridded array of PI clones was clearly visible and the relative position of the
potential positive clone within the grid could be easily identified.
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4.2.2 Colony Blots of the PI clone
The colony blot method used was based on the method that was described in Sambrook
et al., (1989). The PI stab culture was streaked onto an L-Agar plate containing 25
pg/ml kanamycin (kan), inverted, and incubated overnight at 37°C. Single colonies
were then selected from the plate and patched in a grid pattern, onto each of two
BioBlot-NC nitrocellulose blotting filters (Costar®) lying on L-agar +kan (25 pg/ml)
plates, and then directly onto a master plate which also consisted of L-agar +kan (25
(ig/ml) but did not have a nitrocellulose filter on it. These three plates were inverted
and incubated overnight at 37°C to allow the bacterial colonies to regenerate. The
master plate was then sealed with parafilm and stored at 4°C until required. After
removal from the agar plates, the filters were placed colony side up on a pad of 3MM
paper (Whatman) that was saturated in 10% SDS and was left there for 3 minutes to
remove debris from the filter. The filters were then left for 5 minutes on each of a
series of pads of 3MM paper (Whatman) that were saturated in: i) denaturing solution
(1.5 M NaCl, 0.5 M NaOH), ii) neutralising solution (1M NaCl, 0.5 M Tris-HCl pH
7.0), and iii) 2x SSC. After the filters had air dried (-30 minutes), they were placed in
an oven and baked at 80°C for 1.5 hours. Before prehybridisation, the filters were
soaked briefly in 2x SSC, and then pre-washed for 30 minutes, at 50°C, with gentle
shaking, in a solution containing: 5x SSC, 0.5% SDS, and 1 mM EDTA. Any loose
debris that remained was carefully removed from the filters using tissues that had been
soaked in prewash. Prehybridisation, hybridisation, and autoradiography, were carried
out as described in section 4.2.1.
4.2.3 Isolation of PI clone DNA
Method 1
(based on the method provided by the genome analysis group at the ICRF)
A single PI colony was used to inoculate 50 ml of 2x YT + kan (25 |J,g/ml). After
growth overnight at 37°C, the culture was divided in two, and 25 ml of culture was
transferred into each of two conical flasks containing 800 ml of 2x YT broth + kan (25
fig/ml). The 800 ml cultures were grown at 37°C for 1 hour, at which point,
isopropyl-(3-D-thiogalactopyranoside (IPTG) was added to a final concentration of 1
mM. Growth of the cultures was then allowed to continue at 37°C for another 4 hours.
The cells were collected by centrifugation at 4000 rpm for 20 minutes at 4°C in a
Sorvall GSA rotor. After removal of the supernatant, the bacterial pellets from each
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800 ml culture were resuspended in 10 ml of alkaline lysis solution 1, (see Chapter 2)
transferred to two 250 ml pre-cooled centrifuge bottles, and incubated on ice for 15
minutes. Alkaline lysis solution 2 (30 ml; see Chapter 2) was then added to each
centrifuge bottle while gently swirling the bottle, and the bottles were left on ice for
another 5 minutes. Once the cells had lysed, 22.5 ml of alkaline lysis solution 3 was
added, and the bottles were shaken sharply, then left on ice for 30 minutes. The
precipitate (formed on addition of alkaline lysis solution 3) was pelleted by
centrifugation for 30 minutes at 13 000 rpm, and the supernatant was transferred to
fresh tubes. Isopropanol (45 ml) was added to precipitate the DNA, and the bottles
were mixed gently and left at room temperature for 5 minutes, then centrifuged at 9000
rpm for 15 minutes (Sorvall GSA rotor) to pellet the DNA. After removal of the
supernatant, the DNA pellets were air dried for -20 minutes, and each pellet was
resuspended in 10 ml of TE. The DNA solution was transferred to a 30 ml Oakridge
tube, where 19.66 g of CsCl was added and mixed until dissolved. EtBr (1.5 ml of a
10 mg/ml stock) was then added, and the DNA/CsCl/EtBr solution was mixed gently.
Following centrifugation at 10,000 rpm for 10 minutes in a Sorvall SS-34 rotor, the
supernatant was transferred to 6 ml polyallomer quick seal ultracentrifuge tubes
(Sorvall® Instruments). These tubes were then sealed, and centrifuged (together with
suitable balance tubes) in a Sorvall ultracentrifuge (TV-1665 rotor) at 45,000 rpm for
16 hours at 20°C. Isolation and purification of the PI DNA following CsCl banding
was carried out as described in Chapter 2.
* The original method recommended the use of 25 x 89 mm polyallomer ultracentrifuge
tubes and a VTi 50 rotor, but we did not have access to this type of rotor.
Method 2
(based on the method ofPierce and Sternberg, 1992a)
Although this method was originally published as miniprep method for PI DNA
isolation (which yielded 1-2 |lg of DNA from a 10 ml culture), the authors reported that
the method could be scaled up to a 250 ml culture with the expected increase in DNA
recovery (Pierce & Sternberg, 1992a).
During this work, several minor modifications were made to the original method when
it was scaled up to a 250 ml culture: i) a 2 ml overnight PI culture was used to
inoculate 250 ml of L-broth +kan (25 |ag/ml), instead of the single PI colony that was
used to inoculate 10 ml of culture medium in the miniprep method; ii) the cultures were
grown for the maximum recommended time of 12 hours after the addition of IPTG; iii)
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the cells were pelleted in a 250 ml centrifuge bottle by centrifugation in a Sorvall GSA
rotor at -6000 rpm for 7 minutes at 4°C; iv) following potassium acetate treatment,
centrifugation was carried out at 6500 rpm for 25 minutes at 4°C; v) phenol extractions,
chloroform extractions, and ethanol precipitation of the DNA, were carried out in 30 ml
corex tubes.
Method 3
(modification of the Qiagen cosmid maxiprep DNA isolation protocol suggested by
technical staffat Qiagen Ltd)
Isolation of PI DNA was carried out using a Qiagen plasmid maxi kit (Qiagen Ltd).
The isolation procedure used was based on the manufacturer's recommendations for the
large scale isolation of cosmid DNA. However, several modifications which were
published in the Qiagen Winter 92/93 handbook and/or were suggested by members of
their technical assistance group, were also incorporated. These alterations involved: i)
growth of the 250 ml bacterial cultures as described in method 2 (see above); ii)
resuspension of the bacterial pellet in a volume of PI solution that was calculated on the
basis of 10 ml of PI solution for every 500 ml of the original bacterial culture volume;
iii) increases in the volumes of solutions P2 and P3 used, so that they matched the
volume of PI buffer used; and iv) preheating of the elution buffer (buffer QF) to 37°C
prior to use.
N.B. Solutions PI, P2 and P3 are plasmid alkaline lysis solutions that are provided
with the Qiagen plasmid maxi kit.
Method 4
(a modified version of the alkaline lysis/CsCl-ethidium bromide gradient protocolfor
plasmid maxipreps published by Sambrook et al., 1989)
Four test tubes containing 3 ml of L-broth +kan (25 |ig/ml) were each inoculated with a
single PI colony, and left to grow at 37°C overnight. Each of these 3 ml cultures was
then used to inoculate one of four 2 litre flasks that contained 500 ml of L-broth + kan
(25 p.g/ml). The 500 ml cultures were grown for at least 20 hours at 37°C, after which
the bacterial cells were pelleted into two 250 ml centrifuge bottles, by centrifugation at
6000 rpm for 7 minutes at 4°C in a Sorvall GSA rotor. Each bacterial pellet was
resuspended in 18 ml of alkaline lysis solution 1 (see Chapter 2). Forty millilitres of
alkaline lysis solution 2 (see Chapter 2) was added to the bacterial suspensions, which
were mixed by gently inverting the centrifuge bottles several times, and then left at
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room temperature for 5-10 minutes. Once the cells had lysed, ice-cold alkaline solution
3 (20 ml; see Chapter 2) was added, and the suspension was mixed thoroughly by
gently shaking the bottles. The bottles were then stored on ice for 20 minutes before
pelleting the precipitate by centrifuging the lysate at 6500 rpm (Sorvall GSA rotor) for
25 minutes at 4°C. After centrifugation the supernatant was filtered through 4 layers of
cheesecloth (to remove any residual precipitate) and transferred to new centrifuge
bottles. Isopropanol (0.6 volume) was then added to the supernatant, mixed well, and
the bottles were left at room temperature for at least 30 minutes, to allow the DNA to
precipitate. Finally, the DNA was pelleted by centrifugation at 6500 rpm for 20
minutes (Sorvall GSA rotor) at room temperature, the pellets were washed in 70%
ethanol, dried, and resuspended in 2 ml of TE (pH 8.0). Two batches of this DNA
were then pooled to give a total of 4 ml of DNA solution which was further purified by
CsCl-EtBr gradient ultracentrifugation as described in Chapter 2.
4.2.4 Restriction analysis, gel electrophoresis, and hybridisation of
Southern blots, of PI clone and human total genomic DNA
Restriction analysis and Southern blotting of PI clone DNA (see Figure 2.6 for vector
map) and human genomic DNA (Promega) were carried out using methods that differ
slightly from those described in Chapter 2.
Restriction enzyme digestion of PI clone DNA and human genomic DNA was
generally carried out in a total reaction volume of 50 pi, containing either 5-8 pi of PI
clone maxiprep DNA or 10 pg of human genomic DNA, 10-20 units of restriction
enzyme, 5 pi of an appropriate lOx reaction buffer, and ddH20. Digests of PI clone
DNA were incubated at 37°C for a minimum of 5 hours but for no longer than 8 hours
as it was found that overnight incubation of these reactions led to signs of degradation
of the DNA samples (presumably due to the presence of nucleases in the DNA prep.).
Fluman genomic DNA digests were incubated at 37°C overnight.
Agarose gel electrophoresis of PI clone and human genomic DNA was carried out at
40-50 volts over a period of approximately 8-12 hours. Southern blotting of the gels
(onto GeneScreen Plus membrane; NEN/DuPont) was carried out as described in
Chapter 2. The blots were prehybridised and hybridised in 50 ml of solution
containing: 25 ml of 50% formamide (deionised), 4.75 ml of 10% SDS, 12.5 ml of
20x SSPE, 5 ml of 50x Denhardt's solution (see Chapter 2), 2.5 ml of 1 M sodium
phosphate buffer (pH 7.2), and 250 pi of denatured herring testis DNA (10 mg/ml
stock) which was added just prior to prehybridisation. After prehybridisation at 42°C
for at least 1 hour, the probe was added and the blots were left to hybridise overnight at
42°C. Finally, the blots were washed at 60°C for 2x 15 minutes, in a solution
containing 2x SSC and 0.1% SDS. The blots were then left to air-dry, placed in a
cassette with Fuji RX film (Fuji) and two intensifying screens, and stored at -70°C, for
periods of 24-96 hours.
4.2.5 Amplimer-mediated PCR of PI DNA restriction fragments
This method was provided by Dr. A. Wright (MRC Human Genetics Unit,
Edinburgh). The method was originally intended for use on YAC DNA and
consequently some of the initial DNA restriction digestion and clean-up steps have been
modified for use on PI clone DNA.
Five microlitres of PI maxiprep DNA was digested using BamH I and Bgl II in a total
reaction volume of 50 pi . The restriction reaction was incubated at 37°C for 8 hours,
after which the digested DNA was purified using the Wizard™ DNA Clean-up System
(Promega), and eluted in 40 pi of ddH20.
The synthetic amplimers 5' P-GATCGTCGACGGTACCGAATTCT 3' (H3729) and
5' GTCAAGAATTCGGTACCGTCGAC 3' (H3730) were annealed to one another by
heating equimolar concentrations of the amplimers to 98°C for 15 minutes and then
leaving them to cool to room temperature. Annealing of these amplimers results in the
production of a double stranded amplimer which has a Sau3A I cohesive end 5' GATC,
and is thus compatible with the DNA ends created by the restriction enzymes Sau.3A I,
Mho I, BamR I, Bgl II, Xho II, and Bel I. Ligation of the double stranded amplimers
to the BamH I / Bgl II digested PI clone DNA was carried out at 16°C overnight in a
total volume of 20 pi containing either 2 pi, 5 pi, or 10 pi of BamH I/Bgl II digested
PI DNA, 1 unit of T4 ligase (Promega), 2 pi of lOx T4 ligation buffer (Promega), 3 pi
of a 25 pM double stranded amplimer stock solution, and tissue culture grade water
(Sigma). After ligation overnight, the reactions were spun briefly in a microcentrifuge,
diluted to 100 pi with ddH20, and then heated to 65 °C for 10 minutes in order to
inactivate the ligase.
The PCR reactions were carried out in triplicate. In each case, 1 pi of the diluted
amplimer-ligated PI DNA was used as a template in a reaction mix containing: 5 pi of
magnesium-free lOx PCR reaction buffer (Promega), 2 pi of 50 mM MgCl2, 1.25 pi
of 10 mM dNTP mix (Boehringer Mannheim), 1.6 pi of master primer (H3729) 0.8
pM final concentration, 1 pi of Taq Extender (Stratagene), 3 pi of TaqStart™ mti-Taq
antibody (Clontech), 34.15 pi of tissue culture grade water (Sigma), and 1 pi of Taq
DNA polymerase (Promega). The reactions were spun in a microcentrifuge for -20
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seconds, overlaid with 2 drops of light white mineral oil (Sigma), and then spun again
briefly before being transferred to the PCR machine. An initial denaturation at 94°C for
3.5 minutes was then followed by 35 cycles of: 1.5 minutes at 94°C, 1 minute at 64°C,
and 6 minutes at 72°C. After a final extension at 72°C for 15 minutes the reactions
were cooled to 4°C and maintained at that temperature until they could be collected.
The PCR reaction products were separated by electrophoresis through a 1 %
Seaplaque® GTG agarose (FMC Bioproducts) TAE gel. Gel slices were taken from
regions of the gel that contained strong bands of amplified DNA, and extraction of the
DNA from these slices was carried out using a Geneclean II® kit (Bio 101 Inc.). The
purified DNA fragments were then restricted with EcoR I (which cuts within the
amplimer sequence at the ends of the PCR products), and after heat inactivation of the
restriction enzyme (65°C for 20 minutes), a Ready-To-Go™ ligation kit (pUC18/isc0R
1/BAP; Pharmacia) was used to subclone the fragments into pUC18. Ligations were
carried out according to the manufacturer's instructions.
4.2.6 PCR assay for the detection of a 3' region of the human VIPR2
gene
Primers 4334 5' CCAGGTATGGGGTTTAGTGGAC 3' and 4335 5'
GCCGTCCTCTACTGTTTCCTGA 3' were designed to bind to bases 1640-1619 and
1276-1297 of the human VIPR2 cDNA sequence (Svoboda et al., 1994) respectively.
These primer binding sites corresponded to sequences within predicted exons 12 and
13 of the gene, and the primers were expected to amplify the final intron and exon
(including part of the 3' UTR) of the human VIPR2 gene.
Each PCR reaction was carried out in a total reaction volume of 100 pi, containing: 0.5
pi, 1.0 pi, or 1.5 |ll of PI DNA, 2 pi of 10 mM dNTP mix (Boehringer Mannheim),
10 pi of magnesium-free lOx PCR reaction buffer (Promega), 4 pi of 50 mM MgCl2,
2 pi of primer 4334 (15 pM stock), 2 pi of primer 4335 (15 pM stock), 1 pi of Taq
DNA polymerase (Promega), and tissue culture grade water (Sigma) to 100 pi*.
Negative control reactions without template DNA were also set up. The reactions were
spun briefly in a microcentrifuge and then overlaid with 2-3 drops of light white
mineral oil (Sigma). An initial denaturation of the DNA at 94°C for 5 minutes, was
then followed by 30 cycles of: denaturation at 94°C for 1 minute, annealing at 57°C for
1 minute, and extension at 72°C for 1.5 minutes + 4 seconds/cycle. After a final
extension at 72°C for 10 minutes, the reactions were cooled to 4°C. Preliminary
analysis of the products was carried out by running 8 pi of each PCR reaction on a
1.5% agarose TBE gel.
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*In early experiments using this assay TaqStart™ anti-Taq antibody (Clontech) was
used (2 jxl per reaction) in order to obtain a 'hot start' as contamination problems had
made it necessary to set up the PCR reactions in another building. In these cases the
volume of water added was therefore adjusted accordingly.
4.2.7 PCR assay for the detection of a 5' region of the human VIPR2
gene
Two different pairs of primers were used in separate experiments. The first primer pair
consisted of primer 4336 5' AGTGGCGTCTGGGACAACAT 3' and 4337 5'
TCAGGATGAAGGACAGGAACAG 3' which were designed to bind to bases 319-
338 and bases 676-655 of the human VIPR2 cDNA sequence (Svoboda et al., 1994)
respectively, and to predicted exons 3 and 6 of the VIPR2 gene. The second primer
pair also included primer 4336, but this time it was used in conjunction with primer
9796 5' CGTCTCTGACCATCCGTCACT 3' which was designed to bind to bases
465-445 of the human VIPR2 cDNA sequence (Svoboda et al., 1994), and predicted
exon 4 of the VIPR2 gene. The PCR reaction conditions used in these experiments
were essentially the same as those for the 3' VIPR2 gene assay described in section
4.1.6.
4.3 Results
4.3.1 Screening of the bacteriophage PI human genomic library
The first screen of the PI library, which was carried out using the rat Ac(500) 4 probe,
did not result in the identification of any putative positive clones on the filters, a result
that was somewhat surprising as the probe had previously been successfully used in the
isolation of the full length rat Vipr2 cDNA sequence from an olfactory bulb cDNA
library (Lutz et al., 1993), and in the isolation of the mouse Vipr2 genomic clone 7.G4
from the 7.2001 library (Chapter 3). Further attempts to identify a human VIPR2 clone
by screening the PI library with a probe from the 3' half of the rat Vipr2 cDNA (see
4.2.1 and Figure 3.1) were also unsuccessful. However, a final screen of the library,
this time using the 1 kb probe from the 5' end of the rat Vipr2 cDNA, resulted in the
identification of a single putative positive clone (to which hybridisation of the probe
was observed on duplicate filters; Figure 4.1). This clone was then ordered from the
ICRF.
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Figure 4.1: Human PI genomic library filters, hybridised
with the radiolabeled 1 kb 5' rat Vipr2 cDNA probe
(hybridisation signal from identified positive clone is arrowed)
 
4.3.2 Colony blot of the PI clone
On receipt of the PI clone stab culture from the ICRF, a colony blot was carried out
using the rat 1 kb 5' Vipr2 cDNA probe. This was done in order to: i) verify the results
of our PI library screen and confirm that the correct PI clone had been selected, and ii)
to ensure that the bacterial colonies that were to be grown for the generation of glycerol
stocks of the PI clone, had not lost the PI plasmid and/or insert DNA. Out of a total of
34 single colonies that were randomly selected for use in the colony blot (filters were
prepared by K. West), 22 colonies displayed strong hybridisation to the Vipr2 1 kb
cDNA probe, 4 colonies showed weaker hybridisation, and 8 colonies showed little or
no hybridisation to the probe (Figure 4.2). Only colonies that had shown strong
hybridisation to the probe were used in the generation of PI clone stocks.
4.3.3 Isolation of DNA from the PI clone
When we first identified the putative VIPR2 PI clone, there were very few published
methods for the isolation of PI clone DNA. Initial attempts to isolate PI DNA using
the alkaline lysis/CsCl-EtBr gradient ultracentrifugation method that was provided by
the ICRF (see 4.2.3, method 1) were unsuccessful, and despite repeated efforts, did
not produce visible amounts of VIPR2 PI clone DNA following CsCl-EtBr gradient
banding. The reason for the failure of this method in our hands was not clear.
However, during a search of other methods for isolating PI DNA, it became apparent
that the times that were suggested by different investigators, for growth of the bacterial
cultures before beginning DNA isolation, varied significantly. Generally, investigators
seemed to agree that the initial phase of growth prior to the addition of IPTG should be
relatively short, for example 1 hour (ICRF; 4.2.3 method 1), or until the bacteria reach
an OD590 of 0.1- 0.2 (Pierce & Sternberg, 1992a; Pierce & Sternberg, 1992b), but for
the length of time of bacterial growth after the addition of IPTG, recommendations
included: 4 hours (ICRF; 4.2.3 method 1), 7 hours (L. Mullins, personal
communication), 5-12 hours (Pierce & Sternberg, 1992a) and 5-14 hours (Pierce &
Sternberg, 1992b). The method published by Pierce and Sternberg (1992a) was of
particular interest as it differed from that suggested by the ICRF group in that it was
based on an alkaline lysis PI DNA miniprep method (that could be scaled up to a 250
ml culture) which included phenol:chloroform extractions, but no CsCl-EtBr gradient
ultracentrifugation. Furthermore, the authors of this paper also reported that they had
successfully purified PI DNA using commercially available column chromatography
protocols such as those available from Qiagen Ltd. However, although a small amount
of DNA was isolated from our PI clone when a scaled up version of the alkaline lysis
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Figure 4.2: Colony blot of the PI clone, hybridised with the
radiolabeled 1 kb 5' rat Vipr2 cDNA probe
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based miniprep method was used, this DNA was not cut well by restriction enzymes
and partial digestion products were often seen. Nevertheless, the fact that this method
had allowed us to isolate DNA from our PI clone for the first time, seemed to indicate
that the extended period of growth after addition of IPTG, may have been beneficial.
Efforts to isolate PI DNA using Qiagen columns, after overnight (12 hour) growth of
the cultures in the presence of IPTG, were also successful in obtaining small quantities
of PI DNA, but again the DNA did not cut well with restriction enzymes and there was
some evidence of high salt concentration as indicated by narrowing of the lanes of DNA
on an agarose gel. As CsCl-EtBr gradient banding of DNA (used in method 1) is
generally accepted as being the best method for obtaining high quality DNA, and
extending the length of time of bacterial culture (as in methods 2 and 3) seemed to be
necessary in order to obtain even small amounts of DNA from our PI clone, various
methods were then tried that included both a long period of bacterial growth and a
CsCl-EtBr gradient ultracentrifugation step. The method that was finally devised for
use in preparing DNA from the PI clone, was a modified version of the method
published by Sambrook et al., (1989), for the large scale preparation of plasmid DNA
by alkaline lysis and CsCl-EtBr gradient banding (see 4.2.3 method 4). In many ways
this method does not differ greatly from the method provided by the ICRF (method 1),
but the most significant changes are probably those relating the length of time for which
the bacteria were grown before isolation of the PI DNA. In the final method, a 2 ml
overnight culture was used to inoculate a flask containing 500 ml of L-broth +kan, and
the culture was then allowed to grow for at least 20 hours prior to isolation of the PI
DNA, a time which sounds excessively long, but did result in increased DNA yields.
IPTG was not added to these cultures, as surprisingly it was found to make little
difference to the final DNA yield obtained with this clone. The DNA obtained using
this method appeared to be much purer than that obtained using the other methods and
was cut relatively easily by most restriction enzymes. Nevertheless, DNA yields from
the 500 ml cultures were still extremely low, to the extent that it was necessary to pool
the DNA obtained from two 500 ml cultures, prior to the addition of CsCl and EtBr, in
order to be able to visualise the PI DNA band (which was generally no more than 1
mm deep) following ultracentrifugation. Extremely high RNA to DNA ratios, which
had been observed with all of the methods tried, also proved to be a problem when
using this method, even after CsCl-EtBr gradient ultracentrifugation. RNase treatment
of the DNA solution either prior to or following CsCl-EtBr gradient banding, alleviated
this problem to some extent, but considerable amounts of RNA remained.
Consequently quantitation of the DNA by UV spectrophotometry was not practical, and
estimates of the DNA concentration had to be made by running a small volume of the
DNA alongside DNA markers on an agarose gel .
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4.3.4 Southern blots of PI clone DNA
As only very small amounts of PI DNA could be isolated from each maxiprep, the
number of different restriction digests of PI DNA that could be examined was severely
limited. After preliminary Southern blot analysis of the PI DNA had been carried out
using the rat 1 kb 5' Vipr2 cDNA probe on a variety of single restriction enzyme PI
digests, the enzymes Pst I and BamR I were selected for use in subsequent Southern
blots. Unlike the majority of enzymes tested, Pst I and BamR I each generated a series
of PI clone restriction fragments whose pattern of hybridisation to the probe included
hybridising bands of relatively low molecular weight, an important factor as we did not
have pulse field gel electrophoresis equipment.
The main aim at this stage was to confirm that the PI clone contained at least part of the
VIPR2 gene, as this would allow us to use the clone as a probe to determine the human
chromosomal localisation of the gene. However, because isolation of PI DNA from
this clone was difficult, it was important to be certain that the hybridisation of the
cDNA probe to the PI DNA was specific and represented hybridisation of the probe to
the human genomic DNA in the clone's insert, before any attempts at subcloning were
made. A Southern blot was therefore carried out on an agarose gel on which Pst I and
BamR I digests of PI clone DNA and total human genomic DNA digested with the
same enzymes, had been run in parallel (Figure 4.3a). Hybridisation of the blot using
the rat 1 kb 5' Vipr2 cDNA probe, resulted in the identification of strongly hybridising
bands of -1.7 kb and -3.0 kb in the BamR I digested PI DNA, and of -2.2 kb and
-2.8 kb in the Pst I digested PI DNA. Hybridisation of the probe to BamR I digested
total human genomic DNA, appeared to consist almost entirely of hybridisation to high
molecular weight or uncut DNA, and may indicate that digestion of this DNA was
incomplete. However, the hybridisation pattern of the probe on Pst I digested total
human genomic DNA closely mirrored the pattern produced on the Pst I digested PI
clone DNA (with hybridising bands present at both -2.2 kb and -2.8 kb; Figure 4.3b);
a result which strongly suggested that the PI clone contained at least part of the VIPR2
gene. Indeed, although it was recognised that this result did not represent conclusive
confirmation of the identity of the PI clone, we were sufficiently confident at this stage
to proceed with the establishment of collaboration with the MRC Human Genetics Unit
(Edinburgh, UK) in order to determine the chromosomal localisation of the clone (see
Chapter 5).
Finally, it may be worth noting that evidence which might indicate that the 5' end of the
VIPR2 gene is present in the PI clone, was provided by a Southern blot of a Pst I
digest of the PI clone and corresponding digests of total human genomic DNA.
-96-
Figure 4.3a: Restriction digests of VIPR2 PI clone DNA
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Figure 4.3b: Southern blot of gel shown in 4.3a hybridised
with the radiolabeled 1 kb 5' rat Vipr2 cDNA probe
Parallel hybridising bands (of approximately 2.2 kb and 2.8 kb) that are present in Pst I
digests of both the VIPR2 PI clone and total human genomic DNA, are arrowed in red.
(Autoradiograph is shown at actual size)
1kbladder VIPR2P1cloneBamH VIPR2PIclonest humangenomicDNABamRI humangenomicDNAPstI
However in contrast to the pattern of hybridisation that was observed when the 1 kb 5'
probe was used, the hybridisation seen following the use of the 260 bp 5' probe,
consisted almost exclusively of hybridisation to high molecular weight or uncut PI
DNA at the top of the gel. No clear bands of hybridisation to the digests of total human
genomic DNA were seen, and although two faint bands of hybridisation were
observed, hybridisation to these bands was not much stronger than the non-specific
hybridisation to some of the DNA marker bands. This made it very difficult to reach
any firm conclusion as to the whether or not the region of DNA spanned by this probe
was present in the PI clone. The presence of some plasmid vector contamination of the
probe DNA, indicated by the strong hybridisation of the probe to some bands of the
DNA markers, further complicated interpretation of these results as it brought into
question the specificity of the hybridisation to the PI DNA. Although additional
Southern blots using different restriction enzymes would probably have resolved this
issue, it was not pursued any further at this stage, as PI clone DNA was scarce, and
the results were unlikely to make an immediate contribution to our main aim which was
still the verification of the clone's identity.
4.3.5 Attempts at direct subcloning of VIPR2 gene fragments from the
PI clone
Having isolated a PI clone that was thought to contain at least part of the human VIPR2
gene, and identified two Pst I restriction fragments that hybridised to the rat 5' 1 kb
Vipr2 cDNA probe, the most obvious route to confirming that the PI clone did contain
the VIPR2 gene, was to subclone and sequence the hybridising bands (which would be
expected to contain VIPR2 gene exon sequences). Isolation and subcloning of DNA
from gel slices (see Chapter 2) that were thought to contain the 2.2 kb and 2.8 kb Pst I
fragments that had hybridised to the Vipr2 cDNA probe (4.3.4.), resulted in the
identification of six subclones that contained inserts of -2.2 kb and two subclones that
contained inserts of -2.8 kb. As the original bands at these positions on the gel had
appeared to contain multiple restriction fragments, it would have been preferable to
have obtained more transformants and thus increase the chance of isolating the
hybridising fragments, but once again, PI DNA supplies were limiting. Sequencing of
the subclones using T7 and SP6 primers did not produce any sequence data that
contained regions of similarity to the rodent Vipr2 cDNA sequences. However the
sequence obtained from one of the 2.8 kb subclones clearly matched PI vector
sequence, thus confirming that multiple restriction products were present in the original
gel slice. Southern blots carried out on the subclone inserts did not show any
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hybridisation to the rat Vipr2 full length cDNA probe (probe 6.3), suggesting that these
subclones did not contain VIPR2 gene exon sequences.
4.3.6 PCR amplification and subcloning of PI BamYL l/Bgl II
amplimer-ligated restriction fragments
An alternative approach to the isolation of fragments containing VIPR2 sequence from
the PI clone, was suggested by Dr. A. Wright (MRC Human Genetics Unit,
Edinburgh). The proposed method (see 4.2.5) which was PCR based (and thus to a
large extent overcame the problems that we had previously encountered in obtaining
enough DNA for subcloning), involved the ligation of double stranded amplimers
(annealed primer pairs with restriction fragment-compatible ends) to restriction
fragments generated by BamH l/Bgl II double digestion of the PI DNA, and the
subsequent amplification of these fragments using primers that bind to the amplimer
sequence.
PCR amplification of the amplimer-ligated PI restriction fragments generated strong
bands of PCR product at -500 bp, 1 kb, 1.7 kb, and 2.3 kb, which were cut out of the
gel and purified. Following subcloning of these fragments into pUC18 vector,
plasmids that contained inserts of approximately 1 kb (2 different clones), 1.7 kb (1
clone), and 2.3 kb (2 different clones), were isolated. However, sequencing of this
rather limited number of subclones, using forward and reverse primers to the vector
sequence, did not result in the identification of any sequences that appeared to be
VIPR2 gene coding sequences.
4.3.7 Direct PCR from PI clone DNA
The publication of the human VIPR2 cDNA sequence by Svoboda et al., (1994),
finally allowed specific PCR primers to be designed for the amplification of regions of
the human VIPR2 gene. Two pairs of primers were designed initially, one pair (4334
and 4335) to amplify the predicted last intron and exon of the human VIPR2 gene, and
one pair (4336 and 4337) to amplify a region from the 5' end of the gene (see 4.2.6).
PCR reactions in which the primers 4334 and 4335 were used on PI template DNA,
resulted in the generation of a single PCR product of -1.3 kb (Figure 4.4). Restriction
analysis of this product was carried out using the enzyme Pst I. Within the human
VIPR2 cDNA sequence (Svoboda et al., 1994), a Pst I restriction site is found at bp
1421, which lies in the predicted final exon of the gene, -200 bp upstream of the 4334
primer site. Thus the release of a fragment of -200 bp from the 1.3 kb 4334/4335 PCR
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Figure 4.4: PCR amplification of a 1.3 kb fragment from the
VIPR2 PI clone, using primers designed to bind to the 3'
region of the VIPR2 cDNA sequence
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product following digestion with Pst I (Figure 4.5), strongly indicated that this PCR
product was derived from the 3' region of the human VIPR2 gene.
Reactions carried out with the aim of isolating a region from a more 5' area of the
human VIPR2 gene, using either primers 4336 and 4337, or primers 4336 and 9796,
on PI template DNA (see 4.2.7) were unsuccessful.
4.3.8 Subcloning and sequencing of the human 3' VIPR2 gene PCR
product
Following subcloning of the putative 3' VIPR2 gene PCR product (see 4.3.7) into
pGEM®-T vector (Promega; see Chapter 2), plasmid DNA was isolated from 16
randomly selected transformants. Restriction analysis of these plasmids indicated that
they all contained DNA inserts of -1.3 kb, and two of these subclones were
subsequently sequenced using T7 and SP6 primers. As expected, the sequence data
clearly showed that the 1.3 kb product contained sequence that began at the 4335
primer site (just 5' to an exon/intron junction) and followed the human VIPR2 cDNA
sequence (Svoboda et ai, 1994) for an additional 8 bp before entering intron sequence.
In contrast, the sequence extending from the 4334 primer site at the 3' end of the PCR
product, spanned -300 bp of exon sequence that corresponded to the 3' end of the
published VIPR2 cDNA sequence (Svoboda et al., 1994) before entering intron
sequence. This data conclusively demonstrated that the final intron and exon of the
human VIPR2 gene were present in our PI clone, and indicated that the final intron of
the human gene was -1 kb.
4.4 Discussion
Unexpected problems, relating to the selection of a suitable probe for the library screen
and the subsequent isolation of DNA from the putative VIPR2 gene PI clone, were
encountered during this work. These problems were largely the result of: i) trying to
isolate a genomic clone using cDNA fragments as probes in the absence any knowledge
of the gene's intron sizes, and ii) working with a cloning system (PI) that was still
relatively new and was not yet in wide use. If this work had been started 9-12 months
later, it is likely that some of the problems could have been avoided, as by that stage the
structure of the mouse Vipr2 gene had been much more extensively characterised, and
other groups of investigators had reported difficulties in obtaining sufficient amounts of
good quality DNA from PI clones and had begun to look at ways of overcoming this
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problem. However, as it was known that other groups were also working on the
isolation of this gene, it would not have been wise to delay the work in this way.
The detection of the human VIPR2 PI clone by the rat 1 kb 5' Vipr2 cDNA probe was
surprising considering the failure of the rat Ac(500)4 Vipr2 cDNA probe and the rat
Vipr2 3' -1.2 kb cDNA probe to detect this clone, especially as the Ac(500)4 probe had
been successfully used in the previous isolation of the mouse genomic Vipr2 clone
from the ^EMBL3 library. Furthermore, PCR reactions carried out using the PI clone
as a template clearly showed that the predicted final intron and exon (intron 12 and exon
13) of the human VIPR2 gene were present in the PI clone, so the absence of the 3'
end of the VIPR2 gene from the PI clone was not the reason for the failure of the rat 3'
Vipr2 cDNA probe to detect this clone. The presence of large introns within the
regions that were spanned by these cDNA probes, would be the most obvious
explanation for the problems. However, subsequent work on the mouse Vipr2 gene
structure has shown that the introns found towards the 3' end of the mouse gene are
generally smaller than those in the 5' half of the gene (Chapter 3), and preliminary
results from our lab indicate that this is also the case in the human VIPR2 gene.
The decision to screen a bacteriophage PI-based genomic library was in some ways the
right decision, even in light of the problems that were met in trying to isolate DNA from
the PI clone, as it is now known that the mouse Vipr2 gene spans over 59 kb in total
(Chapter 3), and studies of the human gene (carried out in our laboratory) suggest that
the human gene may be even larger. Thus, as had been suspected, it is extremely
unlikely that the entire human VIPR2 gene could have been isolated from a single
cosmid clone. It also appears that earlier concerns regarding the stability of YAC and
cosmid clones, may have been justifiable. The isolation of an unstable mouse Vipr2
gene clone from the EMBL3 genomic library did not in itself suggest that the insert
DNA was responsible. However, later experiments carried out by S. Scherer and
colleagues with the aim of determining the position of the human VIPR2 gene within a
YAC contig (Chapter 5), showed that although the presence of the extreme 3' end of
the gene within the YAC contig could be demonstrated using the 3' VIPR2 gene PCR
assay described in this chapter, the result could not be repeated using hybridisation-
based methods. This led them to conclude that at least part of the gene had been deleted
from the YAC contig during culturing, leaving enough DNA to assay by PCR but not
enough to detect by hybridisation (S. Scherer, personal communication), and together
with the problems encountered with the mouse clone, this begins to raise the possibility
that regions of the VIPR2 gene may be particularly prone to deletion/rearrangement in
clones.
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Following the screening of early PI libraries by several groups it has become
increasingly apparent that in many cases the DNA yield from these clones is
significantly lower than had been anticipated: an observation that prompted Sternberg
and co-workers to report that" the preparation of PI plasmid DNA with cloned inserts
has proven to be a bit more problematical than expected" (Sternberg et al, 1994). The
low levels of PI DNA that were obtained from the VIPR2 gene PI clone in this study
were probably the result of several factors. First, it seems likely that the VIPR2 gene
PI clone was a very slow growing clone in comparison with the majority of clones
studied by other workers. Similar 'slow growing' PI clones were noted by Pierce and
Sternberg, (1992b), who pointed out that such clones would be very difficult to detect
if grown in pooled populations as opposed to an arrayed format. Since the VIPR2 gene
PI clone was found to require a culture time of over 20 hours as opposed to the 5-14
hours recommended for the growth of PI clones, it is likely that this clone would have
been significantly under-represented in a pooled population, and the decision to screen
an arrayed library, although taken purely on the basis of convenience, may have been
fortunate.
The apparent failure of IPTG to lead to a rise in the PI plasmid's copy number and
hence an increase in the yield of PI DNA from the VIPR2 gene PI clone, is puzzling.
However, as IPTG seemed to have little if any effect on the DNA yields obtained from
this clone, there seemed to be little point in continuing to add it to the culture medium.
The fact that the PI DNA was isolated from cells in which it may have been present
only as a single copy plasmid, could have had a very significant effect on the DNA
yield obtained from this clone, as in general the addition of IPTG to culture medium
during the propagation of PI clone is thought to lead to increases of up to 20-fold in the
copy number of the PI plasmid (Pierce & Sternberg, 1992b). However, the actual
copy number of the VIPR2 PI plasmid in the absence of IPTG or in its presence is not
known, and the reason for the apparent failure of the copy number elevation mechanism
in the VIPR2 PI clone is not understood, although it may be worth noting that in
contrast to the other bacterial strains that can be used for the propagation of P1 DNA,
the lacN gene in the host strain containing the VIPR2 PI plasmid, is present on an F'
plasmid (Francis etal., 1994).
Another contributing factor to the low yield of DNA obtained from this PI clone, is
almost certainly the bacterial cell type in which the library was constmcted and the
isolated VIPR2 clone was subsequently propagated, as there is now considerable
evidence to suggest that growth of PI clones in bacterial host strains that express the
Cre recombinase gene (Cre), results in reductions in the yield and quality of PI DNA,
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relative to that obtained from cells that do express the Cre gene (Kimmerly et al., 1994;
Sternberg et al., 1994). Unfortunately, the ICRF PI human genomic library (Francis
et al., 1994) that the VIPR2 PI clone was isolated from, was constructed in the Cre+
host strain NS3145, and at the stage that attempts to isolate DNA from the VIPR2 PI
clone were made, the link between the presence of the Cre gene and problems with PI
DNA isolation was not yet apparent. However, subsequent reports have shown that P1
DNA yields from the Cre+ host NS3592 are up to 10-fold lower than those from the
otherwise identical Cre" host NS3516 (Sternberg et al., 1994), and that the quality of
PI DNA as determined by its ability to successfully act as a template for fluorescent
automated sequencing is significantly higher when the DNA is prepared from Cre"
endA" DH10B host cells, as opposed to the Cre+ endA+ strains NS3145 or NS3529
(Kimmerly et al., 1994). Thus, although in the DH10B host cells it is likely that the
endA mutation contributes at least partly to the improved quality of the PI DNA
isolated, there seem to be distinct advantages in transferring the PI plasmid DNA from
a Cre+ bacterial host into a Cre" strain before attempting to isolate PI DNA.
After the VIPR2 PI clone had been isolated a lot of time was spent trying to establish
the best method of preparing PI DNA from this clone, and it was finally decided that
when paired with an extended growth time for the bacterial cells, a slightly modified
version of the standard alkaline lysis/CsCl-EtBr gradient method for large scale plasmid
preparation, produced the best results for our clone. Since then, several reports in
which methods for preparing PI DNA are compared have been published, but the
conclusions reached by the authors are quite varied. In most of these reports the
primary factor considered is the quality of the PI DNA obtained using different
isolation methods, as the isolation of PI DNA that is of sufficiently high quality for
procedures such as automated sequencing, appears to be particularly problematic. The
methods that are generally used for the isolation of PI DNA do not differ greatly from
those used for the isolation of smaller plasmids, and again, alkaline lysis followed by,
phenol:chloroform extractions, CsCl-EtBr gradient ultracentrifugation, or purification
through commercially available matrix columns e.g. Qiagen columns, seem to be the
most commonly used protocols. However, in this study, although some success was
achieved in isolating small quantities of DNA from the VIPR2 gene PI clone, using
each of the methods listed above, the results presented in this chapter suggest that the
quality of the PI DNA obtained using either Qiagen columns or alkaline
lysis+phenokchloroform extractions, was far below that obtained when alkaline lysis
was combined with CsCl-EtBr gradient banding of the PI DNA. These results are in
agreement with those of Kimmerly et al., (1994), who compared the success rates of
automated fluorescent cycle sequencing reactions carried out on PI DNA that had been
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isolated using: alkaline lysis, triton lysozyme lysis, or Qiagen columns. They found
that although the amounts of DNA isolated by these three methods were roughly the
same, the highest percentage of successful sequencing reactions was obtained when
using DNA that had been isolated using alkaline lysis in conjunction with CsCl-EtBr
gradient ultracentrifugation, whereas PI DNA isolated using Qiagen columns produced
the least successful results when sequenced (only -1/3 of the success rate achieved
from alkaline lysis + CsCl-EtBr gradient banding; Kimmerly et al., 1994). In order to
avoid the time consuming process of CsCl-EtBr gradient ultracentrifugation of the
DNA, this group then went on to develop a modified alkaline lysis method that includes
several additional purification steps (phenokchloroform extractions, PEG precipitation,
and spot dialysis) in place of purification by ultracentrifugation. However although this
modified alkaline lysis protocol was shown to produce results that were at least
equivalent to and possibly slightly better than those obtained using the alkaline lysis +
CsCl-EtBr gradient ultracentrifugation method, it is interesting to note that when using
this improved method of PI DNA isolation (which led to a sequencing success rate of
74% when the DNA was prepared from DH10B cells and 26% when the DNA was
prepared from NS3592 cells), they were still unable to successfully sequence any PI
DNA that had been isolated from NS3145 cells (Kimmerly et al., 1994). Therefore it
appears that even in comparison with PI DNA isolated from the Cre+ strain NS3529,
PI DNA isolated from the NS3145 strain (in which the VIPR2 PI clone used in this
study was grown) is often of particularly poor quality.
The suitability of alkaline lysis methods, for the isolation of PI DNA that is to be used
in Taq polymerase catalysed fluorescent end-labelled primer cycle sequencing, was also
commented on by Pan et al., (1994), who additionally devised a modified
diatomaceous earth (Prep-A-Gene, Biorad) -based method which they found preferable
for the isolation of PI DNA which was to be sequenced by Sequenase catalysed
fluorescent dye-terminator sequencing (Pan et al., 1994). Nevertheless, the alkaline
lysis method used by Pan et al., (1994) differs from that used by Kimmerly et al.,
(1994), in that the former group used a very simple alkaline lysis method which did not
involve either phenokchloroform extractions or CsCl-EtBr gradient ultracentrifugation,
as they were not deemed necessary. In contrast, Kimmerly et al., (1994) emphasised
the importance of CsCl-EtBr gradient ultracentrifugation for the isolation of high quality
PI DNA, and although this step was omitted in their modified alkaline lysis protocol it
was replaced by a battery of other purification steps including three phenokchloroform
extractions, PEG precipitation, and dialysis of the DNA. Extractions with phenol and
chloroform also featured in the method suggested by Pierce and Sternberg, (1992a),
whereas McCormick et al., (1994) reported that the use of Qiagen columns resulted in
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the isolation of better quality PI DNA than that isolated by phenol:chloroform
extraction and ethanol precipitation of the lysate. Of the methods of PI DNA isolation
that were tried during the studies of the VIPR2 PI clone described in this chapter, only
method 2 contained phenol :chloroform extraction steps (see 4.2.3). However as
neither this method nor the Qiagen column method that was tried, resulted in the
isolation of DNA that could be satisfactorily cut by restriction enzymes, the differences
in the results produced by these two isolation methods seemed to be marginal in the
case of the VIPR2 gene PI clone.
Many of the problems that were encountered in trying to subclone fragments of the
VIPR2 gene from the PI clone, were directly related to the fact that only very limited
amounts of PI DNA were available. However, in retrospect it seems likely that if there
had been more time in which to pursue some of these approaches, they might
eventually have been successful. This is especially true for the PCR amplification and
subcloning of amplimer-ligated DNA restriction fragments from the PI clone, as small
amounts of PI DNA were quite sufficient as starting material for this process. It is also
possible that a random 'shotgun' approach to the cloning of VIPR2 gene fragments
from the PI clone, similar to that described for the subcloning of fragments from large
introns of the mouse Vipr2 gene (Chapter 3), might have been more productive than
trying to isolate specific bands from agarose gel slices. However, in both cases it
would probably be more efficient to generate a 'mini-library' of subclones that could
then be screened for the presence of VIPR2 gene exon sequence (by hybridisation with
a rat Vipr2 cDNA probe), than to screen the clones by sequencing as was attempted
during this study. This is because although the human VIPR2 gene is predicted to be
quite large (at least as large as the mouse gene and probably considerably larger) the
regions encoding exons are likely to occupy a very small proportion of the total DNA in
the clone (PI vector + insert DNA), and consequently the chance of identifying VIPR2
gene exon sequences within the small number of BamW I/Bgl II fragment subclones
that were sequenced in this study was very low. If time had been available, the 'mini-
library' approach to subcloning VIPR2 gene fragments would certainly have been tried,
but by this stage, the main aim of this work was the confirmation of the PI clone's
identity, and consequently, upon publication of the human VIPR2 cDNA sequence
(Svoboda et al., 1994) the subcloning approaches described above were superseded by
attempts to amplify regions of the human gene by PCR, using primers that were
specific for human VIPR2 exon sequences.
The successful PCR amplification of an -1.3 kb region of DNA which spans the last
intron and exon of the human VIPR2 gene (including part of the 3' UTR), not only
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supplied the final proof that the PI clone contained at least part of the human VIPR2
gene, but also provided us with a PCR-based assay that could be used to detect the
presence of the VIPR2 gene in DNA samples from other sources. This was to prove
particularly useful when, following the determination of the VIPR2 gene PI clone's
chromosomal localisation, we were able to use this PCR assay to determine the position
of the 3' end of the human VIPR2 gene within a YAC contig that was derived from the
same chromosomal region, and hence provide a starting point for further mapping
studies (see Chapter 5). Thus, although due to problems encountered in isolating DNA
from the VIPR2 gene PI clone, characterisation of this clone was not pursued beyond
the point required for the determination of the VIPR2 gene's chromosomal localisation,
these studies eventually led indirectly to the identification of YAC and cosmid clones
encoding the VIPR2 gene, and characterisation of these clones is currently underway in
our laboratory.
Since the VIPR2 PI clone was initially identified using a rat cDNA probe that spanned
the region from predicted exon 1 to predicted exon 8 of the gene, and this probe was
also successfully used in Southern blots of restriction digests of the VIPR2 PI plasmid,
it appears that sequences located 5' of the end of predicted exon 8 are present in this
clone. However, as inconclusive results were obtained from the one Southern blot that
was hybridised with the 260 bp probe from the extreme 5' end of the rat cDNA, the
question of whether or not the 5' end of the human VIPR2 gene's coding sequence is
present in the PI clone remains unanswered.
Subsequent characterisation of YAC and cosmid clones encoding the human VIPR2
gene, carried out in our laboratory, has demonstrated that the introns 3 and 5 of the
human gene are 7 kb and >12 kb respectively (E. Lutz, unpublished data), thus
explaining the failure of attempts to use PCR to amplify regions of the VIPR2 gene that
spanned introns 3, 4 and 5, or even intron 3 alone. Nevertheless, as intron 1 of the
human VIPR2 gene has now been shown to be -2.1 kb in size (E. Lutz, unpublished
data), this intron and adjacent exon sequences would be a suitable target for future PCR
assays to detect the 5' end of the human gene.
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Chapter 5
Chromosomal localisation of the VIPR2 gene in
mouse and human
5.1 Introduction
The initial aim of investigators involved in the human and mouse genome mapping
projects, is to generate high density physical and genetic maps of these genomes
(Dietrich et al., 1996; Guyer & Collins, 1995; Hunter et al., 1996; Spurr, 1996).
However, the chromosomal localisation of a gene, in addition to providing a new
marker on a genomic map, has the potential to lead to a wide variety of information
about the gene and its product(s), including: determination of the gene's copy number;
evidence for evolutionary relationships between closely related genes; and in some
instances, indications of possible linkage to mapped genetic diseases.
The mouse is often the first choice as a model in which to study genetic diseases that
have been initially characterised in humans, due to the strong similarities between
mouse and human developmental pathways, and the relative ease with which the mouse
genome can be manipulated (Wynshaw-Boris, 1996). Comparative mapping of genes
in the mouse and human genomes has led to the identification of many regions of
synteny (groups of genes that map to the same chromosome) that are conserved
between the two species (O'Brien et al., 1993). To date over 900 loci have been
mapped to the chromosomes of both species, and the syntenic regions defined by these
loci often allow predictions to be made regarding the likely localisation of the human
homologue of a gene that has been mapped in mouse and vice versa (Searle et al.,
1994).
The diverse nature of the physiological functions in which VIP and PACAP have been
implicated, together with the relatively widespread distribution of Vipr2 mRNA within
the body, albeit often at very low levels (see main introduction), suggested many
possibilities for the involvement of the VIPR2 gene in genetic disease, but did not
immediately point towards a specific disease locus. Nevertheless, in light of the
reported neurotrophic properties of both VIP and PACAP, it is interesting to note that
the human PACAP gene maps to the human chromosomal region 18pl 1 (Hosoya et al.,
1992) which, as the authors stated, is associated with holoprosencephaly, a
developmental defect of the brain (Muenke, 1994). The human VIP gene maps to the
human chromosomal region 6q24-q27 (Gotoh et al., 1988; Gozes et al., 1987).
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The genes encoding some very closely related G-protein coupled receptors have been
shown to be quite tightly linked within the human genome, for example the a2/(31 and
a 1/(32 adrenergic receptor gene pairs (which are found on chromosomes 10 and 5
respectively; Yang-Feng et al., 1990), or the olfactory receptor gene cluster on
chromosome 17 (Ben-Arie et al., 1994). However, the recent localisation of the human
PACAPR1 and VIPR1 genes to 7pl4 (Stoffel et al., 1994) and 3p22 (Sreedharan et al.,
1995) respectively, indicates that this is unlikely to be the case for VIP and PACAP
receptors. Instead, these receptors seem to follow the same pattern as other members
of the secretin/glucagon receptor family (Table 5.1) and the G-protein coupled receptor
superfamily as a whole, in that the genes of family members are widely scattered
throughout the human genome (Wilkie et al., 1993), and their chromosomal localisation
is generally unrelated to that of any peptide ligand(s) (Table 5.2).
In collaboration with colleagues at the MRC Human Genetics Unit in Edinburgh, we
have determined the chromosomal localisation of the mouse and human VIPR2 genes
by fluorescence in situ hybridisation (FISH). Several other methods such as PCR
analysis of somatic cell hybrids, or analysis of the European collaborative interspecific
backcross (EUCIB) panel (for the mouse gene), could potentially have been used in our
own laboratory to provide similar information, but the relatively high resolution
attainable with FISH on both mouse and human chromosomes (Heiskanen et al., 1996)
made this our preferred method. Our initial results from the chromosomal localisation
of the human VIPR2 gene suggested the possible involvement of this gene in at least
one previously mapped human genetic disorder, and we therefore proceeded to map the
position of the gene more precisely (with assistance from Dr. S. Scherer and colleagues
at the Hospital for Sick Children, Toronto, Canada), using previously localised YAC
and cosmid contigs from the chromosomal region surrounding the VIPR2 gene.
5.2 Methods
5.2.1 Chromosomal mapping by FISH
Metaphase preparations were made from short-term peripheral blood cultures,
lymphoblastoid or fibroblast cultures and mouse ES cells by standard methods.
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The probe used in the chromosomal localisation of the mouse the Vipr2 gene was a 4
kb BamHl restriction fragment containing the final three introns and exons of the
mouse gene, which had been isolated and subcloned into pBluescript (Stratagene). The
isolation and characterisation of this mouse genomic fragment are described in detail in
Chapter 3. Plasmid DNA for use in FISH was prepared using a Qiagen plasmid maxi
kit (Qiagen Ltd.) according to the manufacturer's instructions.
For the chromosomal localisation of the human VIPR2 gene, a human VIPR2 gene PI
clone, was used as the probe. The isolation and characterisation of this clone are
described in Chapter 4. PI clone DNA for use in FISH was prepared by alkaline lysis
followed by CsCl banding and RNase treatment. A human VIPR2 cDNA (isolated by
E. Lutz in our laboratory) was also used as a FISH probe, to confirm the initial result
obtained with the PI clone.
YACs and cosmids that map to distal 7q
YACs HSC7E207 and HSC7E526 both map to 7q36, YAC HSC7E207 contains the
DNA markers D7S392 and D7S550, and YAC HSC7E526 contains D7S68 (Kunz et
al., 1994). Cosmid 29f5 contains marker D7S168 . Cosmid 30 has been described
previously (Riethman et al., 1993) and contains marker D7S590. YAC HTY146 also
known as HTY3006 (provided by Anna Jauch, University of Heidelberg, Institute of
Human Genetics, Heidelberg; and Harold Riethman, Wistar Institute, Philadelphia) is a
240 kb chromosome 7 telomeric YAC (insert size 230 kb) originally isolated by H.
Riethman (Riethman et al., 1993).
Cell lines
The cell lines used in this study were obtained from the National Institute of General
Medical Sciences (NIGMS) Human Mutant Cell Repository (Camden, USA). Details
of the cell lines are given in Table 5.3.
Probe labelling, hybridisation, and detection
This method was provided by J. Fantes (MRC Human Genetics Unit, Edinburgh) who
also carried out the FISH studies shown in this chapter.
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The PI clone, cDNA, cosmids, YACs, and plasmid, were labelled by nick translation
with biotin-16 or digoxigenin-16 dUTP. Chromosome 7 paint was produced by Alu-
PCR of DNA from somatic cell hybrids containing a single human chromosome 7
(Kofman-Alfaro et al., 1994). Amplified DNA was labelled with biotin-16 or
digoxigenin-16 dUTP by nick translation. Chromosome 13 paint labelled with biotin
was obtained from Cambio.
Hybridisation was carried out as described in Fantes et al., 1992 (Fantes et al., 1992).
After single probe hybridisation, biotin was detected by successive layers of avidin
FITC, biotinylated anti-avidin and avidin-FITC. When two probes, labelled with either
biotin or digoxigenin, were hybridised simultaneously, the signals were detected using
successive layers of FITC conjugated sheep anti-digoxigenin, FITC-conjugated anti-
sheep antibody plus avidin-Texas Red, biotinylated anti-avidin and avidin-Texas Red.
The VIPR2 gene was localised on prometaphase chromosomes produced by early S-
phase synchronisation with methotrexate of PHA stimulated peripheral blood cultures,
followed by release with bromodeoxyuridine (BrdU). In this case hybridisation
signals were detected by successive layers of avidin-Texas Red, biotinylated anti-avidin
and avidin-Texas Red. A final incubation with FITC conjugated anti-BrdU gave a
replication G-banding pattern (Craig & Bickmore, 1994). The chromosomes were
counterstained with DAPI. Texas Red hybridisation signals were visualised
simultaneously with FITC signals through a Chroma Pinkel #1 filter block fitted to a
Zeiss Axioplan microscope, with a Photometries CCD camera and Digital Scientific
software.
5.2.2 Physical mapping of the position of the human VIPR2 gene,
relative to the 7q telomere
PCR analysis of YAC contigs
Unless otherwise stated, ~1 ng of YAC DNA template was used in each PCR reaction.
PCR reaction conditions and cycling parameters were the same as those described for
the characterisation of the human VIPR2 gene PI clone (see Chapter 4, section 4.2.6).
The human genomic DNA (used as a control), was obtained from Promega. DNA
from somatic cell hybrids containing a single human chromosome-7, was provided by
J. Fantes (MRC Human Genetics Unit, Edinburgh).
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Use of YAC and cosmid clones to determine the position and orientation
of the human VIPR2 gene relative to the 7q telomere
This method was provided by Dr. S. Scherer (Hospital for Sick Children, Toronto)
who also carried out the studies relating to the fine mapping of the position and
orientation of the human VIPR2 gene that are shown in this chapter.
Previously isolated YAC and cosmid clones
YAC clones HSC7E526 and HSC7E1357 were isolated from a chromosome 7-specific
library prepared from human-hamster somatic cell hybrid lines (Scherer et al., 1992),
E145A7 was isolated from the St. Louis total human genomic YAC library (Brownstein
et al., 1989), and HTY146 (locus D7S427) also known as HTY3006 was isolated from
a telomeric YAC library that was described previously (Riethman et al., 1993). The
cosmid clones 2, 3 (D7S591), 6 (D7S592), 14, 19, 30 (D7S590), 48 (D7S593), and
49 were derived from a library made from the YAC clone HTY146 and have been
described previously (Riethman et al., 1993).
Hybridisation screening of cosmids.
Hybridisation screening of the Lawrence Livermore National Laboratory chromosome
7-specific library, and of the HYT146-derived cosmid clones described above, was
carried out using a human VIPR2 cDNA (isolated by Dr. E. Lutz in our laboratory)
corresponding to the entire coding region (13 exons) of the published sequence
(Svoboda et al., 1994) as a probe .
5.3 Results
The PISH studies shown in this chapter were carried out by J. Fantes at the MRC
Human Genetics Unit, Edinburgh, with assistance from M. Gray and S. Boyle.
Screening of the chromosome 7 cosmid library, and related work on the fine mapping
of the position and orientation of the human VIPR2 gene, was carried out by Dr. S.
Scherer and colleagues at the Hospital for Sick Children, Toronto, Canada.
5.3.1 Chromosomal localisation of the mouse Vipr2 gene
To determine the chromosomal localisation of the mouse Vipr2 gene, FISH analysis
was carried out on metaphase preparations from mouse embryonic stem cells, using a
- 110-
subcloned 4 kb BamKl restriction fragment of the mouse gene as a probe (see section
5.2 and chapter 3). Initial experiments showed a strong clear signal on the telomeric
region of mouse chromosome 12. However the use of FISH for the chromosomal
localisation of mouse genes is still relatively rare, and requires a high degree of skill,
because the acrocentric nature of mouse chromosomes makes them quite difficult to
type. Therefore, to verify the identity of the chromosome to which mouse Vipr2 probe
hybridised, a co-localisation experiment was carried out using the mouse Vipr2 gene
probe and a cosmid clone containing the Spi-2 gene. The Spi-2 gene has previously
been mapped to mouse chromosome 12 using the interspecific backcross method (Hill
et al., 1985). The results of the co-localisation experiment (Figure 5.1) clearly showed
that the mouse Vipr2 gene is located on mouse chromosome 12 band F2.
5.3.2 Chromosomal localisation of the human VIPR2 gene
Localisation of the human VIPR2 gene was carried out by FISH on human
prometaphase chromosomes, using a human VIPR2 gene PI clone (see section 5.2 and
Chapter 4) as a probe. Two signals, corresponding to hybridisation of the probe to
both sister chromatids, were seen on chromosomal region 7q36.3 (Figure 5.2). No
reproducible hybridisation to any other chromosomal region was observed. This result
was very interesting as several human genetic diseases map to 7q36, and one of these,
holoprosencephaly (HPE), is also associated with the chromosomal region to which the
PACAP gene has been mapped (Hosoya et al., 1992).
The localisation of the human VIPR2 gene was confirmed by FISH of a human VIPR2
cDNA probe (isolated by E. Lutz in our laboratory), and we then proceeded to examine
cell lines derived from patients who had HPE associated with 7q deletions.
5.3.3 Localisation of the VIPR2 gene in holoprosencephaly cases
associated with 7q deletions.
Previous studies by Gurrieri et al., (1993), on cell lines from HPE 7q deletion cases,
have led to the definition of a minimal critical region for 7q associated HPE (HPE3).
The distal extent of the deletion in cell line GM00657 defines the distal boundary of the
HPE3 minimal critical region, and the proximal extent of the deletion in cell line
GM03240 (and 2 other cell lines that have deletions very similar to those of GM03240)




mouseVipr2genomiccl nBSc4(green)a dSpi-osmidr ) maptoousechromosome12;Vipr2apsband2F
Figure5.2:Chromosomallocalisationfthu anVIPR2gene
 
FISH was used to localise the VIPR2 gene in cell lines derived from 4 of the patients
described by Gurrieri et al., (1993) and one unaffected relative. Details of the cell lines
used (and a summary of the results obtained) are given in Table 5.3.
Analysis of metaphase preparations from cell lines GM03240 and GM00657 (the cell
lines used by Gurrieri et al. to define the HPE3 minimal critical region), using the
VIPR2 gene PI clone as a probe, showed that only one copy of the VIPR2 gene was
present (on the normal chromosome 7) in each of these cell lines (GM03240 is shown
in Figure 5.3; GM00657 is shown in Figure 5.4). These results showed that the
VIPR2 gene is located within the HPE3 minimal critical region, as defined by Gurrieri
et al., (1993). Analysis of cell line GM07216, which has a deletion that extends to the
telomere of 7q from a point proximal to the breakpoint in GM03240 (Gurrieri et al.,
1993), also showed that only a single copy of the VIPR2 gene was present (on the
normal chromosome 7; Figure 5.5). This result is in agreement with those obtained
from GM03240 and GM00657.
Cell line GM10064 is thought to contain an interstitial deletion of 7q that extends from a
point centromeric to the proximal boundary of the HPE3 minimal critical region, to a
point that is slightly telomeric to the distal boundary of the HPE3 minimal critical region
(Gurrieri et al., 1993). Since we had already determined that the VIPR2 gene lies
within the HPE3 minimal critical region, it was expected that one copy of the VIPR2
gene would be present, on the normal chromosome 7 in this cell line. We were
therefore surprised to find that two copies of the VIPR2 gene were present in
GM10064. However, while one copy of the VIPR2 gene was present on the normal
chromosome 7 as expected, the other copy of the VIPR2 gene was present on the
otherwise apparently normal (paternal) 13p. Examination of cell line GM 10067 which
was derived from the father of GM 10064, and is thought to contain a balanced
translocation between chromosomes 7 and 13, verified that a copy of the VIPR2 gene
was indeed present at the distal end of the short arm of an otherwise normal
chromosome 13, and showed that a total of three copies of the VIPR2 gene were
present in this cell line, one on the otherwise normal 13p, one on the normal
chromosome 7, and one on the 13q derivative. The phenotype of this patient is normal
(Gurrieri et al., 1993). These results were confirmed by the use of chromosome 7 and
chromosome 13 paints, which also revealed that although GM 10064 contains two
copies of the VIPR2 gene, the majority of chromosome 13 is present in three copies in
this cell line (GM10064 is shown in Figure 5.6; GM10067 is shown in Figure 5.7).
Trisomy 13 is strongly associated with the occurrence of HPE, and it has been
estimated that HPE occurs in 70% of trisomy 13 cases (Taylor, 1968). In contrast,
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estimates of the occurrence of HPE in patients with deletions of 7q36 vary from -30%
(Grass et al., 1995) to -50% (M. Muenke, unpublished observation, cited in
Overhauser et al., 1995). Consequently, although either trisomy 13 or del (7q)(36)
could have resulted in HPE in the patient from which cell line GM10064 was derived,
the balance of probability suggests that it is more likely to have been caused by trisomy
13, and GM10064 was therefore excluded from our study of chromosome-7-linked
HPE.
5.3.4 PCR analysis of a YAC contig spanning the HPE3 minimal
critical region
Having established that the VIPR2 gene was located in the HPE3 minimal critical
region, we were interested in defining more precisely the position of the VIPR2 gene
within this region. In order to achieve this, a collaboration was established with Dr S.
Scherer and colleagues at the Hospital for Sick Children in Toronto, Canada, who have
been extensively involved in the construction of a genetic map of the long arm of
human chromosome 7, and in the mapping of the HPE3 locus. This group provided us
with DNA samples from a contig of 15 YACs which together spanned the 2 Mb HPE3
minimal critical region (Belloni et al., 1995). However, PCR analysis of the YACs
from this contig, using primers 4334 and 4335 which flank the last intron of the human
VIPR2 gene (see 5.2 and chapter 4), failed to identify any YACs that contained this
region of the VIPR2 gene. Nevertheless, the positive control reaction, to which lOOng
of human genomic DNA had been added as a template, did contain a product that was
the expected size (-1.3 kb). These results indicated that the VIPR2 gene was not
present within the YAC contig that spanned the HPE3 minimal critical region, a result
that appeared to conflict with those obtained from the FISH studies.
5.3.5 FISH localisation of YACs on interphase nuclei, and subsequent
PCR analysis of a YAC contig from the telomeric region of 7q
The clue that was to eventually lead to the resolution of the apparent discrepancies
between the FISH studies and our physical mapping data, came from a FISH study on
interphase nuclei, in which the position of the VIPR2 PI probe was compared with
those of YACs HSC7E207 and HSC7E526. Both of these YACs have previously been
localised to 7q36 by Kunz et al. (1994), who also showed that HSC7E207 contains
markers that are found centromeric to the proximal boundary of the HPE3 minimal
critical region, whereas HSC7E526 contains markers that place this YAC telomeric to
the distal boundary of the HPE3 minimal critical region as defined by Gurrieri et al.,
(1993). Our results from FISH of these probes on interphase nuclei, suggested that a
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region of overlap was present between HSC7E526 and the VIPR2 PI probe, as
indicated by the overlapping red coloured signal from HSC7E526 and the
orange/yellow coloured signal from the VIPR2 PI probe (Figure 5.8). This result was
confirmed by using PCR (with primers 4334 and 4335) to demonstrate that at least part
of the human VIPR2 gene was present within YAC HSC7E526. A product of the
expected size (-1.3 kb) was produced from -1 ng of HSC7E526 template DNA, and
also from positive control reactions containing total human genomic DNA (100 ng and
300 ng) or DNA from a human chromosome 7 somatic hybrid cell line (Figure 5.9).
The failure of the PCR reactions containing higher amounts of HSC7E526 template
DNA (-2 ng and -3 ng) was slightly surprising (Figure 5.9), however it was suspected
that this may be due to the presence of contaminants in the mini-prep DNA that was
used in these reactions. Further experiments using a different batch of YAC
HSC7E526 DNA (provided by Dr S. Scherer) produced the expected DNA product at
all concentrations tested.
HSC7E526 was originally isolated from a library of YACs whose average insert size is
around 475 kb (Kunz et al., 1994; Scherer et al., 1992). Therefore, to localise the
VIPR2 gene within this region, a contig of 10 YACs (provided by Dr. S. Scherer) from
the region to which HSC7E526 maps, was screened using the VIPR2 gene PCR assay
described above. A positive result (a product of -1.3 kb) was obtained from one of the
YACs in this contig, HSC7E1355 (Figures 5.10 and 5.11). YACs HSC7E526 and
HSC7E1355 both contain the chromosome 7 marker D7S593 which is located about
200 kb from the 7q telomere (S. Scherer, personal communication; Hing et al., 1993).
These results therefore suggest that the VIPR2 gene lies close to D7S593 and hence the
7q telomere.
5.3.6 Determination of the position and orientation of VIPR2 relative to
the 7q telomere.
Fine mapping of the position and orientation of the VIPR2 gene was carried out by Dr
S. Scherer and colleagues at the Hospital for Sick Children, Toronto, Canada. This
group used our PCR assay for the 3' region of the VIPR2 gene (see above), to
demonstrate that in addition to HSC7E526 and HSC7E1355, two other YACs
HSC7E1357 and E145A7 also contained the 3' region of the VIPR2 gene. All of these
YACs contain the marker D7S593 (S. Scherer, personal communication) which was
originally derived from the 7q telomeric YAC HTY146 (Hing et al, 1993; Riethman et
al., 1993). Therefore it appeared that YACs HSC7E526, HSC7E1357 and E145A7
each overlap with YAC HTY146, thus generating a contig of YACs that extends
inwards from the 7q telomere (see Figure 5.11).
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Figure 5.8: Localisation of the VIPR2 gene relative to the
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Figure 5.9: PCR amplification of a 3' fragment of the VIPR2
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Figure 5.10: PCR amplification of a 3' fragment of the
VIPR2 gene from a contig of human chromosome 7-derived
YACs surrounding HSC7E526
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YAC HTY146 has previously been subcloned into cosmids, and a contig of cosmid
clones spanning the length of this YAC has been established (Riethman et al., 1993).
Eight of these cosmids, which together span the entire length of HTY146, were
screened by hybridisation, for the presence of the VIPR2 gene, using a human VIPR2
cDNA clone as the probe (see 5.2). Two positive clones were identified, cosmid 14,
and cosmid 48 (D7S593), which based on the map generated by Riethman et al.,
(1993), places part of the VIPR2 gene -200 kb from the 7q telomere. Hybridisation
screening of a chromosome 7-specific cosmid library, again using the human VIPR2
cDNA as a probe, resulted in the isolation of a further 22 positive cosmid clones (8dl,
14el0, 66e9, 77e7, 79b6, 79g2, 79g3, 81e9, 107g9, 116h3, 122ell, 124g2, 126g6,
134a8, 135c5, 137g2, 164g2, 215a5, 222fl, 230e6, 245b9, and 250h9), and PCR
analysis (using primers 4334 and 4335) indicated that four of these clones (8dl, 77e7,
79g3, and 137g2) contained the 3' end of the VIPR2 gene. The relative positions of all
24 clones, and the degree of overlap between them, was determined by a combination
of hybridisation analysis and restriction enzyme mapping. Figure 5.11 shows the
positions, relative to the 7q telomere, of 8 representative cosmids that together span the
entire known coding region of the VIPR2 gene. The proximal locations of the cosmids
that have been shown to contain the 3' end of the gene, in comparison with those of
cosmids containing other regions of the gene, revealed that the orientation of the VIPR2
gene along the chromosome is: 7cen-D7S68-(3'-VIPR2-5')-D7S593-D7S591-
D7S592-D7S590-D7S594-7qtel. Together, these results show that the known coding
region of the VIPR2 gene is encoded by -100 kb of genomic DNA, and place the entire
VIPR2 gene within approximately 300-350 kb of the 7q telomere.
5,3.7 Reconciliation of the cytogenetic and physical mapping data:
redefinition of the distal extent of the HPE3 minimal critical
region
Although our FISH results clearly showed that the cell lines used by Gurrieri et al., to
define the HPE3 minimal critical region, were monosomic for the VIPR2 gene, a major
discrepancy existed between these results and those obtained from the physical
mapping study. The FISH localisation of the VIPR2 gene to the HPE3 minimal critical
region as defined by Gurrieri et al., (1993) would be expected to place the VIPR2 gene
somewhere in the region between the chromosome 7 markers D7S392 (which is just
centromeric to the proximal boundary of the minimal critical region) and D7S292
(which is located at the distal boundary of the minimal critical region). However, our
physical mapping data suggest that the VIPR2 gene lies close to the marker D7S593,
which is at least 1.5 Mb telomeric to the proposed distal boundary of the HPE3 minimal
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Figure 5.13: Localisation of cosmid 29f5 on metaphase
chromosomes from cell line GM00657
hybridisation of cosmid 29f5 (green/turquoise)
to cell line GM00657
Figure5.14:Localisationofcosmid30nmet phasechromos mesfr elllineGM0 657
 
critical region (S. Scherer, unpublished data; Gurrieri et al., 1993; see Figure 5.12).
The most likely explanation for this discrepancy was that either the deletion in cell line
GM100657 (used by Gurrieri et al., (1993) to define the distal boundary of the HPE3
minimal critical region) extended much further towards the 7q telomere than was
previously thought, or that a second deletion existed in this cell line, distal to the
deletion that had originally been characterised. Therefore, to examine more closely the
extent of the deletion(s) present in GM 100657, FISH studies on this cell line were
carried out, using cosmids containing D7S168 (cos29f5) which lies just proximal to the
distal boundary of the HPE3 minimal critical region, VIPR2 (cos79g3 and cosl26g6),
and the telomeric marker D7S594 (cos30) as probes (see Figure 5.12 for locations).
Only one copy of each of these probes, was found to be present (on the normal
chromosome 7) in cell line GM 100657 (the results obtained with cos29f5 and cos30 are
shown in Figures 5.13 and 5.14 respectively). The telomeric nature of the deletion in
GM 10064, indicated by the presence of only one copy of D7S594 (cos30), was
confirmed by using the 240 kb 7q telomeric YAC HTY146 (Riethman et al., 1993) as a
FISH probe on this cell line. As expected, only one copy of this YAC was present (on
the normal chromosome 7) in GM 100657. Thus, although it remains possible that a
region of 7q36 between markers D7S168 and the VIPR2 gene is present in cell line
GM 100657, our results clearly show that substantial regions telomeric to the proposed
distal boundary of the HPE3 minimal critical region (D7S292), including the VIPR2
gene and the 7q telomere, are deleted in this cell line. These results redefine the HPE3
minimal critical region, which now extends from D7S392 to the telomere of 7q, and
consequently identify the VIPR2 gene as a positional candidate for the HPE3 locus.
5.4 Discussion
5.4.1 Chromosomal location of the human VIPR2 gene
The results shown in this chapter placed the 5' end of the human VIPR2 gene within
200 kb of the human chromosome 7q telomere, and the whole gene within about 300-
350 kb of the telomere. Currently, the localisation of the 5' end of the gene is based on
the position of the 5' end of a human VIPR2 cDNA within a cosmid contig from the
telomeric region, and it is not yet clear how much further towards the telomere the
regulatory elements (e.g. promoter and enhancer elements) of the VIPR2 gene lie.
Genes that have been localised to 7q36 include: the 5-hydroxytryptamine receptor 5A
gene (7q36.1) (Schanen et al., 1996); the GBX1 gene which encodes a homeobox-
containing protein (7q36.1) (Matsui et al., 1993); the endothelial nitric oxide synthase
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gene (7q36) (Robinson et al., 1994); the engrailed 2 gene (Poole et al., 1989); the sonic
hedgehog gene (7q36) (Marigo et al., 1995); the aquaporin 3 gene (7q36.2-7q36.3)
(Ishibashi et al., 1995); the cyclin-dependent kinase 5 gene (7q36) (Demetrick et al.,
1994); and the RHEB2 gene which encodes a Ras-related GTP-binding protein (7q36)
(Mizuki et al., 1996). However, of the genes localised to this region so far, the VIPR2
gene is the closest to the telomere.
The 7q telomeric YAC HTY146 (also known as HTY3006) has been characterised and
subcloned into cosmids by Riethman et al., (1993) who have shown that the -230 kb
insert of this YAC contains all but the last 12 kb of the terminal 240 kb of 7q (Riethman
et al., 1993). Analysis of these clones indicates that in contrast to many human
chromosome telomeres, the telomeric region of 7q contains single copy DNA
sequences that are positioned very close to the telomere terminal repeat sequences, and
an unmethylated CpG island has been identified which lies at a distance of about 195 kb
from the end of 7q (Riethman et al., 1993). This is almost exactly the position to
which we have mapped the 5' end of the VIPR2 gene (using the cDNA), and it seems
very likely indeed that this unmethylated CpG island forms part of the 5' end of the
human VIPR2 gene.
Other interesting aspects of the region immediately surrounding the 5' end of the human
VIPR2 gene's transcribed sequence include: the marker D7S593 (Hing et al., 1993) for
which at least 4 allele systems can be detected following restriction digestion with
Hindlll, three of which show a combined heterozygosity of 70% (Hing et al., 1993);
and the presence of an L/-type repetitive DNA element (Riethman et al., 1993). An LI
repetitive sequence was also found in the putative promoter region of the mouse Vipr2
gene (see chapter 6), suggesting that sequence conservation between the mouse and
human VIPR2 gene may extend beyond the coding regions of the genes.
In addition to holoprosencephaly type 3 (Gurrieri et al., 1993), the following human
genetic diseases have been mapped to 7q35-36 or 7q36: long QT syndrome (cardiac
arrhythmia, 7q35-36) (Jiang et al., 1994) which is now known to be caused by
mutations of the HERG gene (Curran et al., 1995); various forms of Polydactyly and
polysyndactyly (7q36) (Heutink et al., 1994; Hing et al., 1995; Tsukurov et al., 1994);
and an autosomal dominant form of sacral agenesis (7q36) (Lynch et al., 1995).
Deletions involving 7q have been found in many malignant tumours (Mertens et al.,
1997), particularly testicular, prostate, and ovarian tumours (Atkin & Baker, 1993),
and in several tumour types (especially breast and lung carcinomas) an increase in
deletion frequency has been observed towards the 7q telomere (Mertens et al., 1997),
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leading to the suggestion that an unknown tumour-suppressor gene may be located on
distal 7q (Atkin & Baker, 1993; Mertens et al., 1997). In contrast, isochromosome 7q
is thought to be associated with hepatosplenic y/5 T cell lymphoma (Jonveaux et al.,
1996), gains of the distal region of 7q were among the chromosomal imbalances noted
in a study of primitive neuroectodermal tumours (Schiitz et al., 1996), and duplication
of 7q has been found in about 50% of low-grade astrocytomas occurring in adults
(Schrock et al., 1996). This latter observation is of considerable interest with respect to
the reported role of VIP and PACAP in the stimulation of astrocyte proliferation
(Brenneman et al., 1990; Tatsuno et al., 1996). Nevertheless, despite the frequently
reported stimulatory effects of VIP on neuronal growth and survival, it has become
increasingly apparent that VIP acts as a modulator of cell growth and differentiation
(Muller et al., 1995). VIP has been shown to inhibit the growth of some human
neuroblastoma cell lines, and to promote differentiation of these cells (Hoshino et al.,
1993; Pence & Shorter, 1993). VIP also inhibits mitogen- and antigen-induced T-cell
proliferation (Metwali et al., 1993), and both basal and histamine-stimulated
proliferation of human airway smooth muscle cells (Maruno et al., 1995). However,
although the role of VIP receptors in the transduction of the growth inhibiting and
differentiation promoting effects of VIP would not be inconsistent with the function(s)
of a tumour suppressor gene, a strong candidate gene for the tumour supressor locus
on distal 7q is the neural precursor cell-expressed developmentally down-regulated
gene-2 (NEDD2) which is involved in the regulation of programmed cell death, and
maps to 7q34-35 (Kumar et al., 1995).
5.4.2 VIPR2: a possible contributor to the HPE3 phenotype
Analysis of the cell lines used by Gurrieri et al.., (1993) to define the HPE3 minimal
critical region, clearly showed that the human VIPR2 gene is located within this
minimal critical region. However, inconsistencies between the results that we obtained
and those reported by Gurrieri et al., (1993) have led us to redefine the HPE3 minimal
critical region, which we have shown to extend from the original proximal boundary to
the 7q telomere.
Holoprosencephaly (HPE) is a developmental abnormality that results from incomplete
cleavage of the forebrain at the stage when the prosencephalon would normally divide
to form the cerebral hemispheres, diencephalon and telencephalon, and the olfactory
and optic bulbs (reviewed in Siebert et al., 1990). The HPE phenotype is characterised
by midline stmctural defects of the brain and/or face, the extent of the underlying brain
abnormalities usually, but not always, being reflected by the degree of facial
malformation (DeMyer et al., 1964). Alobar HPE, the most severe form of HPE, is
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found when a complete failure of forebrain cleavage has occured (DeMyer & Zeman,
1963). In alobar HPE a single brain ventricle (or 'holosphere') is present with little or
no evidence of interhemispheric fissure formation, the olfactory bulbs and tracts are
frequently absent and the pituitary is often absent or hypoplastic. Facial abnormalities
found in association with alobar HPE may include cyclopia or extreme orbital
hypotelorism, proboscis formation and/or arhinia, absent nasal bones, or a single
nostril, and median cleft lip. This form of HPE is not usually compatible with postnatal
survival. Nevertheless, the severity of a given HPE phenotype is generally inversely
related to its frequency of occurence, such that alobar HPE with cyclopia is a relatively
rare finding. At the other end of the HPE phenotypic spectrum, are the HPE-like
phenotypes which often include mild facial dysmorphism, and/or mental retardation in
conjunction with a recognised HPE microform eg. microcephaly, hypotelorism, or a
single frontal maxillary incisor. However, although they occur more frequently, these
HPE-like phenotyes are often much more difficult to diagnose unambiguously, because
many of these features are also associated with disorders other than HPE.
HPE has been estimated to occur at a frequency of 1/16000 live births and 1/250
embryos (Cohen, 1989). HPE can occur sporadically or in the form of familial HPE,
and approximately 50% of cases are thought to be associated with chromosomal
abnormalities (Muenke, 1994). However, although there are strong indications that
HPE in humans can be caused by either genetic or environmental factors, the
identification of environmental teratogens that may be responsible for HPE has proved
to be difficult. To date, the only clear case for a link between an environmental factor
and HPE in humans is the increase in the risk of HPE that is associated with maternal
diabetes (Barr et al., 1983), but HPE may also be linked to fetal alcohol syndrome
(Coulter et al., 1993), and maternal use of topical retinoids (Rosa et al., 1994).
Cytogenetic studies have identified several human chromosomal regions in which
deletions or duplications appear to be non-randomly associated with HPE: del(2)(p21),
dup(3)(p24-pter), del(7)(q36), del(18p), del(21)(q22.3), duplications or deletions
involving 13q, trisomy 13, and trisomy 18 (reviewed by Muenke, 1994). As a result
of these findings, four genetic loci at which genes responsible for HPE are thought to
reside have been designated, HPE1 at 21q22.3, HPE2 at 2p21, HPE3 at 7q36, HPE4
in 18p, and minimal critical regions have now been defined for each of these four loci
(Gurrieri et al., 1993; Muenke et al., 1995; Overhauser et al., 1995; Schell et al.,
1996). However, the variability of the HPE phenotype, cannot be explained by the
idea that different phenotypes may be linked with each of the HPE loci, as HPE cases
resulting from deletions at any one of these four loci, display the same wide spectrum
of phenotypes that is associated with HPE in general. This high degree of phenotypic
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variability is exemplified by the familial autosomal dominant (AD) form of HPE, where
even within a given AD HPE family, the phenotype displayed by affected family
members can range from alobar HPE through to the apparently normal phenotype of
some carriers of this form of the disease (Collins et al., 1993; Muenke, 1994). Linkage
studies have shown that in the majority of families with AD HPE, strong linkage can be
demonstrated between this form of HPE and markers from the HPE3 region on 7q36,
suggesting that the HPE3 gene may also be responsible for a large proportion of cases
of AD HPE . The estimated risk for the occurence of HPE in the offspring of an
obligate carrier of AD HPE is -30-35%, indicating that this form of HPE displays
incomplete penetrance (reviewed in Siebert et al., 1990). Indeed, in contrast to the
phenotypic spectrum of HPE which is wide, but does not seem to vary between loci,
the degree of phenotypic penetrance that is observed for HPE, appears to be a locus
specific phenomenon. For example, 30-50% of patients with deletions that encompass
the HPE3 minimal critical region, have some symptoms of HPE (Grass et al., 1995; M.
Muenke, unpublished observation cited in Overhauser et al., 1995), a figure that is
generally consistent with that for AD HPE (which is also thought to be linked to the
HPE3 locus). However, in contrast to this, it has been reported that all patients with
deletions that span the HPE2 minimal critical region on 2p21, have some form of HPE
(Muenke, 1994), and only 10% of patients with deletions encompassing the HPE4
minimal critical region on 18p show signs of HPE (Schinzel, 1984). Moreover, even
when HPE does occur as a result of deletions in 18p or 7q36, the severity of the
phenotype does not appear to correspond to the extent of the chromosomal deletion,
and consequently it could be very difficult to distinguish between very mild forms of
HPE and phenotypic abnormalities that might be associated with the deletion of other
genes in the region.
The presence of two copies of the VIPR2 gene (S. Scherer personal communication),
in two unrelated patients with mild craniofacial HPE symptoms and balanced
chromosomal translocations involving 7q36 (Belloni et al., 1995), indicates that the
VIPR2 gene cannot be the sole gene responsible for the HPE3 phenotype.
Nevertheless, one of these patients is the mother of four children, and it is intriguing to
note that the two children who have a deletion of distal 7q resulting from the
unbalanced segregation of the mother's chromosomal translocation (7;9) (q36;q34),
have a more severe HPE phenotype than the two children who carry the same balanced
translocation as the mother (Belloni et al., 1995; Gurrieri et al., 1993; Hatziioannou et
al., 1991). The association between a more severe phenotype and deletion of the
previously translocated region of 7q in these cases could of course be pure chance.
However, it does raise the possibility that one or more gene(s) lying distal to the
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translocation breakpoint on 7q may be responsible for the increased severity of the
phenotype observed when the region of 7q that lies distal to the breakpoint is lost.
Although research into the function, distribution, and signalling characteristics of the
VIP2 receptor is still in its early stages, several findings reported to date appear to
support the idea that the VIPR2 gene may contribute to the phenotype observed in some
cases of HPE3. One of the first, and perhaps the most compelling piece of evidence,
came from a study carried out by Gressens et al., (1993) in which the effects of VIP on
whole cultured mouse embryos were investigated. This study showed that treatment of
explanted E9.5 mouse embryos with VIP results in a dramatic concentration dependent
increase in embryonic growth, and at a concentration of 10~7 M VIP produces a 5-6
fold increase in cell mitosis in comparison with control embryos (Gressens et al.,
1993). The inverse experiment, in which pregnant mice were treated with a specific
VIP antagonist (a neurotensin-VIP hybrid; Gozes et al., 1991) from E9.3 to El 1.8,
resulted in embryonic growth retardation, and in particular, severe microcephaly
(Gressens et al., 1994). Microcephaly is thought to be one of the most reliable minor
symptoms for the identification of possible carriers of autosomal dominant HPE
(Collins etal., 1993).
Within the developing CNS, the growth-promoting effects of VIP are thought to be
mediated by a population of GTP-insensitive VIP receptors first described by Hill et
al., (1992). Comparison of the binding of 125j_vjp t0 rat brain sections in the
presence and absence of the GTP analogue guanylyl-imidodiphosphate (Gpp(NH)p),
identifies two distinct populations of VIP receptors in the rat CNS, one GTP-
insensitive and the other GTP-sensitive (Hill et al., 1992). In mouse embryos at E9.5,
the vast majority of VIP binding sites are confined to neural tissues and GTP-
insensitive VIP binding sites are estimated to represent 73% of total VIP binding
(Gressens et al., 1993). The suggestion that the GTP-insensitive VIP receptors
mediate the growth effects of VIP in the CNS of mouse embryos (Gressens et al.,
1993), stems from studies using the VIP antagonist neurotensin-VIP(7-28)- This
antagonist which partially blocks VIP-induced embryonic growth at E9.5 (Gressens et
al., 1993) especially that of the brain (E9.3-E11.8) (Gressens et al., 1994), and
completely blocks VIP stimulation of mitosis in the CNS at E9.5 (Gressens et al.,
1993), appears to induce a selective increase in the density of GTP-insensitive VIP
receptor sites in mouse embryos but has no effect on the density of GTP-sensitive VIP
binding sites (Gressens et al., 1993).
Viprl and Vipr2 mRNAs can be detected in the anterior (head) segment of mouse
embryos at E9.5 (Sheward et al., 1996b), and are thus present at the developmental
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stage where VIP is thought to exert its greatest effects on growth in the embryonic
CNS. To date, no reports have been published on the detailed distribution of Viprl or
Vipr2 mRNA within the embryonic brain, or on the early embryonic distribution of the
GTP-insensitive VIP receptors. Nevertheless, the adult distribution of the GTP-
insensitive VIP receptors in the rat CNS has been studied (Hill et al., 1994; Hill et al.,
1992) and appears to be similar but not identical to the pattern that has been reported for
Vipr2 mRNA (Lutz et al., 1993; Sheward et al., 1995; Usdin et al., 1994). Both are
found at relatively high levels in the olfactory bulb and pituitary (structures that can be
severely affected by HPE), the dorsomedial nucleus of the hypothalamus, several
thalamic nuclei (especially the medial geniculate nucleus), and the superior colliculi.
Furthermore, from E14-E16 (the earliest stages examined) in rat embryos GTP-
insensitive VIP binding is reported to be dense and restricted to a few midline structures
of the brainstem and spinal cord, including the roof and floor plates (Hill et al., 1994).
The relationship between the GTP-sensitive/GTP-insensitive VIP receptor populations
and the VIP i receptor and VIP2 receptor is unclear, and will be discussed in more detail
later. However, considering the intrinsic association between midline structure
dysgenesis and HPE, it will be important to establish the timepoint at which VIP
receptors first appear in these structures.
PACAP and PACAP binding sites can be detected in the brain of rat embryos from E14
onwards by radioimmunoassay and radioreceptor assay respectively (Tatsuno et al.,
1994), and Pacaprl mRNA has been shown to be present in mouse embryos from E9.5
onwards (Sheward et al., 1996a). Unlike the VIP] receptor and VIP2 receptor, which
bind both VIP and PACAP with high affinity, the PACAP type I receptor binds
PACAP with much higher affinity than VIP (see chapter 1). The extremely high level
of Pacaprl mRNA found in mouse embryos, relative to those encoding the VIPi
receptor and VIP2 receptor (Sheward et al., 1996a), suggest that a high proportion of
the PACAP binding observed during studies on rodent embryos is likely to represent
binding to PACAP type 1 receptors, and a significant amount of low affinity VIP
binding may also comprise binding to PACAP type 1 receptors. The neurotrophic
properties of PACAP (Arimura et al., 1994), together with the observation that
differential expression of alternately spliced forms Pacaprl mRNAs occurs during
development of the rat brain (D'Agata et al., 1996), suggest that PACAP may play an
important role in the development of the CNS. As noted earlier, the human PACAP
gene maps to the chromosomal region 18p 11 (Hosoya et al., 1992), and its localisation
has been refined to 18p 11.32 by Chang et al., (1993)(Chang et al., 1993). Deletions
of 18p have been associated with HPE, and a minimal critical region for HPE4 on
18p 11.3 has recently been defined (Overhauser et al., 1995). The PACAP gene maps
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within this minimal critical region. However, although the authors note that the
PACAP gene and three other genes lie within the minimal critical region they state that
"the known expression pattern and function of each of these genes does not implicate
them as likely candidates for HPE4" (Overhauser et al., 1995). We believe that the
evidence presented above provides grounds for the consideration of the PACAP and
VIPR2 genes as possible contributors to the HPE phenotype. Although the role of
PACAP in neuronal development is currently less well defined than that of VIP,
PACAP is also indirectly implicated in the effects of VIP by its ability to compete with
VIP for high affinity binding sites on both the VIPi receptor and VIP2 receptor.
Indeed, the observations that: 10% of 18p deletion cases, 50% of 7q36 deletion cases,
and all cases of 2p21 deletion, have symptoms of HPE (M. Muenke unpublished
observation reported in Overhauser et al., 1995) could be interpreted as supporting this
type of interaction between the genes at HPE loci. Unfortunately, the abundance of the
PACAP type 1 receptor makes it unlikely that the effects of PACAP binding to VIP]
receptors and VIP2 receptors during embryogenesis will be clarified until suitable
specific antagonists are found, or the results from transgenic/gene knockout studies of
the receptor genes are available.
Although VIP is readily detectable in rodent embryos from at least as early as El 1 (Hill
et al., 1996; Waschek et al., 1996), controversy exists over its source. The basis of the
problem, is the apparent absence of VIP mRNA in the rat embryo during early
embryogenesis, despite the presence of both VIP and VIP receptors at this time. It has
been reported that VIP mRNA cannot be detected in the rat CNS prior to birth, and
cannot be found in any part of the rat embryo before E16 (Hill et al., 1994). This has
led to the suggestion that embryonic VIP may originate either from the placenta or the
mother (Hill et al., 1994). Subsequent studies have shown that a peak in the VIP
content of the rat embryo at El 1 (with VIP levels four times higher than those at El7)
coincides with a peak in the VIP levels of maternal semm, and the transfer of
radiolabelled VIP from maternal blood to the embryo has also been demonstrated (Hill
et al., 1996). VIP mRNA could not be detected in the placentas of rat embryos by in
situ hybridisation, but was detected in E15-E18 placentas by RT-PCR (Hill et al.,
1996). However, another group has recently reported that VIP mRNA is present in the
CNS of mouse embryos at El 1 (Waschek et al., 1996). As noted by Waschek et al,
possible reasons for the difference between their results and those of Hill et al., include
species-specific variations in the levels of VIP mRNA in embryos, or differences in the
sensitivity of the assays used by the two groups (Waschek et al., 1996). The
possibility of developmental differences between rat and mouse makes it difficult to
draw any firm conclusions from these experiments at present. The finding that VIP
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mRNA is present in mouse embryos, is very exciting, as it may lead to the resolution of
a longstanding problem in this area of research, especially if the methodology is
successfully applied to rat embryos. Nevertheless, the coincident peak of VIP levels in
rat embryos and maternal serum at El 1 is also interesting, and may represent a potential
mechanism by which maternal VIP could augment embryonic VIP levels during critical
stages in embryonic development.
The effects of maternal factors on the developing embryo are of particular interest in the
study of specific congenital malformations that are thought to occur at a higher than
normal frequency in the offspring of mothers who have insulin-dependent diabetes
(EDD). HPE has been reported to display a 200 fold increase in frequency in infants of
mothers who have IDD and thus belongs to this group of malformations (Barr et al.,
1983), which also includes neural tube defects, sacral agenesis (also known as caudal
dysplasia), and congenital heart abnormalities (Cousins, 1983; Mills et al., 1979).
However, although the link between maternal IDD and specific congenital
malformations in infants seems to be widely acknowledged, it is not universally
accepted, and it has been suggested that the retrospective nature of many of the studies
has led to a severe bias in the data (Kalter, 1993). While debate over the existence of a
specific diabetic embryopathy continues, a more general link between maternal IDD and
developmetal abnormalities in infants is not in question. Experiments in which El0.5
rat embryos are grown in vitro using serum obtained from women who have type I
diabetes result in a 71% incidence of embryonic abnormalities in comparison with a 9%
incidence of abnormalities in embryos cultured in serum that was obtained from non-
diabetic women (Ornoy et al., 1995). Serum from diabetic women is also found to
decrease the size of embryos and to reduce the number of somites present relative to
those of control embryos (Ornoy et al., 1995), an effect that is the opposite of that
observed following administration of VIP to E9.5 mouse embryos grown in vitro
(Gressens et al., 1993).
The hyperglycemic environment that results from streptozotocin (STZ) induced diabetes
in mice, has been shown to result in a two-fold increase in the frequency of mutation of
a lacl transgene in mouse embryos, suggesting that a general increase in the level of
DNA mutations may occur in embryos of diabetic mothers (Lee et al., 1995a).
However, there is also evidence to support the idea that alterations in the expression
levels of specific genes may also be involved in diabetic embryopathy. A recent study
on the effects of STZ induced maternal diabetes on the embryonic expression of
mRNAs for insulin-like growth factors (IGFs) and insulin-like growth factor binding
proteins (IGFBPs) in rat, showed that there is a specific increase in the level of
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IGFBP-1 mRNA in E14 embryos from diabetic mothers, and has led to the suggestion
that elevated levels of IGFBP-1 may be involved in the growth retardation that occurs
in the embryos of diabetic mothers (Streck et al., 1995).
The VIPR2 gene is expressed at high levels in the insulin-secreting pancreatic (3-cell
line MIN6 from which the mouse Vipr2 cDNA was cloned, and is also expressed in the
insulin-secreting cell lines HIT-T15 and RINm5F (Inagaki et al., 1994). Both PACAP
and VIP have been shown to amplify glucose-stimulated insulin-secretion in vitro
(Bertrand et al, 1996; Straub & Sharp, 1996), and the pharmacological characteristics
of this response (ineffectiveness of secretin but approximately equipotent effects of VIP
and PACAP at 10~11-10~8 M) strongly suggest that it is mediated by the actions of VIP
and PACAP on the VIP2 receptor (Bertrand et al., 1996). The involvement of VIP,
PACAP, and the VIP2 receptor, in the control of insulin secretion, indicates that the
expression levels of the genes encoding these products may be modified in the diabetic
state.
5.4.3 Sacral agenesis
Although sacral agenesis and HPE are midline developmental defects that affect
opposite ends of the developing neural tube, the frequency at which these abnormalities
are found to coexist suggests that their association is not random (Martfnez-Frias et al.,
1994), and has led to the proposal that they may result from similar deficiencies in the
early development of the neural tube. Sacral agenesis and HPE display similar
increases in incidence (-200 fold) in embryos of diabetic mothers (Barr et al., 1983),
and both developmental defects have been associated with cytogenetic abnormalities
involving trisomy 13, trisomy 18, or deletion of the terminal region of 7q (Martlnez-
Frfas et al., 1994; Morichon-Delvallez et al., 1993). The basis of at least one of these
associations has been partially explained by the recent finding that a gene responsible
for the autosomal dominant form of sacral agenesis, maps to the holoprosencephaly
region on 7q36 (maximum lod scores are obtained with D7S559 and D7S594) (Lynch
et al., 1995). However it is not yet clear whether or not the same gene is responsible
for both defects.
5.4.4 Chromosomal location of the mouse Vipr2 gene
The mouse Vipr2 gene was localised to mouse chromosome 12 band F2, a result that
was unexpected with regard to previously defined regions of synteny between the
mouse and human genomes.
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For several years the only indication of synteny between human chromosome 7 and
mouse chromosome 12 has been the laminin B1 gene. The human laminin B1 gene
(LAMB1) has been mapped to human chromosome 7q22-q31 (Modi et al., 1987;
Pikkarainen et al., 1987), and its mouse homologue lambl-1, has been localised to the
proximal region of mouse chromosome 12 (O'Brien et al., 1993). In the absence of
any other indications of synteny between these two chromosomes, doubts have been
expressed over the validity of this single syntenic marker, particularly with regard to the
functional status of the mouse lambl-1 gene (Khan et al., 1994). Nevertheless, a
recent report that the dihydrolipoamide dehydrogenase gene (DLD) which is located on
human chromosome 7q31-32 (Scherer et al., 1991) has a homologue on mouse
chromosome 12 (Tsui et al., 1995), together with the finding that the mouse homeobox
gene Meox2 which maps to the proximal region of mouse chromosome 12 (Candia et
al., 1992) has a human homologue on 7p22.1-p21.3 (Grigoriou et al., 1995), strongly
suggests that some conservation of synteny does exist between human chromosome 7
and mouse chromosome 12.
Human chromosomal region 7q36 is generally considered to be syntenic with the
proximal region of mouse chromosome 5 (Tsui et al., 1995), and to date at least four
human genes from 7q36 have been shown to have homologues on mouse chromosome
5 (Marigo et al., 1995; Martin et al., 1990; Matthes et al., 1993; Ohshima et al., 1995).
However, as the VIPR2 gene appears to be the most distally located gene that has been
mapped to 7q36 so far, the possibility exists that a chromosomal region showing
synteny with the telomeric region of mouse chromosome 12 may be located distal to the
recognised region of synteny with mouse chromosome 5.
At present, a large section of the distal region of mouse chromosome 12 bordered
proximally by the paired box homeotic gene 9 (Pax9) locus and distally by the
immunoglobulin heavy chain-C (Igh-C) locus, is believed to be homologous in both its
gene content and gene order, to the long arm of human chromosome 14 (D'Eustachio &
Riblet, 1996). However, since both Igh-C (D'Eustachio & Riblet, 1996) and Vipr2
map to 12F2, we do not know whether the mouse Vipr2 gene lies within or distal to the
defined region of synteny with human chromosome 14q, and consequently there are
three possible explanations for our findings: i) the mouse Vipr2 gene lies distal to the
defined region of synteny with human chromosome 14q, and the subtelomeric extremes
of human chromosomal region 7q36 and mouse chromosome 12 could form a
previously unrecognised region of synteny, ii) the mouse Vipr2 gene lies within the
previously defined region of synteny with human chromosome 14q, and other markers
from the distal region of 7q36 also have mouse homologues within the same region of
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mouse chromosome 12, thus dividing the region that is syntenic with human 14q, iii)
the mouse Vipr2 gene may be the only gene from 7q36 that maps to the distal region of
mouse chromosome 12, and for some reason, its subtelomeric location has been
preserved at the expense of conservation of regions of synteny between the two
species.
Although further work will be required in order to clarify the relationship between the
subtelomeric region of human chromosome 7q36 and the distal region of mouse
chromosome 12, the localisation of the mouse Vipr2 gene to chromosome 12F2 is
likely to be of considerable interest with regard to mouse/human comparative genomic
mapping, and may define a new region of synteny between the mouse and human
genomes.
Since we suspect that monosomy at the human VIPR2 locus may contribute to HPE3
phenotype, it was possible that a similar phenotype might be associated with the locus
of the mouse Vipr2 gene. However, a search of the mouse genome databases did not
reveal the existence of any mapped mouse genetic mutations that result in an HPE-like
phenotype. This is not as suprising as it might seem, and may be a reflection of
developmental differences between mice and humans. A review by Searle et al.,
indicates that a corresponding pathological variant in the mouse, is found for only about
20% of the genes that have been shown to be responsible for genetic disease in humans
(Searle et al., 1994). Moreover, in the case of genes responsible for human
craniofacial abnormalities, the percentage of conditions for which a spontaneously
occurring mouse homologue of the defect occurs, appears to be even lower (-10%),
although it has been suggested that this may be due to difficulties in recognising some
of these conditions in mice (Winter, 1996).
HPE can be experimentally induced in mouse embryos by ochratoxin A (Wei & Sulik,
1993), alcohol (Sulik & Johnston, 1982), and all-trans retinoic acid (Sulik et al.,
1995), each of which can cause a wide spectmm of developmental abnormalities, the
type and severity being dependent to a large extent on the dose and the gestational stage
at which the teratogen is administered (Sulik et al., 1995; Sulik & Johnston, 1982; Wei
& Sulik, 1993). A study carried out by Wei and Sulik (1993) on the effects of
ochratoxin A is particularly interesting, as in addition to showing a correlation between
the gestational day of toxin administration (GD7 or GD8) and variations in the HPE-
like phenotype of the embryos, parallels have also been drawn between the patterns of
ochratoxin A-induced cell death in the developing forebrain, and the resultant
phenotype (Wei & Sulik, 1993). However, the effects of these teratogens at the level
of gene expression are not fully understood, and the extent to which the patterns
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observed in these models reflects the pathogenesis of chromosomal HPE in humans is
unknown.
The possibility of examining the effects of monosomy at the mouse Vipr2 locus,
through the use of mice that carry translocations of the distal region of chromosome 12,
was considered, as several such mouse lines are available. Similar experiments have
been carried out previously by Beechey et al., (1980), who used mice carrying the
reciprocal translocation T(5;12)31H which has breakpoints at bands 5B and 12F1 (just
distal to the immunoglobulin heavy chain-1 locus, Igh-1), to generate mice that are
monosomic (5, 12, 12^) for the distal region of chromosome 12, and mice that are
trisomic for this region (5, 5, 12, 12, 5^). Interestingly, both the trisomic and the
monosomic mice show growth retardation, and some of the monosomic mice have
abnormal skull and vertebral fusions (Beechey et al., 1980). However, by definition,
these mice are also either monosomic or trisomic for regions of chromosome 5, thus
making it impossible to reach any clear conclusion about the cause of the observed
phenotype. Moreover, even from the relatively few genes that have been mapped to the
telomeric region of mouse chromosome 12 to date, there are at least two genes that are
thought to have roles in craniofacial development. The goosecoid gene (Gsc), which is
essential for normal craniofacial development (Rivera-Perez et al., 1995; Yamada et al.,
1995a), and maps slightly proximal to Igh-1 (D'Eustachio & Riblet, 1996; Guenet et
al., 1995), is probably not involved in the T(5;12)31H translocation; but the legless
(Igl) insertional mutation, which is situated near to the situs inversus viscerum (iv)
locus (Singh et al., 1991), distal to Igh-1 (D'Eustachio & Riblet, 1996), almost
certainly lies within the T(5;12)31H translocated region. The legless mutation (which
is thought to disrupt more than one gene) is particularly interesting, as in addition to
situs inversus and limb abnormalities, the phenotypes observed in homozygous
mutants include: absent olfactory bulbs, malformed cerebral hemispheres,
hydrocephaly, and in -50% of cases craniofacial clefts (Singh et al., 1991),
characteristics that correspond to some of those seen in deletions of human
chromosomal region 7q36. Mice that are heterozygous for either the legless insertional
mutation or the Gsc-null mutation, are phenotypically normal, indicating that
monosomy at these loci is unlikely to be responsible for the effects seen in the mice
characterised by Beechey et.al., (1980). However, even in the absence of the potential
complications caused by these two known genes, the difficulties associated with
interpreting the information gained from the study of mice derived from the T(5;12)31H
translocation line (Beechey et al., 1980), suggested that this type of approach would be
of limited use for the study of VIP2 receptor function, at present.
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5.4.5 Although initially excluded as a candidate, theSonic Hedgehog
gene has now been shown to be the HPE3 gene.
As discussed previously, the presence of the VIPR2 gene in two unrelated patients who
carry balanced translocations of 7q, and have mild HPE phenotypes, suggests that the
VIPR2 gene cannot be the sole gene responsible for HPE3, although it may contribute
to the phenotype observed in some cases.
The combination of the high gene density that appears to be associated with the
subtelomeric regions of most human chromosomes (Craig & Bickmore, 1994), and the
large number of genes that are already known to be involved in brain and craniofacial
development, indicated that the HPE3 minimal critical region on 7q36 was likely to
contain several genes that would be strong candidates for the HPE3 locus. During our
studies of the VIPR2 gene as a candidate gene for the HPE3 locus, two other candidate
gene's were identified by other laboratories (Marigo et al., 1995; Mizuki et al., 1996):
i) The Sonic hedgehog gene (SHH), was mapped to 7q36, by Margio et al., soon after
we began our cytogenetic studies of the VIPR2 gene. However, although the authors
initially examined the SHH gene as a potential candidate for the polysyndactyly locus
that is situated in this region (Marigo et al., 1995), a possible role for this gene in HPE
was not suggested at this stage.
ii) The Ras homologue enriched in brain 2 gene (RHEB-2) was mapped to 7q36 by
Mizuki et al., shortly after the completion of our studies of the VIPR2 gene, and was
suggested as a candidate gene for holoprosencephaly type 3 and/or sacral agenesis
(Mizuki et al., 1996), although no cytogenetic mapping studies of the gene in cell-lines
derived from individuals with HPE had been carried out.
Of these two positional candidates, the SHH gene was the most promising. SHH
encodes a secreted signalling molecule and is a member of a family of vertebrate genes
that are related to the Drosophila hedgehog (hh) gene (Echelard et al., 1993). So far, at
least seven vertebrate hedgehog genes have been identified (including 3 in mammals),
and, like their Drosophila counterpart, these genes appear to play an important role in
patterning activities during embryonic development (reviewed by Hammerschmidt et
al., 1997). The expression pattern of the Shh gene is generally consistent with a role
for this gene in HPE, as Shh is expressed in midline structures including the notochord
and floorplate during embryogenesis, and has been implicated in the control of
patterning during embryonic limb, brain, and eye development (Chang et al., 1994;
Ekker et al., 1995; Macdonald et al., 1995). Ectopic expression of Shh in zebrafish
- 129-
embryos results in eye defects and absence of the midbrain- hindbrain-boundary
constriction, whereas in homozygous cyclops mutant (eye"/") embryos the ventral
neural structures that usually express Shh are absent (Ekker et al., 1995). Linkage
studies of the SHH gene suggested that the gene is located distal to D7S550 (see Figure
5.12 for location of this marker) and close to the EN2 gene (Marigo et al., 1995), a
result which would probably place the SHH gene within or slightly centromeric to the
proximal boundary of the HPE3 minimal critical region (Gurrieri et al., 1993). Taken
together, these linkage studies and expression data suggested that SHH would be a
strong candidate for HPE3, and we were therefore very surprised to read that the SHH
gene had been excluded as a candidate for the HPE3 locus (M. Muenke, personal
communication cited in Winter, 1996).
Indeed, the exclusion of SHH as a candidate for HPE3 became even more puzzling,
when it was reported that the phenotype observed in Shh"/" mice, includes midbrain
and forebrain defects, cyclopia, a proboscis-like extension from the rostral midline,
severe growth retardation, and severe craniofacial malformations (Chiang et al., 1996).
These characteristics are very similar to those found in patients who have HPE, and
consequently, it was not unexpected when, in November 1996, evidence indicating that
SHH is the primary gene responsible for HPE, was finally published (Belloni et al.,
1996; Roessler et al., 1996). Following an extensive search for candidate genes in the
region spanning the translocation breakpoints of patients who have balanced
translocations involving 7q36, and have mild HPE phenotypes, the SHH gene (which
was found to lie 15 kb from the closest HPE-associated translocation breakpoint and
250 kb from another HPE-associated translocation breakpoint) was found to be one of
only two candidate genes that could be identified within this region, and was the only
candidate gene for which a role in HPE could be established (Belloni et al., 1996).
Subsequent analysis of 30 families who had autosomal dominant HPE, revealed point
mutations within the coding region of the SHH gene in 5 of these families, thus
confirming that SHH is likely to be the HPE3 gene (Roessler et al., 1996).
These findings suggest that distinct differences exist between mice and humans with
regard to their sensitivity to changes in SHH expression (and possibly the level of
functional redundancy or dosage requirements for the Sonic hedgehog gene product),
as mice that are heterozygous for Shh gene disruption are phenotypically normal
(Chiang et al., 1996), whereas it appears that in humans, mutations or deletions that
affect only one copy of the SHH gene can cause HPE3 (Belloni et al., 1996; Roessler
et al., 1996; Roessler et al., 1997). This sensitivity to changes in SHH expression is
thought to be particularly relevant to the ability of chromosomal rearrangements outside
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the immediate vicinity of the human gene, to cause HPE, presumably as a result of
reducing or altering SHH expression, through position effects (which have been
reported to be capable of acting over distances of up to at least 400 kb; Bedell et al.,
1996) or the dismption of distal regulatory elements (Belloni et al., 1996).
Nevertheless, although variations in the precise nature of the SHH mutations or
deletions that lead to HPE3, may to some extent explain the wide range of phenotypes
that can be associated with this condition, some questions relating to the genotype-
phenotype correlations observed in this disorder remain difficult to answer, and it has
been suggested that additional genetic and/or environmental factors may affect the
severity of the observed phenotype (Belloni et al., 1996; Dean, 1996). These
genotype-phenotype inconsistencies are exemplified by the findings that: i) the
phenotypes associated with the deletion of one copy of the SHH gene, range from
microcephaly (a phenotype that is considered to be an HPE microform), to severe HPE
(Roessler et al., 1997), and ii) in some cases, deletions of regions over 250 kb away
from the SHH gene, can result in a phenotype more severe than that found in some
instances where there are deletions that appear to encompass the entire SHH coding
region. Interestingly, the other human hedgehog genes that have been identified to
date do not map to HPE-associated loci (Dean, 1996), although proteins that are
involved in SHH signalling pathways might prove to be strong candidates. As pointed
out by Roessler et al., (1997), further studies on the functional consequences of the
SHH mutations identified in HPE patients, will ultimately be required to confirm that
haploinsufficiency for SHH is responsible for 7q36-associated HPE. However, it is
now generally accepted that SHH is the HPE3 gene, and the emphasis of future work
on HPE3 is likely to centre on determining the molecular basis for the phenotypic
variability of this disorder.
Finally, it may be worth mentioning that an improbable, but nevertheless possible twist
in the SHH/HPE3 story, might conceivably exist, as it has recently been shown that the
effects of Indian hedgehog (Ihh; another member of the hedgehog family) on
chondrocyte differentiation are mediated by PTHrP through the formation of a negative
feedback loop (Vortkamp et al., 1996). These effects of PTHrP are in turn mediated by
the PTH/PTHrP receptor, and chondrocytes from mice that are homozygous for a
targeted deletion of the PTH/PTHrP receptor gene are resistant to the effects of both
PTHrP and Sonic Hedgehog (Lanske et al., 1996). This raises the intriguing
possibility that other members of the secretin/glucagon receptor family including the
VIP2 receptor, may also be involved in mediating some of the effects of Hedgehog
proteins during embryonic development, although at present there is no further
evidence to support this suggestion.
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5.4.6 Is the VIP2 receptor involved in mediating the dramatic effects of
VIP on embryonic growth? Current arguments from a
pharmacological/signal transduction perspective
Much of the evidence supporting the existence of a role for VIP2 receptors in
embryonic growth, hinges on the similarity between the adult distribution of the VIP2
receptor (Lutz et al., 1993; Sheward et al., 1995; Usdin et al., 1994) and the GTP-
insensitive population of high affinity VIP receptors (Hill et al., 1994; Hill et al., 1992)
in the rat CNS; a relationship that was first noted by Harmar and Lutz (1994) (Harmar
& Lutz, 1994). However, although mRNAs encoding the VIPi and VIP2 receptors are
present during early embryogenesis (Sheward et al., 1996b), the known ligand binding
and signal transduction properties of these receptors do not appear to correspond with
those of the GTP-insensitive population of VIP receptors (discussed in Gressens et al.,
1994). These discrepancies between the properties of the pharmacologically
characterised and the cloned VIP receptors, have led several investigators to infer that a
third high affinity VIP-specific receptor may exist. Nevertheless, despite extensive
efforts, no one has yet cloned a receptor that fits this description.
The current arguments against the involvement of the VIP2 receptor in mediating the
growth-promoting effects of VIP in embryos, centre on, the failure of PACAP to
stimulate embryonic growth (J. M. Hill, unpublished data, cited in Hill et al., 1996),
the failure of PACAP to prevent the inhibition of embryonic growth produced by the
VIP antagonist neurotensin-VIP(7-28), and the inability of PACAP antagonist
PACAP6-27 to duplicate the growth inhibitory effects of the neurotensin-VIP7-28
during embryogenesis (Gressens et al., 1994). These observations provide reasonable
grounds for the authors' conclusion that VIP receptors which bind both VIP and
PACAP are unlikely to be involved in mediating the effects of VIP on embryonic
growth. However, it may be worth noting that in reaching this conclusion several
assumptions seem to be made.
The first of these assumptions is that both PACAP and VIP bind to exactly the same
site on VIP/PACAP receptors, and that once bound they have the same effect on
receptor signalling. This may prove to be correct, but it cannot be regarded as a
certainty as there is already evidence from other G-protein coupled receptor systems,
including the PACAP type 1 receptor, which indicates that this might not always be the
case. A large proportion of this evidence centres on the theory of agonist-receptor
trafficking, a concept that is based on the idea that different agonists acting at a given
receptor may be capable of selectively stabilising the formation of different ternary
complexes, which in turn can couple to different G-proteins [(Kenakin, 1995) reviewed
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by (Gudermann et al., 1996)]. One of the examples that is frequently cited in support
of this theory, is the reversal of relative agonist potency that occurs between PACAP i_
27 and PACAPi-38 for the stimulation of cAMP and inositol phosphate accumulation
mediated by the short form of the PACAP type 1 receptor in transfected LLC PK1 cells
(Spengler et al., 1993). A similar effect is also found at the Drosophila octopamine-
tyramine receptor in transfected CHO cells, where it has been shown that a reversal of
agonist potencies occurs between octopamine and tyramine, depending upon whether
cAMP inhibition, or the elevation of intracellular calcium is studied (Robb et al., 1994).
In the case of the PACAP type 1 receptor, studies of a recently isolated mRNA splice
variant that results in the deletion of a 21 amino acid domain from the N-terminal
extracellular region of the receptor, have demonstrated that this 21 amino acid domain
of the PACAP type I receptor is responsible for the differential potencies observed for
PACAPi-27 and PACAPi-38 in stimulating the accumulation of inositol phosphate,
although the same domain appears to have little or no effect on the relative potencies of
these peptides in the stimulation of cAMP (Pantaloni et al., 1996). Inextricably linked
with the concept of agonist-receptor trafficking, is the idea that different agonists
binding to a given receptor could be differentially sensitive to the effects of antagonists
acting at that receptor (Kenakin, 1995). Thus, if agonist-receptor trafficking was
occurring at the VIP2 receptor, it would explain to some extent many of the effects that
to date have been interpreted as arguing against the involvement of this receptor in
mediating the effects of VIP on embryonic growth.
The second assumption that appears to have been made, is that either PACAP type 1
receptors are not present in the developing embryo, or that the effects of PACAP
binding at these receptor sites are the same as those of PACAP binding to VIP/PACAP
receptors. As mentioned previously, it is now known that in E9.5 mouse embryos,
mRNA encoding the PACAP type I receptor is much more abundant than mRNAs
encoding either the VIPi receptor or VIP2 receptor (Sheward et al., 1996a), and it
seems unlikely that these receptors have the same function. Therefore, the results of
the PACAP antagonist study, in which it was shown that PACAP6-27 could not
reproduce the growth inhibition seen after administration of the neurotensin-VIP hybrid
antagonist, will almost certainly represent the net effect of blocking the actions of
PACAP at both the PACAP type 1 receptor and the VIP/PACAP receptors, and may
not necessarily provide a true reflection of the actions of PACAP at VIP/PACAP
receptors. Indeed, in the experiments carried out by Gressens et al., (1994), it was
found that the addition of neurotensin-VIP hybrid antagonist + PACAP, resulted in a
dramatic decrease in embryonic body growth that was not observed after the addition of
the antagonist alone. Interestingly, a recent report on the expression of PACAP type 1
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and VIP/PACAP receptors during phenotypic interconversion in the human
neuroblastoma cell line SH-IN, has shown that a switch from large substrate-adherent
slow-growing cells to focal aggregates of small rapidly growing cells, can be correlated
with a change in the expression of receptors for VIP and PACAP from 95% PACAP
type 1 receptors and 5% VIP/PACAP receptors in the large slow-growing cells to only
13% PACAP type 1 receptors and 87% VIP/PACAP receptors in the small fast-
growing cells (Lelievre et al., 1996). The finding that VIP and PACAP are
approximately equipotent in the stimulation of cell growth in both the large and small
cell-types led the authors to suggest that the stimulation of the growth of these cells is
mediated by VIP/PACAP receptors. However, whereas the addition of either 10 nM or
20 nM VIP or PACAP significantly stimulated the growth rate of both cell-types, the
addition of 10 nM VIP + 10 nM PACAP had very little effect on proliferation (Lelievre
et al., 1996). As noted by the authors, this finding indicates that under certain
circumstances VIP and PACAP27 may have mutually antagonistic effects (Lelievre et
al., 1996), a factor which could be crucial in the interpretation of the experiments on
mouse embryonic growth carried out by Gressens et al. (1994).
Do the growth-promoting VIP receptors couple to G-proteins in the embryonic CNS?
The apparent GTP-insensitivity of the growth-mediating VIP receptors in the
embryonic rat CNS (Gressens et al., 1994; Hill et al., 1994; Hill et al., 1992), is
puzzling, because it seems to imply that no heterotrimeric G-proteins, or at least none
of the known heterotrimeric G-proteins, are involved in the signal transduction
mechanism(s) of this receptor in embryos. This phenomenon is not unique to VIP
receptors, as in certain cell lines, agonist binding to other 7-transmembrane G-protein
coupled receptors, including the 5-hydroxytryptamine type 2 receptor (5HT2), and the
angiotensin II type 2 receptor (AT2), is also reported to be insensitive to GTP
analogues (Buisson et al., 1995; Szele & Pritchett, 1993). However, although the
addition of ImM GTPyS has no effect on the levels of angiotensin II binding to the
AT2 receptor in NG108-15 cells, the inhibition of T-type calcium currents that is
mediated by the AT2 receptor in this cell line, is clearly dependent on a GTPase activity
(as indicated by the ability of GTPyS to replicate the effects of the agonist, and the
ability of GDPpS to reverse these effects) (Buisson et al., 1995). These studies, and
those carried out by Szele and Pritchett (1993) on 5HT2 receptors in transfected HEK
293 cells, indicate that unknown G-proteins may exist for which the presence of GTP-
analogues does not affect the binding of agonists by receptors (Buisson et al., 1995;
Szele & Pritchett, 1993). Interestingly, the signalling pathways in which these 'GTP-
insensitive G-proteins' have been implicated, involve calcium regulation (AT2
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receptor), and inositol phosphate hydrolysis (5HT2 receptor), pathways that are similar
to those through which the GTP-insensitive VIP receptors are thought to signal (Hill et
al., 1994; Hill et al., 1992). The status of the cloned VIP] receptor and VIP2 receptor
with respect to non-cAMP mediated signalling is unclear at present, but there is
increasing evidence to suggest that the VIP2 receptor can stimulate increases in
intracellular calcium (Inagaki et al., 1994; Straub & Sharp, 1996; Xia et al., 1996b),
and may also signal via a novel wortmannin-sensitive pathway (Straub & Sharp,
1996).
It also appears that the effects of Gpp(NH)p (the nonhydrolysable GTP analogue used
to identify the GTP-sensitive receptors) on VIP binding to the VIP2 receptor may differ
from those expected, as it has been shown that in SUP-T1 cells, partial agonists
(including VIP) binding to the helodermin preferring (VIP type 2) receptor in the
presence of 10 |J,M Gpp(NH)p, show a decrease (3.3 fold for VIP) in their Kact f°r
adenylate cyclase stimulation, relative to the Kact of the same partial antagonist in the
presence of 10 pM GTP (Christophe et al., 1990). The same effect is also seen in
cholera toxin treated SUP-T1 cells, and binding studies confirm that the observed
decrease in the Kact, reflects an increase in receptor affinity for partial agonists, and a
decrease in receptor selectivity (Christophe et al., 1990; Robberecht et al., 1989).
However, it is not known whether or not this effect of Gpp(NH)p is specific to VIP2
receptors.
Other explanations for the GTP-insensitivity of the embryonic growth mediating VIP
receptors, include the possibility that these receptors signal through a heterotrimeric G-
protein independent pathway, similar to the Jak/STAT signalling pathway that has
recently been proposed for the angiotensin II type 1 receptor (Marrero et al., 1995).
This would in many ways be consistent with the transduction of mitogenic signals by
these receptors, as this type of signalling pathway has traditionally been associated with
cytokine receptor signalling.
Could cAMP be involved after all?
While there is substantial evidence to suggest that high affinity VIP receptors that
signal through non-cAMP pathways exist (Olah et al., 1994), it is less clear that these
VIP receptors are solely responsible for mediating the growth effects of VIP in the
embryonic CNS, as the neurotensin-VIP hybrid antagonist that implicated the GTP-
insensitive receptors in this process appears to have some unusual properties. The
original suggestion that the GTP-insensitive population of VIP receptors is responsible
for mediating these growth effects, stemmed from the observation that neurotensin-VIP
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hybrid antagonist produces an increase in the density of GTP-insensitive VIP receptors,
but has no effect on the density of GTP-sensitive VIP receptors (Gressens et al.,
1993). However, although this does seem to indicate that the antagonist is acting
selectively on the GTP-insensitive receptors, previous reports have clearly
demonstrated that the neurotensin-VIP hybrid antagonist significantly inhibits VIP
stimulated cAMP production in CNS cell cultures, at antagonist concentrations
equivalent to those used in the Gressens et al., (1993) study (Gozes et al., 1991). The
reason for the antagonist's failure to affect the density of GTP-sensitive VIP receptors
(which are thought to signal via cAMP) is unclear, but it seems unwise to interpret
these results as ruling out the involvement of cAMP or GTP-sensitive VIP receptors in
the effects of VIP on embryonic growth.
Summary
Although there is considerable evidence in support of the existence of a third VIP-
specific VIP receptor, this evidence is not indisputable, as many of the VIP-induced
signalling pathways that have been attributed to this receptor, could equally be found to
be mediated by the VIPi receptor or VIP2 receptor under certain circumstances. The
signalling mechanisms mediated by 7-transmembrane G-protein coupled receptors,
appear to be highly dependent on the cell type in which the receptor is expressed, and
are likely to reflect, both the complement of intracellular signalling components present
in the cells (eg. G-protein and adenylate cyclase subtypes) and the types and levels of
receptors expressed by these cells. However, the majority of studies on VIP 1 receptor
and VIP2 receptor to date, have been carried out in a limited number of transfected cell
lines, eg.COS, CHO, and HEK 293 cells, and the properties of these receptors in other
cell types remain largely unknown. Finally, it is also possible that splice variants of the
VIPi or VIP2 receptors could be involved in regulating embryonic growth, as although
no splice variants of the VIPi or VIP2 receptors have been identified to date, their
existence has not been excluded. Further studies of these receptors should help to
clarify whether or not the VIP2 receptor could be involved in the control of embryonic
growth, but unless a VIP-specific VIP receptor is cloned, this issue seems likely to
remain unresolved for some time.
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Chapter 6
Isolation and sequence analysis of the putative
promoter region of the mouse Vipr2 gene
6.1 Introduction
The transcription factors that bind to the promoter region of a gene, hold the key to
many of the mechanisms that are responsible for the control of the spatial and temporal
patterns of the gene's expression. Ubiquitous, tissue specific, and inducible
transcription factors that can activate or repress transcription, have all been shown to
play important roles in the control of gene expression.
The tissue- and cell-specific expression pattern of the Vipr2 gene, together with the
proposed role of the VIP2 receptor as the neuroendocrine VIP receptor (Usdin et al.,
1994), strongly suggest that the transcriptional regulation of this gene is likely to
involve tissue-specific and hormonally-regulated transcription factors.
However, in order to unambiguously identify the promoter region of a gene, it is first
necessary to determine the position of the gene's transcriptional start site(s). The
published sequence of the mouse Vipr2 cDNA, contains 52 bp of 5' untranslated
sequence (GeneBank accession number D28132, (Inagaki et al., 1994)), but to date
there have been no reports of the use of RACE-PCR, primer extension, or RNase
protection to determine the position(s) of the transcriptional start site(s) of the Vipr2
gene. Preliminary studies carried out by E. Lutz in our laboratory, using 5' RACE-
PCR on RNA isolated from the mouse AtT20 cell line, resulted in the isolation of
several PCR products the largest of which extended 54 bp 5' of the published Vipr2
cDNA sequence. This clearly demonstrates that transcribed sequences of the Vipr2
gene are present upstream of the published cDNA sequence, and although the isolation
of multiple RACE products indicates that premature termination of the extension
reaction may be occurring, the repeated identification of this extension product in
several separate experiments seemed to suggest that the 5' end of the Vipr2 transcript in
AtT20 cells lies at or close to this point.
The 5' regulatory regions of several members of the secretin/glucagon receptor gene
family have been isolated and sequenced, including that of the VIPR1 gene (Aino et al,
1995; Burcelin et al., 1995; McCuaig et al., 1995; Sreedharan et al., 1995; Tsai-Morris
et al., 1996). In general, the proximal promoter regions of these genes appear to be
GC-rich, and contain multiple binding sites for the transcription factor Spl instead of a
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TATA box (Aino etai, 1995; Burcelin et al., 1995; McCuaig et al., 1995; Sreedharan
et al., 1995; Tsai-Morris et al., 1996). In some cases a CCAAT box is also present
upstream of the Spl sites (Aino et al, 1995; Sreedharan et al., 1995).
In order to isolate the 5' region of the mouse Vipr2 gene, a restriction fragment from
the 5' RACE product described above, was used as a probe on Southern blots of
lambda clones ESC4A and ESDI, the latter of which had already been identified (see
chapter 3) as containing sequence corresponding to the 5' end of the published mouse
Vipr2 receptor cDNA sequence (GeneBank accession number D28132 (Inagaki et al.,
1994)). Sequence analysis of a fragment isolated from ESDI demonstrated that the
characteristics of the region immediately upstream of the RACE product were consistent
with those of promoter regions from this family of receptor genes, and also raised the
possibility that additional promoter or enhancer regions may exist further upstream. In
an attempt to confirm the position of the Vipr2 gene's transcription start site(s), primer
extension experiments were carried out using template RNA isolated from mouse
olfactory bulbs and AtT20 cells. However, although control experiments were
successful, no extension product from Vipr2 mRNA was observed. Possible reasons
for this, and the results that have subsequently been obtained in our laboratory through
the use of alternative approaches, are discussed.
6.2 Methods
6.2.1 Southern blotting, subcloning, and sequencing, of clones and
subclones from the 5' region of the mouse Vipr2 gene
Southern blotting of clones ESC4A and ESDI was carried out using Appligene
Positive™ nylon membrane (Appligene Oncor) and alkaline transfer conditions (see
Chapter 2). The Xba I restriction fragments from ESDI were subcloned using the
'shotgun' subcloning method described in Chapter 3, and sequencing of these
subclones was then carried out as described in Chapter 2.
6.2.2 RNA preparation
All glassware and plasticware that was to be used in the preparation of RNA, or in the
subsequent primer extension experiments (6.2.2), was treated with diethyl
pyrocarbonate (DEPC) solution (0.1% in water) overnight at room temperature, then
autoclaved for 20 minutes at 15 lb/sq. in. to remove residual DEPC. Solutions used in
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these experiments were made with DEPC-treated water where possible, and were also
autoclaved before use.
Olfactory bulb RNA
Total RNA was prepared from 50 mouse olfactory bulbs, using the guanidinium
thiocyanate/caesium chloride centrifugation method (Sambrook et al., 1989).
AtT20 cell poly A+ mRNA
The poly A+ mRNA used in this work was isolated by Dr. E Lutz.
Catriomox-14 surfactant (V. H. Bio) was used to extract total RNA from confluent
AtT20 cells. Two millilitres of surfactant was added to each 75 cm^ flask of cells. The
cells were gently scraped into the Catriomox solution, then pelleted by centrifugation at
~1000g for 10 minutes, and washed several times in 2 M lithium chloride to remove
DNA. After the washed pellet had been resuspended in DEPC-treated H2O and
reprecipitated using sodium acetate (pH 4.0) and ethanol, poly A+ mRNA was isolated
using an Oligotex™ mRNA isolation kit (Qiagen Ltd) according to the manufacturer's
instructions.
6.2.3 Primer extension assay
Primer labelling
A 30-mer DNA oligonucleotide (primer 19043)
dCAGCAACCAGCAGTAGCAGGTCAGCACCAC which is complementary to bases
94-65 of the published mouse Vipr2 cDNA sequence (GeneBank accession number
D28132, (Inagaki et al., 1994)), was used as a probe for this assay. For each
experiment 100 ng of primer was end-labelled with [y-32p]ATP, using a Ready-To-
Go T4 Polynucleotide Kinase kit (Pharmacia Biotech). Labelling reactions were carried
out according to the manufacturers instructions.
Primer extension method 1
For each extension reaction 500,000 cpm of 5' end-labelled primer and 50 p,g of total
RNA from mouse olfactory bulbs were co-precipitated in a 1.5 ml Eppendorf, using
sodium acetate (pH 4.0) and ethanol, and the pellet was resuspended in 20 |J,1 of a
solution containing 80% formamide, 40 mM PIPES pH 6.4, 400 mM NaOH. This
RNA/primer mix was overlaid with 30 |ll of mineral oil, and heated to approximately
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90°C for 5 minutes, then placed in a PCR machine which had been pre-heated to 50°C,
and left there overnight to allow the primer to anneal.
The following day, the RNA/primer mix was taken from the PCR machine, and chilled
on ice. The mix was then spun briefly in a microfuge, after which the reaction mixture
was removed from beneath the mineral oil. Following precipitation using 70 pi of 0.3
M NaOAc and 2.5 volumes of EtOH, the RNA/primer pellet was resuspended in 20 )ll
of reverse transcriptase buffer (50 mM Tris pH 7.5, 60 mM KC1, 10 mM MgCl2, 5
mM dNTP, 1 mM DTT, 50 pg/ml actinomycin D, and 5% v/v DMSO). One pi of
RNasin (Promega) per 100 pi of buffer and 2 pi of Superscript II reverse transcriptase
(Gibco BRL) per 100 pi of buffer, were added to the buffer just before the buffer was
added to the RNA. The extension reaction was incubated at 42°C for 1 hour, after
which 80 pi of RNase solution (10 mM Tris pH 7.5, 10 mM EDTA, 10 pg/ml RNase
A) was added and the reaction was incubated at 37°C for a further 30 minutes. Finally,
1/10th of a volume of 3M NaOAc was added to the extension reaction, which was then
phenol/chloroform extracted, and EtOH precipitated using 10 pg of tRNA as a carrier.
The reaction was resuspended in 80% formamide/dye mix, heated at 90°C, and then
loaded onto a sequencing gel beside dideoxy sequencing reactions from plasmid clone
D1X8 (a genomic DNA subclone which contains the primer target site) that had been
sequenced with the same 30-mer primer (19043). Sequencing reactions were carried
out using a Sequenase 2.0 kit (United States Biochemicals) according to the
manufacturer's instructions.
Primer extension method 2
Primer labelling, DNA marker labelling, and primer extension reactions were carried
out using the Promega AMV Reverse Transcriptase Primer Extension System
(Promega). Reactions were carried out according to the manufacturer's instructions.
Sequencing reactions were carried out as described in method 1 (see above).
6.3 Results
6.3.1 Identification and isolation of a -5.5 kb fragment which includes
the putative promoter region of the mouse Vipr2 gene
Southern blot analysis of the ?i2001 ES clones C4A and D1 (see chapter 3) was carried
out using an -190 bp Pst UXba I restriction fragment from the 5' end of the mouse
Vipr2 5' RACE product Q12 as a probe. Q12 (isolated by E. Lutz, and previously
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described in Chapter 3) is the largest of a series of 5' RACE products generated from
RNA from the mouse pituitary AtT20 cell line, and extends from base pair 192 of the
published mouse cDNA sequence (GeneBank accession number D28132, (Inagaki et
al., 1994)) to a point 54 bp 5' of the published sequence (246 bp in total). Southern
blots of gels containing Pst I, Xba I, and Pst UXba I, restriction digests of ESC4A and
ESDI DNA, demonstrated that only clone ESDI contained DNA fragments that
hybridised to the Q12 derived probe. The ESDI restriction fragments that showed
strong hybridisation to the probe were a 1.7 kb fragment from the Pst I digest, a 1.7 kb
fragment from the Pst MXba I digest, and a 5-6 kb fragment from the Xba I digest
(Figures 6.1a and 6.1b).
Since it was known that: i) Xba I cuts the polylinker sites in both arms of the 7,2001
vector (see Chapter 2 Figure 2.5 for vector map), ii) an Xba I restriction site is present
in the published mouse Vipr2 cDNA sequence (GeneBank accession number D28132,
(Inagaki et al., 1994)) at base pair 133, a site which lies 103 bp upstream from the 3'
end of clone ESDI and is located in exon 2 of the Vipr2 gene, iii) the size of intron 1 of
the mouse Vipr2 gene was estimated to be -2.2 kb; it seemed likely that the 5-6 kb Xba
1 restriction fragment that had been identified using the Q12 derived probe would
contain several kilobases of genomic DNA lying upstream of Q12, i.e. the putative
promoter region of the Vipr2 gene. Subcloning of this Xba I restriction fragment into
pGEM7Z(+) was carried out using the "shotgun" subcloning method described in
Chapter 3, and two clones with inserts of the expected size (clones D1X2 and D1X8;
Figure 6.2) were selected. Sequence analysis of the D1X2 and D1X8 insert ends,
using T7 and SP6 primers (Promega) revealed that the 3' end of the insert in clone
D1X8 contained sequence that corresponded to the region directly upstream of the exon
2 Xba I site, whereas the sequence obtained from the 3' end of D1X2 was equivalent to
the intron 2 sequence that was found at the 3' end of the ESDI A- clone insert. Both
subclones also generated sequence data when tested with the Vipr2 gene exon 1 primer
8484, thus generating genomic sequence that extended upstream of Q12. However,
although both D1X2 and D1X8 appeared to contain the region of interest, the presence
of an additional 103 bp of DNA at the 3' end of D1X2 indicated that this subclone
contained a partial digestion product from the Xba I digest of ESDI DNA, and D1X2
was not used in subsequent studies.
6.3.2 Construction of a basic restriction map of subclone D1X8
A series of double digests carried out on D1X8 using the restriction enzyme Xba I in
combination with other restriction enzymes, revealed that Sal I cut the D1X8 insert
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Figure 6.1a
Restriction enzyme digests of DNA from clones ESC4 and ESDI,
separated on an agarose gel in preparation for Southern blotting.
(A ruler has been photographed alongside the gel so that if necessary the positions of
the molecular weight markers can be estimated on the corresponding autoradiograph of










Hybridisation pattern observed when a Southern blot taken from the gel
of restriction digested ESC4 and ESDI DNA shown in Figure 6.1a is
incubated with the radiolabeled Vipr2 mouse 5' RACE product (Q12)
-derived cDNA probe
A 5-6 kb Pst VXba I fragment that hybridised to the probe is arrowed.
(Blotting membrane is shown at actual size)
t
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Figure 6.2: Subcloning of Xba I fragments from ESDI
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once, to produce two fragments (~4 kb and -2 kb) in an Xba I /Sal I digest. This Sal I
site was chosen as the starting point for the construction of a restriction map, and the
orientation of the two Xba I/Sal I restriction fragments relative to the SP6 and T7
polylinker sites of the pGEM7Z(+) vector was determined by Xho I/Sal I double
digestion of D1X8. Xho I cuts in the SP6 polylinker region of pGEM7Z (+), but not
in the T7 polylinker region (see Figure 2.2 for vector map). The release of an ~2 kb
Xho I/Sal I restriction fragment (Figure 6.3), therefore demonstrated that the Sal I site
in D1X8 lies ~2 kb downstream from the SP6 polylinker/insert junction, and ~4 kb
upstream from the exon 2 Xba I site that lies at the T7 polylinker/insert junction.
Subsequent single and double restriction digests of D1X8 using the enzymes Sal I, Pst
I, Nco I, and Xho I, then allowed the positions of restriction sites for these enzymes,
relative to those for Sal I and Xho I, to be established. The preliminary restriction map
of D1X8 that was derived from these results is shown in Figure 6.4.
6.3.3 Sequence analysis of the putative promoter region of the mouse
Vipr2 gene
The D1X8 insert was sequenced by primer walking, beginning with the sequences
obtained using the SP6 primer (5' vector/insert junction) and the internal primer 8484
(exon 1). Successive internal primers were designed to bind to the end of the D1X8
sequences that had been revealed by the previous sequencing primers, and sequencing
was continued until an overlap between the two contigs of sequence data was observed
(see Figure 6.4). Several sequencing reactions were set up for each of the sequencing
primers, and a consensus sequence was derived by comparison of the sequences
obtained from the individual reactions. However, it should be noted that for each
region of DNA that was sequenced, the data results from sequencing of only one strand
of the D1X8 DNA. In total, the sequence data obtained spanned 3325 bp, 3193 bp of
which lay upstream of the 5' end of the Vipr2 5' RACE product derived sequence. The
overall consensus sequence for the putative promoter region of the Vipr2 gene, that was
obtained from D1X8, is shown in Figure 6.5. Although the high GC content of the
proximal region of the putative Vipr2 promoter was apparent even from visual
inspection of the sequence data, the computer-based sequence analysis programs
Genejockey II (Biosoft) and the Genetics Computer Group program "Mapplot"
(HGMP Resource Centre, Cambridge, UK) were used to confirm this, and to examine
the possibility that a CpG island may be present in this region. In contrast to the overall
GC content of the -3.2 kb consensus sequence, which was estimated to be 49%, the
GC content of the 300 bp lying directly upstream of the 5' RACE product derived
sequence was -65%. This region of high GC content extends downstream beyond the
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Figure 6.3: Restriction digest to determine the orientation of
the D1X8 insert.
 
Figure 6.4: Preliminary restriction map of subclone D1X8
(The positions of the sequencing primers that were subsequently used to determine the
sequence of the putative promoter region of the Vipr2 gene, are also shown, and their
direction of extension is indicated by a small arrow)
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Figure 6.5: Sequence data obtained from the 5' flanking
region of the mouse Vipr2 gene
The sequence shown opposite is a consensus sequence (obtained from sequencing of
the ESDI Xba I subclone D1X8, see Figure 6.4) which includes the putative promoter
region of the mouse Vipr2 gene. The sequences shown in blue represent the 5'
untranslated region of the Vipr2 gene. Published untranslated sequence (GeneBank
accession number D28132; Inagaki et al., 1994) is shown in dark blue, whereas the
unpublished untranslated sequence identified from the Vipr2 5' RACE product is
shown in light blue. The transcription start site is shown in red and the remainder of
exon 1 is shown in green.
IUPAC codes for DNA
A or C = M; A or G = R; A or T = W; C or G = S; C or T = Y; G or T = K;
C, G or T = B; A, G, or T = D; A, C, or T = H; A, C, or G =V; Any = N
1 TCTAGAAAAA CTGAGCCTGT GGTATGGGTG
61 ATGAAAACCT GCTCCATTCA CTGACTACCT
121 TGGCCTTTCA GATTTGTATA ATAAAATAAA
181 GATATTAGGT AAAACTCATT TTCACTTTAA
241 TCTTACATTT AGTTTGCTTT GCAGGGTATT
301 CATCTGATGC GTTTTTGCAA AGGAGATTTG
361 CTTCTGTGCA CATGAGAGGT GCAGAAGCCT
421 GGTCGAGTGT CTCTCATAAC CACCCCTCCA
481 CCCCTGAAAT TGCTCCCCTT ATTACAGGGC
541 GTCGTTTTGT AAAAGTAAGA CAAACAGAGA
601 TTGAAGATTT TATGTTGAAC ACCAGGCTCT
661 GGGGAGTCAG CGGATGTTAC TGGGTATTGT
721 GTGCTCATAC AGGCTTCTAA TGTCTCTGAT
781 AAGGTGCTAG CTGTTTGGCC GTCATTGCTG
841 GGACTCTGTG ACCACATCCT AAGAGAACAG
901 CTGCCCCAAA TGCTGCTGCT GCTGCTGCTT
961 ACTGAAACCC TARAGTCTGG AAACCAGAGC
1021 GCCCAAGAGG ATGTCAGTGG GGAAGGGATA
1081 AACGGGGCTA ARAGCAGGTC TGGAGGATGC
1141 TTCATATCCA GGCTGTGAAC AATGTGAAGT
1201 CAAGAGTCTC TCTCTCTCTC TCTCTCTCTC
1261 TCTCCWWACC CCAATTCAGA ARAATGGAGA
1321 GACCTTCGYT CYTCCAGGAT ACCCCCAGGA
1381 TATCTCATCC TTGTCAGGAC TATCACTTCA
1441 ACCCTGGCGT CTCACCCAGT TTTGACCAAT
1501 CTCACAACAA TTCAGGTGTA TCAGCTCTCC
1561 CAATGGCAGG GGTCGATGTT GTGATTTACA
1621 AAACAGTGGA CAGGGGTTGT GGACAAAGCC
1681 GACCTAGTGC CCAGACCTTC TCCTCCATAA
1741 CACAGATAAT GGAAGGGTGA CAGAAAACAG
1801 CTCTGATGTC ATGGAGCACA TGATGAGCTC
1861 ACCCCAAAGT GTGAAGGATA CATTTTGTAC
1921 TTATATYTGA ATAAGAAGTT TAAAACTTGC
1981 CTGGTAGCTT TYTGCTYTTC CCTAGACTGG
2041 ACAGTGGCAG TGTYTCCACA AGCCTAGTGT
2101 TTTGGGGTGC CGATGAGCAG ACCCACTTTT
2161 TAGGTATTTA GCTCATTTAC ATTTCCAATG
2221 AACCCCACTC CCNTACCCAC CCACTCCCCT
2281 GCATATAAAG TTTGCGTGTC CAATGGGCCT
2341 TTTTGATACA TATGCAGCTA GAGTCAAGAG
2401 TTCCACCTAT AGGGTTGCAG ATCCCTTTAG
2461 TGGGGGCCCT GTGATCCATC CAATAGCTGA
2521 CCCAGGCATA YTCTGACAAG AGACAGCTAT
2581 TGTATGCAAT GGTGGAGCAG ACCCACTTTT
2641 CTTGGCCTTA GGCTCTCAAG GGGAGCCATG
2701 CCAGTGCAGA CCTAACCATG GTCGTCCAGC
2761 ACAGGCTTCG CATTTGCACA GGGAGTTGGT
2821 TTACCTGGAA TTGGGCAATG CCCTCTGTGG
2881 CTCCAAAGGC TTGAACATGG CAGCCCACAG
2941 TCGGTTAGCA GAGGGAGCCT GGGAGGAAGG
3001 TACCCAGGCC AGGAGGGGGT CGGGGTGAGG
3061 GGGTGGAAGG AGGGACGTTT GGACAGAGAT
3121 CCCAAAAAGG AGAAAGGGGC GCGAGGCGGG
3181 CAGCCTGGAA GGCGGAGAGG GCGATAGGCG
3241 CGGAGCAGGG GACCGTGCTG CTGAGGCGCC

























































putative promoter region, through the 5' untranslated sequence, exon 1, and into intron
1 of the Vipr2 gene; a pattern that is frequently found in association with CpG islands
(Cross & Bird, 1995). Analysis of the distribution of CpG dinucleotides within the
D1X8 consensus sequence (Figure 6.6), revealed that a CpG island is present at the
putative 5' end of the Vipr2 transcribed sequence, beginning around 160 bp upstream
of the proposed translational start site (base pair 3140), and continuing at least to the
end of the D1X8 consensus sequence, which ends 375 bp into intron 1 (base pair
3722). A search of the DNA sequence databases using the BLASTN program
(National Centre for Biotechnology Information, Bethesda, USA), with the putative
promoter sequence of the Vipr2 gene as a template, revealed the presence of an ZJ-type
repeat sequence in the region from -705 to -1177 bp, but did not identify any other
extensive regions of homology between the putative promoter region of the Vipr2 gene
and the promoter regions of other genes.
6.3.4 Primer extension experiments
Due to the GC rich nature of the sequence lying directly upstream of the Vipr2
translation start site, Superscript II was selected for use in primer extension
experiments as this enzyme is stable at temperatures of up to 55°C. Initial primer
extension experiments carried out using primer extension method 1 (see Methods) on
olfactory bulb RNA failed to produce any detectable extension products, although the
primer successfully primed the dideoxy sequencing reaction from the D1X8 plasmid.
Subsequent attempts at primer extension, carried out using the Promega AMV Reverse
Transcriptase Primer Extension System (Promega) on poly A+ mRNA from mouse
AtT20 cells, also failed to produce any detectable extension products from Vipr2
transcripts. However, using this method (primer extension method 2; see Methods) an
extension product of 87 bp was obtained from the control primer and RNA that were
provided with the kit, suggesting that the problems that were encountered may be
specific to the detection of extension products from Vipr2 transcripts, rather than being
the result of a more general technical problem.
6.3.5 Identification of possible transcription factor binding sites
The transcription factor databases: TRANSFAC 3.0 including Matlnspector 2.0 (GBF
-Braunschweig, Germany; (Wingender et al., 1997)), and TFD ( National Institute of
Health, Bethesda, USA), were used to search for possible transcription factor binding
sites within the putative promoter region of the Vipr2 gene. The analysis programs that
are linked to these databases produced somewhat different results when presented with
the D1X8 consensus sequence, due in part to differences in the content of the individual
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Figure6.6:Amapoftherelativedistribu onCpGandG Cnucleotisit swithi putativeromoterregi nfthemousVipr2gen
(Linear)MAPPLOTof-mus5prck:421,1t :3722Ja ary1,99716:36. EnzymeData:enzy e.dat 50010052305 0
Cp61IIIIH-HH-;1—H —IIIMllllllllliIIJ82C'G GpCIlllllllllllniIImiIHiMII IIPHHtttHlII III IIIIIIII IIIHIIIII IIIIII III111HB » 11111l228G'C EnzyniesthatdoncuI NONE
databases, and whether matrix consensus sequences or sites from individual gene
sequences were used for binding site identification. These differences, together with
the inherent bias towards short recognition sequences that occurs in these analysis
programs, meant that a considerable amount of personal discretion was necessary in the
interpretation of these results. The length and degeneracy of each potential recognition
site were taken into consideration when deciding which sites to include in the overall
picture of the promoter region at this stage. Transcription factor binding sites of 5 bp
or less have generally been excluded from the results presented here even if there is no
degeneracy in the recognition sequence, and binding sites that are 6 bp long have
usually only been included if they have well-defined recognition sequences with little or
no degeneracy, although there are some exceptions. Longer recognition sequences for
transcription factors were also excluded despite their length if they displayed unusually
high levels of degeneracy, but in each case every effort was made to check the Vipr2
sequence against the individual gene sequences from which the consensus recognition
site had been derived. Searches were also carried out for some transcription factor
binding site sequences that were not represented in the databases, particularly if the
known functions or expression patterns of the factors in question suggested a possible
role in the control of Vipr2 gene expression.
The results of the search for transcription factor binding sites in the region of the Vipr2
gene that lay upstream of the sequence obtained from the 5' RACE product indicated
that at least two potential TATA boxes and one pair of potential Spl binding sites were
present within this sequence. The pair of potential Spl binding sites begin at -157 bp
and -138 bp from the translation start site and lie within the CpG island described
above, the latter of the two potential Spl sites ending 24 bp upstream of the 5' RACE
product sequence and 11 bp upstream of a potential cap site. In contrast, the potential
TATA box sequences begin at -3065 bp and -1016 bp relative to the translational start
site of the Vipr2 gene. Although neither of these TATA box consensus sites have a
CCAAT box situated 30-40 bp upstream of the TATA site, a CCAAT box is found
-100 bp upstream of the proximal (-1016 bp) TATA box.
Putative transcription factor binding sites that were identified upstream of the distal (-
3065 bp) TATA box sequence included possible sites for: activator protein 3 (AP3), the
pituitary factor (Pit-1) (Peers et al., 1990), a factor that binds to a T/A rich sequence in
the growth hormone gene (GH-CSE) (Ye et al., 1988), a component of the NF-CLEO
complex (that binds to the promoter regions of several interleukin genes) (Miyatake et
al., 1991), and the Sry-related testis-specific factor Sox-5 (Denny et al., 1992).
Interestingly the TATA box itself appears to overlap with a potential binding site for the
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POU (pit-oct-unc) factor Brn-2 (Li et al., 1993). Possible transcription factor binding
sites that lie upstream of the proximal (-1016 bp) TATA box sequence include potential
sites for: a cAMP responsive factor, several E-box binding proteins (Fisher & Goding,
1992), Brn-2, activator protein 2 (AP2), and serum response factor (SRF) (Treisman
et al., 1992). A putative cap-box sequence is found within the context of a sequence
which corresponds to the Yin Yang 1 (YY1) consensus (Shrivastava & Calame, 1994),
-50 bp downstream from this TATA box. Finally, the GC rich putative promoter
region that lies directly upstream of the 5' untranslated region identified by RACE
PCR, contains possible binding sites for: mammary activating factor (MAF) (Mink et
al., 1992), the transcriptional silencer tramtrack (Ttk 69) (Guo et al., 1995; Read &
Manley, 1992), activating protein (AP2), lymphocyte factor-1 (Lyf-1) (Lo et al.,
1991), E-box binding proteins, and signal transducer and activator proteins (STATs)
(Seidel et al., 1995), interleukin-6 responsive factors (IL-6 RE-BP, NF-IL6) (Hocke et
al., 1992), and an interferon response factor (ISGF2) (Tanaka et al., 1993). The
positions of the sites described above and other putative transcription factor binding
sites within the DNA fragment are shown in Figure 6.7.
6.3.6 Search for extended regions of homology
Selected searches for extended regions of homology between sites in the putative Vipr2
promoter and the promoter sequences of other genes that are expressed in Vipr2
expressing cells or tissues, were carried out using the Genetics Computer Group
program 'Wordsearch' (HGMP Resource Centre, Cambridge, UK). In most cases the
stimulus for these comparisons came from the identification in the Vipr2 gene of one or
more potential transcription factor binding sites (during the computer database searches
described above), which were identical to, or displayed a very high level of similarity
to, a site for a tissue specific or hormonally regulated transcription factor in another
gene. These sites included: the putative isl-1 sites of the Vipr2 gene, which prompted a
comparison of the Vipr2 and insulin gene promoter sequences; and the possible binding
site for component b of the NF-CLEO complex, which led to a comparison of the Vipr2
promoter with the promoter regions of the T-cell expressed interleukin-4 (IL-4) and
interleukin-5 (IL-5) genes. However in some cases, the routes by which the regions of
similarity with the putative Vipr2 promoter were identified were less straightforward.
For example, the similarity between the Vipr2 promoter sequence and the binding site
for a pituitary specific factor PP1 in the rat pro-opiomelanocortin gene, was noticed
largely by chance during a survey of papers on pituitary specific gene expression.
Consequently, the results presented here do not in any way represent a comprehensive
search for regions of homology between the putative Vipr2 promoter and the promoter
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Figure 6.7: Putative transcription factor binding sites within
the 5' flanking region of the Vipr2 gene
(Putative binding sites are shown in green or dark blue, and overlaps between any two
given sites are usually shown in light blue/aqua. TATA box and CCAAT box
consensus sequences are shown in red unless they form part of a binding site overlap.
Sites that match exactly or show a high level of homology, to a well defined consensus
sequence are double underlined; those that match slightly less well defined sequences or
have one or two mismatches are single underlined; and sites that represent transcription
factor consensus sequences that are highly degenerate have been indicated with a dotted
line. The sequence shown in dark blue directly upstream of the ATG start site is the
published 5' untranslated sequence of Vipr2, whereas the extended sequence shown in
aqua, from -53 to -106, represents the sequence derived from the Vipr2 5' RACE
product Q12)
Putative promoter region of the Vipr2 gene
AP3
TCTAGAAAAA CTGAGCCTGT GGTATGGGTG GGTCAGACCT GATAGTGAGG -3250
....P.it-.l.. ...Oct-2...
TGAGACACCC ATGAAAACCT GCTCCATTCA CTGACTACCT CTGTAAAACA -3200
GH-C
SRY ...B1./B2 GH-C.SE
AAAAAAAAAG ACACAAAGGC TGGCCTTTCA GATTTGTATA ATAAAATAAA -3150
SE2
.1 NF-CLEO
TTACAAGGTT GTTTTCCCCA GCTTTGACAG GATATTAGGT AAAACTCATT -3100
TATA-box
WAP-US6 Sox-5 Brn-2
TTCACTTTAA AGACTCATAA CAATATGAAA TGCATATAAA TCTTACATTT -3050
OL-1
C/EBP CAP-box?
AGTTTGCTTT GCAGGGTATT AGCAGGAGTC AGGAGGAGCC ACCAACCCAT -3000
(IUF-1) (Mvb)
E-box E-box
CATCTGATGC GTTTTTGCAA AGGAGATTTG CCCTTTACAA ATCAGTTGCG -2950
(PEA3) E-box
TGTTGTCTTC CTTCTGTGCA CATGAGAGGT GCAGAAGCCT TGGAGACAAC -2900
AP4
E-box Is1—1
CGCAGCTGTA GCCCCTAATG GGTCGAGTGT CTCTCATAAC CACCCCTCCA -2850
(HNF-5)
GGCACAGCAA ATAGATTCAG TTTATGTACT CCCCTGAAAT TGCTCCCCTT -2800
Spl
(Oct-1) PEA3 IL6-RE-BP
ATTACAGGGC GGTGTCAGAA GGAAGTGCTG GGAAAGAACT GTCGTTTTGT -27 50
(HNF-5) Sox-5 .(S.RY)....
AAAAGTAAGA CAAACAGAGA TGAAACAATC GCTTTCATTC TTTGTTGTTG -2700
TTGAAGATTT TATGTTGAAC ACCAGGCTCT TGTAGATACG AAGGCAGCAG -2650
Ets-1 NF-S
CACTTCTGAG GGGGAGTCAG CGGATGTTAC TGGGTATTGT CTTGTCAGCT -2600
Isl-1
CCTGAGGATC CTCTTCTTAT GTGCTCATAC AGGCTTCTAA TGTCTCTGAT -2550
E-box
AAGCTTCATC ACTGGACCCA CTCCATGTGG AAGGTGCTAG CTGTTTGGCC -2500
GTCATTGCTG ACCCAAAACT TCACTGGCAA AAAAGCAAAG GGACTCTGTG -2450
(Mvo mu
ACCACATCCT AAGAGAACAG AGGGTTAGCT AAAATGGCTT GTGAAGAACT -2400
triplet repeat
E-box
CTGCCCCAAA TGCTGCTGCT GCTGCTGCTT TGGGTATGAG AAGCCTCCGT -2350
E-
IL6-RE-BP TTF-1




GTGGAAGGTG CCAGGAAACT GCCCAAGAGG ATGTCAGTGG GGAAGGGATA -2250
PEA3 IUF-1
GGAAGGCCAG ACATCAGTAG GTAGAGATGA AACGGGGCTA ARAGCAGGTC -2200
Ets-1
TGGAGGATGC TGGAGGGCAC AACACAAGGC TGAACTCAGG TTCATATCCA -2150
IUF-1
Sox-5
GGCTGTGAAC AATGTGAAGT CCCATCAGAA CCAAGCAGTC ACCATAGGCA -2100
(GAGA) (GAGA) (GAGA)
CAAGAGTCTC TCTCTCTCTC TCTCTCTCTC TCTCTCTCTC TCTCTCTCTC -2050
Pit-l...
(GAGA) CCAAT
TCTCTCTCTC TCTCCWWACC CCAATTCAGA ARAATGGAGA GACCTTGAAA -2000
PEA3
GACATGACCA GTCTTTTTAG GACCTTCGYT CYTCCAGGAT ACCCCCAGGA -1950
AAACAAGTCC YTCTTGTCTC CCCGTGCCTG TATCTCATCC TTGTCAGGAC -1900
TATCACTTCA TCTCATCATA TATGCCATTG TGTGGTTGGA ACCCTGGCGT -1850
CCAAT (Ets-1) (Pit-l)




CTCACAACAA TTCAGGTGTA TCAGCTCTCC TAATTCTAAT TGTAACCCTC -1750
NF-IL6
RE-BP (AP2) E-box E-box
TGGGATGGAG CAATGGCAGG GGTCGATGTT GTGATTTACA AATGTGCAGG -1700
TGGATCAGGT TCACTGGCTG AAACAGTGGA CAGGGGTTGT GGACAAAGCC -1650
(Ets-1)
AGAGCCCAAG CTTCCTGGCC CCAAGCTGCA GACCTAGTGC CCAGACCTTC -1600
(IUF-1) (HNF-5) E-box
TCCTCCATAA AATCCCCTGA TGGACAAACA CAGGCAGATG CACAGATAAT -1550
GGAAGGGTGA CAGAAAACAG ATAGAAACCT AGGTCCAAGG GTACACGGGG -1500
CARE
(IUF-1) E-box c-Jun
CTCTGATGTC ATGGAGCACA TGATGAGCTC AGTGGGGAGA AAGATAATGG -1450
GCAGATAGAC ACCCCAAAGT GTGAAGGATA CATTTTGTAC TATTTCAGAC -1400
WAP-US6
TTCTGACTTT GGGCTTGAAA TTATATYTGA ATAAGAAGTT TAAAACTTGC -1350
CTGCTTTACT TAATCGAGTA CTATTGTYTG CTGGTAGCTT TYTGCTYTTC -1300
CCTAGACTGG TCTGTCGACA GACAGCCAAA CCATAGCTGA ACAGTGGCAG -1250
E-box E-box
TGTYTCCACA AGCCTAGTGT ACAATGAGCC ACACACGTGT CACCTGAGGG -1200
TTTGGGGTGC CGATGAGCAG ACCCACTTTT TTTTTCTTTT TTTTTTTTTC -115
(Brn-2)
(Oct-1) CCAAT
CGTTTTTTAT TAGGTATTTA GCTCATTTAC ATTTCCAATG CTATACCAAA -1100
AP2
AP2 Yi?
AGTCCCCCCA TACCCAACCC AACCCCACTC CCNTACCCAC CCACTCCCCT -1050
SRE TATA-box C
TTTTTGGCCC TGGCGTTCCC CTGTACTGGG GCATATAAAG TTTGCGTGTC -1000
CAP-box?
CAAT (IL6-RE—BP) YYl E-
CAATGGGCCT CTCTTTCCAG TGATGGCCGC CTAGGCCATC TTTTGATACA - 950
box
TATGCAGCTA GAGTCAAGAG CTCCGGGGTA CTGGTTAGTT CATAATGTTG - 900
TTCCACCTAT AGGGTTGCAG ATCCCTTTAG CTTCTTGGGT ACTTTCTCTA - 850
(CCAAT) CCAAT
GCTCCTCCAT TGGGGGCCCT GTGATCCATC CAATAGCTGA CTGTGAGCAT - 800
HNF-5
CCACTTCTGT GTTTGCTAGG CCCAGGCATA YTCTGACAAG AGACAGCTAT - 750
(NF-IL6 )
ATCAGGGTCC TTTCAGCATA ATCTTGCTAG TGTATGCAAT GGTGGAGCAG - 700
(WAP-US5)
ACCCACTTTT GCGTTGATGA AGTCTCTGCT TTCTGTTCAA CTTGGCCTTA - 650
ISGF2
GGCTCTCAAG GGGAGCCATG CAAGAGCTTT CTCTTTTCTC TCTGCTCACA - 600
(NF-IL6) (PEA3)
CCAGTGCAGA CCTAACCATG GTCGTCCAGC CACTTTCTGC ACTTTTTCCT - 550
MTF-1 E-box E-box




ACCTCAGCGC TCAAGTTCCC TTACCTGGAA TTGGGCAATG CCCTCTGTGG - 450
E-box
GTGAGCATCT GCTTACTTGA GCCACCAGCT CTCCAAAGGC TTGAACATGG - 400
.. AP.2 C/EBP




GAGGGAGC.CT..GGGAGGAAGG AGCGCGAGAG AGCAGAGCTG ACAAGGGAAG - 300
AP2 Ttk
TACCCAGGCC AGGAGGGGGT CGGGGTGAGG CCCAGGGTCC TGCACTTCAG - 250
MAF
AGGGAAGTAG GGGTGGAAGG AGGGACGTTT GGACAGAGAT CTGGTGGACC - 200
(RXRa?)
(UBP-1) Spl
GGAGTGCCAG AGAGAGACTC CCCAAAAAGG AGAAAGGGGC GCGAGGCGGG - 150
GC-box Spl IL6-KE-BP
_ IAP2) CAP site?
GACTGGNCCG AGGGGCGGGN CCGGGACTTG CAGCCTGGAA GGCGGAGAGG - 100
GCGATAGGCG CGAGACTGAG GAAATCCGCG CTGGGAGGCC CGGAGCAGGG - 50
GACCGTGCTG CTGAGGCGCC AAGGACCGAG GCGGCACGCT GAGCCCAAGA + 1
TG
regions of other genes, but instead comprise a very restricted selection of similarities
between the putative Vipr2 promoter and the promoter regions of some genes whose
products have physiological functions/distribution patterns that may be linked to those
of the VIP2 receptor.
A total of 10 regions of sequence similarity were identified using the "Wordsearch"
program (Figure 6.8). Three regions of similarity were identified between the Vipr2
sequence and the promoter region of the human insulin gene, one of which represented
an extended region of homology betweeen one of the Vipr2 gene putative isl-1 sites and
a known transcription factor binding site (CT1 element) of the insulin gene (Petersen et
al., 1994). Several regions of the Vipr2 sequence were found to display a high degree
of similarity with sequences from the promoter regions of the mouse IL-4 and IL-5
genes. These included: the sequence encompassing the putative binding site for the b-
component of the NF-CLEO complex, which was found to exhibit strong similarity to
the NF-CLEO (a and b) elements of both the IL-4 and IL-5 genes (but particularly that
of the IL-4 gene, (Miyatake et al., 1991); Figure 6.8); two other regions of the IL-4
gene's promoter which were found to be similar to sequences that lay within the Ll-
repeat sequence of the Vipr2 gene; and a shorter (8bp) region of the mouse IL-5 gene
which displayed sequence identity to a site in the distal region of the putative Vipr2
promoter. Single regions of sequence similarity with the putative Vipr2 promoter were
found in the promoter regions of the VIP, pro-opiomelanocortin, and epidermal growth
factor receptor genes, in the form of: a previously identified transcription factor binding
site (STAT) site in the promoter of the VIP gene (Symes et al., 1994); an element
composed of adjacent Spl/pituitary factor (PP1) site in the promoter of the rat pro¬
opiomelanocortin gene (Liu etal., 1995); and a composite Spl/thyroid hormone
receptor-retinoid X receptor element in the promoter of the human epidermal growth
factor receptor gene (Xu et al., 1993).
6.3.7 Identification of potential translational- and splice-factor
binding sites
Having identified 3 potential core promoter regions within the 5' region of the Vipr2
gene, a search for alternative translational start sites (upstream ATGs), and potential
splice site sequences, was undertaken in an attempt to gain some indication of whether
alternative promoter usage might occur within the Vipr2 gene, and to examine the
possibility that previously unidentified introns could be present within the D1X8
sequence. In total, 23 ATG sequences were found within the -3.2 kb sequence (Figure
6.9), but only 6 of these sites were located within a strong translational context
(RNNatgG; (Kozak, 1996)). No translational starts were found within 400 bp of the
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Figure 6.8: Selected regions of homology between the Vipr2























































|[ ||||||| STAT element
MVipr2: TTACCTGGAA
-479 -470





|||||||||||||| | Spl/T3R element
MVipr2: GCGAGGCGGGGACTGG
-159 -144
Figure 6.9: A search for potential translational start sites and
splice sites within the putative promoter region of the Vipr2
gene
(ATG sequences that are in a relatively strong translational context are shown in dark
blue, and those that are in a very strong context are marked with an asterisk. ATG
sequences that are in a weaker translational context are shown in light blue. Potential 3'
splice sites (acceptor sites) are shown in pink, and potential 5' splice sites (donor sites)
are shown in green. Sites that match the acceptor and donor consensus sequences
relatively weakly are indicated by a question mark. The regions shown in light and
dark blue directly upstream of the ATG start site, i.e., -1 to -106 are 5' untranslated
sequence)
Putative promoter region of the Vipr2 gene
TCTAGAAAAA CTGAGCCTGT GGTATGGGTG GGTCAGACCT GATAGTGAGG -3250
TGAGACACCC ATGAAAACCT GCTCCATTCA CTGACTACCT CTGTAAAACA -3200
AAAAAAAAAG ACACAAAGGC TGGCCTTTCA GATTTGTATA ATAAAATAAA -3150
7
TTACAAGGTT GTTTTCCCC.A. GCTTTGACAG GATATTAGGT AAAACTCATT -3100
TTCACTTTAA AGACTCATAA CAATATGAAA TGCATATAAA TCTTACATTT -3050
AGTTTGCTTT GCAGGGTATT AGCAGGAGTC AGGAGGAGCC ACCAACCCAT -3000
CATCTGATGC GTTTTTGCAA AGGAGATTTG CCCTTTACAA ATCAGTTGCG -2950
TGTTGTCTTC CTTCTGTGCA CATGAGAGGT GCAGAAGCCT TGGAGACAAC -2900
7
CGCAGCTGTA GCCCCTAATG GGTCGAGTGT CTCTCATAAC CACCCCTCCA -2850
7
GGCACAGCAA ATAGATTCAG TTTATGTACT CCCCTGAAAT TGCTCCCCTT -2800
ATTACAGGGC GGTGTCAGAA GGAAGTGCTG GGAAAGAACT GTCGTTTTGT -27 50
AAAAGTAAGA CAAACAGAGA TGAAACAATC GCTTTCATTC TTTGTTGTTG -2700
TTGAAGATTT TATGTTGAAC ACCAGGCTCT TGTAGATACG AAGGCAGCAG -2650
CACTTCTGAG GGGGAGTCAG CGGATGTTAC TGGGTATTGT CTTGTCAGCT -2600
CCTGAGGATC CTCTTCTTAT GTGCTCATAC AGGCTTCTAA TGTCTCTGAT -2550
AAGCTTCATC ACTGGACCCA CTCCATGTGG AAGGTGCTAG CTGTTTGGCC -2500
GTCATTGCTG ACCCAAAACT TCACTGGCAA AAAAGCAAAG GGACTCTGTG -2450
ACCACATCCT AAGAGAACAG AGGGTTAGCT AAAATGGCTT GTGAAGAACT -2400








































































CTAGGCCATC TTTTGATACA - 950
CTGGTTAGTT CATAATGTTG - 900
CTTCTTGGGT ACTTTCTCTA - 850
CAATAGCTGA CTGTGAGCAT - 800
YTCTGACAAG AGACAGCTAT - 750
TGTATGCAAT...GGTGGAGCAG - 7 00
TTCTGTTCAA CTTGGCCTTA - 650
CTCTTTTCTC TCTGCTCACA - 600
CACTTTCTGC ACTTTTTCCT - 550
GGGAGTTGGT GCCAGATGCT - 500
TTGGGCAATG CCCTCTGTGG - 450
*
CTCCAAAGGC TTGAACATGG - 400
GCAGTACAGC TCGGTTAGCA - 350
GAGGGAGCCT GGGAGGAAGG AGCGCGAGAG AGCAGAGCTG ACAAGGGAAG - 300
TACCCAGGCC AGGAGGGGGT CGGGGTGAGG CCCAGGGTCC TGCACTTCAG - 250
AGGGAAGTAG GGGTGGAAGG AGGGACGTTT GGACAGAGAT CTGGTGGACC - 200
GGAGTGCCAG AGAGAGACTC CCCAAAAAGG AGAAAGGGGC GCGAGGCGGG - 150
GACTGGNCCG AGGGGCGGGN CCGGGACTTG CAGCCTGGAA GGCGGAGAGG - 100
GCGATAGGCG CGAGACTGAG GAAATCCGCG CTGGGAGGCC CGGAGCAGGG - 50
GACCGTGCTG CTGAGGCGCC AAGGACCGAG GCGGCACGCT GAGCCCAAGA + 1
TGAGGGCGTC GGTGGTGCTG ACCTGCTACT GCTGGTTGCT GGTGCGG + 48
previously identified identified start site (+1). However, strong potential translational
sites were found at -403 and -582 bp, each of which could represent the beginning of a
short ORF (encoding 43 and 50 amino acids respectively). The search for potential
splice sites within the D1X8 sequence resulted in the identification of several potential
5' and 3' sites (Figure 6.9), although the degree to which these sites corresponded to
consensus splice site sequences (5' MAG^GTRAGT; 3' Y] ] NYAG-iG: (Mount,
1982)) varied considerably.
6.4 Discussion
6.4.1 General characteristics of the mouse Vipr2 gene's putative
promoter region
The proximal region of the putative Vipr2 promoter is GC rich and CpG rich
As a first step towards characterising the promoter region(s) of the mouse Vipr2 gene, a
3.2 kb fragment of the upstream region of the mouse Vipr2 gene has been isolated and
sequenced. Like the promoter region of the VIPR1 gene (Sreedharan et al., 1995), and
other members of the secretin/glucagon family of receptor genes, the putative promoter
region of the Vipr2 gene has a proximal region that is GC-rich and contains binding
sites for the ubiquitous transcription factor Spl (located at -138 bp and -157 bp).
Although analysis of the methylation status of this region of Vipr2 gene has not been
carried out, the high CpG content of the sequence beginning about 160 bp upstream of
the proposed translational start site and extending into the first intron, strongly suggests
that an unmethylated CpG island is present at the 5' end of the Vipr2 gene. This would
place the Vipr2 gene amongst the -40% of genes isolated to date that have been found
to possess both CpG islands and tissue-specific patterns of expression (reviewed by
(Cross & Bird, 1995)). Moreover, as CpG islands are associated with the region
surrounding the first exon of a gene (Cross & Bird, 1995), the location of this CpG
island within the Vipr2 gene adds weight to the identity of the proposed transcriptional
start site (at -106 bp ) which lies within the CpG rich sequence. The published
promoter sequence (814 bp) of the human VIPR1 gene (Sreedharan et al., 1995) also
appears to contain a CpG island.
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Tissue specific promoter or enhancer sequences may play a role in the regulation of
Vipr2 gene expression
Considering the complex patterns of tissue- and cell- specific expression that are
observed for transcripts of the Viprl and Vipr2 genes (Sheward et al., 1995; Usdin et
al., 1994; Wei & Mojsov, 1996), there appears to be a remarkable absence of putative
binding sites for tissue-restricted transcription factors within the GC rich promoter
region of either the VIPR1 gene (Sreedharan et al., 1995) or to a slightly lesser extent
the Vipr2 gene, when these sequences are subjected to searches for known transcription
factor binding sites. Possible explanations for these findings include: the presence of
binding sites for as yet unidentified tissue-specific transcription factors; the presence of
novel binding sites for known tissue-specific transcription factors; tissue specific
enhancer regions that lie upstream of and interact with the GC rich promoter regions;
the presence of alternative promoter regions within the genes; or any combination of
these possibilities. Alternative promoter usage has been identified in at least one other
gene encoding a member of this subfamily of G-protein coupled receptors, the mouse
parathyroid hormone/parathyroid hormone related peptide (PTH/PTHrP) receptor gene
which has two alternative promoter regions and three 5' untranslated exons (McCuaig
et al., 1995). The proximal promoter region P2, which is linked to untranslated exon
U3, is GC rich and appears to be used in all tissues examined, whereas the distal
promoter region PI, which is linked to untranslated exon U1 and spliced to a second
untranslated exon U2, is not GC rich, contains a CCAAT box, and is used
predominantly in the kidney (McCuaig et al., 1995). However, there are indications
that this type of process may also occur in other members of the secretin/glucagon
receptor gene sub-family, as there is evidence to suggest that alternative splicing of
untranslated 5' exons is utilised in a tissue specific fashion in the rat glucagon receptor
gene (Maget et al., 1996b), and alternative splicing of untranslated 5' exons within the
rat Pacaprl gene has also been reported (Chatterjee et al., 1996a). In both the mouse
PTH/PTHrP receptor gene and the rat Pacaprl gene a consensus 3' splice acceptor
sequence is located in the region immediately upstream of the ATG start site (76 bp
upstream in the case of the Pacaprl gene, and 45 bp upstream in the PTH/PTHrP
receptor gene; (Chatterjee et al., 1996a; McCuaig et al., 1995)). Two TATA box
consensus sequences were identified in the Vipr2 gene ~1 kb and ~3 kb upstream of the
ATG start site, but the distance of these putative core promoter sequences from the
ATG start site would suggest that in order for these putative promoter regions to be
functional these sequences and/or any 5' untranslated exons associated with them,
must be spliced into place upstream of the ATG start site. However no consensus 3'
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splice acceptor sites were found in the region immediately upstream of the ATG start
site in the Vipr2 gene, where the most proximal potential 3' splice site that was
identified was found 596 bp upstream of the translation start site. Thus if alternative
promoter usage is a feature of the Vipr2 gene, the exact mechanisms by which this
occurs are not yet apparent. Interestingly a TATA box consensus sequence has also
been identified within the promoter region of the VIPR1 gene (at -310) although its
position relative to the identified transcriptional start site in HT29 cells led the authors to
conclude that the TATA box sequence was unlikely to be functional in this cell line
(Sreedharan et al., 1995). Nevertheless, despite uncertainties over the functional status
of the TATA box sequences in distal region of the D1X8 sequence, the presence of
several potential binding sites for tissue-restricted transcription factors within the areas
surrounding these sites indicates that regions upstream of the GC rich proximal
promoter sequence may well play a role in the control of the Vipr2 gene in some cells,
either as alternative promoter regions, or by acting as enhancer sequences which
interact with the proximal core promoter sequences.
6.4.2 Tissue-restricted transcription factors that may bind to sites in
the 5' regulatory region of the mouse Vipr2 gene
Conserved lymphokine element 0 bindingfactors may play a role in regulation Vipr2
expression within the immune system
One potential binding site that is of particular interest with regard to the possible role of
tissue-specific alternative promoter or upstream enhancer sequences, is a site at - 3109
bp to - 3095 bp that displays a high level of similarity to the conserved lymphokine
element 0 (CLEO). CLEO sites are found in the promoter regions of several
lymphokine genes that are expressed in T helper 2 (Th2) lymphocytes, including those
of the mouse and human genes encoding IL-4, IL-5, and GM-CSF (Miyatake et al.,
1991). The identity of the transcription factors that bind to the CLEO elements of these
genes in vivo is not entirely clear, although several factors including activator protein 1
(AP-1), nuclear factor of activated T cells (NF-ATp), and the Ets protein Elf-1 are
candidates (Jenkins et al., 1995; Siegel et al., 1995). However, in all of these
promoter regions the CLEO element is located within 40 bp of the TATA box (Miyatake
et al., 1991), appears to be required for the maximal activation of the promoters by
phorbol myristate acetate (PMA) and calcium ionophores (Jenkins et al., 1995), and is
thought to be involved in co-ordinating the stimulation of transcription of these genes in
antigen-activated T-cells (Miyatake et al., 1991).
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Within the immune system VIP is involved in several processes, including the
regulation of cytokine expression (see Chapter 1; reviewed by (Ganea, 1996)). VIP
decreases IL-2 and IL-10 production at the transcriptional level (Ganea et al., 1996;
Ganea & Sun, 1993), decreases IL-4 production at a post transcriptional level
(probably through its effects on IL-2) (Sun & Ganea, 1993; Wang et al., 1996), and
increases IL-5 production (Mathew et al., 1992). Although the individual roles of the
VIPi and VIP2 receptors in some of these processes have not yet been ascribed,
current reports indicate that the VIP] receptor may be responsible for the effects on IL-
10 levels, whilst the VIP2 receptor is thought to be responsible for the down regulation
of IL-2 (the primary cytokine responsible for T-cell proliferation following T-cell
receptor activation) (Delgado et al., 1996b).
Therefore the presence of a site within the Vipr2 gene, that displays a high level of
homology to the CLEO element (13/15 base match with the mouse IL-4 gene CLEO
element; Figure 6.8) and is centred 37 bp upstream of the distal (-3065 bp) TATA box
sequence is intriguing though not entirely surprising in light of the proposed functions
of VIP in the immune system, and could be interpreted as supporting the possibility that
this TATA box might be functional under certain circumstances. Further indications
that the CLEO-like sequence within the Vipr2 gene may be functional are provided by
recent work carried out by Delgado et al., who have shown that Vipr2 gene
transcription in CD4+ and CD8+ T-cells is only induced following T-cell activation,
and requires two signals (anti-CD3 and PMA), a requirement which the authors noted
was similar to the dual signal requirement for cytokine production (Delgado et al.,
1996b).
It may also be significant that the 8 bp sequence TATTAGGT which lies directly
adjacent to the 5' end of the putative CLEO element in the Vipr2 gene, is also found
near to the CLEO element in the promoter region of the mouse IL-5 gene. In the mouse
IL-5 gene this octamer sequence is situated 22 bp upstream of the CLEO element and
spans the region from -83 to -76 bp (Siegel et al., 1995). Although the transcription
factor(s) that bind to this region of the mouse IL-5 gene have not been identified, a
DNase I footprint is detected between -88 and -77 bp in the presence of nuclear extracts
from the mouse thymoma cell line EL-4, and a reporter construct containing the region
from -76 bp to +1 of the IL-5 promoter showed only -40-50% of the activity observed
in constructs containing the -91 bp to +1 region following stimulation with Bt2cAMP
and PMA (Siegel et al., 1995). Two other regions of the Vipr2 gene situated upstream
of the putative CLEO element, also demonstrated high levels of homology with
sequences from the promoter regions of lymphokine genes (Figure 6.8), as did other
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areas of the putative Vipr2 promoter, but the importance of these sequences, if any,
within either the lymphokine or Vipr2 promoter regions, has yet to be demonstrated.
Nevertheless, although functional analysis of this distal region of the Vipr2 promoter
will obviously be required to substantiate a role for this area of the putative promoter
region in the cell-specific expression of the Vipr2 gene, it is tempting to speculate that
the CLEO-like element and possibly other sites within the upstream region of the Vipr2
gene may contribute to the co-induction of transcription of Vipr2 and lymphokine genes
following antigen stimulation of T-cells.
Brain-2-like factors as candidates for a role in the control ofVipr2 expression within
the CNS
Other possible binding sites for tissue-restricted transcription factors, that were of
interest with regard to potential functions of the VIP2 receptor, included a site that
conformed to the consensus binding sequence for the POU transcription factor Brain-2
(Brn-2) and overlapped the distal (-3065 bp) TATA box sequence of the putative Vipr2
promoter. Brn-2, which belongs to the class III group of POU transcription factors, is
found mainly within the CNS (He et al., 1989), although its presence in melanocytes
(Angus et al., 1995; Eisen et al., 1995) and in small cell lung cancer cells (Schreiber et
al., 1992) has also been reported. The distribution patterns of individual POU-III
transcription factors within the developing brain have led to the proposal that these
factors are involved in the differentiation of neuronal subtypes (Alvarez-Bolado et al.,
1995; He et al., 1989). However, these transcription factors are also expressed in a
more restricted pattern in adult brain (He et al., 1989). Evidence that Brn-2 is
important for neuronal development initially came from studies of embryonal
carcinoma cells, which indicated that Brn-2 is required for but is not sufficient for
neuronal differentiation (Fujii & Hamada, 1993), and subsequent gene targeting studies
have shown that Brn-2 is essential for the normal development of the hypothalamic-
pituitary axis (Nakai et al., 1995; Schonemann et al., 1995). In homozygous Brn-2-
null mutant mice, the paraventricular nucleus (PVN) and supraoptic nucleus (SON) of
the hypothalamus are absent, and the posterior lobe of the pituitary is hypoplastic
(Nakai et al., 1995; Schonemann et al., 1995). The precise cause of these defects
(which first start to become apparent at -E12.5) is not known, although the inability of
Brn-2"/" mutants to activate the transcription of certain neuropeptide genes (including
oxytocin, arginine vasopressin, CRF) in the PVN, and SON, or to form correct axonal
projections from the hypothalamus to the posterior lobe of the pituitary, appear to be
contributing factors (Nakai et al., 1995; Schonemann et al., 1995).
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Viprl mRNA has not been reported to be present in the hypothalamus, but Vipr2
transcripts have been detected in several nuclei including the PVN of the hypothalamus
(particularly the posterior magnocellular region and the parvocellular division of the
periventricular region), and the supraoptic nucleus (Sheward et al., 1995; Usdin et al.,
1994). Thus, Viprl is expressed within regions of the hypothalamus where Brn-2 is
also expressed, and it seems entirely possible that Brn-2 could play an important role in
the hypothalamic expression of the Vipr2 gene. Target sites for Brn-2 that have been
identified to date include several high affinity binding sites within the CRF gene's
promoter (Peng et al., 1993), and a possible binding site in the promoter of the
calcitonin/CGRP gene (Schreiber et al., 1992). However, it is interesting that although
the Brn-2 knockout studies indicate that Brn-2 may be involved in the regulation of
oxytocin and vasopressin gene expression, the authors noted that these peptides are not
found in neuronal precursor cells at El2.5 in wild type mice, and go on to suggest that
the Brn-2 target genes essential for the survival of the migrating hypothalamic neurons
"might include genes encoding a receptor for neurotrophic factors or a protein with
anti-apoptotic activity" (Nakai et al., 1995). The Vipr2 gene, which is expressed in
mouse embryos from at least as early as E9.5 (Sheward et al., 1996b), and whose
product binds ligands (VIP and PACAP) that have been shown to be involved in the
promotion of neuronal survival (Arimura et al., 1994; Festoff et al., 1996; Pincus et
al., 1994; Tanaka & Koike, 1994), would be well placed to fulfil this type of function
within the developing hypothalamus.
In addition to the potential Brn-2 binding site at -3067 bp, a second potential site for
Brn-2 binding within the putative promoter region of the Vipr2 gene was found at
-1119 bp. This site lies -100 bp upstream of the more proximal TATA box sequence,
within a region that also contains possible sites for serum- and cAMP- responsive
factors. Thus if these areas of the Vipr2 gene do function as alternative promoter
regions rather than enhancer sequences, it is conceivable that Brn-2 might block
binding of transcription factors to the distal TATA sequence by competing for binding
to this site, whilst binding of Brn-2 upstream of the more proximal TATA sequence
might possibly promote transcriptional activation from this region. However, it is also
important to stress that Brn-2 displays considerable flexibility in its DNA binding
specificity, and can bind to bipartite core CAT and A/TAAT motifs that are separated by
0, 2 or 3 bp (Li et al., 1993). Therefore the probability of a sequence that fits the Brn-2
consensus binding sequence, occuring by chance within a given region of DNA is
much higher than that for an element such as the CLEO-like sequence that was
described earlier, and consequently the suggestion that these sites in the Vipr2 gene
may be functional binding sites for Brn-2 is currently very tentative.
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Transcription factors that may be involved in the pituitary expression of the Vipr2 gene
As Vipr2 transcripts are detected in the pituitary, particularly in the anterior region
where a dramatic increase in the level of Vipr2 expression is seen during pregnancy
(Usdin et al., 1994), it was interesting to find that several possible sites for the anterior
pituitary specific transcription factor Pit-1 (Bodner et al., 1988; Simmons et al., 1990)
were present at various locations in the putative promoter region of the Vipr2 gene.
These sites do not conform to the proposed Pit-1 consensus sequence TATNCAT
(Nelson et al., 1988) but do display a high level of similarity, or in several cases
identity with Pit-1 binding sites found in the human prolactin gene promoter (Peers et
al., 1990). Pit-1 is found in somatotrope, lactotrope, and thyrotrope cells of the
pituitary, and is essential for the determination and maintenance of these cell types (Li et
al., 1990). However, although Pit-1 is required for the transcriptional activation of
several genes encoding peptide hormones and receptors in the pituitary, including the
genes for growth hormone and prolactin (Mangalam et al., 1989), thyroid stimulating
hormone (3 (Haugen et al., 1993), and the thyroid hormone (32 receptor (Wood et al.,
1996b), Pit-1 alone cannot account for the cell-specific regulation of the transcription of
these genes within the pituitary (reviewed by (Rhodes et al., 1994)).
One site that may be involved in the cell-specific regulation of Vipr2 gene transcription
in the pituitary was identified by comparison of the putative Vipr2 promoter with the
promoter region of the rat pro-opiomelanocortin gene. The site in question is located in
the GC rich region of the putative Vipr2 promoter, and is very similar (1/10 bp
mismatch in the form of a C—>G substitution; Figure 6.8) to a binding site for a
chemically unidentified transcription factor named PP1 that plays a major role in the
pituitary cell-specific expression of the pro-opiomelanocortin gene (Liu et al., 1995).
Furthermore, the pro-opiomelanocortin gene PP1 site to which the Vipr2 sequence
shows homology, appears to be aided in its transcriptional activation of the pro¬
opiomelanocortin gene by two Spl sites one of which lies directly adjacent to the PP1
site, and although the putative PP1 site within the Vipr2 gene is in an inverted
orientation relative to that in the pro-opiomelanocortin gene promoter, it was found that
the Vipr2 PP1 site is also situated directly adjacent to a GC rich sequence that may act
as an Spl binding site (2/10 bp mismatches with the pro-opiomelanocortin gene Spl
site, both G<->C substitutions). Transcripts from the pro-opiomelanocortin gene and
Vipr2 gene are both found in the AtT20 pituitary cell line (Liu et al., 1995; Rawlings et
al., 1995). However, the apparent restriction of PP1 expression to cells that express
the pro-opiomelanocortin gene (Liu et al., 1995), suggests that although PP1 may be
involved in cell specific expression of Vipr2 in some pituitary cell types, other cell-
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specific factors must be responsible for directing Viprl gene expression in cell lines
such as GH4C1 where Viprl transcripts are found (Rawlings et al., 1995) but PP1 is
not detected (Liu et al., 1995).
Isl-1 -like factors and other E-box bindingfactors
The promoter region of the insulin gene (which in adults is active only in pancreatic |3-
cells; (Giddings et al., 1985)) has been extensively studied (reviewed by (Dumonteil &
Philippe, 1996), and was thus an ideal template with which to begin to search the
putative Vipr2 promoter for possible binding sites for pancreatic transcription factors.
Of the three regions of strong sequence similarity that were identified in the Vipr2 and
insulin promoter sequences (Figure 6.8), the discovery that the putative islet-1 (isl-1)
binding site (CTAATG) at ~ -2885 bp (identified in the previous computer database
search) displayed an extended homology to the CTI box (CCCTAATGGG) of the
human insulin gene, was the most interesting at present, as transcription factor binding
to this sequence has been demonstrated in the insulin gene (Petersen et al., 1994). The
LIM homeobox transcription factor isl-1 was originally identified in pancreatic islet
cells (Karlsson et al., 1990), and is involved in the islet-specific transcription of several
genes including the rat proglucagon gene (Wang & Dmcker, 1995) and the amylin gene
(Wang & Drucker, 1996). However isl-1 has subsequently been found in other
endocrine tissues including the kidney, thymus, and pituitary, and also in the nervous
system (Dong et al., 1991; Thor et al., 1991) where its functions are thought to include
a role in motor neuron development (reviewed by (Lumsden, 1995)). Two potential
isl-1 sites exist in the putative Vipr2 promoter (just over 300 bp from one another), but
as the isl-1 like binding sites (known as CT sites) in the insulin gene are now thought to
bind the islet-specific homeobox protein insulin promoter factor 1/somatostatin
transcription factor 1 (IPF-l/STF-1) (Petersen et al., 1994), and at least 12 different
homeobox genes are known to be expressed in pancreatic beta cells (Rudnick et al.,
1994), the range of factors that might be capable of binding to the putative isl-1 sites of
the Viprl gene is likely to be quite large. Nevertheless, in both the rat and the human
insulin gene the CTI motif lies a short distance downstream of a sequence GCCATCTG
known as GCI (Boam et al., 1990) which contains the consensus E-box binding site
(CANNTG) for the basic-helix-loop-helix family of transcription factors (Blackwell &
Weintraub, 1990), and it is interesting that the Viprl putative isl-1 site that is identical
to the CTI motif also lies just downstream of an E-box sequence. The E-box sequence
near the 'Vipr2 CTI site' is not the same as the GCI sequence of the insulin gene, but
as synergistic interactions between helix-loop-helix proteins and IPF-l/STF-1 are
involved in the regulation of insulin gene transcription (Peers et al., 1994), the presence
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in the Vipr2 gene of adjacent sites for members of these groups of transcription factors
may indicate that similar types of regulatory mechanisms are operating in these genes.
In addition to the E-box sequence mentioned above, several other E-box sequences
were identified within the putative promoter region of the Vipr2 gene. Due to the
degenerate nature of the E-box consensus sequence, these sequences will occur by
chance on average once every 256 bp. Thus the identification of a total of 18 potential
sites within 3.2 kb is not in itself very significant, although the presence of two 'double
E-box sites' at -1216 and -1711 may suggest that the E-box binding basic-helix-loop-
helix family of transcription factors might be important regulators of Vipr2 gene
transcription. Tissue restricted E-box binding proteins that have been identified in
tissues and cells where the Vipr2 gene is expressed include: myogenic transcription
factors such as MyoD and myogenin (Weintraub et al., 1991; Wright et al., 1989); the
neuron-specific factors such as the HEN (Brown & Baer, 1994; Brown et al., 1992),
and MASH (Guillemot, 1995) subgroups; NeuroD which is found in the nervous
system and also in the pancreas (Lee et al., 1995b; Naya et al., 1995); and the slightly
more widely distributed E-box factor TALI which is thought to be involved in T-cell
leukaemia, but is also expressed in the developing brain, hematopoietic cells, and in
some endothelial cells (Hsu et al., 1994). The basic-helix-loop-helix (bHLH) proteins
bind to E-box sequences as either homodimers or heterodimers, and as each bHLH
protein is thought to interact principally with one half of the E-box sequence, different
bHLH pairs display binding preferences for different E-box sequences (Blackwell &
Weintraub, 1990). However the differences in sequence specificity between the
various E-box binding factors are not clear cut, and it is often difficult to predict which
bHLH pairs might be capable of binding to a given E-box sequence. This seemed to be
particularly true for the putative Vipr2 promoter as two of the E-box binding factors that
were of particular interest with regard to the tissue-specific expression of the Vipr2
gene, TALI and NeuroD, appear to bind to similar E-box sequences. Thus although it
was interesting to see that the preferred core binding sequence (5' CAGATG 3') for
TAL1/E2A heterodimers (Hsu et al., 1994) occurs at several sites within the putative
Vipr2 promoter (including the two most proximal E-box sites), it is equally possible
that these sites may represent regulatory sites for NeuroD or other related E-box
factors, as the opposite strand of this sequence (5' CATCTG 3') corresponds to the
sequence of the GC-I site of the insulin gene which has been reported to bind
heterodimers of the bHLH factors E47 and Beta 2 (the hamster homologue of NeuroD;
(Naya et al., 1995)).
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A site that may be involved in transcriptional repression of the Vipr2 gene
Although research into the factors and mechanisms underlying transcriptional
repression is still in its infancy in comparison with that carried out on transcriptional
activators, the importance of gene-specific transcriptional repressors in the
establishment and maintenance of tissue and cell specific patterns of gene expression
has been clearly established (reviewed by (Gray & Levine, 1996b)). Only one putative
binding site whose sequence is thought to be recognised exclusively by a sequence-
specific transcriptional repressor protein was found within the Vipr2 gene. However ,
this site is of considerable interest for two reasons: i) it is found within 160 bp of the
proposed transcriptional start site, a distance which might be consistent with short
range repression of the core transcription complex (Gray & Levine, 1996a; Gray &
Levine, 1996b); ii) although the site in question is a recognition site for a factor that has
only been identified in Drosophila to date, this factor which is known as Tramtrack
(Ttk) is involved in the establishment and maintenance of cell fates within the nervous
system (Badenhorst et al., 1996; Guo et al., 1995), and also appears to play a role in
the regulation of patterning in early embryonic development (Pritchard & Schubiger,
1996). In the nervous system Ttk is expressed in support cells but not in neurons, and
is thought to suppress the expression of neuronal genes in non-neuronal cells.
Overexpression of Ttk in the sensory organ precursor cells of the PNS stimulates
neuronal to nonneuronal shifts in cell fate, whilst underexpression promotes a shift in
the opposite direction (Guo et al., 1995).
Transcriptional repressors that are known to be involved in the control of neuronal gene
expression in mammalian cells include the neuron-restrictive silencing factor (NRSF)
for which binding sites or potential binding sites have been identified in over 15
neuronal genes (Schoenherr et al., 1996; Wood et al., 1996a), and also in a few non¬
neuronal genes (Schoenherr et al., 1996). However, the binding sites for this factor do
not appear to be related to those that bind Ttk, and to date no putative NRSF binding
sites have been detected within the Vipr2 gene .
6.4.3 Transcription factors and sites that may be involved in elevating
or repressing Vipr2 gene transcription in response to certain
physiological changes
There is increasing evidence to suggest that although Vipr2 transcripts are generally
present at relatively low levels even in tissues where expression of this gene is greatest
(Usdin et al., 1994), Vipr2 gene transcription can be quite dramatically induced in
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response to certain physiological changes. For example, in addition to the induction of
Vipr2 gene expression following T-cell activation (discussed previously), it is
interesting to note that in unactivated T-cells stimulation by VIP results in induction of
Vipr2 gene transcription, but produces no significant change in the levels of Viprl
transcripts (Delgado et al., 1996b). In the pituitary, elevated levels of Vipr2 mRNA are
found during pregnancy (Usdin et al., 1994). There are indications that developmental
regulation of Vipr2 mRNA levels may occur in the testes (Krempels et al., 1995; Usdin
et al., 1994), and preliminary studies of Vipr2 mRNA levels in the suprachiasmatic
nucleus have revealed circadian fluctuations in receptor mRNA levels which appear to
precede photic cues (C. Cohen, unpublished data).
Sites that could be involved in the induction of Vipr2 gene transcription under some of
these conditions include, the putative: cAMP responsive element (CRE), serum
response element (CArG box), Sox-5 and Sry-type sites, and a STAT site.
cAMP responsive factors
The presence of a putative CRE in the Vipr2 gene is not surprising, as both the VIP
gene and the VIPR1 gene also appear to contain CRE sites within their promoter
regions (Sreedharan et al., 1995). In the case of the VIPR1 and Vipr2 genes it is not yet
known whether these proposed sites are functional, but it nevertheless seems likely that
these elements might be involved in the regulation of the relative levels of peptide and
receptor gene transcription. The sequence of the putative CRE in the Vipr2 gene
(TGATGTCA), is particularly interesting because although it does not conform to the
consensus CRE binding sequence, it is identical to the cAMP responsive element-like
element (CARE) 4 site in the P2 promoter of the cAMP response element modulator
(■CREM) gene (Molina et al., 1993). This homology may be relevant to the regulation
of Vipr2 gene expression especially in the suprachiasmatic nucleus, as in the CREM
promoter this sequence can also bind the inducible cAMP early repressor protein
(ICER) which blocks cAMP inducible transcription from CRE sites (Molina et al.,
1993). Transcripts encoding ICER are produced from the P2 cAMP inducible
promoter of the CREM gene, and display a circadian pattern of expression within the
pineal gland where ICER production increases dramatically at night (Stehle et al.,
1993). When ICER was first discovered studies of its distribution showed that it is
found predominantly in neuroendocrine tissues, particularly in the pineal gland (where
it has been implicated in mediating circadian clock-directed modulation of hormone
synthesis; (Foulkes et al., 1996)), the pituitary, and the adrenal gland (Stehle et al.,
1993). However, more recent reports indicate that it is also expressed in other cells of
the neuroendocrine and immune systems, including: hypothalamic magnocellular
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neurons after osmotic stimulation (Luckman & Cox, 1995), the thyroid gland (Lalli &
Sassone-Corsi, 1995), suprachiasmatic nucleus (Stehle et al., 1996), and human T-
cells (where increases in cAMP levels are paralleled by ICER induction which in turn
leads to the inhibition of calcineurin-mediated stimulation of IL-2 expression) (Bodor et
al., 1996).
The observation that ICER is capable of binding to sequences that diverge significantly
from the canonical CRE consensus (TGACGTCA), has led to the proposal that many
cAMP inducible genes could potentially be regulated by this protein in T-cells (Bodor
et al., 1996), and this possibility obviously also applies to the neuroendocrine system.
However there have been suggestions that ICER, and other CRE activator and
repressor proteins, do not display equal affinity for all CRE sites (Foulkes et al.,
1996). Hopefully in the near future characterisation of the affinities of the different
CRE binding proteins for CRE-like sites will help in the identification of potential
binding sites for these factors. Nevertheless from current knowledge, the sequence
identity of the potential CRE site in the Vipr2 promoter and the CARE 4 site of the
CREM gene, which also extends 3 bp 5' of the proposed binding site, would appear to
strongly support the possibility of ICER regulation of Vipr2 expression through this
site, whilst the ability of ICER to bind to sequences that diverge from the CRE
consensus could suggest that a sequence TGAGCTCA 12 bp downstream of the
putative Vipr2 CRE, might conceivably also be involved in cAMP mediated regulation
of this gene.
Serum responsive factors
Serum response element binding factors have been implicated in the regulation of the
expression of two categories of genes: i) the regulation of immediate early gene
transcription in response to mitogen stimulation (Hipskind & Nordheim, 1991;
Karagianni & Tsawdaroglou, 1994; Latinkic & Lau, 1994; Latinkic et al., 1991), and
ii) the regulation of myogenic genes during muscle development (Soulez et al., 1996).
However, as VIP induces immediate-early gene expression (Hisanaga et al., 1993;
Vaccarino et al., 1993), VIP receptor levels are modulated by serum factors (Bellan et
al., 1992), and Vipr2 transcripts are present in skeletal muscle (Wei & Mojsov, 1996),
the putative Vipr2 SRE that we have identified could potentially fall into either or both
of these categories. The basis for the specificity of SRE activated transcription in each
system appears to result from the interaction of SRF with other factors, that bind near
to the SRE sequence. These "SRE accessory factors" are thought to include Ets-family
ternary complex factors (TCFs) in the case of growth factor induced gene expression
(Marais et al., 1993; Price et al., 1996), C/EBPp and TCFs in serum stimulated
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transcriptional activation (Sealy et al., 1997), and muscle-specific factors at the SREs
of muscle-specific genes (Galvagni et al., 1997; Groisman et al., 1996). Of these
accessory proteins, the most extensively studied factors are the TCFs, which are
phosphorylation targets of the MAP kinase signalling pathways (Cahill et al., 1996;
Marais et al., 1993), and bind to the Ets consensus sequence (C/A) (C/A) GGA (A/T)
which is found just upstream of the SRE in several genes, including the prototypical
SRE containing c-fos gene (Treisman et al., 1992). From our Vipr2 gene sequence
data, the Vipr2 putative SRE does not appear to belong to the subgroup of SREs that
possess adjacent upstream sites for known TCFs . However, the presence in the Vipr2
gene of the part of the central TCF binding sequence (Hipskind et al., 1991) CAGG (in
the opposite orientation) lbp downstream of the SRE sequence, makes it difficult to
completely exclude the possibility of TCF-SRF interactions in this gene, as it seems
likely that only a small proportion of the factors that can interact with SRFs have been
identified to date.
Cytokine regulated transcription factors
Cytokines, which include the interleukins, interferons, tumour necrosis factor, and
colony stimulating factors, play an important role in the immune system, where they are
involved in a wide range of functions (reviewed by (Belardelli, 1995)). However,
many of these factors also appear to act as signalling molecules in the neuro-immune
axis, and are synthesised within the CNS where they are involved in the regulation of
homeostatic and developmental processes in the brain, including the control of neuronal
growth and survival (reviewed by (Merrill & Jonakait, 1995)), a process in which VIP
has also been implicated (Festoff et al., 1996; Muller et al., 1995; Pincus et al., 1994;
Tanaka & Koike, 1994). Potential binding sites for IL-6 regulated transcription factors
(NF-IL6 sites or IL-6_REs; (Akira et al., 1995)) were found at several positions
throughout the putative promoter region of the Vipr2 gene. However within the
proximal GC rich region of the putative Vipr2 promoter two additional sites were
identified that could represent binding sites for other cytokine responsive transcription
factors.
The first of these sites, is a possible binding site (at -612 to -624 bp) for the
transcriptional activator interferon regulatory factor-1 (IRF-1, also known as interferon-
stimulated gene factor-2 or ISGF-2; (Pine et al., 1990)), which competes with its
antagonistic repressor IRF-2 for binding to DNA sites that conform to the consensus
sequence (G/C)(A)AAA(N)2-3AAA(G/C)(T/C) (Tanaka et al., 1993). IRF-1 was
initially characterised as a possible regulator of the promoter regions of the type I
interferon genes (Fujita et al., 1989; Pine et al., 1990). However, the discovery that
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the expression of transfected IRF-1 constructs can lead to a decrease or arrest in cell
growth (Kirchhoff et al., 1993), indicates that the effects of IRF-1 and IRF-2 extend
beyond the transcriptional regulation of the interferon system, and is consistent with the
recent identification of putative IRF-l/IRF-2 binding sites in the promoter regions of
several genes that are involved in the regulation of cell growth and apoptosis (Tanaka et
al., 1993; Taniguchi et al., 1995).
The second site is located -150 bp downstream of the IRF-1 site (at -479) and although
it was originally detected as a possible IL-6 RE site in the computer database search for
binding sites, this site was subsequently found to display a high level of similarity
(1/10 bp mismatch in the form of a T/A substitution) to a STAT binding site that lies
within the 180 bp cytokine responsive element (CyRE) of the VIP gene. The promoter
region of the VIP gene has not been characterised in great detail to date, but
considerable work has been carried out on the CyRE, which was identified on the basis
of its ability to mediate transcriptional activation of the VIP gene in response to
leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF) and oncostatin M
(Symes et al., 1994). The STAT site in the VIP gene CyRE is required for but alone is
not sufficient for CNTF/LIF-induced transcriptional activation of the VIP gene (Symes
et al., 1995a; Symes et al., 1995b), which also requires the presence of 3 C/EBP-
related sites that are found downstream of the STAT site (Symes et al., 1995b). Thus,
it is interesting that the putative STAT site within the Vipr2 gene is directly juxtaposed
to a site that fits the C/EBP consensus sequence for NF-IL6 binding
T(T/G)NNGNAA(T/G) (reviewed in (Akira et al., 1995)), although the exact sequence
of this site differs from those found in the VIP gene's CyRE. Similar patterns of quite
closely positioned C/EBP and STAT sites are found in other IL-6 responsive genes
(Dalmon et al., 1993; Kordula & Travis, 1996), and although the basis of the
interactions between these elements is not yet entirely clear it seems that they may
represent a point of convergence between the MAP kinase and JAK-STAT signalling
pathways (Akira et al., 1995).
The specificity of STAT binding to DNA has been shown to be dependent at least in
part on the spacing between the core TT and AA half site sequences (Seidel et al.,
1995), and in this respect it is possible that the putative Vipr2 STAT site and the VIP
gene STAT site may differ in their ability to respond to the STAT signals induced by
some cytokines. In contrast to the VIP gene STAT site TTCCTGGAA (Symes et al.,
1994) which has the 5bp spacing that appears to be associated with general STAT
binding (Seidel et al., 1995), the Vipr2 gene's putative STAT sequence
TTACCTGGAA has a 6bp spacing that is characteristic of genes that selectively bind
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the STAT complexes activated by IL-4 (Hou et al., 1994; Seidel et al., 1995). This
potential selectivity of the putative Vipr2 STAT site could be interesting as the NF-
CLEO element described earlier in this chapter is found in the promoter region of genes
that are expressed in Th2 cells (including the IL-4 gene and possibly the Vipr2 gene),
while one of the functions of IL-4 is the promotion of Th2 lineage expansion over that
of Thl (Kopf et al., 1993; Noble et al., 1993), a function which requires the presence
of the IL-4-induced transcription factor STAT6 (Kaplan et al., 1996).
6.4.4 The Vipr2 gene's transcription start site(s)
Problems that are generally associated with use of primer extension assays to identify
transcriptional start sites include, difficulties in obtaining extension through regions that
have a high GC content, and problems with detecting RNA transcripts that are present
at very low levels. Unfortunately, it is likely that both of these factors contributed to
the failure of the primer extension experiments described in this chapter. In particular,
low levels of Vipr2 transcripts were probably a major factor in the problems
encountered, since Vipr2 transcripts do not appear to be very abundant, even in the
olfactory bulb (which relative to other tissues has high levels of Vipr2 mRNA), and if
heterogeneous transcriptional start sites are present in the gene (as has been found in the
mouse PTH/PTHrP receptor gene; (McCuaig et al., 1994)) this may compound the
difficulties of detecting the extension products.
Possible alternative approaches that were considered included: i) attempting to induce
higher levels of Vipr2 gene expression in cells prior to mRNA isolation, as it appears
that dramatic increases in Vipr2 transcript levels can be induced under certain
physiological conditions; or ii) using nuclease protection assays (which are thought to
be more sensitive than primer extension methods in the detection of low level
transcripts) in order to determine the transcription start site of the Vipr2 gene.
However, as the factors that are responsible for increasing Vipr2 transcript levels have
not yet been established, nuclease protection assays seemed to be the most promising of
the two approaches, and while this thesis was being compiled, this method has been
succesfully used in our laboratory to establish the transcription start site of the Vipr2
gene in AtT20 cells and in mouse olfactory bulb. The results of these assays place the
transcription start site of the Vipr2 gene a short distance (27 bp) upstream of the Vipr2
Q12 5' RACE product described earlier, and indicate that in the RNA sources examined
Vipr2 gene transcripts have a 5' untranslated region of 133 bp that is encoded by the
same exon as theVipr2 gene's ATG translational start site. The results in no way
exclude the possibility that tissue-specific alternative promoter usage and/or alternative
5' untranslated exons may exist within the Vipr2 gene. However, they do suggest that
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although upstream enhancer-like sequences may interact with the proximal GC-rich
putative promoter sequence, this latter sequence (which includes binding sites for Spl)
is likely to represent the major region responsible for the initiation of Vipr2 gene
transcription in mouse olfactory bulb and AtT20 cells.
6.4.5 Future directions
At present this analysis of the putative promoter region of the Vipr2 gene is very
provisional, as there is no functional data to support a role for any of the transcription
factors discussed above, in the regulation of Vipr2 gene expression. Nevertheless,
several interesting sites within the Vipr2 gene's 5' region have been identified that
could act as very useful starting points for further studies.
The best way forward at the moment would probably be to subclone the proximal GC
rich region of the promoter and examine its ability to activate the transcription of
reporter genes in cell lines where the Vipr2 gene is normally expressed. Having
established whether or not this region on its own can mediate Vipr2 gene transcription,
additional reporter gene constructs could then be used to examine the possible role of




The studies presented in this thesis have resulted in the isolation of mouse genomic
clones that span the entire Vipr2 gene with the exception of part of intron 4, and also
contain a considerable amount of the Vipr2 gene's 5' flanking region. Through analysis
of these A. clones, 12 introns were identified within the Vipr2 gene's coding sequence,
and following sequencing of the gene's exon/intron boundaries, a variety of methods
were successfully used to determine the sizes of all but one of these introns. Several of
the Vipr2 gene's introns were considerably larger than had been expected and this
caused some problems, particularly in the case of intron 4, where a gap in the contig of
Vipr2 clones still remains. Nevertheless, even with an estimated minimum size of 19
kb for intron 4 (of which -12 kb has been subcloned), the Vipr2 gene appears to span
at least 59 kb of genomic DNA, and of those members of the secretin/glucagon receptor
gene subfamily that have been characterised to date, only the calcitonin receptor gene
(Zolnierowicz et al., 1994) is larger.
A bacteriophage PI clone containing at least part of the human VIPR2 gene was also
isolated, and both this clone and a subcloned restriction fragment from the 3' end of the
mouse gene were then used to determine the chromosomal localisation of the VIP2
receptor gene in mouse and human. The mouse Vipr2 gene was found to map to the
telomeric band of mouse chromosome 12 (12F2), and the human VIPR2 gene was
localised to the human chromosomal region 7q36.3, a result that contrasts with
previous reports which indicate that human 7q36 is syntenic with mouse chromosome 5
(Marigo et al., 1995; Martin et al., 1990; Matthes et al., 1993; Ohshima et al., 1995).
However, as the VIPR2 gene is the most distal gene that has been mapped on 7q so far,
it appears that this localisation may define a previously unidentified region of synteny
between the subtelomeric area of human 7q and mouse chromosome 12.
The localisation of the human VIPR2 gene to 7q36.3, together with the proposed role
of VIP in the control of embryonic growth (Gressens et al., 1993; Gressens et al.,
1994), prompted the examination of the VIPR2 gene as a candidate gene for the brain
developmental disorder holoprosencephaly. Initial results from the hybridisation of the
VIPR2 PI probe to cell lines from patients who had 7q36 deletions and
holoprosencephaly (HPE3), demonstrated that in each case only one copy of the VIPR2
gene was present (a finding which led to the redefinition of the minimal critical region
for the HPE3 locus). However, further collaborative studies, in which two copies of
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the VIPR2 gene were found in patients who had 7q36 translocations and mild HPE
phenotypes, indicated that the VIPR2 gene could not be the sole gene responsible for
the HPE3 phenotype, and it has subsequently been reported that mutations affecting the
Sonic Hedgehog gene (SHH) are the cause of HPE3 (Belloni et al., 1996; Roessler et
al., 1996; Roessler et al., 1997).
During this work, the position of the VIPR2 gene within a series of YAC and cosmid
contigs from 7q36 was determined, and the 5' end of the VIPR2 gene's coding region
was found to be situated within -250 kb of the 7q telomere. This proximity to the
telomere, raises some interesting questions with regard to both the potential
susceptibility of the VIPR2 gene to chromosomal damage/deletion, and the possibility
that the telomeric position of the gene might be important for the correct regulation of its
expression (as has previously been suggested by Riethman et al., 1993, following the
mapping of a CpG island, which we now suspect to be the 5' end of the VIPR2 gene,
to a position -195 kb from the 7q telomere). Telomeric/subtelomeric rearrangements
and/or deletions are frequently found in tumour cells (see Meltzer et al., 1993), and
have also been detected in some patients who have idiopathic mental retardation (Flint et
al., 1995; Wilkie, 1993). However, very recently, as a result of the high resolution
now attainable with FISH, and the isolation of probes for all human telomeres (see
Yung, 1996), many additional cases of previously undetectable interstitial subtelomeric
deletions/rearrangements, cryptic telomeric translocations, and possible telomere
capture, have been identified (Flint et al., 1996; Johannesson et al., 1997; Tosi et al.,
1996; Wenger et al., 1997), and it is likely that more will follow. As a single copy
gene that lies only a few hundred bp from the telomere, the VIPR2 gene should prove
to be a useful marker for the detection of chromosomal deletions or translocations
involving the terminal region of 7q, and although the effects, if any, that the telomeric
location of the VIPR2 gene has on the gene's regulation, will probably be difficult to
determine, it would nevertheless be interesting to try to examine whether
telomeric/subtelomeric rearrangements lead to alterations in VIPR2 expression levels.
The phenotypic effects of monosomy for the VIPR2 locus are not yet clear, and the
contribution, if any, of VIPR2 gene deletion to the phenotypes observed in some HPE3
patients remains to be established. Fimitations in access to cell lines and
cytogenetic/phenotype descriptions of cases of HPE, make it very hard to assess
whether certain phenotypic abnormalities might be more common in cases where there
is a terminal deletions of 7q that encompasses VIPR2, as opposed to an interstitial
deletion, mutation, or translocation breakpoint that affects only SHH. Nevertheless,
even from the published information currently available (Belloni et al., 1996; Belloni et
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al., 1995; Collins et al., 1993; Grass et al., 1995; Gurrieri et al., 1993; Muenke et al.,
1994; Roessler et al., 1997), it is clear that the HPE3 phenotype is extremely variable,
and it is often difficult to draw a line between HPE microforms and abnormalities that
may be caused by the mutation or deletion of other genes on distal 7q.
Despite the close linkage between the SHH/HPE3 locus and the site of the sacral
agenesis locus described by Lynch et al. 1995, the identity or otherwise of the AD
sacral agenesis locus and the HPE3 gene (SHH) has not yet been determined. Indeed,
in a recent report describing isolated sacral agenesis in association with deletion 7q36.1-
qter, it was suggested that the phenotypes observed in 7q terminal deletion cases could
be more easily explained if the genes at the HPE3 and AD sacral agenesis loci on 7q36
were contiguous rather than allelic (Savage et al., 1997). However, although it seems
that if SHH is responsible for both HPE3 and sacral agenesis, the explanation of the
phenotypic variability is likely to be complex, it is nevertheless a very real possibility in
light of the wide-ranging effects of SHH during development (Hammerschmidt et al.,
1997).
A problem that has frequently arisen during attempts to correlate the known functions of
VIP and PACAP with possible functions of the VIP2 receptor, particularly those related
to the developmental effects of VIP, has been the scarcity of experimental evidence to
support the proposed ability of the VIP2 receptor to signal via non-cAMP mediated
signalling pathways. In contrast to PACAP type I receptor gene transcripts where
splice variation occurs within the region encoding the 3rd intracellular loop (Spengler et
al., 1993), no clear patterns of potential sites of splice variation were identified within
the corresponding region (intron 10) of the mouse Vipr2 gene during this study.
Nevertheless, the recent characterisation of a PACAP type I receptor variant that
stimulates calcium influx by activation of L-type calcium channels (Chatterjee etal.,
1996b); the demonstration that in rat bone marrow-derived stromal cells, in which only
the Vipr2 transcripts can be detected by RT-PCR, VIP and PACAP appear to stimulate
IL-6 production through a dual signal transduction pathway involving both cAMP and
IP3 (Cai et al., 1997); and the demonstration that the GIP receptor can activate the MAP
kinase signal transduction cascade through two different pathways, which differ in their
sensitivity to the phosphatidylinositol 3-kinase inhibitor wortmannin (Kubota et al.,
1997); strongly indicate that the range of signalling pathways to which members of the
secretin glucagon family can couple may be much wider than previously envisaged, and
suggest that the non-cAMP signalling mechanisms reported to be involved in mediating
the growth effects of VIP, need not necessarily imply that additional VIP receptor genes
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exist. Other recent discoveries that may be of relevance regarding the very high affinity
VIP binding sites that have been observed on rat cortical astrocytes (see Olah, et al.,
1994 and Gozes et al., 1991), include reports of additional peptide variants in some
tissues, e.g. miniglucagon, which is produced from glucagon by proteolytic cleavage at
the surface of target cells and has been shown to be active at picomolar concentrations,
although its effects often oppose those of glucagon (Bataille et al., 1996). Therefore,
although to date, the cAMP-mediated signalling pathways of the VIP) and VIP2
receptors have predominated in the literature, the clarification of any additional
pathways through which these receptors signal, and in particular whether or not the
VIP2 receptor can signal via IP3_linked pathways, is likely to be one of the most critical
aspects of studies of these receptors in the immediate future.
The 5' flanking sequence of the mouse Vipr2 gene, was not isolated until near the end
of the studies presented here, and consequently only a preliminary analysis of the its
sequence was possible in the time available. Nevertheless, even from this initial
analysis, it is clear that the putative promoter region of the Vipr2 gene is similar to the
promoter regions of several other members of the secretin/glucagon receptor family
(Aino etal., 1995; Burcelin et al., 1995; McCuaig et al., 1995; Sreedharan et al., 1995;
Tsai-Morris et al., 1996) in that it contains Spl sites as opposed to a TATA box, and is
GC and CpG rich. Of the possible binding sites for transcription factors that were
identified, there were several that are of particular interest in light of either known or
suspected functions of the VIP2 receptor.
These include:
i) a conserved lymphokine element 0 (CLEO) site, which in lymphokine genes is
involved in stimulating gene transcription in T-cells following antigen activation
(Miyatake et al., 1991), a stimulus which has also appears to induce T-cell Vipr2 gene
transcription (Delgado et al., 1996b).
ii) a site that is identical in sequence to the CTI element (a binding site for isl-1 -like
factors) in the human insulin gene (Petersen et al., 1994), and in light of the proposed
role of the VIP2 receptor in mediating the effects of VIP and PACAP on glucose-
stimulated insulin secretion (Bertrand et al., 1996; Inagaki et al., 1994), may be
involved in regulating the expression of the Vipr2 gene in pancreatic islets.
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iii) a region of similarity between the proximal promoter region of Vipr2 gene and that
of the rat pro-opiomelanocortin gene, which (although in the opposite orientation in the
Vipr2 gene) represented the apparent conservation of a composite element consisting of
sites for Spl and the pituitary specific transcription factor PP1 (Liu etal., 1995).
iv) a putative cAMP response element, which is identical in sequence to a site in the
CREM gene that has previously been shown to be capable of binding the inducible
cAMP early repressor 'ICER' (Molina et al., 1993).
The possible role of ICER in the regulation of Vipr2 gene expression is especially
intriguing with regard to the proposed role of VIP in the suprachiasmatic nucleus
(SCN), as it has recently been reported that a light induced upregulation of CREM (and
hence ICER) mRNA occurs in the SCN during the second half of the night (Stehle et
al., 1996). Interestingly, a peak in the level of Vipr2 mRNA (which is expressed
biphasically) within the SCN, is also observed during the latter part of the night
(Cagampang et al., submitted). At present the temporal relationship between the peak
in Vipr2 mRNA and that of ICER (which might be predicted to result in the
downregulation of Vipr2 mRNA levels) is not known, but this might prove to be an
important line of enquiry for future work. At the molecular level, further studies of the
role of the putative Vipr2 cAMP response element and the other proposed binding sites
for transcription factors (described above and in Chapter 6), are likely to take the form
of reporter construct experiments using a set of nested deletions from the Vipr2 gene's
5' flanking sequence (and cell lines in which the Vipr2 gene is usually expressed), to
try to establish the relative contributions that individual regions make to the
transcriptional activation of the gene. Having identified specific regions of interest,
band shift and footprinting assays with appropriate cell extracts could then be used to
characterise the transcription factor binding sites present in these areas. Other
approaches that are likely to be useful include the ectopic expression of transcription
factors in cell lines that express Vipr2. Indeed, within the last few months a paper has
been published in which the effects of ectopic expression of ICER on cell morphology
and adrenocorticotrophic hormone (ACTH) secretion in the pituitary corticotroph AtT20
cell line are described (Lamas et al., 1997). The Vipr2 gene is also expressed in AtT20
cells, and has recently been implicated in mediating the transcriptional stimulation of the
pro-opiomelanocortin gene (which encodes ACTH) by VIP and PACAP (Aoki et al.,
1997). The possible conservation of a pituitary-specific transcription factor binding site
between the Vipr2 and pro-opiomelanocortin genes (see iii), might therefore be
important in co-ordinating or inter-regulating the expression of the two genes in some
pituitary cell types, and as ICER does not affect the transcription of the pro-
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opiomelanocortin gene directly, but acts through the transcriptional regulation of a
prohormone convertase gene (Lamas et al., 1997), AtT20 cells could be a very
interesting system in which to begin to examine the interrelationships between ICER,
Vipr2, and pro-opiomelanocortin gene expression.
The -5.6 kb Xba I fragment that was isolated and subcloned from the 5' end of the
Vipr2 gene (see Chapter 6) has subsequently been used by other members of our
laboratory to produce a Vipr2 replacement construct for use in the generation of Vipr2-
null mice. Viable fertile lines of mice that were heterozygous for the Vipr2 replacement
sequences were successfully generated, and at least one homozygous Vipr2-knockout
mouse has now been produced, although the phenotype associated with loss of the
VIP2 receptor in mice has not yet been studied in detail. Some caution should be
observed when attempting to draw parallels between the functions of the VIP2 receptor
in mouse and those in human, as preliminary analysis of the 5' flanking region of the
human VIPR2 gene (carried out by E. Lutz in our laboratory) indicates that significant
differences may exist between the promoter regions of the mouse and human genes.
Nevertheless, it is anticipated that the physiological, pharmacological and behavioural
studies of the V7pr2-knockout mice will contribute substantially to our understanding of
the role of the VIP2 receptor in mediating the known effects of VIP and PACAP, and
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LOCUS:C NTIGEXON7 1aacaaatggctgccag aa 61cagatggtccctggcattgt 121ctctgccaggccaagat tt 181aacttatccaaacagat gc 241ctctcactgtctctggttcc 301TATCATGGCAAACTTCTA T 361AGCCATCCTTCCT CCAGCA 421cttcatattctc atcttga 481aaaccctactcc gggsata 541tcaacaag
tccttgcctatac tt atc gtatacaaagggttgtgcct aacaatgtctgt caa a tgccccgcctaccataa ta agGTTGGCTGCAA CTCAGC GGCTTCTGGTGGAGGGTCTC GGTGCTTCCTGGCCTACCT ttcctatctctttggg aa ctccatggtca c t ggtg
agagaatcagag ctc ctg cagtataacaca t ttggc gcacgctggctttgctt a tttttaccaactgg atgtt CTGGTATTCTTCCAGTACTG TACCTGCACACC TCCTGGT CTGATCGGATG Ggtaaggg aatatgtaggtttctgt c cactgagggttccatt atg
LOCUS:C NTIGEXON8 1gagtaggctgac gcacacct a t tg 61gggatgaaagctt c t acttagg gt 121ccagtgagcgtgt tctctcttact g c 181ctcggctttcagatatatttgt ctgg tg 241tattgatgaagacatta gtg acttcc 301acatgttctggttc agtac g g 361tgatgggtctctccacaGCATCCCCAGTGT 421CTCTTTAGAAGA ACA Ggtaagtgctata 481ctggtactggtagaatatctag gc aa 541ccagccagtcaag attttagg aa a 601tgatggtcatgggcaag ctcactac agt 661ggtgaaaattaa cc tgtcta tt gc 721gatatttttcatg c c ttg t tc c a 781cgggttggggggtt gggttca ggg a 841ctgga
ctgggagcccagccctttagag ag aa aaacgcacagcccct agacaaca t gag tctctgtcttcaacaga aggtttcagat cttagtaaaatataagtgcaaccttca atatggtcctttg ttgaaaat cctc tt gtgcttctcattgat aacaac a atc GTGTATAGGTCA GG CAGCAACTCG CT tgtgcatccacctgtaaaa a ggcctg gaaacttgtaccattaga aca ctt ttagcacccctgattaaaagac tgt g ctcagtatttagaagatggcc aa t aga taaaatcgggac a cac ga tgagt agagagccaagc gaaacag attttac aatgcattaagatcaggctatgttgg tgc
LOCUS:C NTIGEXON9-INTRON12 1tggagataaaccct ctgagt a g cc 61ttctttgagacagag tata caat tgg 121ccttcatggcat caga caagtg 181tgagacttaccagcc aggagctgcac cc 241ttgactcaccc ggaa gccgcttc ct t 301tgactgtgcat a agtctgattggca a 361gcaagcttcatcct cccaaac g tctg 421gtgacaccagtttc tt tc aac gTT 481GGTGGGTCATTCG ATGCCCATTCTAA TT 541gctatgctctgc tttcttttgt g 601ctgtgtgcaagt gc a cacttcctaca 661ggaagagtggactcc aggcaata g cca 721tagtctgctgcccatt ccaa tg tcagt 781atgcccacacga gtcctctttg gt 841gcaaaatcctatagatgggggtc g at 901tcctttcttgtctctg g agGTCAACTTT 961CTTCAGAAACTAA TTCTCAG TG TGGT 1021tctgcttgtccag atgagaa tgtgc 1081gtatacagaag c tc gggt c t gt 1141tggagtctgccggcc agcatcac ggg 1201ctaaaaataagaacattctctca gttt c 1261ttccttaaatgtg gtcctt ctg t 1321acacattgctcttcgtat tctgtcctcc 1381acagctggccttttgt tcta ac t 1441tttgactggcac gg tcata tgccac 1501aggttacccataattcacaag a aata 1561tttcagcgatgttgtat tggtgcagctca
acttcaatcattttcaagga tttt a aggactatgttttca aaggaa aa a catgccttgaattaa taacc ctg gtgctacctcccatt g aga tgt gg acatgcagggcagttagatctagttg ttgagaccgagaaaggggaagtt ttct cccagagcctagtttatatgttg gtca a GCTGGGACACAAAC ACAGCATCCC T CTATTGTAgtaagtagctgcctttg a ag taccatacagagtatagccac ctgc t a gggccccatcacct gagaa accc gaaggattctag cttggagga tta aa taaccacaactt tgc gtgtac ctca gggcagaccta tacctggggtag tg tg aagatgtaaaggtgctc caca cag GCCCTCTTCAT AGCA GTAAG ATCTTA GGCAATGACCA TCACAGTACAAgtgagta aaagttcatgg gagtacaccta t cc ggccctctaatcaacgtgcactga ac ccaagaaaccac ctgataggatg tggt catcatgcatagagccttctgtg gagtg tcacagcctgcatctarctcc ttta aaccagaccttggggct gtcc aca c ttagcaataatctgacaagttgtgtc c agctaatttgtggtaa ccaag aat ag tatcccagctcaggtgtgatgtgaacat gagcctgggctcagttt tg tgct tat
LOCUS:C NTIGEXON9-INTRO12continued 1621ttggtacaggtcaggagccttcag t 1681ctgggaagtgatca ctcccgccagtt 1741atagaaaaaaaa aat tgcagc tg t 1801agaggggtcttctct ta gct tctcctc 1861ttgggtttgagaaaca ctga ag attc 1921cgtggtgggcatt aa tcttag t 1981tctctttgtggaagaaacctccaggcca 2041cctgatcagacata gg tt tg tc 2101attcttagtcgcctttcaattg gg 2161tgaccttttctctgggc cggg agtgt 2221tattttggaaacaattat tgggtaacg 2281gcagagggctgtttc cccttg gtt ta 2341acaggctttcctag a agatgtgt a a 2401ccatatataaccttagcagg ttgtg 2461cacagagccttgagtgtgtgtt caa 2521agatacctaccact g accat ccatg 2581tcaaatgggaaccctgcccttgat cc 2641aaggcacacatctctaga ttg ata t 2701ttcacgaccaaaaagcaagttaggt ga 2761ctattccttactgcaagaactca g t gg 2821gagctgatgcagaagc ttgg atg 2881cttgcttgcttg tgcttgctt ctt t 2941cttttttgtttgt gg tggg tt 3001ctgtgtagtgtagtcctggcct ctg aa 3061tcagaaatttgcctcccaagtgct gg tt 3121gcatgctttcttatagaacc t ac a 3181ggcacttccccattga cataatta gaa
gatcctgtgctggctaa atctgcatcacc aagttaacacctgc c caggct cttttc gggtgctgagccacca gatggctgaacag tcctgtaaaaggaatgg ttt cctg agtgcctggcaca aagaatagagaa g atgctgtgcacaaaatacag ta gt acataacaaggtat gctcc c t g g ccctctgcagccctggaacagggc g ttttcggcaaatcctgtttgtgcctgtgc tagtgaagaag tcttt gtg atacttt agtctgtgctcttc ag gtgatg aagg gcaaagaaagact agtccttcc ctcct ggtcatgtaaatgt gg cct gca ctt ctcaagagcctgc g cccacct tggg gaagcagctgcagtga tcggttggtag cagaaagtacggctt tgtgc tt caaccctgatag a cca ctgttg gg tgtgtcttagagttaagactg gataaaa agagtgtatgtgacttacattccac gca agctcaaacag gcagg tcct g g ag agggtactgcttact g ttgctc gc tg tgcttgcttgcttt ct tt gtttggtttggtt c a acag tttct ctcactctgtagac aggcga ctggaa aaaggcgagtgcca c cggccggccctca agcccaggggttgcct actca tgg ctg aatgccttacc tgatcttttggag c
LOCUS:C NTIGEXON9-INTRON12continued 3241gttcctcaattga ggt cctcctt aga 3301aacatttgaaat ag gagg aagttttc 3361tttactgctgtgaacagacaccatgaccaa 3421gctggcttacag tt agaggtt a a 3481caggcaagcatgat ctggagg act 3541agaatactggcttccagacagctagga ga 3601acctactctaagggggccaccct yt at 3661accatcacaga ggt atgaat a ag 3721tcccctagctgaa ctagagag tag t 3781agggcttccgcat c tgtta cct cag 3841gcagttggaggcacct gatggtaagct 3901ggacaggataa g cagcagc tcac g 3961gttgcccaactcttcctgtttca aa tct 4021gcctccacacg tt actcag ag gt 4081tccaggaaaaactgatccatctggt 4141tatgtttttggggatgctgcat c at cc 4201tcctgctcctt agtcaccagaacta 4261ggcacttgtgacaaagaacagt tttc 4321tgtaggaatttcatcttcg gtaaac t 4381cgtgcaaagaa c ggttccag c a 4441tgagtcagcctctcaa t tctcatgat 4501catgtccttctc t t actagGAGGCTTG 4561TTGGCGTCCACTACATGGTGT TGC CCT 4621TCCTGTTTGAG TA G GTTG TCCT CC 4681caaactgtgggcagct tgacact g ct 4741ACTGCTTCCTGAACAG GAGgtaagtcctt 4801tcaggaattggccccatc tcaa tctgc
taactctagcttgtg ggact ggaa ga tcctgtgttagaaggtatcttagt g agcaactcttaaa gga attt tt gg ttatcatcaagg aggaactggcagc tc gttctacaacttca ggg ctgctagc gggtcttaaacccaagttcaca tg ca cctgccaytccctgggytaag atatacaa aggaacaggaaccaggaggag yt tgcy gtgtgcttagtga agtaagaagcca g ctggctgctaagatgagcactcactc tt agatacctggtccct gtgtgg gct ata caactggacag a tcagatttt gact gatgaggcctgaatttgagct cca a ctaggaagctttggct gataa tcagat gcctatatcctaatggaagaa cccct cccccccagttctgagaatgga t g tctgtccaaga tagtgtgtc gcagtt ctgtaagctggtgagcc tacaatatgccc gcatgtccacatgtgaaa ttct cc ag aagagagtaagcatttgt tattccct ac tgggtgggagaatt agagcacaa gcat CCAAGTCCACA TGC G TAATCC C TGT TCCCTATTGGCATCTCA CCA ATA CAGA AGgtaagtatg g ggtgctat g ccg ctttgcagGGCCTGGTGGTAG A T CTAT tgtcagctggaatttg cact ttg ccagctatgcccccatgcaac a c
LOCUS:C NTIGEXON9-INTRON12continued 4861acttggtttcctaaagccctcttagcaat 4921ctgtcctccaccaa g cc tt at 4981ctgtatatgag ctctatctgcatg ca 5041agtat
acttccagtccttccagcaaaat g cct caggtatttattta t ttagttagt a catgcatgtcagaag gatca atctc
LOCUS:C NTIGINTRON12+EXON331UTR 1gcctgaggattacttctctctggagccaggaa gcatgg aga tt g 61tggctactagagaaa gctctaa aaccacc gct ttgct t tagtg tt ta 121cacgctacatgct ctttggaggattc ca tt ctgcatttc aa tc tc t 181aacacgctcatccccagGTACAGTGTGAACTGAAAAGAAGATG C A GCC TG CT 241CCCAAGCTGGGAGCC GGACTAC GGCT CA TCATGTCC GGA TG CA 301AAAGTGCCCTC ATA ACCGTG CTGC CCCAGTTT T AGT G CTT 361CAGTCATTTAGCTGTGTCCCTTGTA GAGC CAG GT G TTGA 421TGCTGGATTCCTCTGCTGCCCAG C GG CTTATTG T A CT GTC TA 481CTCTGATCCTATGTG AACTTGATT AACAC AAT TT T CACT C T 541TAAGCCATCTCTTCAT ATA GG T GCAT T TT CAA GAAGCA GA 601CCAGGTGGCTGTGAACATCAAAACT GATTCTA T C AT GA GGAG A 661ATTCCAGTTCCCCTACTGCCTCCTGTCAGGGGGAAT G AACAGCT T 721ACCACCCTGTGA AACCATGCCTATGG T CATT CCT GT TA 781GGCATACCATA A ACAGTGA AG ACCTTCTC T TA A GC T CT GT C T 841AGCCTTGAGTT TG CCTGTGGAA AC TC GAC GCCAC TGCCA T 901ACCAAAGATAGTC AGAGGATATTCATTTT TT CC AA CAGACTC TCC 961TCCTGAGGCACTTA CATCTGC GCTTC TA A G G TGAG A C TG T A 1021TGTCATGAAGGCCCTTGTGAC TGTCCATTA A GT CTCTA AAT 1081AAACTGTTGCTTG TAAAGAAAATC CCATCTTAAAA CTG TAAG G TGTT 1141TTATCAAAGTA AA CAGCATC GT TTCC C CGA TG TA CAAT T 1201ATTTTTCCGATG TGCAACTGTGGAGCAGA TGAATGT T 1261GGAAAAGCAGCTGAAGACAGAGAGT C TTTCCCTGCAGTG C G ACC T AGA 1321TATGTCGTGGTCCAGTGCAAGGACTGTAGGT ACCTA TG TGCA C T 1381GTAACTTCCCCCC ACA AA AC CACAC AC GA AG ACGG 1441AATTCCGTTC
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The neuropeptides vasoactive intestinal peptide
(VIP) and pituitary adenylate cyclase activating poly¬
peptide (PACAP) have been shown to act on a wide
range of tissue and cell types, both in the central ner¬
vous system and in the periphery. Two distinct recep¬
tors for VIP, the VIP receptor type 1 (VIPR1) and the
VIP receptor type 2 (VTPR2), have recently been
cloned, each of which binds PACAP and VIP with equal
affinity. We report here the chromosomal mapping of
the human and mouse VIPR2 genes by fluorescence in
situ hybridization. The VIPR2 gene maps to the human
chromosomal region 7q36.3 and to the F2 region of
mouse chromosome 12. Our localization of the human
gene places it in the region where the locus for the
craniofacial defect holoprosencephaly type 3 (HPE3)
maps. Further mapping experiments, carried out on
cell lines derived from patients with HPE or HPE mi¬
croforms and associated 7q deletions, have led us to
redefine the distal extent of the HPE3 minimal critical
region, originally characterized by Gurrieri et al.
(1993, Nature Genet. 3: 247-251.) The VTPR2 gene lies
within this new HPE3 minimal critical region. Our re¬
sults suggest that deletion of the VIPR2 gene is not
the sole factor responsible for the HPE3 phenotype.
However, it is possible that monosomy at the VIPR2
locus may contribute to the phenotype observed in
many cases of HPE3. © 1996 Academic Press, Inc.
INTRODUCTION
Vasoactive intestinal peptide (VIP), a member of the
glucagon/secretin family of peptides, was first isolated
over 20 years ago. It functions as a neuroendocrine
hormone and neurotransmitter, activating adenylate
cyclase (Magistretti and Schorderet, 1984; Quik et al.,
1 To whom correspondence should be addressed at the MRC Brain
Metabolism Unit, Royal Edinburgh Hospital, Morningside Park, Ed¬
inburgh EH10 5HF, United Kingdom. Telephone: (+44) 131 537
6533. Fax: (+44) 131 537 6110.
1978) through G-protein-coupled receptors (Ishihara et
al., 1992; Lutz et al., 1993). VIP has a number of actions
in the periphery, including vasodilatation, stimulation
of electrolyte secretion, and smooth muscle relaxation
(Gozes and Brenneman, 1989). A more recently discov¬
ered member of this family, pituitary adenylate cyclase
activating polypeptide (PACAP), displays 60% se¬
quence homology to VIP (Miyata et al., 1989). PACAP
has a distinct distribution in the central and peripheral
nervous systems, where it is thought to function as a
neurotransmitter. Possible peripheral targets for PA¬
CAP include the adrenal medulla, the pancreas, and
the reproductive tract (Shivers et al., 1991).
It is only in the past 4 years, however, following the
cloning of receptors through which these peptides act,
that we have been able to begin to examine the routes
by which VIP and PACAP achieve their diverse effects.
Three receptors that bind PACAP have been cloned
to date, two of which also bind VIP with an affinity
approximately equal to that with which they bind PA¬
CAP. The receptors have been designated the PACAP
receptor type 1 (ADCYAP1R1), the VIP type 1 receptor
(VIPR1), and the VIP type 2 receptor (VIPR2). The
PACAP receptor type 1 (Ogi et al., 1990; Spengler et
al., 1993) has a marked preference for PACAP, whereas
VIPR1 (Ishihara et al., 1992; Sreedharan et al., 1993)
and VIPR2 (Inagaki et al., 1994; Lutz etal., 1993;Usdin
et al., 1994) will bind both VIP and PACAP with ap¬
proximately equal affinity. However, VIPR1 and VIPR2
show only about 50% similarity to each other at the
amino acid level and exhibit very significant differences
in their distribution within the brain. VIPR1 mRNA is
most abundant in the cerebral cortex and hippocampus
(Ishihara et al., 1992; Usdin et al., 1994), whereas
VIPR2 mRNA is found principally in the thalamus and
suprachiasmatic nucleus (Sheward et al., 1995; Usdin
et al., 1994). The PACAP receptor type 1 and VIPR1
genes have been mapped to human chromosomal re¬
gions 7pl4 (Stoffei et al., 1994) and 3p22 (Sreedharan
et al., 1995), respectively.
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We report here the chromosomal localizations of the
human and mouse VIPR2 genes. Using fluorescence in
situ hybridization (FISH), we have mapped the VIPR2
gene to the human chromosomal region 7q36.3 (using
both genomic and cDNA probes) and to mouse chromo¬
some 12 region F2. This places the human VIPR2 locus
close to the locus for the craniofacial abnormality holo-
prosencephaly type 3 (HPE3), a defect of embryonic
development that is characterized by incomplete cleav¬
age of the forebrain (reviewed by Muenke, 1994). We
have examined cell lines derived from patients with
HPE or HPE microforms associated with chromosomal
deletions in the distal region of 7q. Our results redefine
the distal extent of the HPE3 minimal critical region,
originally characterized by Gurrieri et al. (1993), and
show that the VIPR2 gene lies within the new minimal
critical region.
MATERIALS AND METHODS
Isolation of a mouse genomic clone. A mouse genomic DNA li¬
brary, in the X vector EMBL3 (Stratagene), was screened using an
[a-32P]dCTP-labeled cDNA probe corresponding to bases 711 to 1192
of the rat VIPR2 cDNA sequence (Lutz et al., 1993). One positive
clone was isolated, and a 4-kb BamUl restriction fragment, con¬
taining the final three introns and exons of the mouse VIPR2 gene,
was subcloned into pBluescript (Stratagene) for subsequent use in
FISH. Plasmid DNA for use in FISH was prepared using a Qiagen
plasmid maxi kit.
Isolation of a human genomic clone. A gridded human genomic
DNA library, constructed in the bacteriophage PI cloning vector
pAdlO-SacBII (Francis et al., 1994), was screened using an [a-32P]-
dCTP-labeled probe encompassing bases 1-947 of the published rat
VIPR2 cDNA sequence (Lutz et al., 1993). One positive clone was
identified. PI clone DNA for use in FISH was prepared by alkaline
lysis followed by CsCl banding and RNase treatment (Sambrook et
al., 1989).
The identity of the PI clone was confirmed by PCR amplification
of a 1.2-kb fragment from the 3' end of the VIPR2 gene using the
primers 4334 (5'-CCAGGTATGGGGTTTAGTGGAC) and 4335 (5'-
GCCGTCCTCTACTGTTTCCTGA), which flank the last intron of the
human VIPR2 gene. After denaturation at 94°C for 5 min, 30 cycles
of PCR were performed under the following conditions: 1 min at 94°C,
1 min at 57°C, 1.5 min + 4 sec per cycle at 72°C. A final extension
at 72°C for 10 min was followed by incubation at 4°C. Sequence
analysis of the PCR product after subcloning into pGEM-T vector
demonstrated that the product contained genomic sequence encoding
bases 1276-1640 of the published human cDNA sequence (Svoboda
et al., 1994) and intervening intron sequence, as expected.
Cell lines. Details of the cell lines used in this study (obtained
from NIGMS Human Genetic Mutant Cell Repository) are given in
Table 1.
Chromosomal mapping by FISH. Metaphase preparations were
made from short-term peripheral blood cultures, lymphoblastoid or
fibroblast cultures, and mouse ES cells by standard methods.
Probes. PI clones, cDNAs, cosmids, and YACs were labeled by
nick-translation with biotin-16-dUTP or digoxigenin-16-dUTP.
Chromosome 7 paint was produced by AU-PCR of DNA from somatic
cell hybrids containing a single human chromosome (Kofman-Alfaro
et al., 1994). Amplified DNA was labeled with biotin-16-dUTP or
digoxigenin-16-dUTP by nick-translation. Chromosome 13 paint la¬
beled with biotin was obtained from Cambio. YAC HSC7E207 con¬
tains the DNA markers D7S392 and D7S550, and YAC HSC7E526
contains D7S68 (Kunz et al., 1994). Cosmid 29f5 contains marker
D7S168. YAC HTY3006 is a 275-kb chromosome 7 telomeric YAC,
originally isolated by H. Riethman (Riethman et al., 1993).
Hybridization and detection. Hybridization conditions were as
described in Fantes et al. (1992). After single-probe hybridizations
biotin was detected by successive layers of avidin-FITC, biotinylated
anti-avidin, and avidin-FITC. When two probes, labeled with either
biotin or digoxigenin, were hybridized simultaneously, the signals
were detected using successive layers ofFITC-conjugated sheep anti-
digoxigenin, FITC-conjugated anti-sheep antibody plus avidin-
Texas Red, biotinylated anti-avidin, and avidin-Texas Red. The
VIPR2 gene was localized on prometaphase chromosomes produced
by early S phase synchronization with methotrexate of PHA-stimu-
lated peripheral blood cultures, followed by release with bromodeoxy-
uridine (BrdU). In this case hybridization signals were detected by
successive layers of avidin-Texas Red, biotinylated anti-avidin, and
avidin-Texas Red. A final incubation with FITC-conjugated anti-
BrdU gave a replication G-banding pattern (Craig and Bickmore,
1994). The chromosomes were counterstained with DAPI. Texas Red
hybridization signals were visualized simultaneously with FITC sig¬
nals through a Chroma Pinkel #1 filter block fitted to a Zeiss Axioplan
microscope, with a Photometries CCD camera and Digital Scientific
software.
Use of YAC and cosmid clones to determine the position and orien¬
tation of the human VIPR2 gene relative to the 7q telomere. YAC
clones HSC7E526 and HSC7E1357 were isolated from a chromosome
7-specific library prepared from human-hamster somatic cell hybrid
lines (Scherer et al., 1992), E145A7 was isolated from the St. Louis
total human genomic YAC library (Brownstein et al., 1989), and
HTY146 (locus D7S427) was isolated from a telomeric YAC library
that was described previously (Riethman et al., 1993). The cosmid
clones 2, 3 (D7S591), 6 (D7S592), 14, 19, 30 (D7S590), 48 (D7S593),
and 49 were derived from a library made from YAC clone HTY146
and have been described previously (Riethman et al., 1993). Another
22 cosmid clones (8dl, 14el0, 66e9, 77e7, 79b6, 79g2, 79g3, 81e9,
107g9, 116h3, 122ell, 124g2, 126g6, 134a8, 135c5, 137g2, 164g2,
215a5, 222fl, 230e6, 245b9, 250h9) were isolated from the Lawrence
Livermore National Laboratory chromosome 7-specific library by hy¬
bridization screening with a human VIPR2 cDNA probe correspond¬
ing to the entire coding region (13 exons) of the published sequence
(Svoboda et al., 1994). Cosmids 8dl, 77e7, 79g3, and 137g2 were
shown to contain primers 4334 and 4335 and therefore encompassed
the 3' end of the gene.
RESULTS
Localization of the Mouse VIPR2 Gene
FISH analysis on metaphase preparations from
mouse ES cells using a 4-kb BamPLl restriction frag¬
ment of the mouse VIPR2 gene as a probe showed that
the gene is located on chromosome 12 band F2. The
identity of the chromosome to which the probe hybrid¬
ized was confirmed by carrying out a colocalization ex¬
periment using the VIPR2 probe and a cosmid con¬
taining the Spi-2 gene (Fig. lb). The Spi-2 gene has
been mapped to mouse chromosome 12 by interspecific
backcross mapping (Hill et al., 1985) and by FISH.
Localization of the Human VIPR2 Gene
FISH analysis using the human VIPR2 gene PI clone
as a probe showed that the human VIPR2 gene is lo¬
cated on 7q36.3 (Fig. la). No reproducible hybridization
to any other chromosomal regions was observed. The
human VIPR2 cDNA was also mapped by FISH to
7q36.3 (data not shown).
Our location of the human VIPR2 gene, close to the
locus for HPE3, prompted us to attempt to refine our
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TABLE 1
Cell Lines Used, Cytogenetic Abnormalities, and FISH Results with the VIPR2 Probe
Cell line Phenotype" Reported cytogenetic abnormalities
Comments and









46,XY,del(7)(q34 > qter) deletion of 7q34-qter
46,XY,t(7;18) (7pter > 7q34::18ql2.2 >
18qter; 18pter > 18ql2.2::7q36 > 7qter) mat
deletion of 7q34-q36
46,XX,-7,+der(7)t(3;7) (7pter > 7q36::3p21.3
> 3pter) deletion of 7q36; duplication of
3p21.3 > pter
46,XX,-7,+der(7)t(7; 13) (7pter
>7q34::13ql2.3 > 13qter) pat deletion of
7q34-qter; duplication of 13ql2.3 > qter
46,XY,t(7; 13)(7pter > 7q34::13ql2.3 > 13qter;
13pter > 13ql2.2::7q34 > 7qter) balanced
translocation between 7 and 13
Gurrieri et al., 1993
Punnett et al., 1979
Gurrieri et al., 1993
One copy of VIPR2 on normal 7q
One copy of VIPR2 on normal 7q
Kurtzman et al., 1987 One copy of VIPR2 on normal 7q
Gurrieri et al., 1993
Gurrieri et al., 1993 One
Father of GM10064
copy of VIPR2 on normal 7q
One copy of VIRP2 on normal 13p
One copy of VIPR2 on normal 7q
One copy of VIPR2 on normal 13p
«flHDDO 1Q„
" MC, microcephaly; MDF, mildly dysmorphic facial features; MR, mental retardation; CP, cleft palate.
localization of the gene by mapping its position and
orientation relative to the 7q telomere. FISH experi¬
ments indicated that a region of overlap existed be¬
tween our VIPR2 PI clone and the 7q telomeric YAC
HSC7E526 (Fig. lc). We therefore used primers (4334
and 4335) that flank the last intron of the human
gene to screen by PCR (see Materials and Methods)
a subset of a collection of YAC clones that have pre¬
viously been mapped to 7q36 (Kunz et al., 1994).
These primers amplified a product of the expected
size (1.2 kb) from three YAC clones (HSC7E526,
HSC7E1357, and E145A7) that were also known to
contain D7S593 (H. Donis-Keller, unpublished data).
The D7S593 locus (Hing et al., 1993) was derived
from the YAC HTY146, which has previously been
shown to encompass the telomeric end of the chromo¬
some (Riethman et al., 1993). Therefore, it was as¬
sumed that HSC7E526, HSC7E1357, and E145A7
overlap with HTY146 to form a contig of clones ex¬
tending inward from the telomere as is shown in Fig.
2. YAC clone HSC7E526 has also previously been
shown to contain D7S68 (Kunz et al., 1994).
Having established that the VIPR2 gene lay directly
adjacent to the 7q telomere, we proceeded to refine fur¬
ther the localization of the VIPR2 gene within this re¬
gion. A fragment of the human VIPR2 cDNA that en¬
compasses all 13 known coding exons was hybridized
against the genomic DNA of 8 cosmids that spanned
the length of the HTY146 telomeric YAC clone (Rieth¬
man et al., 1993). Cosmid clones 48 (D7S593) and 14
gave positive hybridization results, which according to
the map of Riethman et al. (1993) indicated that a por¬
tion of the gene resided approximately 200 kb from the
end of the chromosome. The same cDNA probe was
used to identify 22 additional cosmids from a chromo¬
some 7-specific cosmid library. The relationship of
these clones with respect to each other and cosmids
48 and 14 was determined by comparing the extent of
overlap of restriction enzyme and hybridization pat¬
terns. A set of 8 representative cosmids that encom¬
passed approximately 100 kb and the entire known
coding region of the VIPR2 gene is shown in Fig. 2.
From this analysis the entire VIPR2 gene could be posi¬
tioned within about 350 kb of the terminal end of chro¬
mosome 7q, and the orientation of the gene along the
chromosome (Fig. 2) was 7cen-D7S68—(3 '-VIPR2-5' )—
D7S593-D7S591-D7S592-D7S590-D7S594-7qtel.
The VIPR2 gene is currently the closest known gene to
the telomere of 7q.
Localization of the VIPR2 Gene in HPE3 7q Deletion
Cases
Previous studies (Gurrieri et al., 1993) have led to
the identification of cell lines containing chromosomal
deletions on 7q, the breakpoints of which defined the
minimal critical region for HPE3. Using FISH, we lo¬
calized the VIPR2 gene in cell lines from four of the
patients described by Gurrieri et al. (1993) and in one
unaffected relative. Details of the cell lines used (ob¬
tained from NIGMS Human Genetic Mutant Cell Re¬
pository) are given in Table 1.
The breakpoints in GM03240 and GM00657 had
been used to define the proximal and distal boundaries
of the HPE3 minimal critical region (Gurrieri et al.,
1993). We found that only one copy of the VIPR2 gene
was present (on the normal chromosome 7) in each of
these cell lines (GM00657 shown in Fig. Id; data for
GM03240 not shown). These results placed the VIPR2
gene within the HPE3 minimal critical region. The de¬
letion in GM07216 extends to the telomere from a point
proximal to the breakpoint in GM03240. In this cell
line there was only a single copy of the VIPR2 gene on
the normal chromosome 7 (data not shown), consistent
with the results obtained from GM03240 and
GM00657.
In the cell line GM 10064 two copies of the VIPR2
gene were present, one on the normal chromosome 7
and the other on the normal (paternal) 13p (Fig. ID.












FIG. 1. Localization of the VIPR2 gene in human and mouse cell lines by FISH, (a) The VIPR2 PI clone (red, arrowed) hybridized to
human prometaphase chromosomes. A late replication G-banding pattern (green) is seen superimposed on DAPI (blue)-stained chromosomes.
VIPR2 maps to band 7q36.3. (b) The VIPR2 mouse genomic clone (green, arrowed) and Spi-2 cosmid (red) hybridized to mouse chromosomes.
Signal from the Spi-2 cosmid identifies chromosome 12; VIPR2 maps to band 12F2. (c) Hybridization of the VIPR2 PI clone (orange,
arrowed), YAC HSC7E526 (red), and YAC HSC7E207 (green) to human fibroblast nuclei. The orange signal overlaps with the red signal
in all nuclei examined, (d) Hybridization of the VIPR2 PI clone (green) to a metaphase from the cell line GM00657. The normal chromosomes


































FIG. 2. Localization of the VIPR2 gene to the terminal end of chromosome 7q. The positions of the VIPR2 gene, D7S68, D7S593, and
D7S594 among four YAC clones and 14 cosmids that encompass the terminal portion of the long arm of human chromosome 7 are shown.
The 5' end of the gene was located approximately 200 kb from the end of the chromosome, and the gene extended centromeric about 100
kb. VIPR2 (4334, 4335) are oligonucleotide primers specific for the last intron of the 3' end of the gene.
Chromosome 7 and chromosome 13 paints were used
to confirm this result. We also examined a cell line
(GM10067) derived from the father of GM10064. This
cell line, which carried a balanced translocation
t(7; 13), had three copies of the VIPR2 gene: one on
the normal chromosome 7, one on the translocated
chromosome 13 derivative, and one on the otherwise
apparently normal 13p. The phenotype of GM10067
was normal. However, the relevance of the GM10064
cell line to chromosome 7-linked HPE is uncertain,
as studies using chromosome 7 and chromosome 13
paints revealed that in addition to two copies of the
VIPR2 gene, most of chromosome 13 was present in
three copies in GM10064 (Fig. If), raising the possi¬
bility that HPE in this patient may be due to trisomy
13. Trisomy 13 is one of the most common cytogenetic
abnormalities associated with HPE, and reports sug¬
gest that 70% of trisomy 13 cases have HPE (Taylor,
1968), compared to ~50% of del(7)(q36) cases (Over-
hauser et al., 1995). As there was no way of establish¬
ing which of these chromosomal abnormalities was
responsible for HPE in this patient, and it was statis¬
tically more likely to be due to trisomy 13, cell line
GM10064 was excluded from our study of HPE3.
7 and 18 and the der7 and derl8 are labeled in (e), a black and white enhanced DAPI image. Only one copy of VIPR2 (arrowed in d) on
the normal 7, is present in this cell line, (f) Hybridization of the VIPR2 PI clone (green) and a chromosome 13 paint (red; appears pink in
figure) to a metaphase from the cell line GM10064. Signals from VIPR2 are found on the normal chromosome 7 and on 13p (arrowed). The
13 paint identifies both chromosome 13s and additional 13 material on the der7. (g) Hybridization of cosmid 29f5 (green) to a metaphase
from the cell line GM00657. Hybridization with a chromosome 18 paint (image not shown) identifies the der7, 18, and derl8 chromosomes.
Only one copy of cosmid 29f5(D7S168) is present on the normal chromosome 7 in this cell line.
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Reconciliation of the Cytogenetic and Physical
Mapping Data: Redefinition of the Distal Extent of
the HPE3 Minimal Critical Region
The HPE3 minimal critical region defined by Gur-
rieri et al. (1993) spans the region of 7q36 from marker
D7S392 to D7S292. Our mapping experiments using
the YAC and cosmid contigs from distal 7q indicated
that the VIPR2 gene was situated close to the marker
D7S593, which is at least 1.5 Mb telomeric to the pro¬
posed breakpoint in GM00657 that defines the distal
boundary of the HPE3 minimal critical region (S.
Scherer, unpublished data; Gurrieri et al., 1993). This
suggested either that the deletion in cell line GM00657
extended much further toward the telomere than pre¬
viously thought or that a complex rearrangement had
occurred in this cell line resulting in a second deletion
distal to that originally characterized. To investigate
these possibilities, cosmids containing D7S168
(cos29f5), VIPR2 (cos79g3 and cosl26g6), and D7S594
(cos30) were used as FISH probes on this cell line (see
Fig. 3 for location). A single copy of each of these cos¬
mids, and a single copy of the 275-kb 7q telomeric YAC
HTY3006 (Riethman et al., 1993), were found on the
normal chromosome 7 (the result obtained with the
cosmid containing D7S168 is shown in Fig. lg). The
order of markers on distal 7q has been reported as
cen-D7S550-D7S392 (proximal HPE3 critical region
boundary)—D7S468-D7S104-D7S168-D7S292 (dis¬
tal HPE3 critical region boundary)-D7S559-D7S68-
D7S427-D7S594 (Tsui et al., 1995). Although we can¬
not rule out the possibility that a segment of 7q36 be¬
tween D7S168 and the VIPR2 gene remains, our re¬
sults clearly show that significant areas of the region
distal to D7S292, including the VIPR2 gene and the 7q
telomere, are deleted in this cell line. These results
redefine the distal extent of the HPE3 minimal critical
region.
DISCUSSION
We have mapped the human VIPR2 gene to 7q36.3
and demonstrated that it lies within the HPE3 minimal
critical region.
HPE is a relatively common developmental abnor¬
mality in humans, occurring at a frequency of 1/16,000
live births and 1/250 conceptuses (Cohen, 1989). Pheno-
typic findings in patients with HPE vary widely, with
the degree of facial malformation generally correspond¬
ing to the extent of the brain abnormalities (DeMyer
et al., 1964). In the most severe form of HPE, alobar
HPE, a single brain ventricle is seen, which encom¬
passes both the telencephalon and the diencephalon
(DeMyer and Zeman, 1963). The olfactory bulb and
tracts are absent, and the pituitary may be absent or
hypoplastic. There is often abnormal development of
the optic tracts and underdevelopment of the thalami.
Microcephaly is very common. Facial abnormalities
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FIG. 3. Physical map of the terminal region of 7q36 that is de¬
leted in HPE3. The order of the DNA markers at the extreme end of
7q36 as determined by YAC and cosmid contig analysis and linkage
mapping is shown. The schematic diagram is drawn to the best possi¬
ble scale based on all available data. A YAC and cosmid contig ex¬
tending in from the telomere, which is encompassed by D7S427 (also
called YAC HTY146 or Y3006, Riethman et al., 1993), is shown (see
Fig. 2 for a higher resolution map). VIPR2 is located in this region.
Extending centromeric, a gap in the YAC map exists, but linkage
mapping has positioned the D7S22 and D7S98 markers in this inter¬
val (Tsui et al., 1995; and Helen Donis-Keller, unpublished data).
The YAC contig then extends centromeric approximately 2 Mb (E.
Belloni, unpublished data). The vertical bars on the right indicate
the region in the four HPE3 patients that has been determined to be
deleted in this study. The proximal deletion breakpoint in GM03240,
which was precisely mapped between D7S392 and D7S468 (Gurrieri
et al., 1993), defines the proximal boundary of the critical region.
The distal boundary of the HPE3 critical region is now defined as the
7q telomere. The translocation breakpoints of two unrelated HPE3
patients with apparently balanced rearrangements have been posi¬
tioned between D7S392 and D7S104 (Belloni et al., 1995).
ocular hypotelorism, and cebocephaly (Siebert et al.,
1990).
Our interest in the VIPR2 gene as a potential con¬
tributor to the HPE phenotype stems from a number
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of observations: (i) Gressens et al. (1993) have reported
a dramatic effect of VIP on the growth of the CNS
of mouse embryos in culture. Administration of a VIP
receptor antagonist (Gozes et al., 1991) during E9-E11
(the period during which subdivision of the prosenceph¬
alon begins) blocks these growth effects and induces
severe microcephaly (Gressens et al., 1994). (ii) In adult
rats, VIPR2 mRNA is abundant in many of the struc¬
tures that can be affected in HPE, including the pitu¬
itary, olfactory bulb, thalamus, and hypothalamus
(Lutz et al., 1993; Sheward et al., 1995; Usdin et al.,
1994). Unfortunately no studies on the prenatal distri¬
bution of VIPR2 have been published to date, (iii) HPE
has been found to occur at a higher incidence in chil¬
dren of diabetic mothers (Barr et al., 1983). The VIPR2
gene is expressed at high levels in pancreatic /Lcells
(Inagaki et al., 1994), where it is thought to be involved
in the amplification ofglucose-stimulated insulin secre¬
tion (Inagaki et al., 1994; Straub and Sharp, 1994). (iv)
Deletion of 18p has also been implicated in holopro-
sencephaly (HPE4), and a minimal critical region on
distal 18pll.3 has recently been defined (Overhauser
et al., 1995). The gene encoding PACAP (an alternative
endogenous ligand for VIPR2) maps to 18pll.32 within
this minimal critical region (Chang et al., 1993).
Our results from analysis of HPE3-associated 7q de¬
letions have shown that the cytogenetic rearrange¬
ments in the cell lines GM00657 and GM10064, used
by Gurrieri et al. (1993) to define the distal boundary
of the HPE3 minimal critical region, are more complex
than originally thought. The new HPE3 minimal criti¬
cal region extends to the telomere of 7q and includes
the VIPR2 gene locus. VIPR2 can therefore be consid¬
ered as a candidate gene for HPE3.
The HPE phenotype is extremely variable, and this
makes it difficult to distinguish patients who have mild
forms of HPE3 from those who may have phenotypes
associated with the deletion/rearrangement of other
genes in the 7q36 region. Even among families with
autosomal dominant HPE3, phenotypic expression
within a family can vary from alobar HPE through to
obligate carriers who have a normal phenotype
(Muenke et al., 1994).
Although the VIPR2 gene was shown to be monoso-
mic in all of the HPE3-associated deletion patients ex¬
amined, two unrelated patients with mild HPE symp¬
toms and balanced translocations mapping between
D7S392 and D7S104 (Belloni et al., 1995) were both
found to have two copies of the VIPR2 gene (data not
shown). These findings suggest that the VIPR2 gene is
unlikely to be the sole gene responsible for the HPE
phenotype. However, one of the translocation patients
is the mother of four children. Two of the children carry
the same balanced translocation as the mother, and the
other two have inherited an unbalanced translocation
resulting in the deletion of one copy of the terminal
region of 7q36 (Gurrieri et al., 1993; Hatziioannou et
al., 1991). The children with the balanced translocation
display a mild HPE phenotype, whereas those with the
deletion have more severe HPE (Gurrieri et al., 1993;
Hatziioannou et al., 1991). This seems to suggests that
the gene(s) responsible for the more severe form of
HPE3 lies distal to the translocation breakpoint. Our
current knowledge of the expression pattern of the
VIPR2 gene, the proposed involvement of at least one
of the receptor's ligands in embryogenesis, and in par¬
ticular the relatively high levels ofVIPR2 mRNA found
in olfactory bulb make the VIPR2 gene a strong con¬
tender for this role.
Our localization of the mouse VIPR2 gene to the te-
lomeric region of mouse chromosome 12 was unex¬
pected. There is no previously defined region of synteny
between human 7q36 and mouse chromosome 12, al¬
though synteny has been demonstrated between other
regions of human chromosome 7 and mouse chromo¬
some 12 (Tsui et al., 1995). HPE can be induced in
mouse embryos by teratogens (Sulik et al., 1995; Wei
and Sulik, 1993); however, the apparent absence of
HPE-like phenotypes in mouse genetic mutants map¬
ping to chromosome 12 or to any other mouse chromo¬
somes may reflect developmental differences between
the two species.
Another midline defect, sacral agenesis, maps within
the HPE critical region on 7q36 and, like HPE, has
been found to occur at a higher incidence in children
of diabetic mothers (Lynch et al., 1995). It is not clear
whether a different gene is responsible for this defect
(Lynch et al., 1995). Further work will be necessary to
assess the involvement of the VIPR2 gene in HPE3.
However, it seems likely that a delicate balance be¬
tween the various components of the VIP/PACAP sig¬
naling pathway is required for normal brain develop¬
ment and that deletion of the VIPR2 gene may contrib¬
ute to the phenotypic symptoms seen in many cases of
HPE3.
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